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A B S T R A C T
Background
Venous leg ulcers are open skin wounds on the lower leg which can be slow to heal, and are both painful and costly. The point prevalence
of open venous leg ulcers in the UK is about 3 cases per 10,000 people, and many people experience recurrent episodes of prolonged
ulceration. First-line treatment for venous leg ulcers is compression therapy, but a wide range of dressings and topical treatments are
also used. This diversity of treatments makes evidence-based decision-making challenging, and a clear and current overview of all the
evidence is required. This review is a network meta-analysis (NMA) which assesses the probability of complete ulcer healing associated
with alternative dressings and topical agents.
Objectives
To assess the effects of (1) dressings and (2) topical agents for healing venous leg ulcers in any care setting and to rank treatments in
order of effectiveness, with assessment of uncertainty and evidence quality.
Search methods
InMarch 2017we searched theCochraneWounds SpecialisedRegister; theCochraneCentral Register ofControlledTrials (CENTRAL);
Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid Embase and EBSCO CINAHL Plus. We
also scanned reference lists of relevant included studies as well as reviews, meta-analyses, guidelines and health technology reports to
identify additional studies. There were no restrictions with respect to language, date of publication or study setting. We updated this
search in March 2018; as a result several studies are awaiting classiﬁcation.
Selection criteria
We included published or unpublished randomised controlled trials (RCTs) that enrolled adults with venous leg ulcers and compared
the effects of at least one of the following interventions with any other intervention in the treatment of venous leg ulcers: any dressing,
or any topical agent applied directly to an open venous leg ulcer and left in situ. We excluded from this review dressings attached to
external devices such as negative pressure wound therapies, skin grafts, growth factors and other biological agents, larval therapy and
treatments such as laser, heat or ultrasound. Studies were required to report complete wound healing to be eligible.
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Data collection and analysis
Two review authors independently performed study selection, ’Risk of bias’ assessment and data extraction. We conducted this NMA
using frequentist meta-regression methods for the efﬁcacy outcome; the probability of complete healing. We assumed that treatment
effects were similar within dressings classes (e.g. hydrocolloid, foam). We present estimates of effect with their 95% conﬁdence intervals
(CIs) for individual treatments focusing on comparisons with widely used dressing classes, and we report ranking probabilities for each
intervention (probability of being the best, second best, etc treatment). We assessed the certainty (quality) of the body of evidence using
GRADE for each network comparison and for the network as whole.
Main results
We included 78 RCTs (7014 participants) in this review. Of these, 59 studies (5156 participants, 25 different interventions) were
included in the NMA; resulting in 40 direct contrasts which informed 300 mixed-treatment contrasts.
The evidence for the network as a whole was of low certainty. This judgement was based on the sparsity of the network leading to
imprecision and the general high risk of bias in the included studies. Sensitivity analyses also demonstrated instability in key aspects
of the network and results are reported for the extended sensitivity analysis. Evidence for individual contrasts was mainly judged to be
low or very low certainty.
The uncertainty was perpetuated when the results were considered by ranking the treatments in terms of the probability that they
were the most effective for ulcer healing, with many treatments having similar, low, probabilities of being the best treatment. The two
most highly-ranked treatments both had more than 50% probability of being the best (sucralfate and silver dressings). However, the
data for sucralfate was from one small study, which means that this ﬁnding should be interpreted with caution. When exploring the
data for silver and sucralfate compared with widely-used dressing classes, there was some evidence that silver dressings may increase
the probability of venous leg ulcer healing, compared with nonadherent dressings: RR 2.43, 95% CI 1.58 to 3.74 (moderate-certainty
evidence in the context of a low-certainty network). For all other combinations of these ﬁve interventions it was unclear whether the
intervention increased the probability of healing; in each case this was low- or very low-certainty evidence as a consequence of one or
more of imprecision, risk of bias and inconsistency.
Authors’ conclusions
More research is needed to determine whether particular dressings or topical agents improve the probability of healing of venous leg
ulcers. However, the NMA is uninformative regarding which interventions might best be included in a large trial, largely because of
the low certainty of the whole network and of individual comparisons.The results of this NMA focus exclusively on complete healing;
whilst this is of key importance to people living with venous leg ulcers, clinicians may wish to take into account other patient-important
outcomes and factors such as patient preference and cost.
P L A I N L A N G U A G E S U M M A R Y
Dressings and topical agents (gels, ointments and creams) for treating venous leg ulcers
What is the aim of this review?
The aim of this review is to ﬁnd out which dressings and topical agents (gels, ointments and creams) are most effective for treating a
type of wound known as venous leg ulcers. These are long-term wounds in the lower leg caused by problems with blood ﬂow back up
the leg through the veins. Researchers from Cochrane found 78 relevant studies (randomised controlled trials) to answer this question.
Randomised controlled trials are medical studies where patients are chosen at random to receive different treatments. This type of trial
provides the most reliable evidence.We evaluated these studies using a method known as network meta-analysis (NMA), which allowed
us to compare treatments across different studies and to rank them in terms of complete ulcer healing.
Key messages
We cannot be certain which dressings and topical agents are most effective for healing venous leg ulcers: over all studies there were not
enough participants per treatment and there was high risk of bias; this means that many of the studies were conducted or reported in
a way that means we cannot be sure if the results are accurate. The main treatment for venous leg ulcers is compression bandages or
stockings and the choice of additional dressings or topical treatments should take into account the review ﬁndings and their uncertainty,
alongside factors such as patient preference and cost.
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What was studied in the review?
Venous leg ulcers are open wounds caused by poor blood ﬂow through the veins of the lower leg. Increased pressure in the leg veins may
cause damage to the skin and surrounding tissues, leading to an ulcer. Venous leg ulcers can be slow to heal and are painful and costly to
treat. The main treatment is compression bandages or stockings but these are often combined with dressings (e.g. foam or nonadherent
dressings) and topical creams, gels or ointments. We wished to know which of these additional treatments are most effective when it
comes to ulcer healing.
What are the main results of the review?
We found 78 studies relevant to this question, dating from 1985 to 2016. The studies involved 7014 participants (a majority were
women, and average age ranged from 46 to 81 where reported). Our NMA included 59 studies (5156 participants) and compared 25
different treatments such as hydrocolloid and silver-impregnated dressings and a variety of creams and gels.
Silver dressings may increase the probability of venous leg ulcer healing compared with nonadherent dressings. However, in the light of
the rest of the NMA evidence, we cannot be very conﬁdent about any conclusion, and the network as a whole represents low-certainty
evidence. This was due to the small numbers of people involved across all included studies, the small number of studies focusing on
each treatment, and the high risk of bias. We cannot therefore be certain which are the most effective treatments for venous leg ulcers,
or even which treatments it would be best to compare in future trials.
How up to date is this review?
We searched for studies published up to March 2017.
3Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
NMA evidence for base-case network: proportion with complete healing
Patient or population: people with venous leg ulcers
Intervention: dressing or topical agent
Comparator: alternat ive dressing or topical agent
Settings: hospital, community or care home, or combinat ions
Contrasts Relative effect
(95% CI)
Anticipated absolute effects* (95% CI) -
from median of control groups in direct evidence
Certainty of
the evidence
(GRADE)
Comments
Median CGR With intervention
Sucralfate versus
nonadherent
RR 6.80
(2.24 to 20.7)
242 per 1000 1000 per 1000
(542 to 1000)
⊕⊕©©
Lowa,b
Base-case: RR 17.2
(95% CI 1.52 to 193). Large
dif ferences between base-
case and extended base-
case
The calculated absolute ef -
fect for the intervent ion is
more than 1000 per 1000 for
the point est imate and its
upper conf idence lim it ; and
so the corresponding values
for the absolute risk dif f er-
ence are also approximated
by 1000 per 1000
1000 more people healed per 1000
(300 to 1000 more)
Sucralfate versus
foam
RR 5.94
(1.96 to 18.0)
376 per 1000 1000 per 1000
(737 to 1000)
⊕⊕©©
Lowa,b
Base-case: RR 14.8
(95%CI 1.30 to 169)
Large dif ferences between
base-case and extended
base-case.
The calculated absolute ef -
fect for the intervent ion is
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more than 1000 per 1000 for
the point est imate and its
upper conf idence lim it ; and
so the corresponding values
for the absolute risk dif f er-
ence are also approximated
by 1000 per 1000
1000 more people healed per 1000
(361 to 1000 more)
Sucralfate versus
hydrocolloid
RR 6.51
(2.17 to 19.6)
433 per 1000 1000 per 1000 (940 to 1000) ⊕⊕©©
Lowa,b
Base-case: RR 16.24
(95%CI 1.43 to 185)
Large dif ferences between
base-case and extended
base-case
The calculated absolute ef -
fect for the intervent ion is
more than 1000 per 1000 for
the point est imate and its
upper conf idence lim it ; and
so the corresponding values
for the absolute risk dif f er-
ence are also approximated
by 1000 per 1000
1000 more people healed per 1000
(507 to 1000 more)
Silver versus
nonadherent
RR 2.43
(1.58 to 3.74)
242 per 1000 588 per 1000 (382 to 905) ⊕⊕⊕©
Moderatea
346 more people healed per 1000
(140 to 663 more)
Silver versus
foam
RR 2.12
(1.46 to 3.07)
376 per 1000 797 per 1000 (549 to 1000) ⊕⊕©©
Lowc
Direct evidence: Analysis
1.24
421 more people healed per 1000
(173 to 786 more)
Silver versus
hydrocolloid
RR 2.32
(1.58 to 3.41)
433 per 1000 1000 per 1000 (684 to 1000) ⊕⊕©©
Lowa,d
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567 more people healed per 1000
(251 to 1000 more)
Sucralfate versus
silver
RR 2.80
(0.88 to 8.97)
81 per 1000 225 per 1000 (71 to 722) ⊕©©©
Very lowa,e
Base-case: RR 6.99
(95%CI 0.60 to 82.0)
Large dif ferences between
base-case and extended
base-case
145 more people healed per 1,000
(10 fewer to 642 more)
Foam versus
hydrocolloid
RR 1.10
(0.93 to 1.28)
433 per 1000 476 per 1000 (402 to 554) ⊕©©©
Very lowf,g,h
Direct evidence: Analysis
1.18
43 more people healed per 1000
(f rom 31 fewer to 121 more)
Foam versus
nonadherent
dressing
RR 1.15
(0.91 to 1.44)
242 per 1000 278 per 1000 (220 to 348) ⊕⊕©©
Lowa,h
36 more people healed per 1000
(f rom 22 fewer to 106 more)
Hydrocolloid versus
nonadherent dressing
RR 1.04
(0.85 to 1.29)
242 per 1000 251 per 1000 (206 to 312) ⊕©©©
Very lowa,h,i
Direct evidence: Analysis 1.6
9 more people healed per 1000
(f rom 36 fewer to 70 more)
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparator group and the relative effect of the
intervent ion (and its 95%CI).
CGR: control group risk; CI: conf idence interval; NMA: network meta-analysis; RR: risk rat io
GRADE Working Group grades of evidence
High certainty (quality): we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty (quality): we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect,
but there is a possibility that it is substant ially dif f erent
Low certainty (quality): our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the
ef fect
Very low certainty (quality): we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the
est imate of ef fect
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a. NMA risk of bias f rom contribut ions matrix and direct evidence risk of bias (downgrade once)
b. Imprecision - direct evidence involving sucralfate: 1 study 43/ 50 events (sucralfate); 5 events (hydrogel) (downgrade once)
c. Heterogeneity in point est imates for direct evidence; signif icant inconsistency in node split t ing and in inconsistency factor
(loop) (downgrade twice)
d. Signif icant inconsistency in node split t ing and in inconsistency factor (loop) (downgrade once)
e. Imprecision - CI crosses one MID (1.25) and direct evidence involving sucralfate: 43/ 50 events (sucralfate) and 5 events
(hydrogel) (downgrade twice)
f. NMA risk of bias f rom contribut ions matrix and direct evidence risk of bias (downgrade twice)
g. Slight heterogeneity in point est imates for direct evidence; signif icant inconsistency in node split t ing and inconsistency
factor (downgrade once)
h. Imprecision - CI crosses one MID (1.25) (downgrade once)
i. High heterogeneity in direct evidence (downgrade twice)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Venous leg ulcers are common and recurring complex wounds
that heal by secondary intention (that is by the growth of new
tissue rather than by primary closure). Problems with the leg veins
(such as damage to the valves, or blockages) reduce the efﬁcient
return of blood to the heart and increase the pressure in the veins
(Ghauri 2010), which may result in venous leg ulcers. The precise
chain of events that links high venous pressures (chronic venous
hypertension) with skin breakdown and a chronic wound is not
fully understood (Coleridge Smith 1988; Valencia 2001).
Venous leg ulcers commonly occur on the gaiter region of the lower
leg (from just below the ankle up to mid-calf ). A venous leg ulcer
is deﬁned as any break in the skin that has either been present for
longer than six weeks or occurs in a person with a history of venous
leg ulceration. Differential diagnosis of the type of leg ulcer (i.e.
the underlying cause) is made by taking a clinical history, physi-
cal examination, laboratory tests and haemodynamic assessment
(RCN 2013; SIGN 2010). True venous ulcers are moist, shallow
and irregularly shaped and lie wholly or partly within the gaiter
area of the leg. Leg ulcers can be associated with venous disease in
combination with vascular disease, which impairs arterial blood
supply; in these instances they are said to have a ’mixed’ aetiology
(to have more than one cause). Open skin ulceration due solely to
limb ischaemia from vascular disease is less common.
Accurate, current estimates of leg ulcer prevalence are hard to iden-
tify because most surveys do not differentiate between causes of
leg ulceration, or do so per limb but not per person (Moffatt 2004;
Srinivasaiah 2007; Vowden 2009b). Estimates of the prevalence
of open leg ulceration (any cause) range from 4 to 48 cases per
10,000 (Graham 2003; Johnson 1995; Walker 2002), with the
point prevalence of venous leg ulceration in Australian and Eu-
ropean studies being between 10 per 10,000 and 30 per 10,000
(Nelzen 2008). A recent estimate suggests that venous ulceration
has a point prevalence of 2.9 cases per 10,000 in the United King-
dom (UK), whilst mixed arterial/venous leg ulceration has a point
prevalence of 1.1 per 10,000 (Hall 2014).
Venous disease is a chronic condition which can be characterised
by periods of ulceration (i.e. an open wound) followed by healing
and then recurrence. An early cross-sectional survey reported that
half of current or recent ulcers had been open for up to nine
months and that 35% of people with leg ulcers had experienced
four ormore episodes (Callam 1987b). This picture was supported
by a subsequent cross-sectional study (Nelzen 1994). More recent
analysis of almost 1200 people with venous leg ulcers documented
a 24-week healing rate of 76% and a recurrence at one year of
17% (Gohel 2005).
Venous ulcers are painful, can be malodorous and prone to in-
fection, and may severely affect people’s mobility and quality of
life. The presence of leg ulceration has been associated with pain,
restriction of work and leisure activities, impaired mobility, sleep
disturbance, reduced psychological well-being and social isolation
(Herber 2007; Maddox 2012; Persoon 2004). In severe cases, ul-
ceration can lead to limb amputation, although this may be more
common in people with comorbid arterial insufﬁciency (Dumville
2009; Nelzen 1997; Valencia 2001). Recent research suggests that
people with complex wounds, including those with venous leg ul-
cers, commonly see complete wound healing as the most impor-
tant outcome to them (Cullum 2016; Madden 2014).
The ﬁnancial cost of treating an unhealed leg ulcer in the UK
has most recently been estimated at around GBP 1700 per year
(price year 2012) (Ashby 2014). An earlier evaluation estimated
the average cost of treating a venous leg ulcer in the UK (based on
costs for material for dressing changes) as between EUR 814 and
EUR 1994 and, in Sweden as lying between EUR 1332 and EUR
2585 (price year 2002), with higher costs associated with larger
and more chronic wounds (Ragnarson 2005). In Bradford, UK,
GBP 1.69 million was spent on dressings and compression ban-
dages, and GBP 3.08 million on nursing time (estimates derived
from resource use data for all wound types) during the ﬁnancial
year 2006 to 2007 (Vowden 2009a). Data from a German study,
which estimated total costs including those classiﬁed as indirect
or intangible costs, estimated mean annual costs of leg ulcers as
EUR 9060 per patient (price year 2006). This ﬁgure is higher than
other estimates because it includes non-health service costs to the
patient and to society (Augustin 2012). These data are all derived
from high-income countries and thus may not be a true reﬂection
of costs elsewhere, which may be higher or lower.
Description of the intervention
The review includes all dressings and topical agents applied directly
onto or into wounds and left in situ. This contrasts with products
used to irrigate, wash or cleanse wounds and that are only in
contact with wounds for a short period. First-line treatment for
venous leg ulcers is compression therapy in the form of bandages,
stockings or mechanical devices (Nelson 2014; O’Meara 2012).
This application of external pressure around the lower leg assists
venous return and reduces venous reﬂux (Woo 2013).We therefore
anticipated that wound dressings would commonly be used in
combination with compression therapy.
Dressings are widely used inwound care with the aim of protecting
the wound and promoting healing by inﬂuencing the local wound
environment (Bradley 1999), typically by physical means, such
as thermal insulation, absorption of exudate and physical protec-
tion. Dressings may also have pharmacological, immunological or
metabolic actions. Topical agents include hydrogel gels, ointments
and creams that are placed in contact with the wound and left in
situ.
Dressings
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The classiﬁcation of dressings usually depends on the key material
used in their construction, and whether additional substances are
added to the dressing. Several attributes of an ideal wound dress-
ing have been described (BNF 2016), including the ability of the
dressing to:
• absorb and contain exudate without leakage or strike-
through, in order to maintain a wound that is moist but not
macerated;
• achieve freedom from particulate contaminants or toxic
chemicals left in the wound;
• provide thermal insulation, in order to maintain the
optimum temperature for healing;
• allow permeability to water, but not bacteria;
• optimise the pH of the wound;
• minimise wound infection and avoid excessive slough;
• avoid wound trauma on dressing removal;
• accommodate the need for frequent dressing changes;
• provide pain relief; and
• be comfortable.
There is a wide range of types of dressings available which may
be used for treating wounds including venous leg ulcers; some
of these and their properties are described below (BNF 2016).
Impregnated dressings may have a range of bases, such as foams
or alginates.
Absorbent dressings are applied directly to the wound and may
be used as secondary absorbent layers in the management of
heavily exuding wounds. Examples include Primapore (Smith &
Nephew); this can be lifted off at dressing removal, or removed
by irrigation. Bonding to a secondary viscose pad increases ab-
sorbency. Examples include: Curasorb (Covidien), SeaSorb (Colo-
plast) and Sorbsan (Unomedical).
Capillary-action dressings consist of an absorbent core of hy-
drophilic ﬁbres held between two low-adherent contact layers. Ex-
amples include: Advadraw (Advancis) and Vacutex (Protex).
Permeable film and membrane dressings are permeable to water
vapour and oxygen, but not to water or micro-organisms. Exam-
ples include Tegaderm (3M) transparent ﬁlm and OpSite (Smith
& Nephew).
Foam dressings contain hydrophilic polyurethane foam and are
designed to absorb wound exudate and maintain a moist wound
surface. There are a variety of versions and some include additional
absorbent materials, such as viscose and acrylate ﬁbres, or particles
of superabsorbent polyacrylate, which are silicone-coated for non-
traumatic removal. Examples include: Allevyn (Smith&Nephew),
Biatain (Coloplast) and Tegaderm (3M) foam adhesive and non-
adhesive dressings.
Honey-impregnated dressings contain medical-grade honey that
is purported to have antimicrobial and anti-inﬂammatory prop-
erties and can be used for acute or chronic wounds. Examples in-
clude: Medihoney (Medihoney) and Activon Tulle (Advancis).
Hydrocolloid dressings are usually composed of an absorbent
hydrocolloid matrix on a vapour-permeable ﬁlm or foam backing.
Examples include: Granuﬂex (ConvaTec) and NU DERM (Sys-
tagenix). Fibrous alternatives that resemble alginates and are not
occlusive have also been developed: Aquacel (ConvaTec).
Iodine-impregnated dressings release free iodine, which is
thought to act as a wound antiseptic when exposed to wound exu-
date. Examples include Iodoﬂex (Smith&Nephew) and Iodozyme
(Insense).
Low-adherence dressings and wound contact materials usually
consist of cotton pads that are placed directly in contact with the
wound. They can be non-medicated (e.g. parafﬁn gauze dress-
ing, saline gauze dressing) or medicated (e.g. containing povidone
iodine or chlorhexidine). Examples include parafﬁn gauze dress-
ing, BP 1993 and Xeroform (Covidien) dressing - a nonadher-
ent petrolatum blend with 3% bismuth tribromophenate on ﬁne
mesh gauze.
Odour-absorbent dressings contain charcoal and are used to ab-
sorb wound odour. Often this type of wound dressing is used in
conjunction with a secondary dressing to improve absorbency. An
example is CarboFLEX (ConvaTec).
Other antimicrobial dressings are composed of a gauze or low-
adherent dressing impregnated with an ointment thought to have
antimicrobial properties (e.g. chlorhexidine gauze dressing (Smith
& Nephew)). Alternatively, a dressing such as Cutimed Sorbact
(BSNMedical) uses a hydrophobic layer to bind micro-organisms
to the dressing surface, allowing them to be removed from the
wound when the dressing is changed.
Protease-modulating matrix dressings alter the activity of prote-
olytic enzymes in chronic wounds. Examples include: Promogran
(Systagenix).
Silver-impregnated dressings are used to treat infected wounds,
as silver ions are thought to have antimicrobial properties. Sil-
ver versions of most dressing types are available, including silver
impregnated dressings (e.g. silver hydrocolloid etc). Examples in-
clude: Acticoat (Smith & Nephew) and Urgosorb Silver (Urgo).
Soft polymer dressings are composed of a soft silicone polymer
held in a nonadherent layer; these are moderately absorbent. Ex-
amples include: Mepitel (Mölnlycke) and Urgotul (Urgo).
Topical agents
The following types of topical agents are considered as interven-
tions in this review.
Cadexomer-iodine paste consists of a water-soluble, modiﬁed
starch polymer containing iodine. It releases free iodine when ex-
posed to wound exudate. The free iodine acts as an antiseptic on
the wound surface, and the cadexomer absorbs wound exudate
and encourages de-sloughing. Examples include: Iodosorb (Smith
& Nephew) ointment and powder.
Collagenase-containing ointment is an enzymatic debriding
ointment. Collagenase is thought to digest collagen in necrotic
tissue and to contribute to granulation and epithelialisation (the
ﬁnal stage of wound healing).
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Hydrogels consist of a starch polymer and up to 96% water. They
can absorb wound exudate or rehydrate a wound depending on
the wound moisture levels. Hydrogels are often considered to be
dressings, but are also topical in nature. They are supplied in either
ﬂat sheets, an amorphous hydrogel or as beads. Examples include:
ActiformCool (Activa) and Aquaﬂo (Covidien).
Topical phenytoin is thought to promote wound healing by a
number of mechanisms, including stimulation of ﬁbroblast pro-
liferation, facilitation of collagen deposition and antibacterial ac-
tivity.
Silver sulfadiazine cream is a topical antimicrobial cream that
is used to treat and prevent infection in wounds by damaging
bacterial cell membranes. Examples include Flamazine (Smith &
Nephew) and Silvadene (Pﬁzer).
We did not consider studies evaluating any products containing
growth factors, platelet-rich plasma or other platelet-derived prod-
ucts and colony-stimulating factors.
How the intervention might work
Animal experiments conducted over 40 years ago suggested that
acute wounds healmore quickly when their surfaces are keptmoist
rather than left to dry and scab (Winter 1962; Winter 1963a;
Winter 1963b). A moist environment is thought to provide opti-
mal conditions for the cells involved in the healing process with
faster revascularisation (Dyson 1992), and development of gran-
ulation tissue (Svensjö 2000), as well as allowing autolytic de-
bridement (removal of dead tissue by natural processes), which is
thought to be an important part of the healing pathway (Cardinal
2009).
The desire to maintain a moist wound environment is a key driver
for the use of wound dressings and related topical agents. Whilst a
moist environment at thewound site has been shown to aid the rate
of epithelialisation in superﬁcial wounds, excess moisture at the
wound site can cause maceration (breakdown) of the surrounding
skin (Cutting 2002), and it has also been suggested that dressings
that permit ﬂuid to accumulate might predispose wounds to in-
fection (Hutchinson 1991). Wound treatments vary in their level
of absorbency, so that a very wet wound can be treated with an ab-
sorbent dressing (such as a foam dressing) to draw excess moisture
away and avoid skin damage, whilst a drier wound can be treated
with a more occlusive dressing or a hydrogel to maintain a moist
environment.
Some dressings are now also formulated with an ’active’ ingredient
(e.g. silver, honey or protease modulators).
Why it is important to do this review
Venous leg ulcers are a relatively common type of complex wound
that have a negative impact on people’s lives and incur high costs
for health services and society. Leg ulcers are painful, sometimes
malodorous, prone to infection, and may severely affect people’s
mobility and quality of life, and in severe cases, there is a risk of
limb amputation. There are a number of treatments for venous
leg ulcers, but many ulcers prove hard to heal, although healing is
a key outcome for patients.
We conducted an open consultation with consumers to ask them
which treatments for treating venous leg ulcers they would like to
see considered. Respondents self-selected through their response
to a short questionnaire posted on the Cochrane Wounds website
and Facebook page. Although some identiﬁed compression as the
main consideration, others mentioned speciﬁc types of dressings.
These included many of the dressing types listed in Description
of the intervention, including charcoal-containing (odour-absorb-
ing) dressings, dressings designed to reduce formation and pres-
ence of bioﬁlms (bacteria which grow on a surface to form a ﬁlm
of cells) and dressings with antimicrobial properties and debriding
actions. Also speciﬁcally identiﬁed as being of interest was Unna’s
boot; a specialised dressing which consists of gauze wraps impreg-
nated with zinc oxide and calamine, sometimes in combination
with other agents.
The diversity of dressings and related materials available to health
professionals for treating venous leg ulcers makes evidence-based
decision-making difﬁcult when determining the optimum treat-
ment regimen for a particular patient (NICE 2016a). With in-
creasingly sophisticated technology being applied to wound care,
practitioners need to know the relative effectiveness and cost-effec-
tiveness of these sometimes expensive dressings. Even where cost
is not an issue, the most effective treatment may not be available
(e.g. in some developing countries) or may be difﬁcult or to use,
so that information on the second and third best treatments is
important too (Salanti 2011).
There are a number of existing or ongoing evidence syntheses
on venous leg ulcer treatments, including Cochrane reviews of
different types of dressings or topical treatments (Briggs 2012;
O’Meara 2013; O’Meara 2014; O’Meara 2015; Ribeiro 2013;
Ribeiro 2014; Westby 2016). There are also wider reviews of par-
ticular types of treatment for all wound types which include data
on venous leg ulcers for treatments such as honey, silver, aloe
Vera, and phenytoin (Dat 2012; Jull 2015; Shaw 2007; Vermeulen
2007).Other reviews onnon-healing or chronic ulcers have also in-
cluded a substantial number of relevant trials (Greer 2013; AHRQ
2013), and there are also older general reviews (e.g. Bouza 2005;
O’Donnell 2006).
Guidance drawing on reviews available at the time has also been
published (Robson 2006; SIGN 2010). The SIGN 2010 guide-
line recommended that low-adherent dressings be used routinely
but that alternative dressings (hydrocolloids, alginates or hydro-
gels) may be considered to assist with pain, exudate and slough
respectively. Earlier guidance (Robson 2006), recommended that
maintaining amoist wound environment be prioritised in dressing
choice. Most recently the UK National Institute for Health and
Care Excellence (NICE) issued advice on the use of advanced and
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antimicrobial dressings for chronic wounds including venous leg
ulcers (NICE 2016b). This updated the SIGN 2010 guidance to
include the ﬁndings of the most recent systematic reviews.
However, despite the existence of high-quality recent systematic
reviews, there is insufﬁcient evidence to support the use of any
particular type of advanced or antimicrobial dressing or treatment
as the direct evidence is of low certainty and no network meta-
analysis (NMA) has previously been undertaken in this area. De-
cision-makers currently have to consider the ﬁndings of a plethora
of pairwise randomised controlled trials (RCTs) simultaneously
and to make qualitative judgements across these in the face of un-
certainty, when considering the evidence on dressing use.
NMA is the simultaneous comparison of linked, multiple, com-
peting treatments in a single statistical regression model (Caldwell
2005; Lu 2004; Salanti 2008). NMA utilises evidence from both
’direct’ (head-to-head or ’pairwise’) comparisons (e.g. trials directly
comparing treatments A and B) and ’indirect’ comparisons (e.g.
the combination of trials comparing A with C and trials compar-
ing B with C). If both direct and indirect estimates are available,
they can be meta-analysed, preserving within-trial randomisation
(Grant 2013; Thorlund 2012; Tu 2012).
Where there are relevant common comparators, NMA produces a
set of effect estimates for each treatment linked into the network,
relative to every other, whether or not they have been compared in
head-to-head trials: thus, NMA is a method of obtaining estimates
for comparisons for which there is no (direct) trial evidence. Even
when direct evidence is available there may not be much of it,
so pooling it with data from indirect comparisons generally gives
more robust evidence and reduces uncertainty in the estimates of
effect (Higgins 1996; Thorlund 2012). It is also possible to cal-
culate the probability of one treatment being the best for a spe-
ciﬁc outcome, reﬂecting the precision surrounding the estimates
(Caldwell 2014; Salanti 2011).
A glossary of NMA terms is given in Appendix 1.
This review comprised a network meta-analysis (NMA) for the
outcome of venous leg ulcer healing, for alternative dressings and
topical agents for the treatment of venous leg ulcers. We drew on
methods previously used in related work (Soares 2014; Westby
2017). The NMA was expected to enable us to determine which
(if any) dressing or topical agent is the most effective for healing
venous leg ulcers, taking into account direct and indirect evidence
simultaneously. We also presented uncertainty around treatment
estimates, and explored assumptions being made in the analysis.
O B J E C T I V E S
To assess the effects of (1) dressings and (2) topical agents for heal-
ing venous leg ulcers in any care setting and to rank treatments in
order of effectiveness, with assessment of uncertainty and evidence
quality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published and unpublished randomised controlled
trials (RCTs), irrespective of language of report. We only included
cross-over trials that reported outcome data at the end of the ﬁrst
treatment period and prior to cross-over. We excluded studies us-
ing quasi-random methods of allocation (such as alternation). We
highlighted trials in which three or more interventions were ran-
domised and included all relevant arms.
Types of participants
We included trials recruiting adults (aged at least 18 years) de-
scribed as having venous leg ulcers, managed in any setting. We
accepted study authors’ deﬁnitions of venous leg ulcers. Where
wounds were described only as “leg ulcers” without information
as to aetiology, we assumed that they were venous in origin. Trials
in which a minority of leg ulcers are described as having a mixed
or arterial pathology were included provided that these were fewer
than 25% of participants. Trials including other types of mixed
wound populations were not included. We included participants
at any stage of their treatment process - for example, participants
with or without ulcers described as being hard to heal or clinically
infected.
Types of interventions
The interventions evaluated are all those that can be directly ap-
plied as dressings or topical agents to open venous leg ulcers. We
presented results for these interventions and included them in
summary tables. In the context of a network of competing treat-
ments, there are no ’comparators’. We used the term ’comparison’
tomean two interventions compared in a single study and the term
’contrast’ to mean two interventions compared across all studies
with that comparison. A contrast may be represented by a single
study, a simple direct meta-analysis or by the NMA.
We considered trials for which at least one of the interventions was
(1) any dressing, including impregnated dressings or saline-moist-
ened dressings or combination dressings*, or (2) any topical agent
applied directly to an open venous leg ulcer and left in situ. The
treatment of interest had to be the only systematic difference be-
tween treatment groups. We did not take into account secondary
dressings. We also considered ’no dressing’ as a valid intervention,
where the wound is left open/covered only by compression ban-
daging.
* ’combination dressings’ means two or more dressings applied
sequentially over time (e.g. hydrocolloid for four weeks followed
by alginate for four weeks), or a product containing two or more
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types of dressing material (e.g. a multilayer product comprising
silicone polymer and hydrocolloid).
Some of the interventions we considered are as follows; we used
the categories listed below as the basis for grouping the treatments
used in individual studies:
• basic wound contact dressings (includes low-adherence
(including parafﬁn gauze) or absorbent dressings (of any
absorbency));
• saline-moistened gauze (all degrees of moistness);
• hydrogel dressing (includes hydrogel sheet or hydrogel
application (amorphous) or sodium hyaluronate);
• vapour-permeable ﬁlms and membranes (includes adhesive
ﬁlm (semi-permeable) or adhesive ﬁlm with absorbent pad);
• soft polymer dressings (with/without absorbent pad or
cellulose);
• hydrocolloid dressing (with/without adhesive border or
matrix hydrocolloid);
• ﬁbrous (spun) hydrocolloid;
• foam dressings (all absorbencies);
• alginate dressings;
• capillary action dressings;
• alginate dressing with charcoal;
• other charcoal-containing dressing;
• honey sheet dressing or topical honey;
• cadexomer Iodine ointments;
• iodine-containing dressings;
• soft polymer dressing (with silver);
• hydrocolloid (with silver);
• foam dressings (with silver);
• alginate dressings (with silver);
• silver sulfadiazine (SSD) cream;
• protease-modulating matrix (PMM) dressings;
• collagenase-containing ointment;
• topical phenytoin;
• topical zinc oxide;
• no dressing (wound left exposed); and
• other treatments considered by the review team (with
additional clinical advice where required) to be dressings or
topical agents applied directly to the wound and left in situ.
The following interventions were excluded from evaluation: treat-
ments in which dressings were attached to external devices such
as negative pressure wound therapies, skin grafts, growth factor
treatments, platelet gels and larval therapy. We also excluded in-
terventions which, although topical, are not delivered as a physical
presence (liquid or solid) on the wound surface such as oxygen,
ultrasound, laser or radiant heat therapies. These treatments were
considered to be outside the scope of a review focused on dressings
and topical treatments used in place of dressings. Where studies
compared an eligible with an ineligible intervention we included
them if they usefully linked the network of studies evaluating two
eligible treatments. Data from these linking studies were fully ex-
tracted and they were assessed for risk of bias. Studies which eval-
uated only one eligible intervention and did not perform this link-
ing function were treated as excluded studies and are clearly iden-
tiﬁed in the list of excluded studies (Characteristics of excluded
studies). Where studies used a placebo comparator for an eligible
intervention, we included them and treated the placebo as being
the vehicle used to deliver it; for example as an emollient cream,
an inactive powder or a hydrogel. For example, a comparison of a
cream containing an antibiotic with a placebo would be treated as
a comparison of topical antibiotic with an emollient cream.
We grouped together dressings in the same class, for example,
all hydrocolloid dressings were grouped together regardless of
whether they were adhesive or non-adhesive (BNF 2016). This
grouping was regardless of a particular brand’s stated absorbency,
size, concentration of active component or degree of moistness.
Thus, where studies only compared two dressings from the same
class (for example, two alginates or two foam dressings), we ex-
cluded them from the review as they contributed no information
about the effectiveness of the class. We considered an impregnated
dressing to be in a different class from a non-impregnated dress-
ing. Judgements about whether particular dressings belonged to
the same class were made on the basis of British National Formu-
lary (BNF) classiﬁcations (BNF 2016), and clinical expert advice
where there was remaining uncertainty. Evidence from compar-
isons between dressings of the same class can be found in the indi-
vidual Cochrane reviews of particular types of dressings. Trials of
this type are also identiﬁed as such in the list of excluded studies.
We anticipated that the great majority of participants would be
treated with concurrent compression therapy and noted the type
of compression therapy used. We also included any RCT in which
other concurrent therapies were given (e.g. antibiotics, debride-
ment), provided that these treatments were delivered in a stan-
dardised way across the trial arms of the individual trial (such that
the treatment of interest is the only systematic difference). We
did not treat separately comparisons with and without concurrent
therapies, that is, we considered intervention 1 + concurrent ther-
apy versus intervention 2 + concurrent therapy to be the same as
intervention 1 versus intervention 2.
We assumed that the interventions are exchangeable, that is, par-
ticipants in the network could, in principle, be randomised to
any of the treatments being compared. For example, that a person
with a venous leg ulcer could be equally likely to be randomised
to a silver dressing, a polyurethane foam dressing, honey or saline
gauze. Depending on the wound requirements for the dressing
(e.g. highly absorbent), this may not always be a good assumption
for individual wounds, but may be reasonable across the popula-
tion in the trials.
Types of outcome measures
We reported outcome measures at the last time point available
(assumed to be at the end of follow-up if not speciﬁed) and the
time point speciﬁed in the methods as being of primary interest
(if this was different from latest time point available). Initially,
12Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
we noted when studies reported results at other time points, or
whether they included Kaplan-Meier plots, or both.
Primary outcomes
The primary outcome for this review is complete wound healing.
We regarded the following as providing themost relevantmeasures
of outcome for the analyses:
• the proportion of wounds healed (frequency of complete
healing: arm-level data);
• time to complete healing (survival data: study-level data
reported as a hazard ratio (HR) with standard error (SE)).
We accepted the authors’ deﬁnitions of what constitutes a healed
wound.
Secondary outcomes
We did not consider any secondary outcomes here, however they
are considered in other relevant reviews (Briggs 2012; O’Meara
2013; O’Meara 2014; O’Meara 2015;Westby 2016) and ongoing
reviews (Ribeiro 2013; Ribeiro 2014).
Search methods for identification of studies
Electronic searches
We searched the following electronic databases to identify reports
of relevant randomised clinical trials:
• Cochrane Wounds Specialised Register (searched 29 March
2017);
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 2) (searched 29 March 2017);
• Ovid MEDLINE (1946 to 29 March 2017);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations, to 29 March 2017);
• Ovid Embase (1974 to 29 March 2017);
• EBSCO CINAHL Plus (1937 to 29 March 2017).
The search strategies for the Cochrane Wounds Specialised Reg-
ister, CENTRAL, Ovid MEDLINE, Ovid Embase and EBSCO
CINAHL Plus can be found in Appendix 2. We combined
the Ovid MEDLINE search with the Cochrane Highly Sensi-
tive Search Strategy for identifying randomised trials in MED-
LINE: sensitivity- and precision-maximising version (2008 re-
vision) (Lefebvre 2011). We combined the Embase search with
the Ovid Embase ﬁlter developed by the UK Cochrane Centre
(Lefebvre 2011). We combined the CINAHL searches with the
trial ﬁlters developed by the Scottish Intercollegiate Guidelines
Network (SIGN 2018). There were no restrictions with respect to
language, date of publication or study setting.
An updated searchwas conducted on 16March 2018; these results
have been added to Studies awaiting classiﬁcation and Ongoing
studies, andwill be incorporated into the review at the next update.
Searching other resources
We tried to identify other potentially eligible trials or ancillary
publications by searching the reference lists of retrieved included
studies as well as relevant systematic reviews, meta-analyses, guide-
lines and health technology assessment reports. We used any ad-
ditional unpublished data for included studies obtained by pre-
vious reviews, contacting review authors where appropriate, and
undertook cross-checking to ensure that all relevant studies with
evaluable outcome data were included.
Data collection and analysis
Data collection and analysis were carried out according tomethods
stated in the publishedprotocol (Norman 2017), whichwere based
on the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a).
Selection of studies
Two review authors independently assessed the titles and abstracts
of the citations retrieved by the searches for relevance. After this
initial assessment, we obtained full-text copies of all studies consid-
ered to be potentially relevant. Two review authors independently
checked the full papers for eligibility; disagreements were resolved
by discussion and, where required, the input of a third review au-
thor. Where required and possible, we attempted to contact study
authors where the eligibility of a study was unclear. We recorded
all reasons for exclusion of studies for which we had obtained full-
text copies. We completed a PRISMA ﬂowchart to summarise this
process (Liberati 2009).
Where studies were reported in multiple publications/reports we
sought to obtain all publications. Whilst the study was included
only once in the review, we extracted data from all reports to ensure
maximal relevant data were obtained.
Data extraction and management
We extracted the following information from each included study:
• interventions being compared, including any ineligible
interventions randomised to additional trial groups;
• duration of the intervention;
• details of any co-interventions;
• unit of randomisation (e.g. participant or ulcer);
• number of ulcers per person;
• unit of analysis (including any selection methods for people
with multiple ulcers);
• number of participants in each arm;
13Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• hazard ratio (HR) and its 95% conﬁdence interval (CI) (or
any data that will allow its calculation (Parmar 1998; Tierney
2007)) for comparisons between arms);
• number of participants who healed in each arm, both at the
latest time point and (if different) at another time speciﬁed as of
primary interest in the study’s methods section;
• all other follow-up times reported;
• if a Kaplan Meier plot is displayed;
• missing data rates per arm, and reasons for ’missingness’,
including the number of people dying.
Data on potential effect modifiers
We are not aware of any population-speciﬁc effect modiﬁers for
this research question: there is no existing evidence to suggest
that one type of dressing works better than another for certain
subgroups, such as different baseline ulcer characteristics (e.g. size
and duration of ulcer), although it may be the case that some
dressings are evaluated only in particular groups (e.g. those classed
as having ’hard-to-heal’ ulcers).
However, we extracted from each included study data that may
act as effect modiﬁers (in this context):
• type of funding (e.g. industry, academic, government); this
was grouped into not-for-proﬁt and other where reported;
• risk of bias; this was classed as low or unclear, high or very
high.
We did not give more weight to any individual domains of the
’Risk of bias’ assessment.
Other data
We also extracted the following baseline and study data, reporting
separately for each intervention arm if possible:
• care setting;
• age of participants;
• duration of leg ulcer(s);
• size of venous leg ulcer(s) (area/volume);
• wound status (e.g. sloughy, necrotic, infected, ’hard-to-
heal’).
Assessment of risk of bias in included studies
We assessed risk of bias for each included study, and calculated
separately the overall risk of bias for each direct pairwise meta-
analysis for the complete healing data. Two review authors inde-
pendently assessed included studies using the Cochrane tool for
assessing risk of bias (Higgins 2011b); a third review author was
consulted where consensus could not be reached. The Cochrane
risk of bias tool addresses six speciﬁc domains: sequence genera-
tion, allocation concealment, blinding of outcome assessors, in-
complete outcome data, selective outcome reporting and other is-
sues (Appendix 3). We then summarised data for the key biases
reﬂected by these domains: selection bias, detection bias, attrition
bias, reporting bias and other bias. We also noted the comparabil-
ity of participant characteristics at baseline across the two groups,
including whether an adjusted analysis was conducted. We used
these data to help inform decisions on the risk of selection bias. For
the category of “other bias” we paid particular attention to unit of
analysis errors since they are highly prevalent in wounds research.
We recorded all problems of unit of analysis, for example, where
participants with multiple wounds were randomised and each of
their wounds contributed outcome data.
We interpreted the overall risk of bias for each contrast of the
network meta-analysis, drawing on both indirect and direct data
(see the section on Quality Assessment of Evidence (GRADE
2013), below).
Overall risk of bias and linking to GRADE assessment
In order to link these Cochrane risk of bias ratings to the GRADE
assessment for study limitations (downgrading 0, 1 or 2 times),
we used a two-stage process. Firstly, we obtained an all-domain
(overall) risk of bias classiﬁcation for each study and then we used
this to produce an overall risk of bias for each contrast.
All-domain risk of bias for each study
We summarised data for each of the key domains of selection bias,
detection bias, attrition bias, reporting bias and other bias, assign-
ing one of four ratings: low, unclear, high and very high. For ex-
ample, selection bias was informed by sequence generation, allo-
cation concealment and comparability of baseline characteristics.
In an adaption of the GRADE approach (Guyatt 2011), we pro-
duced an all-domain risk of bias, with four ratings deﬁned as:
• ’very high’ - two or more key domains with a high risk of
bias or a single domain with very high levels of uncertainty (e.g.
very high degree of differential missing data);
• ’high’ - high risk of bias for any one domain or ’almost high’
risk of bias across more than one domain;
• ’low’ - low risk of bias for each of the key domains;
• ’unclear’ - insufﬁcient information for at least one key
domain (with the other domains being at low risk of bias).
We included this all-domain risk of bias in the summary ’Risk
of bias’ ﬁgure, by adding additional columns to the ’Risk of bias’
ﬁgure for each study. For the purposes of the GRADE assessment,
we then grouped together studies with low and unclear all-domain
risks of bias.
Overall risk of bias for a direct comparison (the comparison
of two intervention in one or more trials)
Where a single study contributed to a comparison, the overall risk
of bias was that of the all-domain risk of bias assigned to that study.
Where more than one study contributed to a comparison, we as-
signed an overall comparison risk of bias by calculating a weighted
average based on the inverse variance-derived weights from the
14Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
meta-analysis, and using this in conjunction with the overall risk
of bias (where numerical values were assigned to the all-domain
ratings for each study: low/unclear (1), high (2) and very high (3)).
We aligned comparison ’Risk of bias’ assessment with the GRADE
categories of no limitations (not downgraded for risk of bias), se-
rious limitations (downgraded once), and very serious limitations
(downgraded twice) (Guyatt 2011; Salanti 2014). We presented
the overall risk of bias associated with each direct estimate in a
network diagram using colours to represent different ratings.
Overall risk of bias in the network
Each direct contrast in the network contributed differently to the
estimation of each NMA summary effect (each NMA compar-
ison). The contribution of each piece of indirect evidence to a
mixed treatment contrast depends on its point estimate, precision
and relative location within the network, and on that of any di-
rect evidence or other indirect evidence (Chaimani 2013; Salanti
2014). A recently published tool, Krahn 2013, allows the contri-
bution of each direct estimate to be determined for each contrast
in the network informed by mixed evidence (direct and indirect),
or when multiple loops of indirect evidence inform the same link.
We used the CINeMA web tool (CINeMA 2017) to calculate the
percentage contribution of each direct contrast to each network
estimate. The overall risk of bias for each NMA comparison es-
timate is a composite measure of the risks of bias for all the di-
rect contrasts contributing to that NMA comparison and was de-
termined by calculating a weighted average risk of bias using the
percentage contributions and the all-domain risks of bias for all
the direct contrasts. We acknowledge that this approach returns
approximate weights.
Measures of treatment effect
Relative treatment effects
Wewere not able to calculate the hazard ratio (HR) for themajority
of studies, and therefore presented the risk ratio (RR) (95%CI) for
the proportion of people healed. In order to conduct these analyses
(see Data synthesis), we used outcome data reported in individual
studies, as raw data at the latest time point, unless otherwise stated.
If there had been sufﬁcient data, we had planned to calculate the
HR with 95% CI and to model time-to-event data.
Unit of analysis issues
We expected themain unit of analysis issues to occur when partici-
pants hadmore than one wound per person.We treated the partic-
ipant as the unit of analysis when the number of wounds assessed
appeared equal to the number of participants (e.g. one wound
per person). This included studies in which participants were ran-
domised to treatments and there was more than one wound per
person, but results were reported for one selected wound; we con-
sidered whether there was risk of bias in the selection process.
Where studies randomised at the participant level, we used the
allocated treatment on multiple wounds per participant, and mea-
sured and analysed outcomes at the wound level, (e.g. wound heal-
ing), there were unit of analysis issues if the data were not cor-
rectly analysed. In these cases, we assessed whether it was possible
and appropriate to approximate the correct analyses in accordance
with Chapter 16 of the Cochrane Handbook for Systematic Reviews
of Interventions, using information adapted from Higgins 2011c.
Where this was not possible, we made a decision about inclusion
of data in the analysis, and recorded these studies as being at high
risk of bias if the number of participants and the mean number of
wounds per person were judged to warrant this.
If cluster-randomised trials had been identiﬁed, we would have
decided the analytical approach based on the type and volume of
cluster data. We accounted for the correlation between the effect
sizes from multi-arm studies in the analysis.
Dealing with missing data
It is common to have data missing from trial reports. Excluding
participants post-randomisation, or ignoring those participants
who withdraw from the trial or are lost to follow-up, compro-
mises the randomisation and potentially introduces bias into the
trial. Where there were missing data for the primary outcome of
proportion of ulcers healed, we assumed participants did not have
the outcome (i.e. they will be considered in the denominator but
not the numerator). We considered examining this assumption
in a sensitivity analysis but decided this was not necessary given
the small numbers of trials with differences in attrition between
treatment groups.
Assessment of heterogeneity
Assessment of clinical and methodological heterogeneity
within treatment comparisons
We assessed the presence of clinical heterogeneity within each pair-
wise comparison (i.e. the degree to which studies vary in terms of
participant, intervention and outcome characteristics) by compar-
ing data extracted for included studies. We focused on key vari-
ables that are potential effect modiﬁers, such as whether studies
were at high risk of bias in key domains and the source of funding
for the study. We also considered the generalisability of our ﬁnd-
ings with reference to participant characteristics such as ulcer size
and duration.
Assessment of transitivity across treatment comparisons
’Transitivity’ refers to the situation in which an intervention effect
measured using an indirect comparison is valid and equivalent to
the intervention effect measured using a direct comparison. Thus,
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where there are differences in effect modiﬁers across comparisons,
the transitivity assumption may not be met and there will be in-
consistency in the network (Grant 2013; Jansen 2013). We did
not identify any potential effect modiﬁers from the literature, and
therefore had to assume that there is transitivity with respect to
known effect modiﬁers across the pairwise comparisons. There are
also limited underlying theoretical reasons to consider effect mod-
iﬁcation for these treatments - however, in preparing the network
we explored the effect of differences in risk of bias as possible effect
modiﬁers across the network.We investigated inconsistency in the
network (see Data synthesis).
We had also planned to investigate the effect of funding source as a
potential effectmodiﬁer.However althoughmany studies reported
funding by a manufacturer of one of the assessed interventions, a
substantial number of studies did not report the funding source.
Only a minority of trials clearly reported a third sector or public
funding source; a much smaller number reported non-industry
funding or a mixture of industry and non-industry sources. In
view of this imbalance and the high level of uncertainty around
trials which did not report funding sources we did not attempt
this analysis.
Assessment of reporting biases
We assessed the presence of reporting bias using a contour-en-
hanced funnel plot, (Peters 2008; Salanti 2014).
Data synthesis
General methods
We performed pairwise meta-analyses in a frequentist framework
using the statistical software STATA 13 (STATA 2011; Salanti
2014). Experience (Westby 2017) suggested that there were likely
to be insufﬁcient data for us tomodel the impact of follow-updura-
tion on estimates of effect. We therefore conducted analyses based
on binary data, analysed using risk ratios (RRs). We had planned
to extract or calculate HRs where possible using established meth-
ods (Parmar 1998; Tierney 2007), and would have considered
modelling the hazard function (Dias 2014; Soares 2014) using
WINBUGS (WinBUGS 2016). However, there were insufﬁcient
HR data.
We used STATA 13 (STATA 2011) to calculate the contribu-
tions matrix for the network and used the results of this together
with the evaluation of risk of bias (see Assessment of risk of bias
in included studies) to inform a GRADE evaluation for the en-
tire network (Salanti 2014). We summarised the ﬁndings accord-
ing to GRADE principles (GRADE 2013; Schünemann 2011a;
Schünemann 2011b). Where there were zero events in any trial
arm, we followed the general approach taken by STATA and added
0.5 to the numerator and 1 to the denominator for each arm in
the trial.
Methods for standard meta-analysis
We performed pairwise meta-analyses in a frequentist framework
using Review Manager 5 (RevMan 2014) or STATA 13 (STATA
2011) as appropriate, using inverse variance weighting and a ran-
dom-effects model, and only analysing trials reporting that pair-
wise comparison. We also presented the data for these direct com-
parisons from the network in forest plots (Schünemann 2011a);
for reasons of space we did not present all possible comparisons.
While we report treatment effects for all data (see appendices), we
focus on discussing selected comparisons chosen for their clinical
relevance.
Methods for network meta-analysis
We used STATA 13 to produce a network diagram based on all
included studies in order to inform the analysis plan (Chaimani
2013). We excluded from the analysis two-arm studies in which
one of the interventions could be described as ’standard care’ or
’mixed care’. These are treatment arms where the ’intervention’
involves the choice of more than one treatment: they are unlikely
to be consistently applied. We had anticipated that such interven-
tions might have been acceptable for a grouped sensitivity analysis
(see section on Sensitivity analysis), but experience (Westby 2017)
led us to conclude that this was unlikely to be informative; such
studies are therefore summarised in Appendix 4, but not consid-
ered further. We also excluded from the main analysis studies that
had one intervention of direct interest (e.g. hydrocolloid) com-
pared with one ineligible intervention (e.g. ultrasound), unless we
found, after examining the network diagram, that the ineligible
intervention linked two or more interventions of direct interest;
such interventions were included in a sensitivity analysis looking
at an expanded base-case.
We performed multivariable network meta-analysis using STATA
13. We used the ’mvmeta’ command and adopted a random-ef-
fects approach and a consistency model.We used per-arm data (see
Data extraction and management) throughout. The STATA rou-
tine took into account correlations between the effect sizes from
multi-arm studies. The NMA results were reported for all ’mixed
treatment contrasts’, whichmeans themeta-analysis involved both
direct evidence and indirect evidence from across the whole net-
work. The output was reported as pooled RRs, with their 95%
CIs. If there were sufﬁcient data we had also planned to perform an
analysis of time-to-event data using the log HR with its standard
error (SE).
We carried out analyses for network comparisons (where indirect
evidence alone, or both direct and indirect evidence contributes) in
a frequentist framework as above. Where required, we accounted
for correlations induced by multi-arm studies. We also presented
the data in forest plots.
We obtained a treatment hierarchy using the surface under the cu-
mulative ranking curve (SUCRA) and mean ranks (Salanti 2011)
for each treatment. Both these measures are based on an assess-
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ment of the probability of each treatment being best, second best,
etc. in terms of being the most likely to heal venous leg ulcers
(when compared with all other evaluated treatments).We used the
STATA methods described by Chaimani 2013.
We had planned to present two different networks: one for indi-
vidual treatments and a sensitivity analysis in which interventions
were grouped in broader clinically relevant categories. In practice,
there were many different dressings and a wide range of topical
agents too, and we decided, post-hoc, to restrict the main analysis
to treatments that were considered most important and widely
used. Selection of treatments for analysis was decided by two re-
view authors working independently, with guidance from a clinical
review author who had not seen the data.This set of interventions
was termed the ’base-case network’.
Interventions which were considered in the base-case were: al-
ginate, cadexomer iodine, ﬁlm, foam, gentian violet, hyaluronic
acid, hyaluronic-acidwith povidone iodine, hydrocolloid, hydroﬁ-
bre, hydrogel, ibuprofen-releasing foam, nonadherent, octenidine,
paste bandage, saline gauze, phenytoin, povidone iodine, protease-
modulatingmatrix (PMM), PMMsilver, silver sulfadiazine (SSD),
sucralfate, silver and zinc oxide. Only one of these - phenytoin
- could not subsequently be joined into the network. Sensitivity
analyses explored the impact of extending the number of treat-
ments included or further restricting it (see Sensitivity analysis).
Comparisons of two eligible interventions not joined into the
network remained in the review and we reported the direct evi-
dence.These included comparisons between a speciﬁed interven-
tion such as cadexomer iodine, silver or honey and “standard care”
as well as comparisons between two individual interventionswhere
one or both were only partly relevant to the network or could not
be joined to the network.
There was a very large number of contrasts in the NMA and we
decided to focus our reporting of the analysis ﬁrstly on results for
the network as a whole, and then in the ’Summary of ﬁndings’ ta-
ble to report the treatment effect data for some speciﬁc treatment
comparisons. This was done in order to maximise the clinical util-
ity of the NMA and the accessibility of the review. We decided,
post-hoc to focus on the two treatments with the highest probabil-
ities for being one of the best treatments and to examine in detail
the results of their comparisons with three of the most common
and widely used treatments (foam, hydrocolloid and nonadherent
dressings). The results for all contrasts are also shown in forest
plots.
Subgroup analysis and investigation of heterogeneity
Assessment of statistical heterogeneity
We assessed the presence of heterogeneity within each pairwise
comparison using the I² statistic that measures the percentage of
variability that cannot be attributed to random error (Higgins
2003). We also took into account the overlap of conﬁdence inter-
vals and the variability in the point estimates. We regarded effect
estimates where an I² was less than 50% as having low levels of
heterogeneity, given the potential for wide conﬁdence intervals in
pairwise comparisons within a network, which we had anticipated
may be sparse.
Assessment of statistical inconsistency
We assessed inconsistency in two main ways: determining local
inconsistencies (around particular contrasts in the network) and
assessing inconsistency for the network as a whole. These tests are
often underpowered so we carried out the assessment using the
90% signiﬁcance level.
Local approaches to evaluating inconsistency
To evaluate the presence of inconsistency locally we used twomain
approaches. Firstly, we considered a loop-speciﬁc approach. This
method evaluates the consistency assumption in each closed loop
of the network separately as the difference between direct and indi-
rect estimates for a speciﬁc comparison in the loop (inconsistency
factor, IF). Then, the magnitude of the inconsistency factors and
their 90% CIs can be used to make inferences about the presence
of inconsistency in each loop.We assumed a common heterogene-
ity estimate within each loop.
Secondly, we considered a ’node splitting’ approach (Dias 2010;
Salanti 2014). Thismethod was applied, singly, to each direct con-
trast (called a ’node’ by Dias 2010). A STATA routine was used
to calculate an indirect estimate using the rest of the network,
by running the NMA after excluding the direct evidence for that
contrast. The indirect estimates were then compared with the re-
spective direct estimates.
For both approaches a ratio of risk ratios (RoRR) with its 90%
CI was calculated for each contrast. If the CI excluded 1, there is
statistically signiﬁcant inconsistency. We also considered whether
the CI included 2 or more (or 0.5 or less). This would mean that
the direct estimate could be twice as large (or half as big) as the
indirect estimate, which is an indication of potential inconsistency
(Chaimani 2013).
Where we detected serious inconsistency, either in the direct evi-
dence or between the direct and indirect evidence for a contrast,
we downgraded the evidence for that contrast.
Global approaches to evaluating inconsistency
We evaluated consistency in the entire network simultaneously,
by extending the analysis to include an inconsistency model that
omits consistency equations (Dias 2013). This used a design-by-
treatment interaction model, which allows for different trial de-
signs (Higgins 2012; White 2012). This approach produced a set
of inconsistency parameters. After ﬁtting the inconsistency model
we tested the null hypothesis of consistency by globally testing the
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set of inconsistency parameters using a global Wald test. This test
may lack power and we considered a signiﬁcance level of P < 0.1.
Inconsistency in the entire network was considered a reason for
downgrading the certainty of the evidence which the network, as
a whole, represented.
Investigation of heterogeneity and inconsistency
Where sufﬁcient studies were available, we planned to perform
network meta-regression (data permitting) or subgroup analyses
using funding source and risk of bias as possible sources of in-
consistency or heterogeneity, or both. In the event we were able
to perform an analysis using risk of bias as a possible source of
heterogeneity.
Sensitivity analysis
We re-analysed the network with studies removed if they were
considered to be at high risk of bias for any one ormore of selection,
attrition or detection bias (Appendix 3).
We considered a sensitivity analysis to assess the possible impact
of missing outcome data on the network estimates, via assessment
of risk of attrition bias (as deﬁned in Appendix 3), testing the
assumption of imputation of no event for missing data.
Where one or more studies were clearly outliers (i.e. in terms of
direction or size of relative treatment effect, or both, or as ﬂagged
in inconsistency testing), we had planned to conduct a sensitivity
analysis where the study was removed from the network, as long
as the network was still analysable; in the event we did not need
to do this.
We had planned to conduct a sensitivity analysis, in which dress-
ings interventions were grouped in broader categories, with clini-
cal guidance, but this was not conducted. Instead, we conducted
two post-hoc sensitivity analyses for the base-case network: one
restricted the dataset to a narrower set of clinically appropriate in-
terventions; the other included additional treatments outside the
base-case, which reinforced the network with more links. The re-
duced network excluded the following interventions which were
included in the base-case: gentian violet, hyaluronic-acid with
povidone iodine, ibuprofen-releasing foam, octenidine, phenytoin
and sucralfate. The expanded base-case added nine trials and the
following supplementary interventions to the base-case decision
set: blood product (non-eligible intervention); emollient cream;
and growth factor (non-eligible intervention). We conducted this
sensitivity analysis to investigate the impact of strengthening the
network through indirect evidence provided by comparisons of
key decision set interventions such as saline gauze and hydrogel
with these supplementary interventions.
Quality assessment of evidence (GRADE) generated
from the network meta-analysis (NMA)
We summarised the ﬁndings according to GRADE principles
(Schünemann 2011a; Schünemann 2011b). The quality and cer-
tainty of the data included in any synthesis model are key to deter-
mining the validity of the results and of inferences made. We ex-
plored the application of GRADE methodology to NMA, focus-
ing on the approach of Salanti 2014. We assessed evidence quality
in twomain ways, for each contrast and separately, for the network
as a whole, in order to assess the quality of the ranking order. We
assessed individual GRADE factors as follows.
• Risk of bias: contributions for each particular contrast were
considered, and used to assess the overall risk of bias for that
contrast. We assessed overall risk of bias per contrast and also for
the network as a whole (see Assessment of risk of bias in included
studies).
• Indirectness: this was assessed as without limitations
because we did not identify any effect modiﬁers.
• Inconsistency: at the level of the contrast, we considered
both heterogeneity in the direct evidence for that comparison
and inconsistency related to different routes of analysis for the
comparison (e.g. direct versus indirect evidence). We noted that
inconsistency can only be assessed where there is both direct and
indirect evidence. GRADE inconsistency was assessed as a
serious limitation if there was heterogeneity in the direct estimate
or inconsistency in the network with respect to that comparison.
Very serious limitations were attributed to the comparison if
there was severe heterogeneity or severe inconsistency or
limitations with both heterogeneity and inconsistency. At the
level of the network, we considered the global Wald test for
inconsistency (see Data synthesis; Assessment of heterogeneity).
Tests of this nature are typically underpowered, so a P value less
than 0.1 was considered signiﬁcant. Additionally, if several
contrasts showed direct and indirect results that would have led
to different clinical decisions, we considered inconsistency to be
present.
• Imprecision: at the level of the contrast, we assessed
imprecision for each pairwise comparison using the GRADE
default minimally important difference (MID) values of 1.25
and 0.75 for the RR. For contrasts that were not part of the
’core’ of the network, we also took into account the number of
events informing the direct evidence and considered it in relation
to the optimal information size. At the level of the network, we
assessed the overlap of the rankograms and the magnitude of the
SUCRA estimates.
• Publication bias: was assessed for each pairwise comparison
using standard GRADE (where there were 10 or more studies);
we used contour-enhanced funnel plots where appropriate to
examine publication bias in the network as a whole.
’Summary of Findings’ tables
We presented the main results of the review in a ’Summary of
ﬁndings’ table, reporting the results for a representative set of con-
trasts, with one row for each contrast. We focused on interven-
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tions which the SUCRA suggested were likely to be high ranked
and the comparisons between these and commonly-used types of
intervention. This table presents key information concerning the
certainty of the evidence, the magnitude of the effects for the con-
trasts examined, and the sum of the available data (Schnemann
2011a). The ’Summary of ﬁndings’ table also includes an overall
grading of the evidence using the GRADE approach.
For calculating absolute risk differences for the probability of heal-
ing we used a ’control group risk’, calculated as the median of
the risks for the comparator across all direct evidence studies with
these comparators.
R E S U L T S
Description of studies
Results of the search
Electronic searches identiﬁed 1836 records after deduplication. Of
these, we excluded 1024 after initial screening of title and abstract.
Full-text screening of 812 records led to the identiﬁcation of 127
relevant reports of 78 studies (see Figure 1).
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Figure 1. Study flow diagram.
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We included studies that compared two eligible interventions (see
criteria for inclusion - interventions (Types of interventions). We
also included studies that assessed only one eligible intervention,
but which provided linking for the network of eligible studies.
Therefore there were three types of included study:
• studies which compared two eligible interventions and
which were included in the NMA;
• studies which compared two eligible interventions but
which could not be joined into the NMA;
• studies which compared an eligible intervention with one
or more ineligible interventions but which strengthened the
network by linking other two or more eligible interventions.
A total of 78 studies with 7014 randomised participants was in-
cluded in one or more of these categories.
Anupdated search inMarch 2018 retrieved 100 additional records.
Of these 23 required consideration in detail. Two records were
added as additional publications to studies already identiﬁed as
excluded studies in the review. Ten studies (11 records) could be
clearly excluded (see excluded studies) and nine studies were added
to Studies awaiting classiﬁcation. One study was added to ongoing
studies (see Characteristics of ongoing studies).
Included studies
There were 47 studies that we joined into the network with two
relevant interventions as outlined in Data synthesis: (Armstrong
1997; Backhouse 1987; Banerjee 1997; Blair 1988a; Blair 1988b;
Bowszyc 1995; Brandrup 1990; Callam 1992; Casoni 2002;
Charles 2002; Dimakakos 2009; Fogh 2012; Gottrup 2008;
Hanft 2006; Hansson 1998; Harding 2001; Humbert 2013; Ivins
2006; Jørgensen 2005;Kelechi2012;Kucharzewski 2013; Lanzara
2008; Leaper 1991; Meaume 2012; Meredith 1988; Moffatt
1992a; Moffatt 1992b; Nelson 2007; Norkus 2005; Ohlsson
1994; Ormiston 1985; Petkov 1997; Romanelli 2015a; Rubin
1990; Schulze 2001; Scurr 1994; Senet 2014; Smith 1992; Smith
1994; Sopata 2016; Stacey 2000; Taddeucci 2004; Thomas 1997;
Tumino 2008; Vanscheidt 2012; Vin 2002; Zuccarelli 1992).
A further 13 studies (Alvarez 2012; Beckert 2006; Bishop 1992;
Caprio 1992; De Araujo 2016; Dereure 2012a; Greguric 1994;
Luiza 2015; Kalis 1993; Moss 1987; Romero-Cerecero 2012;
Solovastru 2015; Tarvainen 1988), all assessed comparisons be-
tween two eligible treatments, which could be linked to the net-
work but where one or both interventions was considered to be
only partly relevant and therefore only the direct evidence was
considered, or the trial was included only in a sensitivity analy-
sis. These interventions included dextranomer, A. Pinchinsensis ex-
tract, ozonated oil, shale oil, papain, magnesium sulphate and cel-
lulose. Summaries of these comparisons are provided in Appendix
4.
There were a number of studies that evaluated relevant interven-
tions but which could we could not connect into the network.
This included the following studies that compared a particular
treatment with ’standard care’ (which was either not speciﬁed
or included a range of different dressings or topical treatments):
Arnold 1994; Brown 2014; Jull 2008; Harcup 1986; Lindsay
1986; Michaels 2009; Steele 1986. Other studies not joined into
the network were Hokkam 2011, which compared two interven-
tions which did not otherwise link to the network: phenytoin with
no treatment and Salim 1992, which compared sulphadryl pow-
ders to inactive powder. Summaries of these comparisons are also
provided in Appendix 4.
We includednine studies that had only one relevant intervention in
an expanded base-case to strengthen the network (Arenbergerova
2013; Biland 1985; Rasmussen 1991; Robson 1995; Robson
2001; Robson 2004; Senet 2003; Senet 2011; Stacey 1997). These
were all two-arm trials with one relevant intervention from the
base-case or partly relevant interventions such as emollient cream
or an ineligible intervention.
Summary details of all trials in the review are shown in Table 1; a
summary of the status of individual studies within the review and
the networks is shown in Table 2, which clearly denotes which
trials are included in the base-case and the sensitivity analyses and
which are included only in the review and not in the network.
Interventions
Included studies evaluated a wide range of dressings and topical
treatments. A total of 20 different types of dressings were evalu-
ated; this included dressings which were impregnated with agents
such as ibuprofen, silver, povidone iodine or zinc oxide. Sixteen
different topical treatments were included. Although the majority
of trials compared two dressings or two topical treatments (and
most of these compared two dressings), some compared a dressing
with a topical treatment (e.g. a hydrocolloid dressing compared
with silver sulfadiazine (SSD)). Aminority of trials compared arms
which included more than one treatment option and these in-
cluded both dressings and topical treatments.
The number and types of Interventions are fully detailed in the
effects of interventions section (Effects of interventions) and in
supplementary tables (Table 2; Table 3; Table 4), which also show
the status of each trial in the review and network analyses.
Characteristics of participants in included studies
See Characteristics of included studies for full details
Most studies included only people with venous leg ulcers; six stud-
ies also included some participants withmixed aetiology or arterial
ulcers (although we excluded those with more than 25% of such
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participants); in 10 studies it was not clear whether a minority of
people with non-venous ulcers were included. The mean or me-
dian age range reported for participants ranged between 46 and
81 years. Almost all studies enrolled a majority of women; there
were no single sex studies. The mean sizes of ulcers at baseline
varied by up to a factor of 10 but were typically between 5 cm²
and 10 cm². Themean duration of ulceration at enrolment ranged
between one month and 75 months. Many studies excluded par-
ticipants with either any type of infection or with a speciﬁed sever-
ity of infection (typically requiring systemic antibiotics); only one
study speciﬁed that the participant must have an infected ulcer
at baseline (Dimakakos 2009). Reporting of other types of ulcer
characteristics such as level of slough or exudate was limited. All
studies reported some use of compression although the methods
and the speciﬁcity of the reporting of this varied.
Characteristics of studies
Where funding was reported, it was often industry funding by
a manufacturer of one of the assessed interventions (30 studies).
However, a substantial number of studies reported no funding or
did not report the funding source. A minority of trials reported
a third sector or public funding source. Most studies used partic-
ipants as the unit of both randomisation and analysis, only two
reported data at the ulcer or leg level Caprio 1992; Stacey 1997),
while a small number appeared to randomise at the level of the
person but analyse at the level of the ulcer; in each case these were
dealt with in the ”Risk of bias’ assessment. Follow-up ranged be-
tween four weeks and 12 months but most trials had follow-up of
three months or less.
For more details on study characteristics see Table 1.
Excluded studies
A large number of records were rapidly excluded after reading the
full-text. A list of these studies is available on request from the
authors (see Figure 1). Some studies were excluded after more de-
tailed consideration. These studies are listed with reasons for their
exclusion in Characteristics of excluded studies. An additional ten
studies were excluded from records retrieved by an update search
in March 2018.
Two studies are awaiting classiﬁcation (Belcaro 2011; Polignano
2010) from the original search. A further nine studies are awaiting
classiﬁcation following an update search in March 2018 (Alvarez
2017; Cavalcanti 2017; Colenci 2016; Cullen 2017; Glukhov
2017; Moreno-Eutimio 2017; Oliveira 2017; Robinson 1988;
Somani 2017). One ongoing study was identiﬁed in the update
search (Jull 2018).
Risk of bias in included studies
Allocation
Risk of selection bias is assessed based on generation of randomi-
sation sequence and allocation concealment. Many studies were at
unclear risk of bias for one or both of these, most commonly for
allocation concealment. High risk of bias for randomisation was
documented for only one study where errors were noted to have
compromised the process. However only a minority (20 studies)
were considered to have a low risk of bias. The remainder did not
report the processes used clearly enough for us to determine the
risk of bias. The number of studies considered to be at low risk for
allocation concealment was even lower, with only 12 considered
to be clearly at low risk of bias.
Blinding
Many studies were at high or unclear risk of performance bias. Al-
though only a minority (18 studies) were clearly at high risk, many
more had an unclear risk. Only 10 studies were considered to be
at low risk. For detection bias, we observed a similar pattern al-
though more studies clearly had outcomes determined by blinded
observers; 20 were considered to be at low risk of detection bias.
Incomplete outcome data
Twenty-six studies were considered to be at high risk of attrition
bias. However, a larger number had a low risk of bias and only ten
were considered to be at unclear risk.
Selective reporting
Only four studies were at high risk of selective reporting bias; a
further 16 had an unclear risk in this domain; the remainder were
considered to be at low risk of bias.
Other potential sources of bias
Thirteen studies were considered to be at high risk from other
forms of bias, mostly due to issues with the analysis. A further 27
had an unclear risk of bias, again primarily related to the reporting
of the analysis.
All-domain risk of bias
All-domain (overall) risk of bias was assessed for each study. In
total 51 studies were considered to have a high or very high all-
domain risk of bias (Figure 2) and 27 studies were considered to be
at unclear or low overall risk of bias (these were grouped together
for analysis purposes). No study was at low overall risk of bias since
all studies had an unclear rating for one or more domains.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison NMA
evidence: proportion with complete healing
Interventions and comparisons: base-case network and
sensitivity analyses
The base-case network comprised 47 studies assessing 22 interven-
tions: 12 eligible dressings (foam, hydrocolloid, hydroﬁbre, algi-
nate, ibuprofen-releasing foam, nonadherent, paste bandage, pro-
tease-modulating (PMM), PMM-silver, silver-containing, ﬁlm,
saline gauze); and 10 topical agents (hydrogel, cadexomer iodine,
gentian violet, hyaluronic acid, hyaluronic-acid with povidone io-
dine, octenidine, povidone iodine, silver sulfadiazine (SSD), su-
cralfate and zinc oxide). One study was a three-arm trial (Hansson
1998; hydrocolloid, nonadherent and cadexomer iodine). The to-
tal number of comparisons was 49, encompassing a total of 4026
participants, who experienced a total of 1479 events (complete
healing).
The sensitivity analysis using an extended base case contained 59
studies assessing 25 interventions in 5156 participants with 1925
events; added interventions were blood product, emollient cream
and growth factor. This explored the impact of strengthening the
network with more links by including trials which contained an
eligible intervention compared to one of three ineligible interven-
tions.
An additional sensitivity analysis looked at a narrower set of 17 in-
terventions assessed in 41 studies that included 3435 participants
with 1331 events; removed interventions were ibuprofen-releas-
ing foam, gentian violet, hyaluronic-acid with povidone iodine,
octenidine and sucralfate. This explored the impact of restricting
the network to a narrower set of interventions which excluded in-
terventions that are not widely used in clinical practice.
In the base-case network, there were 31 different direct contrasts
and 12 triangular loops; the extended base-case sensitivity analysis
had 40 direct contrasts, 15 triangular loops and six quadratic loops;
and the narrower network had26direct contrasts and12 triangular
loops.
We carried out network meta-analysis for the base-case and the
two sensitivity analyses (Appendix 5). The extended base-case sen-
sitivity analysis identiﬁed instability in the base-case results for
contrasts of some treatments and in the rank order of treatments.
Additionally, in the extended base-case, the point estimates and
conﬁdence intervals (CIs) for contrasts with sucralfate were of-
ten considerably reduced compared with the base-case; and the
direction of effect was reversed for most contrasts with hydrogel.
This instability for some treatments is likely to occur because, in
the base-case, the direct evidence (from single small studies) had
an important contribution. As a consequence, we placed more re-
liance on the extended base-case sensitivity analysis and therefore
report the results for this sensitivity analysis in the rest of the re-
sults section. Full details and results for the base-case and both
sensitivity analyses are given in Appendix 5.
The network diagram for the extended base-case is shown in
Figure 3. We weighted node (circle) size by the number of studies
reporting each intervention and weighted the thickness of the
edge lines according to the inverse variance of the treatment effect
estimates for the direct evidence contrast (Chaimani 2013).
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Figure 3. Network diagram - extended network, by risk of bias (3 categories)Key: green = low/unclear;
yellow = high; red = very high overall risk of bias for the contrast. The number of studies for each contrast is
given in .
Most treatments in the extended base-case were part of at least one
loop (’core interventions’) and eight interventions were ’hanging’
treatments (ﬁlm, gentian violet, hyaluronic acid plus povidone
iodine, ibuprofen dressing, octenidine, povidone iodine, sucralfate
and zinc oxide).
Risk of bias for the extended base-case network
We report risk of bias in three ways (see Methods: Assessment of
risk of bias in included studies):
• for each study, as the all-domain risk of bias - taking into
account selection bias, detection bias, attrition bias, reporting
bias and other bias;
• for each direct comparison of two interventions, as an
overall risk of bias - taking into account the all-domain risk of
bias for the studies (1 above) and the weighting in the meta-
analysis for that comparison;
• for each contrast in the network (any pair of interventions
in the network) as the overall risk of bias - taking into account
the risk of bias for each direct comparison (2 above) and their
percentage contributions to the network estimate. We also
calculated the overall risk of bias in the network as a whole.
All-domain risk of bias for each study is shown in Figure 2. For
the extended base-case network , we judged no included studies
to be at low risk of bias and 21 at unclear risk of bias (Backhouse
1987; Bishop 1992; Casoni 2002; Charles 2002; De Araujo 2016;
Dereure 2012a; Dimakakos 2009; Ivins 2006; Jørgensen 2005;
Meredith 1988; Moffatt 1992a; Moffatt 1992b; Ohlsson 1994;
Petkov 1997; Robson 1995; Robson 2004; Romanelli 2015a;
Scurr 1994; Senet 2003; Vin 2002; Zuccarelli 1992). Twelve were
at very high risk of bias (Arenbergerova 2013; Banerjee 1997;
Callam 1992;Harding 2001; Nelson 2007; Norkus 2005; Schulze
2001; Smith 1992; Smith 1994; Sopata 2016; Taddeucci 2004;
Thomas 1997), and the rest we assessed to be at high risk of bias.
We grouped the low and unclear categories together.
We have indicated the overall risk of bias for each direct compar-
ison in the network diagram in Figure 3, using colour for three
risk of bias ratings: low/unclear (green), high (yellow), very high
25Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(red). There is a substantial amount of direct evidence at high or
very high risk of bias. For selected contrasts in the network, we
calculated the overall risk of bias as described in Appendix 6.
Network meta-analysis results
We examined the results in two ways: as risk ratios (RRs) with
their 95% CIs for each intervention compared with every other
intervention in the network (NMA effect estimates); and for the
network as a whole, giving the rank order for the interventions in
the network and the probability that a particular intervention is
the best, second best, etc treatment.
There are 300 mixed treatment contrasts in the extended network,
so we report results for the rank order ﬁrst, and then, for the
NMA effect estimates, we focus on contrasts involving the top
two treatments and three common and widely used treatments.
In Appendix 5, we report results for all contrasts in the extended
network, and give the full rank orders for the base-case and the
two sensitivity analyses.
Extended base-case network
The NMA generated results for 300 mixed treatment contrasts
(i.e. all possible pairwise combinations of the interventions). There
were 40 direct contrasts, of which 32 were informed by only one
study and the average number of events per mixed treatment con-
trast was around six (1925/300). The data were sparse and there
was uncertainty around the estimates.
As a consequence of the sparseness in the network, only 55 of 300
contrasts had precise estimates. The majority of CIs were wide or
very wide, crossing at least one defaultminimally important differ-
ence (MID); i.e. the value of 0.75 or 1.25 was included in the CI
(see Sensitivity analysis, GRADE assessment). Fifty-four contrasts
with precise estimates had the whole of the CI above the default
MID (i.e. the whole conﬁdence interval lay above 1.25), but 21
of these involved treatments for which the direct evidence com-
prised one study and had small numbers of events in at least one
arm (’fragility’): this applied to contrasts with sucralfate. Overall,
89% of the contrasts were considered to have imprecise results: the
exceptions (ignoring contrasts with ineligible interventions) were
silver versus each of the following: nonadherent, alginate, foam,
hydrocolloid, hydrogel, povidone iodine, saline gauze, SSD; hy-
drocolloid versus foam; and saline gauze versus alginate,foam, hy-
droﬁbre, hyaluronic acid/povidone iodine, paste bandage, PMM
and PMM silver.
Ranking of treatments
The NMA produced a large number of estimates. An alternative
way of presenting and interpreting data from the whole NMA was
to summarise using rankograms: data for each intervention were
shown as the probability that each intervention is the best, second
best, third best treatment, etc. These probabilities are based on
uncertainty, reﬂecting the effectiveness from the network contrasts
and the precision around the estimates. The closer the probability
of a rank to 100% (or 0%) and the narrower the distribution across
different ranks, the greater the conﬁdence in the ranking. Results
are given in Figure 4, Figure 5 and Appendix 5 and summarised
here, but must be interpreted in the light of the uncertainty and
sparseness in the network.
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Figure 4. Rankograms for the extended base-case showing the probability that each intervention is the best,
second best, third best treatment, etc.
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Figure 5. Rankograms for all treatments in the extended base-case network showing the probability that
each intervention is the best, second best, third best treatment, etc.
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Numerically, sucralfate had by far the highest probability of be-
ing the best treatment (93%), and saline gauze was most likely to
be the worst treatment (33%). However, the sucralfate ranking is
likely to be artiﬁcially high: sucralfate is connected to the core of
the network via hydrogel and the direct evidence for sucralfate ver-
sus hydrogel involves one study with 43 (of 50) healing events for
sucralfate and ﬁve healing events for hydrogel. The NMA results
for all comparisons with sucralfate have very wide CIs and large
point estimates. Consequently, sucralfate (versus other interven-
tions) has a high probability of having a very large effect estimate
(at the upper conﬁdence limit), in turn leading to an artiﬁcially
high probability of being the best treatment. Silver also had a high
probability of being among the most effective treatments (50%
at rank 2). Surface under the cumulative ranking curve (SUCRA)
values were generally between 0.3 and 0.8, but one treatment had
a SUCRA value of 1 or 0 (sucralfate was 1), with another two
treatments having values of 0.9 or 0.1 (silver 0.9 and saline gauze
0.1).
The rankograms formany treatments are broad and uninformative
(Figure 4, Figure 5). Of the eligible interventions in the extended
network, only ﬁve had a maximum probability above 20%. The
mean ranks for these treatments were: sucralfate 1.1, silver 2.7,
hyaluronic acid plus povidone iodine 5.3, paste bandage 5.4 and
saline gauze 23.0.
Certainty/quality assessment of the evidence across the whole
network
Further details of information used for GRADE assessment can
be found in Appendix 5, Appendix 6 and Appendix 7.
The risk of bias across the extended base-case network was esti-
mated to be high (Appendix 6). There appeared to be little incon-
sistency in the network (Appendix 7) and there were relatively few
contrasts with conﬂicting results for direct and indirect or NMA
estimates, so across the network we did not downgrade for incon-
sistency. We downgraded the evidence once for imprecision: in
addition to the sparseness (and probably as a consequence of it),
there is some overlap of the individual rankograms (see Appendix
5). A contour-enhanced funnel plot is shown in Figure 6. There
does not appear to be a small-studies effect. Overall, we classed the
evidence for the whole network as being of low certainty (down-
graded once for risk of bias and once for imprecision).
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Figure 6. Contour-enhanced funnel plot for the extended base-case network showing comparison-specific
pooled effect sizes1=non-adherent, 2=alginate, 3=blood product, 4=cadexomer iodine, 5=emollient cream,
6=film, 7=foam, 8=gentian violet, 9=growth factor,10=hyaluronic acid + povidone iodine, 11=hyaluronic acid,
12=hydrocolloid, 13=hydrofibre, 14=hydrogel, 15=ibuprofen, 16=octenidine,17=paste bandage, 18=PMM,
19=PMM silver, 20=povidone iodine, 21=saline gauze, 22=silver, 23=SSD, 24=sucralfate, 25=zinc oxide
Results and quality assessment for selected individual
comparisons
Here we focus on the treatment effect data for some speciﬁc treat-
ment combinations to provide further insights into the results of
the NMA. We considered comparisons of sucralfate, silver, foam,
hydrocolloid and nonadherent dressings. These represent the two
with the highest probabilities for ranks 1 to 3 in Figure 4. (su-
cralfate and silver) and three common and widely used treatments
(foam, hydrocolloid and nonadherent dressings). These widely
used treatments were selected by authors who did not have knowl-
edge of the precise results of the network. The results for the ex-
tended base-case are shown in Table 5. We calculated absolute
risk differences using the median risk for the comparator, which
was obtained from the risks for that comparator in all direct ev-
idence studies. For all four comparators, the risk varied widely
across studies. We report GRADE assessment of selected contrasts
in Summary of ﬁndings for the main comparison. Most of the
evidence for these individual contrasts was of low or very low cer-
tainty.
For the contrast of the two interventions with the highest mean
ranks - sucralfate and silver dressing - it is unclear whether there is a
difference in the probability of venous leg ulcer healing (RR 2.80,
95% CI 0.88 to 8.97; very low-certainty evidence, downgraded
once for risk of bias and twice for imprecision).
Silver dressings may increase the probability of venous leg ulcer
healing, compared with nonadherent dressings (RR 2.43, 95% CI
1.58 to 3.74; moderate-certainty evidence, downgraded for risk
of bias). This corresponds to an absolute risk difference of 346
more people healed per 1000 (95% CI 140 to 663 more), for
a nonadherent median probability of healing of 242 per 1000.
Although this contrast was assessed as itself representingmoderate-
certainty evidence, it sits in the context of a network which was,
overall, judged to represent low-certainty evidence, and should
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therefore be considered with appropriate caution. We also note
that many of the trials which contributed to the contrast (and
the direct comparison) were at an unclear risk of bias. Therefore,
although there is no clear high risk of bias, there is also a lack of
clarity about the true risk of bias.
For each of six contrasts the low certainty of the evidence means
it is unclear whether the intervention increases the probability of
healing; for two more the certainty of the evidence was very low:
• sucralfate versus foam dressing (RR 5.94, 95% CI 1.96 to
18.0);
• sucralfate versus hydrocolloid dressing (RR 6.51; 95% CI
2.17 to 19.6);
• sucralfate versus nonadherent dressing (RR 6.80, 95% CI
2.24 to 20.7);
• silver dressing versus foam dressing (RR 2.12; 95% CI 1.46
to 3.07);
• silver dressing versus hydrocolloid dressing (RR 2.32; 95%
CI 1.58 to 3.41);
• foam dressing versus nonadherent dressing (RR 1.15; 95%
CI 0.91 to 1.44);
• foam dressing versus hydrocolloid dressing (RR 1.10; 95%
CI 0.93 to 1.28);
• hydrocolloid dressing versus nonadherent dressing (RR
1.04; 95% CI 0.85 to 1.29).
In each of these six contrasts, the evidence was graded as low
certainty; downgraded either once for imprecision and once for
risk of bias (sucralfate versus foam; sucralfate versus hydrocolloid;
sucralfate versus nonadherent dressing; foam versus nonadherent)
or twice for inconsistency (silver versus foam); or once for risk of
bias and once for inconsistency (silver versus hydrocolloid).
It is unclear whether there is a difference in the probability of
healing for the remaining two contrasts because the evidence is of
very low certainty (downgraded for risk of bias (twice) and impre-
cision (once) or for risk of bias, imprecision and inconsistency):
foam versus hydrocolloid; and hydrocolloid versus nonadherent
dressing. The contrasts with sucralfate were informed by one study
with 100 participants in the direct evidence, with 43/50 events for
sucralfate and ﬁve events for hydrogel; we therefore downgraded
further for imprecision to allow for the fragility this invoked.
Comparison of results from the NMA with the direct
evidence
Of the eight contrasts with more than one study, ﬁve had an I²
of 0%; the remaining three were downgraded for inconsistency;
one was downgraded twice for inconsistency. Details are given in
Table 3.
D I S C U S S I O N
Summary of main results
We conducted a network meta-analysis (NMA) of dressings and
topical agents for healing venous leg ulcers. The network included
59 studies with 5156 participants. The systematic review that un-
derpins the NMA includes 78 RCTs involving a total of 7014 par-
ticipants, comparing different dressings or topical agents or com-
binations of treatments for the healing of venous leg ulcers. This
included a range of treatments from the most widely-used cate-
gories of dressings to experimental treatments assessed by a single
research study.
We treated each topical agent as a separate intervention, but
grouped dressings by class as described in the BNF 2016 (e.g.
alginates, hydrocolloids). There were many interventions, often
involving small single studies with atypical or experimental treat-
ments. In order to simplify and rationalise theNMA, we produced
a list of important and more widely-used treatments with clinical
direction and input from review authors who had not seen the
results. This led to the ’base-case’ NMA, which we extended fol-
lowing sensitivity analysis, adding three linking ’ineligible’ inter-
ventions to obtain greater robustness.
Alongside the analysis, we have applied a new method of GRADE
assessment (Salanti 2014), which allows us to view the results in
the light of the certainty of their ﬁndings. Using this approach,
we found the evidence for the network as a whole was of low cer-
tainty (downgraded for risk of bias and imprecision). The network
presents results derived from 59 studies of 25 interventions eval-
uating 40 direct comparisons: we highlight the results from con-
trasts involving the two treatments with the highest mean ranks
(sucralfate and silver): the majority of the evidence for individual
contrasts was of low or very low certainty, and was mainly down-
graded for risk of bias and imprecision; there was a limited degree
of inconsistency for some contrasts (see Quality of the evidence).
In summary:
• overall ﬁndings reﬂect the uncertainty of the component
evidence and the sparseness of the network. For the network as a
whole, the evidence was of low certainty. With so many
interventions that appeared to have similar efﬁcacies, there was
considerable uncertainty in the middle ranks, but numerically
two treatments had more than 50% probability of being the best
(sucralfate and silver dressings); - see also Quality of the evidence.
• for the head-to-head comparison of these two treatments
with the highest mean ranks, it is very uncertain whether there is
a difference between sucralfate and silver dressing in the
probability of venous leg ulcer healing (very low-certainty
evidence);
• silver dressings may increase the probability of venous leg
ulcer healing, compared with nonadherent dressings: RR 2.43,
95% CI 1.58 to 3.74 (moderate-certainty evidence in the
context of a low-certainty network);
• in the other contrasts between these treatments with the
highest probability of being best and the most widely-used
dressing classes, it was unclear whether the intervention increased
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the probability of healing; in each case this was low- or very low-
certainty evidence characterised by wide conﬁdence intervals;
• one of the sensitivity analyses highlighted some instability
in key aspects of the network; this instability is likely to be due to
sparseness. As a consequence, we reported the results of the
extended sensitivity analysis.
Overall completeness and applicability of
evidence
The studies included in the review do not represent all the studies
which have been conducted on relevant interventions; substantial
numbers of studies were excluded because they did not report the
outcome of complete wound healing. However, this was an issue
across treatments and did not appear to impact disproportionately
on any particular treatment or comparison. As discussed below we
believe that this approach was the appropriate one for the purpose
of the review.
The populations represented in the included studies appear rep-
resentative of the people who present with venous leg ulcers in
clinical practice in terms of age, gender and ulcer characteristics at
enrolment. However, although many studies speciﬁed characteris-
tics such as ulcer dimensions, duration and infection in inclusion
criteria or reported these in participant details, they were much
less likely to specify or describe wound characteristics such as levels
of slough, exudate or necrosis.
We identiﬁed a wide range of eligible interventions, and included
both dressings and topical treatments; speciﬁc dressing types such
as impregnated dressings and modern ’advanced’ dressings were
well represented. We conducted sensitivity analyses in order to
assess the stability of the network and the impact of decreasing
the number of included interventions to a smaller clinically-de-
ﬁned set, or expanding it in order to increase the amount of
evidence available for key interventions which were particularly
poorly linked into the network.
The review included a substantial number of studies not included
in the network; in particular, studies which compared speciﬁc in-
terventions such as honey with standard care or choices of multi-
ple treatments. The inclusion of these studies in the review means
that they are easily identiﬁable for researchers who may wish to
conduct alternative analyses using this type of data. We believe
that the choices we have made concerning data to include in the
network meta-analysis are likely to maximise its relevance to clini-
cal decision-making, but acknowledge that this is balanced against
the availability of only direct evidence for some comparisons.
Quality of the evidence
A high proportion of the included studies were considered to be at
high risk of bias for one ormore domains and a substantial number
were at very high risk of overall bias. The principal reasons for a
study to be considered at high risk of bias were lack of blinding
of one or more groups of participants, professionals and outcome
assessors, and attrition bias. However, many studies which were
not considered to be at high risk of bias had unclear risks of bias for
several or even all domains. Therefore, even when a contrast has
not been downgraded due to high risk of bias in the contributions
matrix, this does not mean that we are conﬁdent that there is a
low risk of bias pertaining to the contrast, but merely that there is
no known high or very high risk of bias.
Many comparisons (the majority) were informed by a single trial,
and most trials were small and underpowered. Only a few com-
parisons - between some of the most widely-used dressing types
- were represented by multiple trials and substantial numbers of
participants and events. This is reﬂected in the wide conﬁdence
intervals and therefore the imprecision of most contrasts in the
NMA. Some contrasts were also judged to be affected by inconsis-
tency. These factors, together with high risks of bias, meant that
many key contrasts were judged to be low or very low certainty
while the network as a whole was judged to represent low-certainty
evidence.
The inclusion criteria and the nature of the evidence included
meant that we did not downgrade for indirectness and we also
found no evidence of publication bias.
Potential biases in the review process
Although all the included studies were reported in English, we
ordered a number of full-texts in languages other than English;
including Polish, German, Portuguese, Dutch, Norwegian, Chi-
nese, Italian and Spanish. These were ultimately excluded as they
did not meet the inclusion criteria, but would clearly have been
included if they had proved eligible.
We searched a number of databases and checked the references
of reviews and included studies; time constraints meant that the
planned searches of trials registers were not conducted. We found
no evidence of publication bias, and our focus on the single out-
come of healing means that trials identiﬁed from registers were
unlikely to have data which would have led to their inclusion in
the network. We found a relatively small number of unobtainable
records; close examination of the records for these led us to con-
clude that the studies they represented were unlikely to have been
included in the review.
This NMA and review focused on the outcome of complete heal-
ing. The impact of including only studies reporting healing in this
way was considerable; lack of these data was the single most com-
mon substantive reason for excluding a study. Complete healing is
the outcome which is most important to people living with venous
leg ulcers and therefore we believe that the decision to focus the
network on this outcome was the right one. Other reviews include
studies that focused on other outcomes considered important to
people with lived experience of the condition; this review stands
alongside those syntheses and does not seek to replicate them.
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There is potential for bias in our choice of base-case and sensitiv-
ity analysis and also our choice of studies with only one eligible
intervention for the expanded base-case sensitivity analysis. We
made a post-hoc decision to focus on a base-case of interventions
which were likely to be used in clinical practice. Clearly post-hoc
decisions of this nature could be a source of bias in their impact
on which interventions were included. However, no interventions
were excluded from the review on the basis of this decision: com-
parisons including interventions judged to be partly relevant are
included in the review and the direct evidence is available to the
reader. The decisions on which interventions should be included
in the base-case and the narrow sensitivity analysis were made on
clinical grounds rather than on the basis of known results; they
were made independently by two authors, one of whom had no
access to the extracted data at that point, and who were in almost
complete agreement when the decisions were compared; where
there was a disagreement a more inclusive approach was adopted.
The effect of the approach adopted was to remove some of the
noise in what was a sparsely-populated network and to increase
our ability to examine the relative effectiveness of treatments rel-
evant to clinical practice.
Our updated search in March 2018 identiﬁed nine studies, which
may be eligible for inclusion but which have not yet been incor-
porated into the review. None of these was large in absolute terms
but the results of these studies may nevertheless have some impact
on our sparse network.
Agreements and disagreements with other
studies or reviews
Wehave been unable to identify any otherNMAs examining dress-
ings and topical agents for healing venous leg ulcers. The high level
of uncertainty around contrasts between most dressings reﬂects
that in the most recent NICE guidance (NICE 2016a) and the
most recent report by the AHRQ (AHRQ 2013); these reﬂect in
part the ﬁndings of a number of Cochrane reviews of individual
types of dressing (see Why it is important to do this review). The
2010 guidance by SIGN (SIGN 2010) recommended the use of
nonadherent dressings with possible alternatives being hydrocol-
loids, alginates or hydrogels. The results of the NMA do not con-
ﬂict with this advice, suggesting broadly comparable efﬁcacy for
complete healing in these dressing categories.
The ﬁnding that silver dressings may increase the number of ul-
cers healed does not take account of the largest trial available for
silver (Michaels 2009). This is because both arms of this trial con-
tained more than one treatment class (speciﬁcally, silver-contain-
ing dressings and silver sulfadiazine (SSD)), and hence could not
be integrated into the NMA. Michaels 2009 found no difference
in overall healing between the silver and non-silver arms of this
study (an RR of 1.00, 95% CI 0.95 to 1.06 at one year’s follow-
up), but we note that the ’silver’ arm included 39% of participants
receiving SSD, which may have substantially changed the effect in
this study. Nevertheless, the data from this trial should be borne in
mind when considering the results and when planning any further
research on these treatments.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results of this network meta-analysis (NMA) are mostly ﬁnd-
ings of low-certainty evidence for key comparisons. Although there
was some evidence that silver dressings may increase the prob-
ability of venous leg ulcer healing, compared with nonadherent
dressings, this needs to be seen in the context of the low certainty
of the network as a whole. We do not therefore believe that this
evidence is a sufﬁcient basis for treatment decisions. It is possible
that the results may be affected by the studies which are awaiting
classiﬁcation and have not yet been incorporated into the review.
The results of this NMA focus exclusively on complete healing;
whilst this is of key importance to people living with venous leg
ulcers, clinicians may wish to take into account other patient-im-
portant outcomes reported in other reviews on this subject, whilst
cost considerations will also be a factor for decision makers.
Implications for research
There is a lack of high-quality research evidence relating towhether
particular wound dressings or topical treatments have a beneﬁcial
impact on healing of venous leg ulcers. This is despite the existence
of a large number of trials relating to a range of treatments. The
poor or uncertain quality of the evidence is problematic given the
impact on the lives of individuals of living with chronic wounds
and the substantive healthcare implications of caring for them.The
NMA’s ﬁndings of low-certainty evidence make clear the generally
poor quality of randomised controlled trials (RCTs) of venous leg
ulcer treatments, suggesting a need for radical improvements in
the planning, conduct and reporting of trials in this ﬁeld.
There was uncertainty surrounding most of the interventions eval-
uated when we look at the rankings of their relative effectiveness.
Therefore, any future evaluations of interventions should focus -
as this NMA does - on those most widely used in clinical practice;
they may wish to look in particular at silver-containing dressings.
Where trials are conducted, they should be adequately powered to
assess differences in complete wound healing, which should ide-
ally be reported as time-to-event data. Choice of secondary out-
comes should be informed by consultation with people with lived
experience of leg ulcers. Trials should adhere to international guid-
ance on design, conduct and reporting of randomised trials. In
particular, they should undertake and report adequate randomisa-
tion and allocation procedures and blinded outcome assessments,
while losses to follow-up should be fully accounted for.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alvarez 2012
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: conﬁrmed non-healing (no progress after 4 weeks of compression and
standard care)VLUofminimum2months duration and requiring autolytic debridement
(> 50% ulcer bed covered with non-viable yellow tissue). If participants had multiple
VLU, the ulcer of longest duration was used for the study, or if duration equal, the one
with largest surface area
Exclusion criteria: clinical signs of infection, cellulitis, osteomyelitis, inadequate nutri-
tion, uncontrolled diabetes, any other clinically-signiﬁcant conditions that would impair
wound healing. Use of corticosteroids, immunosuppressants, radiation or chemotherapy
within 1 month prior to study entry
Number participants: 48
Participant characteristics
Age: 69.0 (8.3) vs 63.0 (10.3) years (range 55 to 72 vs 58 to 70)
N male: 12 (48) vs 11 (48)
Ulcer details
Size: 743.9 (103.8) vs 629.0 (106.9) mm² (median 785 vs 627 mm²)
Duration: 10.9 (2.2) vs 8.9 (1.2) months (range 8 to 14 vs 4 to 12)
Interventions Intervention 1 class: biosynthetic (bio-cellulose)
Intervention 1 details (name and details of application): Suprasorb X (Lohmann &
Rauscher) changed weekly
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): Adaptic (Systagenix) changed
weekly
Compression: modiﬁed Unna’s boot or a 4-layer bandage system (Viscopaste, Profore;
Smith & Nephew Inc, Coban LF; 3M Inc)
Other co-interventions: wound cleansing with saline, without forceful irrigation
Outcomes Intervention 1: 7/25
Intervention 2: 7/23
Notes Funding type: industry
Funding details Xylos corporation
Risk of bias
Bias Authors’ judgement Support for judgement
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Alvarez 2012 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “eligible patients were allocated ...
according to a block randomisation sched-
ule”
Comment: method of generating the se-
quence was not stated
Allocation concealment (selection bias) Unclear risk Quote: “randomisation was done using
sealed envelopes, which were opened after
pre-test measurements were taken”
Comment: unclear if the envelopes were
sequentially numbered and opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “digital photographs were assessed
by a clinician who was blinded as to the
treatment allocation”
Comment: blinded outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 28% and 35% of participants
were excluded from the analysis - variety
of reasons and it is not clear if these were
reasonable
Selective reporting (reporting bias) Low risk Comment: all outcomes appear to have
been reported
Other bias Low risk No evidence of other bias
All domain risk of bias High risk
Arenbergerova 2013
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 13 weeks
Participants Inclusion criteria: VLU minimum 1.6 cm in all directions, maximum area 50 cm², > 8
weeks duration, ABI > 0.8
Exclusion criteria: vasculitis, non-venous leg ulcer, treatment with systemic antibiotics,
corticosteroids or oral immunosuppressants, pregnancy
Participant characteristics
Number participants: 72
Age: 65 vs 59 years
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Arenbergerova 2013 (Continued)
N (%) male: 11 (30.6) vs 15 (41.7)
Ulcer details
Size: mean (SD) 18.7 (9.9) cm² vs 17.5 (9.3) cm²
Duration: mean (range) 2 years (3 months to 6 years) vs 2 years (3 months to 6 years)
Interventions Intervention 1 class: blood product
Intervention 1 details (name and details of application): haemoglobin spray (10% pu-
riﬁed porcine haemoglobin in aqueous solution) + Nanotextile (Elmarco), ﬁxed with
gauze. Daily dressing change. Treated in hospital for 2 weeks, then at home
Intervention 2 class: placebo
Intervention 2 details (name and details of application): placebo spray (0.9% saline) +
Nanotextile (Elmarco) ﬁxed with gauze
Compression: compression therapy used in all according to current guidelines in Czech
Republic based on clinical experience, initiated 2 weeks prior to study inclusion. All used
Ideal/Hartmann bandages
Other co-interventions: meticulous wound cleaning and disinfection prior to dressing
Outcomes Intervention 1: 1/36
Intervention 2: 0/36
Notes Funding type and details: non-industry
Funding details: Czech Ministry of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: study described as randomised
but no methods reported
Allocation concealment (selection bias) Unclear risk Comment: no information reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “the nurses involved in treatment
and wound care were not blinded”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the attending doctor whom eval-
uated the wound surface area and assessed
the condition of the wound were blinded”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 2/36 vs 5/36 dropped out of
study, reasons reported but disparity and
higher than healing rate
Selective reporting (reporting bias) Low risk Comment: all outcomes appear to be re-
ported
Other bias Low risk Comment: no evidence of other bias
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Arenbergerova 2013 (Continued)
All domain risk of bias High risk
All domain risk of bias 2 High risk
Armstrong 1997
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 6 weeks
Participants Inclusion criteria: ulcer 7.5 cm or larger in diameter producing moderate to heavy
amounts of exudate
Exclusion criteria: not reported
Participant characteristics
Number participants: 44
Age: 71 (10) vs 65 (11) years
N (%) male: 10 (48) vs 13 (57)
Ulcer details
Non VLU: < 25% mixed/arterial); 3 (14%) vs 3 (13%) mixed aetiology, 1 (5%) vs 1
(4%) other
Size: median (range) 491 (64 to 2081) mm² vs 611 (60 to 1830) mm²
Duration: median (range) 9 (1 to 47) months vs 12 (1 to 120) months
Interventions Intervention 1 class: hydroﬁbre
Intervention 1 details (name and details of application): Aquacel; dressing changed every
7 days (or sooner if leakage, infection suspected or pain)
Intervention 2 class: alginate
Intervention 2 details (name and details of application): Kaltostat; dressing changed
every 7 days (or sooner if leakage, infection suspected or pain)
Compression: class 3c compression bandage (Tensopress)
Other co-interventions: secondary dressing, occlusive hydrocolloid (DuoDerm Extra
Thin) and, if indicated, orthopaedic padding
Outcomes Intervention 1: 6/21
Intervention 2: 2/23
Notes Funding type: industry
Funding details: ConvTec Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “subjects were then randomised to
the primary dressings under investigation
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Armstrong 1997 (Continued)
by the use of sealed envelopes opened in
numerical order”
Comment: unclear how the randomisation
sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “subjects were then randomised to
the primary dressings under investigation
by the use of sealed envelopes opened in
numerical order”
Comment: not clear whether the envelopes
used were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: high levels ofwithdrawals (24%
vs 30%) all but one due to adverse events
Selective reporting (reporting bias) Low risk Comment: no evidence of selective report-
ing
Other bias Unclear risk Comment: no evidence of other bias but
secondary dressing appears to have been a
problem; cause of the high adverse events
All domain risk of bias High risk
Arnold 1994
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 10 weeks
Participants Inclusion criteria: non-infected lower leg ulceration secondary to venous stasis
Exclusion criteria: ulcers resulting from arterial insufﬁciency, vasculitis, rheumatoid
arthritis, sickle cell anaemia, tumours, other dermatological conditions. Evidence of peri-
wound erythema, cellulitis, oedema. Deep dermal involvement and exposure of muscle,
tendon or bone
Participant characteristics
Number participants: 70
Age: 65 (SE 3.3) vs 60 (SE 2.9) years
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Arnold 1994 (Continued)
% male 36 or 37(calculating from %) (52)
Ulcer details
Size: 2100 mm² (SE 685) vs 1983 mm² (SE 659)
Duration: 47.8 weeks vs 46.2 weeks
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): DuoDERM CGF (ConvaTec);
dressing changed every 7 days
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): gauze (parafﬁn-impregnated
in US study centres, saline/betadine-impregnated in UK); US centres: Telfa (Kendall
Healthcare Products); dressing changed every 7 days
Compression: zinc oxide paste bandage (Unna’s boot) and gradient compression bandage
(worn during working hours)
Other co-interventions: not reported
Outcomes Intervention 1: 11/35
Intervention 2: 14/35
Notes Funding type: not reported
Funding details: 2 of the authors are from Bristol-Myers Squibb Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “following the initial assessment,
patients were randomly assigned to the
study or control treatment”
Comment: unclear how the randomisation
sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “following the initial assessment,
patients were randomly assigned to the
study or control treatment”
Comment: unclear whether allocation was
adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 20% vs 26% withdrawal for
various reasons but ITT analysis
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Arnold 1994 (Continued)
Selective reporting (reporting bias) Low risk Comment: no evidence of selective report-
ing
Other bias High risk Comment: authors highlight differences
between outcomes in different study cen-
tres
All domain risk of bias High risk
All domain risk of bias 2 High risk
Backhouse 1987
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: Doppler-assessed venous or gravitational ulcers
Exclusion criteria: ulcers > 10 cm² in area
Participant characteristics
Number participants: 56
Age: 69.9 vs 67.5 years
% male: 23 (41)
Ulcer details
Non VLU: comment: ulcers were “gravitational or venous”
Size: 3.4 (0.4) cm² vs 3.1 (0.4) cm²
Duration: 22 vs 21 months (median)
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application) Granuﬂex (Squibb Surgicare),
no further details
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): NR (Johnson & Johnson), no
further details
Compression: below-knee graduated compression bandage; layer crepe bandage, layer
Elset bandage (Seton Products Ltd); layer Coban cohesive bandage (3M Health Care
Ltd)
Other co-interventions: saline wash, removal of slough, absorbent velband (Johnson &
Johnson) over dressing
Outcomes Intervention 1: 21/28
Intervention 2: 22/28
Notes Funding type: industry
Funding details: Johnson & Johnson Ltd, 3M Health Care, Sigvaris (Camp Ltd), Zyma
UK Ltd, Squibb Surgicare
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Backhouse 1987 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “ﬁfty-six patients referred to a ve-
nous ulcer clinic were randomized”
Comment: no detail on how randomisa-
tion sequence generated
Allocation concealment (selection bias) Unclear risk Quote: “ﬁfty-six patients referred to a ve-
nous ulcer clinic were randomized”
Comment: no information on whether al-
location was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: no informationwas reported on
blinding participants or personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: no information on who per-
formed the assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all randomised participants
were included in the analysis
Selective reporting (reporting bias) Unclear risk Comment: planned outcomes were not
clearly reported so difﬁcult to be sure
whether they were fully reported
Other bias Unclear risk Comment: no evidence of other bias but
reporting insufﬁcient to be certain
All domain risk of bias Low risk unclear/low
Banerjee 1997
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 17 weeks
Participants Inclusion criteria: in-patient or attendee day hospital for elderly with varicose leg ulcer
Exclusion criteria: signiﬁcant peripheral vascular disease (Doppler assessed)
Participant characteristics
Number participants: 71
Age: 75.9 (7.7) vs 81.2 (7.3) years
% male: 7 (19) vs 7 (20)
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Banerjee 1997 (Continued)
Ulcer details
Size: median (range) 12.2 cm² (1.1 to 138.0) vs 11.4 cm² (1.3 to 134.0)
Duration: ’“approximately 2 years in each group”
Interventions Intervention 1 class: ﬁlm
Intervention 1 details (name and details of application): polyurethane ’synthetic skin’;
Synthaderm (Arrow Pharmaceuticals)
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): paratulle (no further details)
Other co-interventions: warm saline poured over ulcer to clean. Primary dressing was
backed by a pad and a support bandage applied using a K-bnd Parema conforming
bandage from toes to just below the knee
Outcomes Intervention 1: 11/36
Intervention 2: 8/35
Notes Funding type and details: not reported
Notes: a high proportion of ulcers were infected 29 (81%) vs 21 (60%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “treatment allocation was random”
Comment: unclear how randomisation se-
quence was generated
Allocation concealment (selection bias) Unclear risk Quote: “treatment allocation was random”
Comment: unclear whether allocation was
adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal was 3% vs 23% giving a large
imbalance between the arms
Selective reporting (reporting bias) Low risk Comment: no evidence of selective report-
ing
Other bias High risk Comment: differences in nursing time/vis-
its noted by authors
All domain risk of bias High risk
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Banerjee 1997 (Continued)
All domain risk of bias 2 High risk
Beckert 2006
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 20 weeks
Participants Inclusion criteria: leg ulcer due to CVI > or = 3 cm², ABI > 0.8
Exclusion criteria: ulceration not due to CVI, severe cardiac, respiratory, gastrointestinal,
live or renal disease, malignancy, signs of wound infection. Pregnant or nursing mothers
Participant characteristics
Number participants: 119
Age: 66.8 (13.7) vs 70.6 (11.1) years
% male: 20 (32.3) vs 19 (33.3)
Ulcer details
Size: mean (SD) 26.2 (49.0) cm² vs 17.2 (21.0) cm²
Duration: mean (SD) 24.9 (51.2) months vs 17.8 (18.4) months
Interventions Intervention 1 class: pale sulphonated shale oil (PSSO) gel
Intervention 1 details (name and details of application) 10% Leukichtan (Ichthyol-
Gesellschaft); gel applied to wound daily as 2 mm to 2.5 mm thick layer
Intervention 2 class: vehicle (gel)
Intervention 2 details (name and details of application): gel applied to wound daily as 2
mm to 2.5 mm thick layer
Compression: short stretch elastic bandages (Putter-Bandages, Hartmann)
Other co-interventions: Jelonet (Smith &Nephew) nonadherent gauze dressing applied
over the gel
Outcomes Intervention 1: 21/62
Intervention 2: 13/57
Notes Funding type and details: industry
Funding details: Ichthyol-Gesellschaft Cordes, Hermanni & Co (GmbH & Co)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomized to one
of the treatment groups by using a cen-
tralized computer system with block ran-
domization (1:1) (Randcode, IDV, Gaut-
ing, Germany)”
Comment: appropriate method of se-
quence generation
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Beckert 2006 (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “investigators were blinded to the
randomization process to eliminate bias”
Comment: unclear howallocationwas con-
cealed and hence whether the process was
adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote:“[ulcer] area was calculated in a
blinded manner using a standardized com-
puter system”
Comment: it appears that blinded outcome
assessment was conducted for healing
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “ultimately, 119 patients were en-
rolled in the study; 62 were randomized to
PSSO 10% and 57 to vehicle treatment.
Eighteen (15%) of the 119 patients-nine
each in the in the PSSO 10% and vehi-
cle groups- did not complete the study for
other reasons than ulcer healing. These pa-
tients were included in data analysis with
their assigned group”
Comment: ITT analysis
Selective reporting (reporting bias) Low risk All speciﬁed outcomes were fully reported
Other bias Low risk No evidence of other bias and reporting
sufﬁcient
All domain risk of bias Low risk low/unclear
Biland 1985
Methods RCT
Arms: 4
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 6 weeks
Participants Inclusion criteria: venous or mixed arteriovenous ulcers, minimum diameter 1.5 cm,
without claudication
Exclusion criteria: purely arterial ulcers, neuropathy, treatment with vaso-active drugs,
antibiotics or steroids
Participant characteristics
Number participants: 197
70Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Biland 1985 (Continued)
Age: 61 (15) vs 60 (12) vs 60 (12) vs 61 (12) years
N (%) male: 15 (34) vs 13 (23) vs 17 (33) vs 10 (22)
Ulcer details
Non VLU: < 25% mixed/arterial
Size: range 2 cm² to 321 cm², median 32 cm²
Duration: < 12 weeks 26 (59%) vs 30 (54%) vs 31 (60%) vs 27 (60%), 12-24 weeks
6 (14%) vs 11 (20%) vs 6 (12%) vs 3 (7%), > 24 weeks 12 (27%) vs 15 (27%) vs 15
(29%) vs 15 (33%)
Interventions Intervention 1 class: blood product
Intervention 1 details (name and details of application): haemodialysate ointment
(dialysate of calf blood: Solcoseryl (Solco Basle Ltd)) plus placebo IV
Intervention 2 class: placebo
Intervention 2 details (name and details of application): placebo ointment plus placebo
IV
Intervention 3 class: blood product
Intervention 3 details (name and details of application): haemodialysate ointment +
haemodialysate IV
Intervention 4 class: placebo
Intervention 4 details (name and details of application): placebo ointment +
haemodialysate IV
Compression: all received continuous compression with foam-rubber padded bandage
Other co-interventions: twice daily application of compress with isotonic saline. 3 x
weekly painting of skin around ulcer with 4% methylrosaniline chloride
Outcomes Intervention 1: 21/44
Intervention 2: 18/56
Intervention 3: 25/52
Intervetnion 4: 19/45
Notes Funding type: not reported
Funding details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: described as randomised and
mentionof stratiﬁcationbut nomethodde-
tails
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: described as “double blind” but
no method detail
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Biland 1985 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: described as “double blind” but
no method detail
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: 13/210 dropped out of study,
reasons given; unclear which arms these
were from
Selective reporting (reporting bias) High risk Comment: no evidence of selective report-
ing but withdrawals not clearly reported
Other bias Low risk Comment: no evidence of other bias
All domain risk of bias High risk
Bishop 1992
Methods RCT
Arms: 3
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 4 weeks
Participants Inclusion criteria: age 21-90, venous stasis ulcer of at least 3months duration, surface area
3 cm² to 50 cm², for relevant participants negative pregnancy test and use of adequate
contraception
Exclusion criteria: hypersensitivity to test medication, > 10 bacteria/g of tissue in ul-
cer, systemic sepsis or bone infection arm/ankle arterial perfusion index < 0.5, hyper-
cupraemia, systemic immunosuppressive or cytotoxic therapy, insulin-dependent dia-
betes
Participant characteristics
Number participants: 93 randomised (86 analysed)
Age: 58.2 (14.5) vs 58.2 (17.3) vs 51.6 (14.6) years
% male: 14 (48) vs 9 (32) vs 20 (69)
Ulcer details
Size: mean (SD) 9.9 (8.5) cm² vs 11.9 (11.2) vs 9.6 (8.1) cm² median 6.5 vs 6.9 cm² vs
6.2 cm²
Duration: mean (SD) 57.1 (94.9) vs 44.1 (58.0) vs 38.0 (88.7) months, median 11.0 vs
19.0 vs 12.0 months
Interventions Intervention 1 class: copper tripeptide
Intervention 1 details (name and details of application): copper tripeptide complex
cream; GHK: Cu; participant applied cream and covered with nonadherent dressing
Intervention 2 class: SSD
Intervention 2 details (name and details of application): 1% silver sulfadiazine cream;
Silvadene (Marion Laboratories); participant applied cream and covered with nonadher-
ent dressing
Intervention 3 class: vehicle (cream)
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Bishop 1992 (Continued)
Intervention 3 details (name and details of application): Unibase (Parke-Davis); partici-
pant applied cream and covered with non adherent dressing
Compression: “elastic wrap”
Other co-interventions: saline used to clean wound at dressing change
Outcomes Intervention 1: 0/29
Intervention 2: 6/28
Intervention 3: 1/29
Notes Funding type: industry
Funding details: Schering-Plough Research
Notes: 1-year follow-up found 5/6 healed participants in silver sulfadiazine group still
healed, as well as the healed placebo-treated participant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “this study reports a prospective
randomized evaluator-blinded trial com-
paring ...”
Comment: no information on how the ran-
domisation sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “this study reports a prospective
randomized evaluator-blinded trial com-
paring ...”
Comment: no information on whether al-
location was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk There is no information on this but the fact
that studymedicationwas removedbefore a
blinded assessor saw the wound means that
there may be an inherent lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “before evaluation, all study medi-
cation was removed and the ulcer cleansed
to keep the evaluator blinded”
Comment: assessors were blinded to treat-
ment allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all the participants were in-
cluded in the analysis
Selective reporting (reporting bias) Low risk Comment: all planned outcomes were re-
ported
Other bias Unclear risk Comment: no evidence of other bias but
reporting insufﬁcient to be certain
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All domain risk of bias Low risk low/unclear
Blair 1988a
Methods RCT
Arms: 2 [see notes]
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: venous ulcers < 10 cm²
Exclusion criteria: ABPI < 0.8 on Doppler (arterial insufﬁciency)
Participant characteristics
Number participants: 120
Age: 69.9 (range 34 to 92) vs 67.5 (30 to 90) years
% male: not reported
Ulcer details
Size: 3.4 (SEM 0.4) vs 3.1 (SEM 0.4) cm²
Duration: 22 (SEM 1.9) vs 21 (SEM 2.7) months
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): Granuﬂex (Squibb Surgicare);
no further details
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): manufactured by Johnson &
Johnson; no further details
Compression: standard high-pressure graduated compression bandage 4 layers: Velband
(Johnson & Johnson) + crepe bandage + Elset (Seton Products) + Coban (3M Health
Care)
Other co-interventions: ulcers cleaned with saline prior to dressing
Outcomes Intervention 1: 22/30
Intervention 2: 23/30
Notes Funding type and details: not reported
Notes: study was in 2 parts which actually form 2 different randomised trials
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the ulcers were cleaned with saline
and the dressing applied according to ran-
domisation using a sequential system of
sealed envelopes with treatment allocation
by random number table”
Comment: an appropriate method for de-
riving the randomisation sequence was re-
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Blair 1988a (Continued)
ported
Allocation concealment (selection bias) Unclear risk Quote: “the ulcers were cleaned with saline
and the dressing applied according to ran-
domisation using a sequential system of
sealed envelopes with treatment allocation
by random number table”
Comment: unclear if the envelopes used
were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all participants were included
in the analysis
Selective reporting (reporting bias) Unclear risk Comment: there was no evidence of selec-
tive reporting
Other bias High risk Comment: it is unclear how the randomi-
sation was managed across the two trials re-
ported together
All domain risk of bias High risk
Blair 1988b
Methods RCT
Arms: 2 (see notes)
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: venous ulcers < 10 cm²
Exclusion criteria: ABPI < 0.8 on Doppler (arterial insufﬁciency)
Participant characteristics
Number participants: 120
Age: 70.1 (42 to 90) vs 67.3 (36 to 86) years
% male: not reported
Ulcer details
Size: 3.8 (SEM 0.6) cm² vs 3.4 (SEM 0.5) cm²
Duration 27.8 (SEM 3.4) months vs 33.4 (SEM 4.1)
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Interventions Intervention 1 class: nonadherent
Intervention 1 details (name and details of application): manufactured by Johnson &
Johnson; no further details
Intervention 2 class: SSD
Intervention 2 details (name and details of application): Flamazine (Smith & Nephew);
no further details
Compression: standard high-pressure graduated compression bandage 4 layers: Velband
(Johnson & Johnson) + crepe bandage + Elset (Seton Products) + Coban (3M Health
Care)
Other co-interventions: ulcers cleaned with saline prior to dressing
Outcomes Intervention 1: 24/30
Intervention 3: 19/30
Notes Funding type and details: not reported
Notes: Study was in 2 parts which actually form 2 different randomised trials
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the ulcers were cleaned with saline
and the dressing applied according to ran-
domisation using a sequential system of
sealed envelopes with treatment allocation
by random number table”
Comment: an appropriate method for de-
riving the randomisation sequence was re-
ported
Allocation concealment (selection bias) Unclear risk Quote: “the ulcers were cleaned with saline
and the dressing applied according to ran-
domisation using a sequential system of
sealed envelopes with treatment allocation
by random number table”
Comment: unclear if the envelopes used
were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all participants were included
in the analysis
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Blair 1988b (Continued)
Selective reporting (reporting bias) Unclear risk Comment: there was no evidence of selec-
tive reporting
Other bias High risk Comment: it is unclear how the randomi-
sation was managed across the two trials re-
ported together
All domain risk of bias High risk
Bowszyc 1995
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: leg
Follow-up: 16 weeks
Participants Inclusion criteria: chronic venous ulcer
Exclusion criteria: API < 0.8 (arterial insufﬁciency), diabetes, heavily exuding wounds,
necrotic tissue in ulcer, clinically infected wound, general poor state of health, immuno-
suppressed, receiving corticosteroid treatment
Participant characteristics
Number participants: 80
Age: 64.2 (14.4) vs 55.5 (14.7) years
% male: 12 (29) vs 15 (37)
Ulcer details
Size: 3.95 (6.89) cm² vs 3.47 (7.76) cm² (total ulcer area)
Duration: 26.2 (37.6) vs 36.1 (70.9) weeks
Interventions Intervention 1 class: foam
Intervention 1 details (name and details of application): Lyofoam; changed weekly or
when exudate leaked visibly through bandage
Intervention 2 class: hydrocolloid
Intervention 2 details (name and details of application): Granuﬂex; changed weekly or
when exudate leaked visibly through bandage
Compression: high compression bandage (Setopress)
Other co-interventions: sloughy wounds treated with sodium chloride solution (Chlo-
rasol) before entry to the study
Outcomes Intervention 1: 24/41
Intervention 2: 24/41
Notes Funding type: industry
Funding details: Seton Healthcare Group
Notes: 2 participants had ulcers on both legs and analysis was by leg giving n = 82
Risk of bias
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Bowszyc 1995 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were allocated to treat-
ment groups according to a pre-prepared
randomisation listing”
Comment: unclear how the randomisation
sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “patients were allocated to treat-
ment groups according to a pre-prepared
randomisation listing”
Comment: unclear how allocation conceal-
ment was undertaken
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 withdrew in each group for various rea-
sons
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias High risk There is uncertainty over the unit of analy-
sis as participants/legs/ulcers referred to in
different places, see notes
All domain risk of bias High risk
Brandrup 1990
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 8 weeks
Participants Inclusion criteria: ulcers with area between 1 cm² to 100 cm², with lowest edge in lower
two-thirds of the lower leg and upper edge above the malleoli. Negative patch tests to
the dressings
Exclusion criteria: not reported
Participant characteristics
Number participants: 43
Age: 73 (14) vs 77 (9) years
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% male: 5 (31)vs 2 (13)
Ulcer details
Non VLU: < 25% mixed/arterial - 7 (16%) arterial
Size: 13.7 cm² (15.9) vs 11.1 cm² (9.1)
Duration: median (range) 8 months (2 to 24) vs 5 months (1 to 68)
Interventions Intervention 1 class: nonadherent
Intervention 1 details (name and details of application): occlusive zinc-oxide medicated
dressing; Mezinc (Mölnlycke); applied to ulcer and 0.5 cm surrounding skin. Changed
daily for ﬁrst 14 days, then every third day
Intervention 2 class: hydrocolloid
Intervention 2 details (name and details of application): Duoderm; applied to ulcer and
0.5 cm surrounding skin. Changed daily for ﬁrst 14 days, then every third day
Compression: compression bandage Dauerbinde (Lohmann) used on venous ulcers
Other co-interventions: loosely attached necrotic material removed and ulcers cleaned
with 0.9% NaCl at each dressing change. Absorbent material used on top of dressings
for heavily discharging ulcers
Outcomes Intervention 1: 4/22
Intervention 2: 4/21
Notes Funding type and details: not reported
Notes: baseline stats were given for completers (n = 16 vs n = 15). For participants with
multiple ulcers, all were treated but only largest was monitored
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “pa-
tients were consecutively matched in pairs
within these two groups [venous and arte-
rial]” “from sealed envelopes, eachmember
of the pair was randomly allocated.”
Comment: no information on how the ran-
domisation sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “Pa-
tients were consecutively matched in pairs
within these two groups [venous and arte-
rial]” “from sealed envelopes, eachmember
of the pair was randomly allocated.”
Comment: no information on how alloca-
tion was concealed.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
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Brandrup 1990 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Data are only presented for completers
(withdrawal 27% vs 29% for various rea-
sons)
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing
Other bias Unclear risk Protocol was incorrectly followed in one
participant. No other evidence of other
sources of bias but reporting insufﬁcient to
be certain
All domain risk of bias High risk
Brown 2014
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks (24 weeks but optional cross-over at 12)
Participants Inclusion criteria: chronic venous ulcer (conﬁrmed with duplex or Doppler sonography
and ankle/brachial arterial Doppler pressure index between 0.8 and 1.3), duration be-
tween 3 months and 5 years, size 5 cm² to 40 cm², viable wound bed with granulation
tissue and no exposed muscle, tendon or bone
Exclusion criteria: ulcers of non-venous aetiology, signs of ulcer infection, medications
and therapies inhibiting wound healing, uncontrolled diabetes, uncontrolled organ fail-
ure, active malignancies, pregnant or nursing women
Participant characteristics
Number participants: 121
Age: 65.5 (13.3) vs 70.1 (13.8) years
% male: 28 (46.7) vs 30 (50.0)
Ulcer details
Size: mean (SD) 13.7 (8.2) cm² vs 13.4 (9.0) cm²
Duration: mean (SD) 18.9 months (16.0) vs 18.1 (15.3) months
Interventions Intervention 1 class: silica gel ﬁbre
Intervention 1 details (name and details of application): dressing 0.2 cm thick, cut to
exact size and applied at baseline visit. Re-application only took place if it was completely
absorbed
Intervention 2 class: mixed standard comparators
Intervention 2 details (name and details of application): Mepilex for exudative wounds
or Mepitel for non-exudative (Molnlycke Healthcare); dressing changed at least twice
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weekly, debridement or cleansing with isotonic sodium chloride solution was performed
as necessary
Compression: 4-layer bandaging system (Profore, Smith & Nephew) from toe to knee
Other co-interventions: complete sharp or ultrasonic debridement of all non-viable tissue
prior to initial dressing
Outcomes Intervention 1: 10/60
Intervention 2: 16/60
Notes Funding type: industry
Funding details: Bayer Innovation GmbH
Note: authors were contacted to conﬁrm that compression treatment was applied equally
to both groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the randomization list was gen-
erated by the Biometrical Department of
Winicker Norimed GmbH”
Comment: appears to be appropriate com-
puter-generated randomisation sequence
Allocation concealment (selection bias) Low risk Quote: “randomization numbers were as-
signed to eligible subjects in ascending
order at each centre. Enrolment of sub-
jects was competitive across all participat-
ing centres”
Comment: appears that central allocation
will have ensured adequate concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Trial was described as “open”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Trial was described as “open”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 127 entered study; 121 participants “ran-
domised and treated at least once”; 120
analysed
Selective reporting (reporting bias) Low risk No evidence of this
Other bias Low risk No evidence of other bias
All domain risk of bias High risk
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All domain risk of bias 2 High risk
Callam 1992
Methods RCT
Arms: 4 (factorial design; participants also randomised to different types of bandaging)
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: patients attending leg ulcer clinics with a VLU of at least 4 weeks
duration
Exclusion criteria: Doppler ultrasound ABPI < 0.8; unable to walk; on waiting list
for inpatient treatment; rheumatoid arthritis or diabetes; taking medication for venous
disorders, e.g. Paroven, Trental, stanozolol
Participant characteristics
Number participants: 132
Age: 63 vs 64 years
% male: 30 (45) vs 29 (44)
Ulcer details
Size: 8.35 cm² vs 10.87 cm2
Duration: 11.2 vs 11.7 months
Interventions Intervention 1 class: foam
Intervention 1 details (name and details of application): Allevyn (Smith and Nephew)
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): knitted viscose dressing (Trico-
tex)
Compression: factorial design - half participants randomised to elastic bandaging and
half to non-elastic bandaging
Other co-interventions: cleansed with water and if necessary loose debris and slough
removed physically. If appropriate surrounding skin treated for dry eczema (Betnovate
RD cream) or weeping eczema (2% aqueous eosin)
Outcomes Intervention 1:31/66
Intervention 2: 23/66
Notes Funding type: industry
Funding details: Smith and Nephew
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study described as randomised - currently
no additional information
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Allocation concealment (selection bias) Unclear risk Study described as randomised - currently
no additional information
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study described as “open”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study described as “open”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis
Selective reporting (reporting bias) Low risk No evidence of this
Other bias Low risk No evidence of other bias
All domain risk of bias High risk
All domain risk of bias 2 High risk
Caprio 1992
Methods RCT
Arms: 2
Unit of randomisation: ulcer
Unit of analysis: ulcer
Follow-up: 8 weeks
Participants Inclusion criteria: clean leg ulcers of venous origin
Exclusion criteria: not reported
Participant characteristics
Number participants: 93 with 98 ulcers
Age: not reported
% male: not reported
Ulcer details
Size: not reported
Duration: not reported
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): Duoderm E covered by gauze
and cotton bandage
Intervention 2 class: collagen
Intervention 2 details (name and details of application): lyophilised collagen tablets
covered by gauze and cotton bandage
Compression: not reported
Other co-interventions: not reported
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Outcomes Intervention 1: 25/47
Intervention 2: 20/49
Notes Funding type and details: not reported
Abstract only so information incomplete and numbers unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote “ulcers were randomised”
Comment: no information on how the ran-
domisation sequence was generated
Allocation concealment (selection bias) Unclear risk Quote “ulcers were randomised”
Comment: no information on how alloca-
tion was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “a clinical examination was made”
Comment: no information on who made
the assessment and whether they were
blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All ulcers were included in the analysis
Selective reporting (reporting bias) Unclear risk Insufﬁcient reporting to be certain whether
this was an issue
Other bias Unclear risk Insufﬁcient reporting to be certain whether
this was an issue
All domain risk of bias Low risk low/unclear
Casoni 2002
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 3 months
Participants Inclusion criteria: non-healing vascular leg ulcers (failed to reduce by 10% after 4 weeks
conventional treatment)
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Casoni 2002 (Continued)
Exclusion criteria: diabetes, severe peripheral atherosclerotic disease with ABPI < 0.6,
severe chronic cardiac or hepatic failure, nephrotic syndrome
Participant characteristics
Number participants: 65
Age: not reported
% male: not reported
Ulcer details
Size: not reported
Duration: not reported
Interventions Intervention 1 class: hyaluronic acid plus povidone iodine
Intervention 1 details (name and details of application): occlusive dressing with
hyaluronic acid and povidone iodine
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): no details
Compression: Unna bandage changed weekly
Other co-interventions: not reported
Outcomes Intervention 1: 15/32
Intervention 2: 8/33
Notes Funding type and details: not reported
Abstract only so information incomplete
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”65 homogeneous [sic] cases with
non-healing vascular leg ulcers were ran-
domized 4 weeks after conventional treat-
ment“
Comment: no information on how the ran-
domisation sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: ”65 homogeneous [sic] cases with
non-healing vascular leg ulcers were ran-
domized 4 weeks after conventional treat-
ment“
Comment: no information on how alloca-
tion was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information was reported on blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ”The main end point for this trial
was the time to complete healing, anyway a
comparison of images and of life tables up
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to 3 months of treatment was done.“
Comment: no information on who per-
formed the outcome assessment or whether
they were blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: ”Results: At the end of the study
48% of patients treated with occlusive
dressing and 24% to an NA pancement
[sic] had completely healed
Comment: Reportingwas insufﬁcient to be
sure whether all participants were included
in the analysis
Selective reporting (reporting bias) Unclear risk Reporting was insufﬁcient to know
whether this was an issue
Other bias Unclear risk Reporting was insufﬁcient to know
whether there were additional sources of
potential bias
All domain risk of bias Low risk Low/unclear
Charles 2002
Methods RCT
Arms: 3
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: ambulatory participants with venous leg ulcer 2 cm to 12 cm at widest
perpendicular diameter, ABPI > or = 0.8
Exclusion criteria: corticosteroid treatment within last 2 months, insulin-dependent
diabetics, allergy to test product, history of radiation or cytotoxic treatment near ulcer
site, primary arterial occlusive disease, HIV+, registered alcoholic, unlikely to comply
with treatment/follow-up
Participant characteristics
Number participants: 91
Age: mean (range) 71 (53-84) vs 72 (53-91) vs 72 (56-85) years
N (%) male: 15 (48) vs 12 (39) vs 13 (45)
Ulcer details
Size: mean (range) 881 (271 to 3182) mm² vs 930 (234 to 3642) mm² vs 1035 (205 to
3795) mm²
Duration: mean (range) 137 (4 to 1560) vs 95 (1 to 1560) vs 104 (3 to 1040) weeks
Interventions Intervention 1 class: foam
Intervention 1 details (name and details of application): Cutinova; applied according to
manufacturer’s instructions and changed as frequently as necessary
Intervention 2 class: hydrocolloid
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Intervention 2 details (name and details of application): Granuﬂex new formulation;
applied according to manufacturer’s instructions and changed as frequently as necessary
Intervention 3 class: hydrocolloid
Intervention 3 details (name and details of application): Comfeel; applied according to
manufacturer’s instructions and changed as frequently as necessary
Compression: short-stretch compression bandaging Comprilan (Beiersdorf UK)
Other co-interventions: secondary dressing of padding on bony prominences
Outcomes Intervention 1: 18/31
Intervention 2: 17/31
Intervention 3: 17/29
Notes Funding type: industry
Funding details: Biersdorf UK (BSN Medical)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly allocated
... using a minimisation method derived
from that of Pocock and Simon (1976)”
Comment: insufﬁcient information on
how the randomisation sequence was gen-
erated
Allocation concealment (selection bias) Unclear risk Quote: “patients were randomly allocate ...
using a minimisation method derived from
that of Pocock and Simon (1976)”
Comment: insufﬁcient information on
how allocation concealment was achieved
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information was reported on blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information was reported on blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: 7%withdrawal but all included
in analysis; some slight imbalance between
groups but unclear whether this was sufﬁ-
cient to impact analysis
Selective reporting (reporting bias) Low risk Comment: no evidence of selective report-
ing
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Other bias Low risk Comment: no evidence of other sources of
bias; extensive reporting
All domain risk of bias Low risk Low/unclear
De Araujo 2016
Methods RCT
Arms: 3
Unit of randomisation: participant
Unit of analysis: ulcer
Follow-up: 60 days
Participants Inclusion criteria: chronic venous ulcer > 5 cm², wound bed with devitalised tissues, no
use of venonic drugs or active topical agents for prior 2 weeks
Exclusion criteria: severely infected ulcer (criteria given) arterial or mixed aetiology, ABI
< 0.9 or chronic ulcer of other aetiology, pregnancy or breastfeeding
Participant characteristics
Number participants: 55 with 63 ulcers
Age: median (range) 62 (28 to 85) for all participants years
% male: 12 (57) vs 8 (42) vs 11 (48)
Ulcer details
Size: data presented on a graph only
Duration: mean (SD) 62.9 (2.9) vs 57.9 (3.4) vs 63.9 (3.5) months
Interventions Intervention 1 class: blood product
Intervention 1 details (name and details of application): ﬁbrin gel; gel prepared from
pool of 5 cryoprecipitate units, 100 I/mL puriﬁed human thrombin cryoprecipitate, 6%
vitamin A and E, 5% calcium gluconate in carbopol gel; participants received pack and
instructions and followed up every 15 days
Intervention 2 class: papain
Intervention 2 details (name and details of application): papain gel; 8% papain in car-
bopol gel; participants received pack and instructions and followed up every 15 days
Intervention 3 class: placebo
Intervention 3 details (name and details of application): carbopol gel (carrier vehicle used
for the other interventions); participants received pack and instructions and followed up
every 15 days
Compression: Compressive elastic bandage (Surepress)
Other co-interventions: wound bed ﬂushed with warm 0.9% saline at dressing changes
Outcomes Intervention 1: 3/21
Intervention 2: 4/19
Intervention 3: 7/23
Notes Funding type: non-industry
Funding details: funded by Botucatu Medical School, and Boston Medical Device do-
nated high compression bandages
88Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
De Araujo 2016 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “randomization protocol was based
on numbers randomly generated by soft-
ware”
Comment: appropriate method of ran-
domisation sequence generation
Allocation concealment (selection bias) Low risk Quote: “the pharmacist ... prepared all the
products which were numbered and sim-
ilar in appearance and presentation. The
pharmacist kept the envelopes and the ran-
domization list. The investigators were un-
blinded only by the end of the study”
Comment: appears that allocation conceal-
ment was adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the pharmacist ... prepared all the
products which were numbered and sim-
ilar in appearance and presentation. The
pharmacist kept the envelopes and the ran-
domization list. The investigators were un-
blinded only by the end of the study”
Comment: appears that both personnel
and participants were blinded to treatment
allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the investigators were unblinded
only by the end of the study”
Comment: presume this means they were
blinded for duration of study including for
outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “no dropouts, data presented for
all”
Selective reporting (reporting bias) Low risk Comment: no evidence of selective report-
ing
Other bias Low risk Comment: no evidence of other bias; ade-
quate reporting
All domain risk of bias Low risk
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Dereure 2012a
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 60 days
Participants Inclusion criteria: in- or outpatient with at least one leg ulcer of venous ormixed aetiology
of 2 months to 4 years duration, surface area 5 cm² to 40 cm² with no necrotic tissue,
suitability to and use of compression therapy, ABPI > 0.8, albuminaemia > 25 g/L,
history of DVT or clinical evidence of post-thrombotic syndrome or Doppler evidence
of residual thrombosis or a reﬂux on the venous system. If more than one ulcer, target
ulcer selected as best meeting inclusion criteria
Exclusion criteria: ulcer of non-vascular origin or due to general cause, signiﬁcant arterial
insufﬁciency (ABPI < 0.8), clinical suspicion of infection, hepatic or renal failure, venous
thrombosis within previous 3 months, diabetes, allergy to local anaesthetic or study
treatment, treatment that delays healing process
Participant characteristics
Number participants: 101 (multiple ulcers, one selected per participant)
Age: 68.6 (12.4) vs 69.7 (14.7) years
N (%) male: 23 (46) vs 22 (43)
Ulcer details
Non VLU: not clearly reported how many had mixed aetiology
Size: median (range) 11.1 (2.8 to 39.3) cm² vs 11.7 (3.67 to 41.1) cm²
Duration: median (range) 7.5 (1 to 48) months vs 9.0 (2 to 42) months
Interventions Intervention 1 class: hyaluronic acid
Intervention 1 details (name and details of application): Ialuset cream (Laboratoires
Genevrier); applied daily, in a 2 mm to 3 mm-thick layer, then covered with a bandage
(grade 2 or 3) in accordance with standard care
Intervention 2 class: placebo
Intervention 2 details (name and details of application): same formulation as Ialuset
cream without hyaluronic acid (Laboratoires Genevrier); applied daily, in a 2 mm to 3
mm-thick layer, then covered with a bandage (grade 2 or 3) in accordance with standard
care
Compression: type 2 long-stretch elastic (90% participants) or multilayer bandages
Other co-interventions: systemic antibiotics could be used if clinically relevant infection
Outcomes Intervention 1: 3/50
Intervention 2: 4/51
Notes Funding type: industry
Funding details: Laboratoires Genevrier
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”the randomisation list was gen-
erated by a computer and prepared by
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Dereure 2012a (Continued)
the data management and statistics unit of
IBSA using validated software“
Comment: an appropriate method was
used to generate the randomisation se-
quence
Allocation concealment (selection bias) Unclear risk Quote: ”the randomisation list was gen-
erated by a computer and prepared by
the data management and statistics unit of
IBSA using validated software“
Comment: not clear how allocation con-
cealment was ensured although remote
management of randomisation suggests it
may have been adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”both treatments were supplied in
the same form, external packaging, shape,
odour and texture, in order to maintain the
double blinding“
Comment: effective double-blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”treatment allocation and evalua-
tion were assessed by a blinded physician“
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ”The primary analysis was con-
ducted on an intention-to-treat (ITT) basis
on all randomised patients who received, at
least once, the allocated treatments
Comment: ITT analysis - 0 patients re-
ceived no treatments
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk Quote: “in patients with multiple ulcers,
only one ulcer was selected by the inves-
tigator (on the basis that it complied best
with the inclusion criteria)”
Comment: if allocation concealment/
blinding was effective this would not
present a risk, allocation concealment has
an unclear risk of bias, however
All domain risk of bias Low risk Low/unclear
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Dimakakos 2009
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 9 weeks
Participants Inclusion criteria: infected venous leg ulcer(s) with clinical signs of inﬂammation
Exclusion criteria: pregnancy, psychiatric disorders, diabetes, collagen disease, steroid
use, history of allergies, ABPI < 1
Participant characteristics
Number participants: 42
Age; 61.2 vs 58.7 years
N (%) male: 9 (43) vs 7 (33)
Ulcer details
Size: diameter = 2.37 cm vs 2.23 cm
Duration: not reported
Interventions Intervention 1 class: silver
Intervention1details (name anddetails of application):Contreet Ag (Coloplast); dressing
size 10 cm x 10 cm or 15 cm x 15 cm depending on ulcer size. Changed twice a week
Intervention 2 class: foam
Intervention 2 details (name and details of application): Biatain (Coloplast); dressing
size 10 cm x 10 cm or 15 cm x 15 cm depending on ulcer size. Changed twice a week
Compression: short-stretch bandage
Other co-interventions: wounds cleansed with sterile water and 10% povidone iodine
solution (Betadine, Lavipharm Hellas) prior to initial dressing
Outcomes Intervention 1: 17/21
Intervention 2: 10/21
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “forty-two patients were included
in the study and were randomized into two
groups.”
Comment: unclear whether an appropriate
method was used to generate the randomi-
sation sequence
Allocation concealment (selection bias) Unclear risk Quote: “forty-two patients were included
in the study and were randomized into two
groups.”
Comment: unclear whether an appropriate
method was used to ensure allocation con-
cealment
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Dimakakos 2009 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in the anal-
ysis
Selective reporting (reporting bias) Low risk There was no evidence of selective outcome
reporting
Other bias Unclear risk There was no evidence of other sources of
bias but reporting was not sufﬁcient to be
certain
All domain risk of bias Low risk Low/unclear
Fogh 2012
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 6 weeks
Participants Inclusion criteria: moderately to highly exuding, painful (at least 4 on 11 point scale)
VLUon lower limb.Duration > 8weeks, ABI > 0.8, size 1.6 cm to 11 cm in any direction.
Treated with moist wound-healing dressings and compression for 2 weeks prior
Exclusion criteria: use of per need medication in 3 days prior, painful ulcer resistant
to analgesics for 6 months, hypersensitivity to study products, infection, vasculitis,
erysipelas, cellulitis, contraindication to analgesics, diabetes, use of systemic antibiotics
corticosteroids, immunosuppressants cancer chemotherapy, pregnancy or lactation
Participant characteristics
Number participants: 120
Age: 71.6 (12.8) vs 69.5 (12.5) years
% male: 18 (30) vs 20 (33)
Ulcer details
Size: mean (SD) 9.1 (10.9) cm² vs 12.2 (9.4) cm², median (range) 4.82 (1.09 to 57.6)
cm² vs 8.18 (0.93 to 40.1) cm²
Duration: mean (SD) 1.5 (3.0) vs 11.5 (2.5) years
Interventions Intervention 1 class: ibuprofen-releasing foam
Intervention1details (name anddetails of application): Biatain IbuNon-Adhesive (Colo-
plast) [foam]
Intervention 2 class: foam
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Fogh 2012 (Continued)
Intervention 2 details (name and details of application); Biatain Non-Adhesive (Colo-
plast)
Compression: use of compression mandatory, appropriate compression selected by inves-
tigator. No change in compression type during ﬁrst 5 days of study. Actual compression
used included short stretch (48% vs 50%), long stretch (32% vs 42%), 4 layer (5% vs
0%), other mainly compression stockings (15% vs 8%)
Other co-interventions: not reported
Outcomes Intervention 1: 9/60
Intervention 2: 11/60
Notes Funding type: industry
Funding details: Coloplast
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “by using the IVRS, the subjects
were centrally randomized and allocated to
one of the two treatment groups.”
Comment: external company randomised
participants centrally using interactive
voice response system. Stratiﬁcation by
pain intensity
Allocation concealment (selection bias) Low risk Quote: “by using the IVRS, the subjects
were centrally randomized and allocated to
one of the two treatment groups.”
Comment: appropriate methods to ensure
allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “therefore, allocation of treatment
to each patient was blinded to the clini-
cians, the patient, and the sponsor.”
Comment: blinding of relevant groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the ulcer margins were traced on
wound tracing sheets and ulcer area and
perimeter were calculated at Coloplast A/
S”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 12/60 vs 15/60 withdrawals,
reasons given but a high number
Selective reporting (reporting bias) Low risk Comment: no evidence of selective report-
ing
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Fogh 2012 (Continued)
Other bias Low risk Comment: no evidence of other sources of
bias and reporting sufﬁcient to be reason-
ably conﬁdent
All domain risk of bias High risk
Gottrup 2008
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 42 days
Participants Inclusion criteria: painful chronic venous leg ulcer > 8 weeks duration, diagnosis based
on ABPI > 0.8, duplex scan/phlebography, clinical diagnosis, toe pressure and palpable
foot pulse. Minimum length 1.6 cm, maximum area 50 cm². Minimum moderate pain
score on 5-point verbal rating scale
Exclusion criteria: painful ulcers resistant to analgesic treatment for 6+ months, pregnant
or lactating women, clinical infection, local infection or bacterial imbalance, vasculitis,
allergy to ibuprofen or related analgesics, history of asthma, rhinitis or urticaria, diabetes,
use of various medications
Participant characteristics
Number participants:122
Age: 66.0 (14.8) vs 70.0 (11.7) years
% male: 19 (31) vs 23 (38)
Ulcer details
Size: mean (SD) 11.0 (9.6) cm² vs 7.3 (5.7) cm²
Duration: mean (SD) 23.1 (42.9) months vs 19.8 (41.8) months
Interventions Intervention 1 class: ibuprofen
Intervention 1 details (name and details of application): Biatain-Ibu Non-Adhesive foam
dressing (Coloplast A/S); dressing changed every 48 hours
Intervention 2 class: foam
Intervention2details (name anddetails of application): BiatainNon-Adhesive (Coloplast
A/S); dressing changed every 48 hours
Compression: compression use required for 2 weeks prior to inclusion and throughout
study period. Same compression to be used throughout and to keep a constant circum-
ference at the ankle
Other co-interventions: not reported
Outcomes Intervention 1: 8/62
Intervention 2: 8/60
Notes Funding type: industry
Funding details: Coloplast A/S
Risk of bias
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Gottrup 2008 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomization in closed envelopes
took place after inclusion and before study
initiation. The patients were randomized
1:1 either to the ibuprofen-foam group or
to the comparator group. Block random-
ization was applied in blocks of 4.”
Comment: unclear how the blocked ran-
domisation sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “randomization in closed envelopes
took place after inclusion and before study
initiation ... The randomization was car-
ried out before packaging of the products,
which were packed and labelled speciﬁcally
for each patient due to the blinding.”
Comment: not completely clear how allo-
cation concealment was achieved
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “study personnel and patients were
blind to treatment” “both dressings were
specially designed for this double-blind
study to be anonymous with the use of top-
ﬁlms without any print”
Comment: blinding of these groups
recorded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the ulcer area was assessed with
wound tracings of the ulcermargins at base-
line, at days 15, 29, and at day 42. Wound
healing was also tested using a linear heal-
ing parameter”
Comment: it was not clear who performed
the outcome assessment but since person-
nel were blinded it was likely to have been
a blinded assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “there were 29 dropouts: 16 in the
ibuprofen-foam group and 13 in the com-
parator group”; at 42 day crossover point
these numbers were 15 vs 11
Comment: there were a substantial number
of dropouts who were not included in the
analysis
Selective reporting (reporting bias) Low risk Comment: there was no evidence of selec-
tive reporting of outcomes
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Gottrup 2008 (Continued)
Other bias Low risk Comment: there was no evidence of other
bias and reporting was sufﬁcient to be rea-
sonably conﬁdent
All domain risk of bias High risk
Greguric 1994
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: until healing or 10 dressings used but dressing changes were at different
frequencies in the two groups (2.10 days vs 1.01 days)
Participants Inclusion criteria: venous ulcer 2.5 cm to 5 cm diameter. Diagnosis based on medical
history and ABPI > or = 0.9
Exclusion criteria: ulcer due to arterial insufﬁciency, rheumatoid arthritis, sickle cell
disease, known sensitivity to treatment materials, malignant ulcers, malignant disease
including use of antineoplastic agents, corticosteroid treatment > 5mgprednisolone daily,
immune deﬁciency, use of immune suppressive drugs, pregnancy, conditions causing
abnormal wound healing, those better treated by alternative regimen
Participant characteristics
Number participants: 110
Age: 61 (15) vs 61 (13) years
% male: 21 (38) vs 24 (44)
Ulcer details
Size: not reported
Duration: median (95% central range) 1737 (15902) days vs 1987 (12218) days
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): Varihesive E; 10cm x 10cm
dressing. Held in place with tubular gauze over lower leg. Changed before the softened
area reached the edge of the dressing or when leakage occurred
Intervention 2 class: magnesium sulphate paste
Intervention 2 details (name and details of application): approximately 15 g magnesium
sulphate paste spread into ulcer, Vaseline type ointment rubbed gently onto surrounding
skin, then ulcer covered with approximately 6 pieces of sterile gauze
Compression: two tubular bandages used to create toe-to-knee compression
Other co-interventions: ulcer cleansed with mixture of normal saline and hydrogen
peroxide solution and dried with sterile gauze
Outcomes Intervention 1: 3/55
Intervention 2: 0/55
Notes Funding type and details: not reported
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Greguric 1994 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: study described as randomised
but no details given on how sequence was
generated
Allocation concealment (selection bias) Unclear risk Quote: “a sealed envelope with the next
consecutive patient number was then
opened todeterminewhich dressing the pa-
tient had been randomized to receive”
Comment: unclear whether envelopes were
opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: it appears that all participants
were included in the analysis
Selective reporting (reporting bias) Low risk Comment: there was no evidence of selec-
tive reporting
Other bias High risk Comment: duration of study was 10 dress-
ing changes and frequency of dressing
change was different in the two groups
All domain risk of bias High risk
Hanft 2006
Methods RCT
Arms: 2
Unit of randomisation: unclear
Unit of analysis: unclear
Follow-up: 12 weeks
Participants Inclusion criteria: ≥18 years; VLU ulcer area > 3 cm² but < 25 cm²; ulcer open for > 1
month but < 18 months; ABI > 0.8, HbA1c < 10; free of clinical signs of infection
Exclusion criteria: prior treatment with becaplermin or other topical recombinant ther-
apy within 30 days; prior treatment with skin substitute or growth factor; signiﬁcant
acute or chronic disease; enzymatic debridement in previous 7 days
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Hanft 2006 (Continued)
Participant characteristics
Number participants: 49
Age: not reported
% male: not reported
Ulcer details
Size: mean 6.9 cm² vs 5.6 cm²
Duration: mean 4.3 months vs 5.1 months
Interventions Intervention 1 class: PMM silver
Intervention 1 details (name and details of application): protease-modulating matrix +
silver dressing + hydrocolloid dressing: collagen, silver & oxidised regenerated cellulose
matrix dressing + hydrocolloid (Collagen/ORC + silver + Adaptic®)
Intervention 2 class: hydrocolloid
Intervention 2 details (name and details of application); hydrocolloid dressing: non-
adherent petrolatum impregnated dressing (Adaptic® (Johnson & Johnson)); (n = 27;
duration 12 weeks)
Compression: standardised compression therapy
Other co-interventions: prior treatment: 1 week run in with standardised leg compres-
sion; debridement
Outcomes Intervention 1: 14/22
Intervention 2: 16/27
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “randomized, prospective, open-la-
bel, multicenter, comparative trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “randomized, prospective, open-la-
bel, multicenter, comparative trial”
Comment: outcome assessors likely to be
unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote from author communication: “in-
tervention group 9% (2/22) did not com-
plete the study, 1 was lost to follow up
and 1 chose to withdraw. In the control
group 11% (3/27) did not complete, 2 sub-
jects died from severe AEs (unrelated to the
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Hanft 2006 (Continued)
study interventions) and one chose to with-
draw.” Healing risks were 64% and 59%
Selective reporting (reporting bias) High risk Limited reporting of results - some ob-
tained from the author, but some protocol
outcomes not reported
Other bias Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
All domain risk of bias High risk
Hansson 1998
Methods RCT
Arms: 3
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: exudating or sloughy venous leg ulcer 1 cm² to 100 cm² on lower leg
Exclusion criteria: systolic ankle pressure < 80 mmHg or systolic ankle/arm index < 0.8,
clinical infection in or around ulcer with redness and pain, diabetes, known sensitivity to
study products, treatment with systemic antimicrobials or study product in week before
trial, systemic corticosteroids or cytostatic drugs in 4 weeks before trial, disease that could
affect ulcer healing, undergoing investigation of thyroid gland
Participant characteristics
Number participants: 153
Age: 74 vs 74 vs 72 years
N (%) male: 48 (31)
Ulcer details
Size: 8.8 (11.9) cm² vs 10.7 (20.6) cm² vs 7.1 (7.1) cm²
Duration: not reported
Interventions Intervention 1 class: cadexomer iodine
Intervention 1 details (name and details of application): cadexomer iodine paste Iodosorb
(Perstorp AB); changed when moisture saturated
Intervention 2 class: hydrocolloid
Intervention 2 details (name and details of application): Duoderm E (ConvaTec);
changed when leaking or saturated with ﬂuid
Intervention 3 class: nonadherent
Intervention 3 details (name and details of application) parafﬁn gauze; Jelonet (Smith
& Nephew); changed when leaking or saturated with ﬂuid
Compression: short stretch bandage; Comprilan (Beiersdorf AG)
Other co-interventions: not reported
Outcomes Intervention 1: 8/56
Intervention 2: 5/48
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Hansson 1998 (Continued)
Intervention 3: 7/49
Notes Funding type: industry
Funding details: Perstorp Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomized to re-
ceive one of three treatments”
Comment: no detail ofmethod of sequence
generation
Allocation concealment (selection bias) Unclear risk Quote: “patients were randomized to re-
ceive one of three treatments”
Comment: no information on allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants withdrawn due to reasons un-
related to efﬁcacy were excluded from anal-
ysis (18%) but those who withdrew for
reasons related to efﬁcacy (11%) were in-
cluded
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing
Other bias Unclear risk There was no evidence of other sources but
reporting was limited
All domain risk of bias High risk
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Harcup 1986
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 4 weeks (8 weeks, cross-over at 4 weeks)
Participants Inclusion criteria: aged over 30, exuding chronic venous ulcers of lower limbs, not
responding favourably to existing treatments
Exclusion criteria: concomitant serious or life-threatening disease, suspected malignant
change in ulcer, insulin-dependent diabetes, pregnancy, iodine-sensitivity, psychiatric
disease, very low intelligence, dementia or other condition affecting patient compliance
Participant characteristics
Number participants: 72
Age: mean (range) 67.8 (40 to 85) years
N (%) male: 22 (31)
Ulcer details
Size: 7.74 (1.04) cm² vs 9.08 (1.37) cm²
Duration: mean (range) 16.9 (1 to 256) months
Interventions Intervention 1 class: cadexomer iodine (CI)
Intervention 1 details (name and details of application): cadexomer iodine microbeads;
Iodosorb (Stuart Pharmaceuticals and Perstorp AB) applied to the whole ulcer area - at
least 3 mm depth and covered with dry sterile dressing. CI replaced daily, ulcer cleaned
using sterile wet swab, stream of water or saline and/or soaking
Intervention 2 class: standard dressing (various)
Intervention 2 details (name and details of application): “Dry dressing” or elastocrepe
bandaging, Sofra-Tulle, Melolin, Polyfax ointment, Betadine ointment, Dermicel tape,
Aserbine cream, Gamgee tissue, Flamazine cream, Tubigrip, bactigras. Generally a dry
dressing plus support bandaging. Use of a topical antibacterial cleanser (e.g. Eusol)
permitted
Compression: support bandaging or stocking
Other co-interventions: not reported
Outcomes Intervention 1: 13/41
Intervention 2: 1/31
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomised to re-
ceive either standard dressing or CI”
Comment: sequence generation methods
were not reported.
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Harcup 1986 (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “patients were randomised to re-
ceive either standard dressing or CI”
Comment: allocation concealment was not
reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: it appears that all participants
were included in the 4 week analysis al-
though two participants assigned to stan-
dard treatment received CI so were in-
cluded in that group instead
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing of outcomes
Other bias Unclear risk There was no evidence of other sources of
bias but reporting insufﬁcient to be sure
All domain risk of bias Low risk Low/unclear
Harding 2001
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: not reported in available copy
Exclusion criteria: not reported in available copy
Participant characteristics
Number participants: 131
Age: not reported
% male: not reported
Ulcer details
Size: not reported
Duration: not reported
Interventions Intervention 1 class: hydroﬁbre
Intervention 1 details (name and details of application): Aquacel (ConvaTec) frequency
of dressing change according to clinical need, could be left up to 7 days
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Harding 2001 (Continued)
Intervention 2 class: alginate
Intervention 2 details (name and details of application): Sorbsan (Maersk) frequency of
dressing change according to clinical need, could be left up to 7 days
Compression: Class 3c bandage (SurePress, ConvaTec Ltd) over orthopaedic padding
Other co-interventions: if wound became infected, systemic antibiotic prescribed and,
if in alginate group, dressing changed daily
Outcomes Intervention 1: 17/66
Intervention 2: 17/65
Notes Funding type and details: industry
Funding details: Convatec Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “an open, prospective, randomized,
controlled, multicenter evaluation”
Comment: no information on how the ran-
domisation sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “an open, prospective, randomized,
controlled, multicenter evaluation”
Comment: no information on how alloca-
tion was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “an open, prospective, randomized,
controlled, multicenter evaluation”
Comment: The trial had an open design
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “an open, prospective, randomized,
controlled, multicenter evaluation”
Comment: the trial had an open design
Incomplete outcome data (attrition bias)
All outcomes
Low risk It appeared that all participants were in-
cluded in the ITT analysis
Selective reporting (reporting bias) Low risk Comment: there was no evidence of selec-
tive outcome reporting
Other bias Unclear risk Comment: there was no evidence of other
sources of bias but the reporting was insuf-
ﬁcient to be sure
All domain risk of bias High risk
All domain risk of bias 2 High risk
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Hokkam 2011
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 8 weeks
Participants Inclusion criteria: single chronic venous leg ulcer (clean and with healthy granulation
tissue)
Exclusion criteria: allergy to phenytoin, Marjolin’s ulcers, ulcers with infected gangrene,
multiple ulcers, surgery within previous 6 months
Participant characteristics
Number participants: 104
Age: 47.3 (6.4) vs 45.9 (3.8) years
N (%) male: 21 (38.9) vs 21 (42)
Ulcer details
Size: 5.7 (2.8) cm² vs 6.1 (3.1) cm²
Duration: 3.1 (1.3) weeks vs 3.9 (1.0) weeks
Interventions Intervention 1 class: phenytoin
Intervention 1 details (name and details of application): phenytoin lotion; thin layer of
phenytoin applied then covered with gauze. Daily dressing
Intervention 2 class: placebo
Intervention 2 details (name and details of application) placebo unclear, saline stated,
possibly covered with gauze
Compression: compression bandage
Other co-interventions: oral phlebotrophic drug (Diosmin). Washed with normal saline
Outcomes Intervention 1: 35/54
Intervention 2: 26/50
Notes Funding type and details: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the study was carried out as ran-
domized controlled trial.” “they were di-
vided into study group and control group
using coin ﬂipping technique”
Comment: Coin toss represents an ade-
quate method of sequence generation
Allocation concealment (selection bias) Unclear risk Quote: “the study was carried out as ran-
domized controlled trial.”
Comment: no information on how alloca-
tion was concealed
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Hokkam 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk There was no information on this
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “the ulcer status was assessed every
week and at the end of the eight weeks the
ulcer’s condition was evaluated as complete
healing, partial healing, no improvement
and worsening”
Comment: no information on who per-
formed the evaluation
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were evaluated
Selective reporting (reporting bias) Low risk There was no evidence of selective outcome
reporting.
Other bias Unclear risk There was no evidence of other sources of
bias but reporting insufﬁcient to be certain
All domain risk of bias Low risk Low/unclear
Humbert 2013
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 60 days
Participants Inclusion criteria: venous or mixed leg ulcers, present for 2 months to 4 years, 5 cm²
to 40 cm², no necrotic tissue, history/evidence of DVT or post-thrombotic syndrome,
post-phlebitic sequels, reﬂux on venous system, ABPI 0.8+. No use of HA in previous 3
months. Use of compression device. If several, target ulcer selected
Exclusion criteria: ulcer of non-vascular or general cause, diabetes, arterial insufﬁciency
(ABPI < 0.8), hepatic or renal failure, recent history of venous thrombosis (< 3 months)
, pregnancy or breastfeeding, allergy to local anaesthetic or study materials, treatment
delaying healing process
Participant characteristics
Number participants: 89
Age: mean (SEM) 59.4 (2.5) vs 64.1 (2.7) years
N (%) male: 25 (55.6) vs 20 (45.5)
Ulcer details
Non VLU - not clear
Size: Mean (SEM) 13.8 (1.3) cm² vs 12.9 (1.3) cm²
Duration: Mean (SD) 12.4 (12.3) vs 12.8 (12.2) months
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Humbert 2013 (Continued)
Interventions Intervention 1 class: hyaluronic acid (HA)
Intervention 1 details (name and details of application): 0.05% hyaluronic acid impreg-
nated cotton gauze pad, Ialuset (Laboratoires Genevrier), pad applied then covered with
sterile gauze and appropriate bandage. Changed daily
Intervention 2 class: placebo
Intervention 2 details (name and details of application): neutral vehicle pad; Ialuset
without HA (Laboratoires Genevrier); pad applied then covered with sterile gauze and
appropriate bandage. Changed daily
Compression: type 2 compression with long stretching elastic bandage (> 96% partici-
pants)
Other co-interventions: surgical wound excision procedures, systemic analgesia, systemic
antibiotics used if necessary
Outcomes Intervention 1: 17/45
Intervention 2: 7/43
Notes Funding type and details: industry
Funding details: Laboratoires Genevrier
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”for each patient included in the
study, a target ulcer was selected by the in-
vestigator and randomly assigned to be lo-
cally treated“
Comment: unclear how the randomisation
sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: ”for each patient included in the
study, a target ulcer was selected by the in-
vestigator and randomly assigned to be lo-
cally treated
Comment: unclear how the allocation was
concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “double-blind clinical trial”
Comment: it was not clearwhowas blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “double-blind clinical trial”
Comment: it was not clearwhowas blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All except one participant, who died, were
included in the analysis
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Humbert 2013 (Continued)
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing
Other bias High risk Unclear how the investigator selected the
target ulcer; potential for bias here given
the lack of clarity over risk of selection bias
All domain risk of bias High risk
Ivins 2006
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 4 weeks
Participants Inclusion criteria: chronic venous or mixed venous/arterial e.g. ulcers with delayed heal-
ing
Exclusion criteria: not reported
Participant characteristics
Number participants: 45
Age: not reported
% male: not reported
Ulcer details
Non VLU - unclear how many mixed venous/arterial ulcers
Size: not reported
Duration: not reported
Interventions Intervention 1 class: silver
Intervention 1 details (name and details of application): not reported
Intervention 2 class: foam
Intervention 2 details (name and details of application): not reported
Compression: not reported
Other co-interventions: not reported
Outcomes Intervention 1: 2/25
Intervention 2: 1/20
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “[the patients] were re-randomised
to receive treatment with either the silver
foam or the non-silver foam”
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Ivins 2006 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details
Selective reporting (reporting bias) Unclear risk Abstract only so limited reporting
Other bias Unclear risk Not enough information to judge
All domain risk of bias Low risk Unclear
Jull 2008
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: venous ulcer (ankle brachial pressure index > 0.8) or mixed venous/
arterial ulcer (ankle brachial pressure index > 0.7), can tolerate compression
Exclusion criteria: history of diabetes, rheumatoid arthritis or peripheral arterial disease,
allergy to calcium alginate or Manuka honey, already using honey treatment
Participant characteristics
Number participants: 368
Age: 66.9 (17.5) vs 68.3 (17.1) years
N (%) male: 91 (48) vs 89 (49)
Ulcer details
Non VLU: 2 (1%) vs 5 (3%) mixed
Size: median (range) 2.7 (0.1 to 193) cm² vs 2.6 (0.2 to 81) cm²
Duration: median (range) 20 (3 to 688) weeks vs 16 (2 to 999) weeks
Interventions Intervention 1 class: honey
Intervention 1 details (name and details of application): Manuka-honey-impregnated
calcium alginate; Apinate UMF 12+ (Comvita New Zealand); changed at frequency
determined by clinical need
Intervention 2 class: standard care
Intervention 2 details (name and details of application): usual care; various dressings
(alginate, hydroﬁbre, hydrocolloid, foam, hydrogel, nonadherent, iodine, silver); dressing
dependent on local availability and as deemed appropriate by district nurse
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Jull 2008 (Continued)
Compression: all received compression bandaging varying according to range available
at study centres and nurse/patient choice
Other co-interventions: not reported
Outcomes Intervention 1: 104/187
Intervention 2: 90/181
Notes Funding type: Mixed
Funding details: Funding both non-industry (Health Research Council of NewZealand)
and industry (Comvita New Zealand, USL Medical)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “participants were randomly as-
signed to one of two groups by an indepen-
dent central telephone service; The alloca-
tion sequence was stratiﬁed by study cen-
tre and theMargolis index using minimiza-
tion.”
Comment: appears that an appropriate
method was used to generate the randomi-
sation sequence
Allocation concealment (selection bias) Low risk Quote: “participants were randomly as-
signed to one of two groups by an indepen-
dent central telephone service”
Comment: appears that appropriate meth-
ods were used to conceal allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “this open-label, multicentre ran-
domized controlled trial”
Comment: the trial was open label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “the primary outcome measure
was….Determined by the research nurse.
The research nurse was not blind to alloca-
tion”
Comment: unblinded outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in the ITT
analysis
Selective reporting (reporting bias) Low risk There was no evidence of selective outcome
reporting
Other bias Low risk There was no evidence of other potential
sources of bias
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Jull 2008 (Continued)
All domain risk of bias High risk
All domain risk of bias 2 High risk
Jørgensen 2005
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 4 weeks
Participants Inclusion criteria: moderately or highly exuding, chronic venous ormixed venous/arterial
leg ulcer with delayed healing (0.5 cm² or less area reduction) and at least one sign of
critical colonisation (increased exudate, increased pain, discolouration of granulation
tissue, foul odour) in past 4 weeks, ABI > 0.65, compression therapy for past 4 weeks,
ulcer dimension > 2 cm² and ﬁtting within 10x10cm dressing with 1.5 cm edge
Exclusion criteria: clinical infection including erysipelas and cellulitis of peri-ulcer skin,
treatment with antiseptics or antibiotics from 1 week prior to inclusion, uncontrolled
diabetes, treatment with systemic corticosteroids > 10 mg/day, immunosuppressants
from 4 weeks prior to inclusion, diseases that may interfere with ulcer healing
Participant characteristics
Number participants: 129
Age: median (range) 72.0 (40 to 99) vs 75.5 (42 to 90) years
N (%) male: 21(32) vs 26 (41)
Ulcer details
Non VLU - not clear
Size: median (range) 6.1 (1.1 to 53.4) cm² vs 6.7 (1.3 to 50.6) cm²
Duration: median (range) 1.1 (0.1 to 32.0) years vs 1.0 (0.1 to 10.0) years
Interventions Intervention 1 class: silver
Intervention 1 details (name and details of application): silver foam;Contreet (Coloplast)
; dressing changes left as long as clinically possible - max 7 days
Intervention 2 class: foam
Intervention 2 details (name and details of application): Allevyn (Smith & Nephew)
Compression:mandatory compression (according to clinical practice of treatment centre)
Other co-interventions: wound cleansed with sterile saline or tap water at dressing
changes. When necessary, peri-ulcer area treated with mild zinc cream (Conveen) or
topical steroid ointment
Outcomes Intervention 1: 5/65
Intervention 2: 5/64
Notes Funding type and details: industry
Funding details: Coloplast A/S
Risk of bias
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Jørgensen 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomised ... by
computer-generated randomisation”
Comment: appropriate method of ran-
domisation
Allocation concealment (selection bias) Unclear risk Quote: “patients were randomised ... by
computer-generated randomisation”
Comment: no information on how alloca-
tion was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all participants included in ITT
analysis, PP analysis also performed exclud-
ing participants withdrawn for protocol vi-
olation
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing
Other bias Low risk There was no evidence of other forms of
bias
All domain risk of bias Low risk Low/unclear
Kalis 1993
Methods RCT
Arms: 2
Unit of randomisation: unclear
Unit of analysis: ulcer
Follow-up: 56 days
Participants Inclusion criteria: leg ulcer of venous or mixed origin
Exclusion criteria: not reported
Participant characteristics
Number participants: 89 participants with 109 ulcers
Age: not reported
% male: not reported
Ulcer details
Non VLU - some unknown
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Kalis 1993 (Continued)
Size: not reported
Duration: not reported
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): Granuﬂex
Intervention 2 class: dextranomer
Intervention 2 details (name and details of application): paste covered by dressing and
cotton band
Compression: not reported
Other co-interventions: not reported
Outcomes Intervention 1: 13/54
Intervention 2: 10/54
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “we carried out an open, compara-
tive and randomised good clinical practice
(GCP) trial”
Comment: no information on how ran-
domisation sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “we carried out an open, compara-
tive and randomised good clinical practice
(GCP) trial”
Comment: no information on how alloca-
tion was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “we carried out an open, compara-
tive and randomised good clinical practice
(GCP) trial”
Comment: open trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “we carried out an open, compara-
tive and randomised good clinical practice
(GCP) trial”
Comment: open trial
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “drop-outs were more frequent in
the dextranomer group (10 cases), due to
deterioration (2 patients), clinical infection
(3), cutaneous reaction (4), or pain (1); in
the Granuﬂex group (2 cases): 0, 0, 2 and
0 patients, respectively”
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Kalis 1993 (Continued)
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to determine
Other bias High risk Unclear if there is a difference between the
unit of randomisation and the unit of anal-
ysis; potential for unit of analysis issues very
unclear
All domain risk of bias High risk
All domain risk of bias 2 High risk
Kelechi 2012
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 20 weeks
Participants Inclusion criteria: people aged 21+ with partial-thickness venous ulcer, diagnosed in
previous 4 weeks, size 2 cm² to 20 cm², no recent skin grafts or use of growth factors,
viable clean wound bed 90% free of necrotic debris
Exclusion criteria: full thickness ulcers extending beyond dermis, infection, ABI < 0.8 or
> 1.3, duration > 6 months, history of collagen vascular disease, severe arterial disease,
organ transplant, Charcot disease, sickle cell disease, radiation therapy, haemodialysis,
pregnant
Participant characteristics
Number participants: 82
Age: 59 (13.5) vs 63.2 (14.8) vs 60.8 (12.2) vs 63.0 (15.3) years
N (%) male: 5 (25) vs 13 (59.1) vs 13 (65) vs 10 (50)
Ulcer details
Size: mean (SD) 12.1 (11.3) cm² vs 9.8 (7.3) cm² vs 10.5 (10.3) cm² vs 12.8 (12.0) cm²
Duration: mean (SD) 3.4 (1.5) months vs 3.6 (1.8) months vs 2.7 (2.1) months vs 2.7
(1.6) months
Interventions Intervention 1 class: nanoﬁbre matrix
Intervention 1 details (name and details of application): pG1cNAc nanoﬁbre matrix
(Talymed,Marine Polymer Technologies) applied once + nonadherent dressing (Mepilex,
Molnlycke HealthCare)
Intervention 2 class: nanoﬁbre matrix
Intervention 2 details (name and details of application): pG1cNAc nanoﬁbre matrix
(Talymed,Marine Polymer Technologies) applied every other week + nonadherent dress-
ing (Mepilex, Molnlycke HealthCare)
Intervention 3 class: nanoﬁbre matrix
Intervention 3 details (name and details of application): pG1cNAc nanoﬁbre matrix
(Talymed,Marine Polymer Technologies) applied every third week + nonadherent dress-
ing (Mepilex, Molnlycke HealthCare)
Intervention 4 class: nonadherent
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Kelechi 2012 (Continued)
Intervention 4 details (name and details of application): Mepilex (Molnlycke Health
Care)
Compression: zinc oxide impregnated bandage (Viscopaste PB7, Smith & Nephew),
cotton padding wrap, self-adherent elastic wrap (Coban, 3M)
Other co-interventions: wound cleaned with saline, patted dry with gauze, moisture
barrier applied
Outcomes Intervention 1: 9/20
Intervention 2: 19/22
Intervention 3: 13/20
Intervention 4: 9/20
Notes Funding type: industry
Funding details: supported by Marine Polymer Technologies Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization to treat-
ment groups after informed consent, eligi-
ble patients were randomly assigned to 1
of 4 study arms using computer-generated,
stratiﬁed, permuted block randomization”
Comment: appropriate generation of ran-
domisation sequence
Allocation concealment (selection bias) Low risk Quote: “randomization was stratiﬁed by
site to ensure equal subject allocation across
the 4 treatment arms. Block size was ran-
domly varied to minimize the likelihood
that study nurses could guess the next allo-
cation on the basis of previous allocations”
Comment: appears that central allocation
took appropriate steps to ensure conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “patients and certiﬁed wound care
nurses, who provided wound treatment
and applied the wound-healing product,
were not blinded to subject group assign-
ment”
Comment: neither participants nor person-
nel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quotes:
“randomized, investigator-blinded, parallel
group, controlled trial” “study nurses mea-
suredwound length andwidth at each visit”
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Kelechi 2012 (Continued)
Comment: it is not clear whether the un-
blinded study nurses or the blinded inves-
tigators determined outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “82 subjects were randomly as-
signed to one of the 4 study groups, and 71
completed the study. Seven subjects were
lost to follow-up and 4 subjects who devel-
oped systemic infections were withdrawn”
Comment: an ITT analysis was performed
with clear procedures for dealing with data
from participants lost to follow-up
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No evidence of other sources of bias
All domain risk of bias High risk
Kucharzewski 2013
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 16 weeks (data extracted at 7 weeks)
Participants Inclusion criteria: chronic venous ulcer due to primary varicosis
Exclusion criteria: not reported
Participant characteristics
Number participants: 58
Age: 65.3 (9.1) vs 66.9 (6.4) years
N (%) male: 11 (37) vs 10 (36)
Ulcer details
Size: mean (range) 8.52 (7.02-9.89) cm² vs 8.29 (7.02-10.1) cm²
Duration: mean (range) 2.5 (1.2-3.4) years vs 2.4 (1.1- 3.6) years
Interventions Intervention 1 class: silver
Intervention 1 details (name and details of application): silver membrane plus gauze;
Texts Bioactiv (Biocell); ulcer washed with Ringer’s solution before application of silver
membrane, then gauze pads and elastic bandage. Dressing rinsed several times daily with
Ringers. External dressing changed daily, membrane every 7 days
Intervention 2 class: hydrocolloid
Intervention 2 details (name and details of application): hydrocolloid with Unna’s boot,
applied after saline rinse, changed every 7 days
Compression: all received compression therapy
Other co-interventions: wounds were bathed in detergent (pH 5.5), washed with saline
and rinsed with Octenisept, surgically cleaned, washed with saline and covered with an
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Kucharzewski 2013 (Continued)
Octenisept compress
Outcomes Intervention 1: 30/30
Intervention 2: 6/28
Notes Funding type and details: not reported
Notes: Data reported for healing curve; time point selected
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were divided randomly ..
.”
Comment: no information on sequence
generation
Allocation concealment (selection bias) Unclear risk Quote: “patients were divided randomly ..
.”
Comment: no information on how alloca-
tion was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients were followed until healing
Selective reporting (reporting bias) High risk There was no deﬁned endpoint
Other bias Unclear risk There was no evidence of other sources of
bias but reporting was insufﬁcient to be
conﬁdent
All domain risk of bias High risk
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Lanzara 2008
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: venous leg ulcers
Exclusion criteria: not reported
Participant characteristics
Number participants: 30
Age: not reported
% male: not reported
Ulcer details
Size: not reported
Duration: not reported
Interventions Intervention 1 class: PMM silver
Intervention 1 details (name and details of application): PMM + silver dressing + foam
dressing - collagen, silver & oxidised regenerated cellulose matrix dressing + hydropoly-
mer foam (Collagen/ORC + silver (Systagenix) + Tielle Family® (Systagenix) + Tielle
Family® (Systagenix)): dressing changes every week; (n = 15; duration 12 weeks)
Intervention 2 class: foam
Intervention 2 details (name and details of application): foam dressing (Tielle Family®
(Systagenix)); (n = 15; duration 12 weeks)
Compression: short stretch multilayer compression for all
Other co-interventions: not reported
Outcomes Intervention 1: 11/15
Intervention 2: 7/15
Notes Funding type: industry
Funding details: appears to be Systagenix
Notes: poster presentation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients... were randomized”
Comment: no information on how se-
quence was generated
Allocation concealment (selection bias) Unclear risk Quote: “patients... were randomized”
Comment: no information on how alloca-
tion was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: dressings were sufﬁciently dif-
ferent for participants and personnel to be
unblinded - two dressings versus one dress-
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Lanzara 2008 (Continued)
ing
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “study duration was 12 weeks, with
dressing changes every week as well as mea-
surements on wound size and assessment of
wound appearance”
Comment: implication that outcome as-
sessors were also responsible for dressing
changes, who were not blinded as above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Apparently no missing data, but no details
Selective reporting (reporting bias) Low risk Unclear reporting. Some results (healing)
only reported on the Systagenix website
Other bias High risk Baseline differences in ulcer size: 6 cm² ver-
sus 9 cm²
All domain risk of bias High risk
Leaper 1991
Methods RCT
Arms: 2
Unit of randomisation: unclear
Unit of analysis: ulcer
Follow-up: 12 weeks; cross-over of some participants at 6 weeks
Participants Inclusion criteria: leg ulcers, community or hospital based
Exclusion criteria: critically Ischaemic vascular disease (Doppler index < 0.5), insulin-
dependent diabetes, terminal illness
Participant characteristics
Number participants: 76 participants with 94 ulcers
Age: 75.0 (10.4) vs 73.8 (9.8) years
% male: 17 (45) vs 11 (29)
Ulcer details
Non VLU: unclear - “the majority of leg ulcers were of venous origin”
Size: 15.9 (38.3) cm² vs 19.4 (31.4) cm²
Duration: range 2 weeks to 43 years “the durations of the ulcer existence were similar in
the two dressing groups”
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): Comfeel Ulcer Dressing (Colo-
plast); dressing covered minimum 2 cm rim of skin around ulcer. Changed every 2-
3 days during debridement stage, 3 to 4 days during healthy granulation, 5 to 7 days
during epithelialisation and contraction
Intervention 2 class: nonadherent
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Leaper 1991 (Continued)
Intervention 2 details (name and details of application): gauze (parafﬁn-impregnated);
Jelonet (Smith & Nephew); dressing covered minimum 2cm rim of skin around ulcer.
Changed every 2 to 3 days during debridement stage, 3 to 4 days during healthy granu-
lation, 5 to 7 days during epithelialisation and contraction
Compression: venous leg ulcers (Doppler index > 0.7) used Venosan bandages
Other co-interventions: irrigation and wash with sterile saline solution and cotton wool
soaks before dressing. Some ulcers required surgical debridement
Outcomes Intervention 1: 14/46
Intervention 2: 3/48
Notes Funding type: industry
Funding details: Coloplast
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “a clinical assessment was made for
each patient ... prior to randomization to a
treatment group, with stratiﬁcation”
Comment: no details of sequence genera-
tion method
Allocation concealment (selection bias) Unclear risk Quote: “a clinical assessment was made for
each patient ... prior to randomization to a
treatment group, with stratiﬁcation”
Comment: no details of allocation conceal-
ment given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Information reported for all participants/
ulcers
Selective reporting (reporting bias) Unclear risk There is no evidence of selective reporting
but it is not clearly reported enough to be
sure
Other bias High risk There is strong potential for a unit of anal-
ysis issue as it appears that randomisation
was at the participant level but that analysis
was at the level of the ulcer
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Leaper 1991 (Continued)
There was cross-over at 6 weeks for some
but not all participants; they were anal-
ysed in the groups to which they were ran-
domised however
All domain risk of bias High risk
Lindsay 1986
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 4 weeks - but see notes
Participants Inclusion criteria: female, over 30, chronic exuding venous ulcer(s) of lower limbs, not
responding favourable to existing treatments
Exclusion criteria: concomitant serious or life-threatening disease, suspected malignant
change in ulcer, insulin-dependent diabetes, pregnancy, iodine sensitivity, psychiatric
disease, very low intelligence, dementia or other condition affecting patient compliance
Participant characteristics
Number participants: 28
Age: mean (range) 66.7 (52 to 90) years
% male: 0
Ulcer details
Size: not reported
Duration: mean 20.1 months
Interventions Intervention 1 class: cadexomer iodine (CI)
Intervention 1 details (name and details of application): Iodosorb (Stuart Pharmaceuti-
cals and Perstorp AB); cadexomer iodine applied to whole ulcer surface to depth of at
least 3mm and wound covered with dry sterile dressing. Changed on alternate days. CI
removed using sterile wet swab or stream of water or saline or soaking
Intervention 2 class: standard care
Intervention 2 details (name and details of application): various, generally sterile non-
adherent dressing including Terra-Sortril, povidone iodine, Savlon, Bactigras, Melolin,
Sofra Tulle, crepe bandage, elastocrepe bandage; changed on alternate days
Compression: see other co-interventions
Other co-interventions: “dressing secured with support bandaging or stocking as re-
quired” (cadexomer iodine and most of the standard treatment)
Outcomes Intervention 1: 4/14
Intervention 2: 1/14
Notes Funding type and details: industry
Funding details: Stuart Pharmaceutical
Notes: 10 week trial but optional cross-over at 4 weeks so main analysis applied at this
point (with numbers N = 12 vs N = 13). 1 participant was removed from demographic
data - her ulcer duration was “60+”. It is not clear whether the healing data refer to the
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Lindsay 1986 (Continued)
4 weeks time point
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomised to re-
ceive either standard dressing or CI”
Comment: no details of sequence genera-
tion
Allocation concealment (selection bias) Unclear risk Quote: “patients were randomised to re-
ceive either standard dressing or CI”
Comment: no details of allocation se-
quence
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how many participants had
dropped out and for what reason - 4 weeks
analysis appears to include 25/28 partici-
pants
Selective reporting (reporting bias) Unclear risk Unclear whether outcomes were pre-speci-
ﬁed
Other bias Unclear risk No evidence of other bias but reporting in-
sufﬁcient to be conﬁdent
All domain risk of bias Low risk Low/unclear
Luiza 2015
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: ulcer
Follow-up: 12 weeks
Participants Inclusion criteria: leg ulcer(s) of at least 6 weeks duration
Exclusion criteria: infected ulcer, erysipelas, cellulitis, lymphangitis, devitalized tissue
covering wound bed, circular limb lesions, non-palpable distal pulse, alcoholism or
psychiatric disease, liver or kidney problems, allergy to study materials or latex
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Luiza 2015 (Continued)
Participant characteristics
Number participants: 21 participants (data reported for 18 completers and 28 ulcers)
Age: all: 61.94 (12.5) range 45 to 85; grouped: < 60 years 40% vs 50%, > 60 years 60%
vs 50%
% male: 4 (40) vs 5 (62.5)
Ulcer details
Non VLU: unclear
Size: not reported
Duration: not reported by group > 10 years 53.6%, 7 to 10 years 3.6%, 4 to 6 years 32.
1%, < 3 years 10.7%
Interventions Intervention 1 class: papain
Intervention 1 details (name and details of application): 2% papain gel developed at
university pharmacy
Intervention 2 class: placebo
Intervention 2 details (name and details of application): 2% carboxymethyl cellulose gel
developed at university pharmacy
Compression: not reported
Other co-interventions: dressing kit contained gauze, bandage, 0.9% saline solution,
soothing solution for the skin surrounding the lesion
Outcomes Intervention 1: 2/16
Intervention 2: 0/12
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “for the sake of randomization a re-
search collaborator used a table with ran-
dom numbers”
Comment: appropriate method of alloca-
tion concealment
Allocation concealment (selection bias) Unclear risk Quote: “the study participants were only
informed about which group the patient
would be allocated to at the moment of
each volunteer’s ﬁrst consultation”
Comment: it was unclear whether alloca-
tion was also concealed from personnel
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “the blinding of the participants
and researchers was compromised due to
the product characteristics”
Comment: appears that unblinding oc-
curred
123Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Luiza 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the evaluators of the result, who
carried out the statistical analysis of the
data, were blinded”
Comment: appears that outcome assess-
ment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Three participants (unknown number of
ulcers) did not complete; 1 in the interven-
tion group and 2 in the control group. Be-
cause the number of ulcers is unknown the
impact on the estimate is unclear
Selective reporting (reporting bias) Low risk There was no evidence of selective outcome
reporting
Other bias High risk There is a probable unit of analysis issue be-
cause randomisation took place at the level
of the participant while analysis took place
at the level of the ulcer
All domain risk of bias High risk
Meaume 2012
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 8 weeks
Participants Inclusion criteria: venous leg ulcer, 5 cm² to-50 cm², 6 to 36 month duration, ABPI 0.8-
1.3, at least 50% wound bed covered with granulation tissue without any black necrotic
tissue. If multiple ulcers, the one best meeting selection criteria was selected (had to be
at least 3 cm from other wounds)
Exclusion criteria: infection requiring systemic antibiotics, known sensitivity to car-
boxymethylcellulose, venous surgery in previous 2 months, DVT in previous 3 months,
concomitant severe comorbid disease or poor health status, malignant wound degener-
ation, treatment with immunosuppressive agents or high-dose corticosteroids
Participant characteristics
Number participants: 187
Age: 72.6 (13.0) vs 74.4 (12.1) years
% male: 31 (33.3) vs 34 (36.2)
Ulcer details
Size: mean (SD) 17.0 (15.6) cm² vs 16.6 (15.8) cm², median (range) 12.9 (2.3 to 86.9)
cm² vs 10.5 (2.7 to 85.3) cm²
Duration: mean (SD) 15.6 (9.1) vs 15.1 (8.7) months, median (range) 12 (3 to 35) vs
12 (6 to 36) months
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Meaume 2012 (Continued)
Interventions Intervention 1 class: PMM
Intervention 1 details (name and details of application): Urgostart (Laboratoires Urgo)
Intervention 2 class: foam
Intervention 2 details (name and details of application): Urgotul Absorb (Laboratoires
Urgo)
Compression: “an appropriate compression therapy system, according to patient and
ulcer status, was selected and applied by the investigating physician”
Other co-interventions: not reported
Outcomes Intervention 1: 6/93
Intervention 2: 7/94
Notes Funding type: industry
Funding details: Laboratoires URGO
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the randomization code was gen-
erated in blocks of two using a computer
program and was stratiﬁed by center”
Comment: computer-generated randomi-
sation sequence
Allocation concealment (selection bias) Low risk Quote: “Individual sterile dressings were
packed in boxes of 35 dressings per partic-
ipant. Each box and dressing was identi-
ﬁed by a center identiﬁcation number and
participant number corresponding to the
chronological participant inclusion num-
ber... the procedure to break the random-
ization code was not provided to the par-
ticipating centers”
Comment: probably sufﬁcient for low risk
of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “both dressings were identical in
appearance, shape, color and packaging ...
they could be used in a double-blind trial”
“the procedure to break the randomization
code was not provided to the participating
centers”
Comment: appears personnel and partici-
pants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the VLU was evaluated by the in-
vestigating physician ... at each visit, the
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Meaume 2012 (Continued)
wound evaluations were repeated (clini-
cal assessment, acetate tracing, and wound
photo)”
Comment: double-blind trial and outcome
assessors were the investigators
Incomplete outcome data (attrition bias)
All outcomes
High risk 4/93 (4%) and 6/94 (6%) withdrew and
were lost to follow-up. An additional 11/
93 (12%) and 11/94 (12%) switched to
“another” dressing, but were followed up in
the groups to which they were randomised.
Number missing comparable with number
of events for healing (6 and 7)
Selective reporting (reporting bias) Unclear risk High risk for outcomes other than healing;
unclear whether there may be issues with
the healing reporting
Other bias Unclear risk Potential for baseline differences between
groups but unclear what the impact of these
would be
All domain risk of bias High risk
Meredith 1988
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 6 weeks
Participants Inclusion criteria: leg ulcer diagnosed clinically as due to venous insufﬁciency. All clinic
attendees eligible, including diabetics
Exclusion criteria: treatment with Jelonet or Granuﬂex in previous 2 weeks, treatment
with systemic corticosteroids exceeding 0.5 mg/day, malignant ulcer, obvious peripheral
arterial ischaemia
Participant characteristics
Number participants: 50 (49 reported on)
Age: mean (range) 70.4 (32 to 92) years
% male: 15 (30)
Ulcer details
Size: not reported
Duration: not reported
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): Granuﬂex; applied to extend at
least 3cm beyond ulcer margin. Changed weekly, or sooner if exudate leaked
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Meredith 1988 (Continued)
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): parafﬁn gauze; Jelonet; applied
to cover the ulcer then cotton dressing gauze pad placed over and secured with micropore
tape. Changed when exudate penetrated to outer layers of dressings
Compression: support bandaging with elastocrepe or non-shaped Tubigrip
Other co-interventions: ulcers cleaned with saline and/or povidone iodine
Outcomes Intervention 1: 19/25
Intervention 2: 6/25
Notes Funding type: not reported
Funding details: not reported but Squibb Surgicare employees listed in acknowledge-
ments
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “they were randomised to either of
the two treatments according to a table of
random numbers held by ourselves”
Comment: appropriate method of random
sequence generation
Allocation concealment (selection bias) Unclear risk Quote: “they were randomised to either of
the two treatments according to a table of
random numbers held by ourselves”
Comment: unclear howallocationwas con-
cealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant withdrew and was ex-
cluded from results but this is unlikely to
have impacted the estimate of effect
Selective reporting (reporting bias) Unclear risk Not clear which outcomes were pre-speci-
ﬁed
Other bias Unclear risk No evidence of other bias but reporting in-
sufﬁcient to be certain
All domain risk of bias Low risk Low/unclear
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Michaels 2009
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: leg (1 limb/participant designated as index)
Follow-up: 12 weeks
Participants Inclusion criteria: ulceration of lower leg present for > 6 weeks. If ulceration on both
legs, that with greater ulcer area was index limb
Exclusion criteria: insulin-controlled diabetes, pregnancy, sensitivity to silver, ABPI < 0.
8, ulcer with maximum diameter < 1 cm, atypical ulcers, oral or parenteral antibiotics
Participant characteristics
Number participants: 213 (107 vs 106), 208 included in results
Age: 68.8 (16.7) vs 72.4 (13.7) years
% male: 54 (50) vs 44 (42)
Ulcer details:
Size: > 3 cm: 30 (28%) vs 30 (28%), < 3 cm 77 (72%) vs 76 (72%)
Duration: not reported
Interventions Intervention 1 class: silver
Intervention 1 details (name and details of application): choice of Aquacel Ag (Conva-
Tec), Acticoat, Acticoat 7, Acticoat Absorbent (all Smith & Nephew), Contreet Foam
(Coloplast), Urgotul SSD (Urgo); dressings changed on weekly basis (or sooner if judged
necessary)
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): Urgotul, Biatain (Coloplast)
, Atrauman (Paul Hartmann Ltd), Allevyn (Smith & Nephew); dressings changed on
weekly basis (or sooner if judged necessary)
Compression: multilayer compression bandaging
Other co-interventions: debridement if clinically appropriate
Outcomes Intervention 1: 62/104
Intervention 2: 59/104
Notes Funding type and details: non-industry
Funding details: HTA (NIHR)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “treatment allocation ... was carried
out using a computer program to generate
stratiﬁed block randomisation with vari-
able block size”
Comment: appropriate methods of se-
quence generation
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Michaels 2009 (Continued)
Allocation concealment (selection bias) Low risk Quote: “trial numbers and randomisation
were allocated through a telephone-based
service”
Comment: appropriate method of alloca-
tion concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “it was not possible to blind ei-
ther the patients or the nurses applying the
dressings”
Comment: neither participants nor person-
nel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the staff measuring ulcers sizes
based upon tracings ... were all blinded to
the treatment allocation of the patient”
Comment: blinded outcome assessment re-
ported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 5 participants were not included in
the analysis. This is unlikely to have af-
fected the treatment effect
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No evidence of other sources of bias
All domain risk of bias High risk
Moffatt 1992a
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: venous ulcer that had failed to heal within 24 weeks of high compres-
sion therapy or had failed to reduce in size by more than 20% within 12 weeks
Exclusion criteria: arterial disease (ABI < 0.8), known allergy to study products
Participant characteristics
Number participants: 60
Age: median (range) 74 (50 to 89) vs 71 (26 to 87) years
% male: 15 (50) vs 12 (40)
Ulcer details
Size: median (range) 7.3 (1.3 to 66.3) cm² vs 6.7 (2.6 to 14.9) cm2
Duration: not reported
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Moffatt 1992a (Continued)
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): Comfeel (Coloplast)
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): not reported
Compression: 4 layer bandage technique
Other co-interventions: not reported
Outcomes Intervention 1: 13/30
Intervention 2: 7/30
Notes Funding type and details: industry
Funding details: Comfeel Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomization took place by as-
signing sequential numbers to each patient
as they entered the trial, and relating this
number to a randomization group”
Comment: unclear how the randomisation
sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “randomization took place by as-
signing sequential numbers to each patient
as they entered the trial, and relating this
number to a randomization group”
Comment: unclear how allocation conceal-
ment was carried out
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “patients were followed up to 12
weeks with the exception of four patients,
two of whom refused to continue with
the treatment, and two patients who died
within the 12-week period”
Comment: it was not clear to which group
participants whowere not followed upwere
assigned
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Moffatt 1992a (Continued)
Selective reporting (reporting bias) Low risk The main endpoint was speciﬁed and re-
ported
Other bias Unclear risk There was no evidence of other sources of
bias but reporting was insufﬁcient to be
conﬁdent of this
All domain risk of bias Low risk Low/unclear
Moffatt 1992b
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: Venous leg ulcer with surface area < 10 cm²
Exclusion criteria: ABPI < 0.8 (arterial component to ulcer)
Participant characteristics
Number participants: 60
Age: median (range) 78 (44 to 88) vs 70 (38 to 88) years
% male: 10 (33) vs 13 (44)
Ulcer details
Size: median (range) 3.6 (0.9 to 9.8) cm² vs 6.4 (1.1 to 9.9) cm²
Duration: median (range) 2.0 (1 to 192) vs 3 (1 to 20) (units not reported - months?)
Interventions Intervention 1 class: alginate
Intervention 1 details (name and details of application) Tegagel (3M); Dressing changed
weekly unless excessive exudate or infection
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): NA (Johnson & Johnson);
Dressing changed weekly unless excessive exudate or infection
Compression: Graduated compression bandage system- 40 mmHg2 at ankle
Other co-interventions: not reported
Outcomes Intervention 1: 26/30
Intervention 2: 24/30
Notes Funding type: industry
Funding details: 3M Health Care Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
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Moffatt 1992b (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were entered into the trial
and randomised to either of the two dress-
ing types”
Comment: unclear how the randomisation
sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “patients were entered into the trial
and randomised to either of the two dress-
ing types”
Comment: unclear how the allocation was
concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk This was not reported on
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This was not reported on
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants appeared to be included in
the analysis.
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing; reporting was limited but the trial ap-
peared designed to measure the outcome
reported
Other bias Unclear risk There was no evidence of other sources of
bias but reportingwas insufﬁcient to be cer-
tain
All domain risk of bias Low risk Low/unclear
Moss 1987
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 6 weeks (26 week trial with optional cross-over at 6 weeks)
Participants Inclusion criteria: unresponsive leg ulcer of > 3 months duration which did not improve
after 6 weeks observation on a variety of treatments. Venous insufﬁciency diagnosed by
history of DVT or signs e.g. swelling, dermatosclerosis, pigmentation, atrophie blanche
Exclusion criteria: not reported
Participant characteristics
Number participants: 42 (43 randomised, one dropped out and not included in analysis)
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Moss 1987 (Continued)
Age: median (SD) 70 (8) vs 68 (11) years
% male: 6 (29) vs 3 (14)
Ulcer details
Size: median (SD) 19.7 (19.8) cm² vs 25.5 (29.5) cm²
Duration: median (SD) 75 (127) months vs 61 (68) months
Interventions Intervention 1 class: cadexomer iodine (CI)
Intervention 1 details (name and details of application): Iodosorb; ulcer cleaned with
saline, then ﬁlled with powder and covered with non-adhesive pad. Changed daily
Intervention 2 class: dextranomer
Intervention 2 details (name and details of application): Debrisan; ulcer cleaned with
saline, then ﬁlled with powder and covered with non-adhesive pad. Changed daily
Compression: see other co-interventions
Other co-interventions: saline wash; treatment powder dressing covered with non adhe-
sive pad, cotton-wool wadding, stockingnette and ﬁrm elastic bandage
Outcomes Intervention 1: 0/21 at 6-week cross-over
Intervention 2: 0/21 at 6-week cross-over
Notes Funding type: industry
Funding details: TIL (Medical) Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “those still not improving (n = 42)
were randomly allocated to treatment with
either dextranomer or CI”
Comment: unclear how the randomisation
sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “those still not improving (n = 42)
were randomly allocated to treatment with
either dextranomer or CI”
Comment: unclear howallocationwas con-
cealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “although the trial was not blind
because the treatments can easily be distin-
guished by colour”
Comment: trial not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “assessments [...] could not be blind
because, even after the dressings were re-
moved, difference in colour were still ap-
parent”
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Moss 1987 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only one participant was not included in
the analysis
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing of outcomes
Other bias Low risk There was no evidence of other sources of
bias; it was not clear whether the cross-over
was planned but this does not impact on
the data before the cross-over point
All domain risk of bias High risk
All domain risk of bias 2 High risk
Nelson 2007
Methods RCT
Arms: 2 relevant groups (a 2 x 2 x 2 factorial design for compression and pentoxifylline
also)
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 24 weeks
Participants Inclusion criteria: clinically diagnosed (clinical signs andDoppler conﬁrmation of venous
pathology) venous leg ulcer at least 1 cm length and 8 weeks duration
Exclusion criteria: signiﬁcant arterial disease (ABPI < 0.8), diabetes mellitus, pregnant
or lactating women, known concurrent severe illness, sensitivity to methylxanthines or
caffeine, using warfarin, steroids, oxpentifylline, oxerutins, Naftidrofuryl, life expectancy
< 6 months, grossly infected or gangrenous ulcer, immobile, immunosuppression
Participant characteristics
Number participants: 245
Age: 70.3 (12.0) vs 69.7 (10.6) years
% male: 43 (34) vs 37 (31)
Ulcer details
Size:mean (SD) 794 (1210) mm² vs 910 (2600) mm²,median (range) 404 (50 to 10118)
mm² vs 359 (63 to 26311) mm²
Duration: mean (SD) 11.3 (25.0) months vs 14.8 (29.8) months, median (range) 4.0
(2 to 204) months vs 6.5 (2 to 240) months
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): Granuﬂex E (ConvaTec), also
known as Duoderm CGF; dressing changed weekly or more frequently if required
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): NA (Johnson & Johnson);
dressing changed weekly or more frequently if required
Compression: participants were randomised to either 4-layer bandage applied using
Charing Cross technique or single layer hydrocolloid-lined, woven, elastomeric, adhesive
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Nelson 2007 (Continued)
bandage applied in ﬁgure-8 technique
Other co-interventions: ulcers cleansed with tap water and skin moisturised with arachis
or olive oil. Within factorial design participants were also randomised to receive pentox-
ifylline or placebo
Outcomes Intervention 1: 72/127
Intervention 2: 69/118
Notes Funding type and details: industry/mixed
Funding details: “supported by Hoechst Roussel Ltd, ConvaTec UK Ltd and Chief
Scientist Ofﬁce, Scotland”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization was stratiﬁed by
clinical center and simple/non simple ve-
nous disease using permuted blocks of
length 8”
Comment: likely that appropriate method
used to generate sequence
Allocation concealment (selection bias) Low risk Quote: “sealed, sequentially numbered
opaque envelopes were use to allocate par-
ticipants”
Comment: appropriate method used to en-
sure adequate allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “both patients and nurses were
aware of the allocated bandage and dress-
ing after assignment”
Comment: neither participants nor person-
nel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “nurses completed a dressing log at
each leg ulcer dressing visit, which recorded
whether or not an ulcer was healed”
Comment: outcome assessed by unblinded
nurses
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis
Selective reporting (reporting bias) Low risk There was no evidence of selective outcome
reporting and reporting was clear
Other bias Low risk There was no evidence of other sources of
bias
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Nelson 2007 (Continued)
All domain risk of bias High risk
All domain risk of bias 2 High risk
Norkus 2005
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: up to 12 months
Participants Inclusion criteria: highly exuding leg ulcer present for at least 4 weeks, maximum ulcer
size 8 cm x 8 cm, ABPI ≥ 0.8. Largest ulcer used if more than one cm
Exclusion criteria: clinical signs of wound infection, severe eczema, lymphatic or malig-
nant ulcers, systemic treatment with corticosteroids other immunosuppressants during
study or in 3 months prior
Participant characteristics
Number participants: 97
Age: median (range) 70 (33 to 89) vs 70 (29 to 97) years
% male: 21 (43) vs 23 (48)
Ulcer details
Non VLU: 89.6% vs 93.5% venous, protocol violation meant some mixed (10.4% vs
4.4%) and arterial (0% vs 2.1%) were included
Size: median (range) 9.3 cm² (0.9 to 38.1) cm² vs 6.4 cm² (0.5 to 51.4) cm²
Duration: median (range) 1.0 (0.1 to 19.0) years vs 0.7 (0.1 to 27.0) years
Interventions Intervention 1 class: foam
Intervention 1 details (name and details of application): Alione (Coloplast A/S);Dressing
changed when necessary (maximum 7 days)
Intervention 2 class: hydrocolloid
Intervention 2 details (name and details of application): Tielle and Tielle plus (Johnson
& Johnson); Tielle Plus used at start of study, changing to Tielle when dressing changes
required less than once per day. Dressing changed when necessary (maximum 7 days)
Compression: those treated with compression at the start continued using it throughout
study (36 (75%) vs 32 (68%) participants used it)
Other co-interventions: ulcers cleaned and debrided if necessary according to normal
practice at centre
Outcomes Intervention 1: 25/49
Intervention 2: 19/48
Notes Funding type and details: industry
Funding details: Coloplast A/S
Risk of bias
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Norkus 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the study used an open compara-
tive block randomised multicentre design”
Comment: appears very likely that appro-
priate sequence generation methods were
used
Allocation concealment (selection bias) Low risk Quote: “the study used an open compara-
tive block randomised multicentre design”
Comment: appears that centralised alloca-
tion will have ensured concealed allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “the study used an open compara-
tive block randomised multicentre design”
Comment: an open design was used
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “after cleansing with water or iso-
tonic saline, the ulcer was traced using
planimetry, photographed and redressed”
Comment: it was not clear who assessed
healing but the open design means there is
a high risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “the statistical analysis was carried
out as intention to treat (ITT) with last
observation carried forward (LOCF)”
Comment: ITT analysis
Selective reporting (reporting bias) Low risk All the speciﬁed outcomes were fully re-
ported
Other bias Low risk There was no apparent risk of other bias
and reporting was sufﬁcient to be reason-
ably conﬁdent of this
All domain risk of bias High risk
All domain risk of bias 2 High risk
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Ohlsson 1994
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 6 weeks
Participants Inclusion criteria: leg ulcer of venous or mixed aetiology
Exclusion criteria: not reported
Participant characteristics
Number participants: 30 (28 analysed)
Age: median (range) 76 (49 to 89) years
% male: 4 (13)
Ulcer details
Non VLU: 4/14 (29%) vs 2/14 (14%) mixed venous/arterial (21% overall)
Size: mean 1387 mm² vs 857 mm²
Duration: not reported
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): changed once a week or more
frequently if needed
Intervention 2 class: saline gauze
Intervention 2 details (name and details of application): changed once a week or more
frequently if needed
Compression: low-stretch compression bandage
Other co-interventions: ulcers cleaned with soap and water
Outcomes Intervention 1: 7/14
Intervention 2: 2/14
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the patients were randomly allo-
cated ...”
Comment: no information on how the ran-
domisation sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “the patients were randomly allo-
cated ...”
Comment: no information on how alloca-
tion was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
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Ohlsson 1994 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “changes in ulcer area/healing were
blindly measured by two independent in-
vestigators”
Comment: blinded outcome evaluation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants dropped out of the study one
in each group, reasons were given
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing of outcomes
Other bias Unclear risk There was no evidence of other sources of
bias but reportingwas insufﬁcient to be cer-
tain
All domain risk of bias Low risk Low/unclear
Ormiston 1985
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 24 weeks (optional cross-over at 12 weeks)
Participants Inclusion criteria: chronic venous ulcer > 3 months
Exclusion criteria: clinical or laboratory evidence ulcer was of non-venous aetiology,
ABPI < 0.7, expected poor compliance
Participant characteristics
Number participants: 61 (60 analysed)
Age: 67.3 (9.7) vs 70.3 (13.3) years
% male: 13 (43%) vs 8 (27%)
Ulcer details
Size: mean (SD) 12.1 (13.9) cm² vs 10.2 (8.7) cm²
Duration: mean (SD) 45.9 (105.9 months) vs 15.9 (19.5) months, median (range) 8.5
(3 to 517) vs 6 (3 to 96) months
Interventions Intervention 1 class: cadexomer iodine
Intervention 1 details (name and details of application): ulcer cleaned with saline; sprin-
kled in layer 0.3 cm to 0.5 cm deep, covered with gauze pad
Intervention 2 class: gentian violet
Intervention 2 details (name and details of application): gentian violet and polyfax
(polymyxin and bacitracin) ointment; gentian violet painted on, polyfax applied over in
generous layer, covered with nonadherent (Melolin) pad
Compression: crepe bandage followed by cotton crepe compression bandage
Other co-interventions: ulcer cleaned with saline
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Ormiston 1985 (Continued)
Outcomes Intervention 1: 12/30
Intervention 2: 7/30
Notes Funding type and details: not reported; Perstorp AB provided cadexomer iodine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “for each number there was a dou-
ble sealed envelope that contained a paper
stating which treatment the patient should
receive. The sequence [...]Was randomised
and the code of randomisation was not
available to the investigators”
Comment: generationof randomisation se-
quence was unclear
Allocation concealment (selection bias) Low risk Quote: “for each number there was a dou-
ble sealed envelope that contained a paper
stating which treatment the patient should
receive. The sequence .. Was randomised
and the code of randomisation was not
available to the investigators”
Comment: appropriate concealment of al-
location
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Almost all participants were included in the
analysis
Selective reporting (reporting bias) Unclear risk There is no obvious selective reporting but
outcomes are not clearly speciﬁed
Other bias High risk Quote: “ulcers in the group receiving
cadexomer iodine had not healed for a
mean of 46 months, compared with 16
months for the standard group”
Comment: impact of this baseline im-
balance was unclear but it is substantial
enough to constitute a risk of bias
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Ormiston 1985 (Continued)
All domain risk of bias High risk
Petkov 1997
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 6 months
Participants Inclusion criteria: exuding venous ulcers, < 100 cm², not infected, ABPI > 0.7
Exclusion criteria: current treatment with topical medications, ulcer covered with dry
necrotic tissue, undergoing therapy which may retard wound healing, pregnant or lac-
tating, silver sulphadiazine used in previous 7 days, in another research study in previous
3 months
Participant characteristics
Number participants: 100
Age: not reported
% male: not reported
Ulcer details
Size: not reported
Duration: not reported
Interventions Intervention 1 class: PMM
Intervention 1 details (name and details of application): Fibracol (Johnson & Johnson)
Intervention 2 class: alginate
Intervention 2 details (name and details of application): Kaltostat (ConvaTec)
Compression: “standardized compression bandaging”
Other co-interventions: not reported
Outcomes Intervention 1: 34/50
Intervention 2: 32/50 (author information - public data says 31/50)
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “100 patients ... were randomised”
Comment: no details on method
Allocation concealment (selection bias) Unclear risk Quote: “100 patients ... were randomised”
Comment: no details on method
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
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Petkov 1997 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Insufﬁcient information to determine if re-
porting bias
Other bias Unclear risk Insufﬁcient information to assess whether
an important risk of bias exists
All domain risk of bias Low risk Low/unclear
Rasmussen 1991
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: chronic leg ulceration
Exclusion criteria: diabetes mellitus, malignant or rheumatic disease, allergy to dressings,
peripheral arterial disease, cellulitis, anaemia, sever maceration of surrounding skin
Participant characteristics
Number participants: 37 randomised, 29 included in analysis (18 vs 11)
Age: 80.7 (6.7) vs 78.1 (11.8) years
% male: 5 (28) vs 4 (36)
Ulcer details
Non VLU: 2 (11%) vs 1 (9%) mixed
Size: mean (SD) 10.7 (2.0) cm² vs 8.15 (2.5) cm²
Duration: not reported (minimum 3 weeks)
Interventions Intervention 1 class: human growth hormone
Intervention 1 details (name and details of application): Norditropin (Novo-Nordisk) +
Comfeel (Coloplast); biosynthetic human growth hormone + hydrocolloid; Norditropin
dissolved inwater administered 5 days per week through connecting piece in the dressing.
Treatment for at least 2 weeks
Intervention 2 class: placebo + hydrocolloid
Intervention 2 details (name and details of application): Comfeel (Coloplast); placebo
administered 5 days per week through connecting piece in the dressing. Treatment for
at least 2 weeks
Compression: Compression bandages worn by all (Comprilan, Beirsdorf )
Other co-interventions: not reported
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Rasmussen 1991 (Continued)
Outcomes Intervention 1: 3/18
Intervention 2: 1/11
Notes Funding type and details: Coloplast and Beiresdorf provided study materials, but study
funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: stratiﬁcation before randomisa-
tion explained but randomisation method
not described
Allocation concealment (selection bias) Unclear risk Comment: not reported how allocation
was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 18/37 withdrawals which were not in-
cluded in analysis. Reasons provided
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing
Other bias Low risk There was no evidence of other sources of
bias
All domain risk of bias High risk
Robson 1995
Methods RCT
Arms: 3
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 6 weeks
Participants Inclusion criteria: chronic venous ulcers 1 cm² to 25 cm², > 3 months duration, or
proximal to malleolus and distal to tibial tuberosity, no clinical signs of infection, aged
18 to 90, > 45 kg, ABI > 0.5, if female, postmenopausal or surgically sterile
Exclusion criteria: bleeding disorder, severe dermatosclerosis, organised oedema, local
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Robson 1995 (Continued)
or systemic infection, disease or medication interfering with healing, hypersensitivity to
bovine collagen
Participant characteristics
Number participants: 36
Age: 48.4 (17.6) vs 56.3 (8.0) vs 54.2 (11.4) years
% male: 4 (33) vs 7 (58) vs 5 (42)
Ulcer details
Size: mean (SD) 3.9 (3.20) cm² vs 5.9 (5.6) cm² vs 7.1 (5.6) cm²
Duration: mean (SD) 22 (40 vs 14 (13) vs 20 (16) months
Interventions Intervention 1 class: human growth hormone + collagen
Intervention 1 details (name and details of application): bTGF-B2 in collagen matrix
(Celtrix Pharmaceutical); matrix cut to ﬁt ulcer, hydrated with sterile saline if necessary,
covered with non-absorbant dressing and layer of gauze sponge
Intervention 2 class: placebo + collagen
Intervention 2 details (name and details of application): placebo collagen matrix (Celtrix
Pharmaceutical); matrix cut to ﬁt ulcer, hydrated with sterile saline if necessary, covered
with non-absorbant dressing and layer of gauze sponge
Intervention 3 class: nonadherent
Intervention 3 details: gauze dressing; Xeroform (Sparta Surgical Corp), 3 x per week
Compression: ace elastic compression bandage (Becton-Dickenson) consisting of 2 layers
in opposing ﬁgure of eight conﬁguration
Other co-interventions: sterile saline used to cleanse ulcer at weekly clinic visits
Outcomes Intervention 1: 3/12
Intervention 2: 3/12
Intervention 3: 2/12
Notes Funding type and details: Celtrix Pharmaceuticals produced clinical studymaterial, some
authors work for them
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients [...] were randomized to
one of the treatment groups. Randomiza-
tion was balanced for gender and age and
for ulcer area and duration”
Comment: no method detail for sequence
generation
Allocation concealment (selection bias) Unclear risk Quote: “patients [...] were randomized to
one of the treatment groups. Randomiza-
tion was balanced for gender and age and
for ulcer area and duration”
Comment: no information on how alloca-
tion was concealed
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Robson 1995 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “all assessments were performed by
an observer blinded to the ulcer treatment”
Comment: blinded outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 participants withdrew (3 from bTGF-B2
group, 1 from standard dressing), decision
to exclude from analysis made before un-
blinding. (randomised numbers extracted
here, however)
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing
Other bias Low risk There was no evidence of other sources of
bias
All domain risk of bias Low risk Low/unclear
Robson 2001
Methods RCT
Arms: 3
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: venous insufﬁciency with ulcer 3 cm² to 30 cm² and 3 to 36 months
duration
Exclusion criteria: signiﬁcant arterial insufﬁciency, increased bacterial burden, active
vasculitis, cellulitis or collagen vascular disease, active skin disease, malignant neoplasm,
signiﬁcant acute or chronic systemic disease, signiﬁcant clinical laboratory abnormalities,
known allergies to study materials, treatment with investigational agents, pentoxifylline,
immunosuppressive or cytotoxic agent, pregnancy, use of topical antibiotics in 7 days
prior or during treatment
Participant characteristics
Number participants: 94
Age: 61 (13) vs 59 (14) vs 59 (13) years
% male: 71(22) vs 66 (21) vs 58 (18)
Ulcer details
Size: mean (SD) 8.7 (6.2) cm² vs 8.4 (.5) vs 8.1 (6.7) cm²
Duration: mean (SD) 11 (8) vs 14 (10) vs 11 (7) months
Interventions Intervention 1 class: human growth hormone
Intervention 1 details (name and details of application): Repifermin spray (20 µg/cm²)
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Robson 2001 (Continued)
+ nonadherent dressing
Intervention 2 class: human growth hormone
Intervention 2 details (name and details of application): Repifermin spray (60 µg/cm²)
+ nonadherent dressing
Intervention 3 class: nonadherent (placebo spray)
Intervention 3 (name and details of application): placebo + nonadherent dressing
Compression: self-adherent elastic wrap
Other co-interventions: not reported
Outcomes Intervention 1: 10/31
Intervention 2: 12/32
Intervention 3: 9/31
Notes Funding type and details: industry
Funding details: Human Genome Sciences Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients with venous insufﬁciency
(aged 18 years or older) were randomized
as follows”
Comment: described as randomised but no
methods given
Allocation concealment (selection bias) Unclear risk Quote: “Patients with venous insufﬁciency
(aged 18 years or older) were randomized
as follows”
Comment: described as randomised but no
methods given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind, placebo-con-
trolled but no details given so not clear who
was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double-blind, placebo-con-
trolled but no details given so not clear who
was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 5 withdrawals (9.7% vs 3.1% vs 3.2%),
ITT
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Other bias Low risk No evidence of other sources of bias
All domain risk of bias High risk
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Robson 2004
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 20 weeks
Participants Inclusion criteria: venous ulcer 3 cm² to 25 cm² and 3 to 36 months duration, venous
insufﬁciency (venous duplex scanning or impedance plethysmography), prescribed com-
pression for 7 to 28 days prior to trial
Exclusion criteria: participated in a clinical trial of an investigational agent within the
last 30 days, been treated with repifermin (KGF-2) have the designated ulcer below the
malleolus, on the foot, or above the base of the knee, have had the study ulcer treated with
Regranex (PDGF-BB) within the last 30 days or treated at any time with a skin substitute
or an autologous growth factor, had a surgical procedure to treat venous or arterial disease
within the last 90 days, evidence of signiﬁcant arterial insufﬁciency (an ankle brachial
index of 1.2 must have a toe brachial index of > 0.6 or a supine transcutaneous oxygen
measurement (TcPO2) > 30 mmHg, clinical evidence of active infection at the ulcer site,
a granulation tissue colony count ≥ 106/g of tissue or beta-haemolytic streptococci at
any level, evidence of active vasculitis, cellulitis, or collagen vascular disease, a history of
malignant neoplasm within the last 5 years, except for adequately treated cancers of the
skin or uterine cervix, signiﬁcant acute or chronic diseases (i.e. cardiovascular, pulmonary,
gastrointestinal, hepatic, renal, neurological, or infectious diseases), which are not ade-
quately controlled by medical treatment as determined by the investigator’s judgment,
diabetes mellitus with a haemoglobin A1c ≥8%, active skin disease, such as psoriasis,
which could impair the ability to assess the wound, an allergy to the dressings used in
the study,require treatment to the study ulcer with any topical agent other than normal
saline within 7 days of the ﬁrst repifermin/placebo treatment or with topical lidocaine for
anaesthesia prior to study ulcer debridement after the ﬁrst repifermin/placebo treatment,
or concomitant use of pentoxifylline or clopidogrel bisulphate during the study, under-
gone enzymatic debridement at any time during the screening period, known history of
allergies to Escherichia coli-derived or paraben-containing products, any requirement for
the use of systemic steroids or immunosuppressive or cytotoxic compounds during the
period of the study,expected to undergo hyperbaric oxygen therapy at any time during
treatment or through the 4-week follow-up visit, pregnant female or nursing mother (all
females with an intact uterus, regardless of age must have a negative serum pregnancy
test result at screening and use contraception during the study), during the ﬁrst 20 weeks
of the study be expected to miss 3 or more consecutive visits or be expected to miss 2
consecutive visits more than once
Participant characteristics
Number participants: 352
Age: 61.8 (15.6) vs 60.9 (13.7) vs 61.0 (15.4) years
% male: 59 (52.7) vs 76 (61.8) vs 81 (69.2)
Ulcer details
Size: mean (SD) 8.7 (5.3) cm² vs 9.4 (5.4) cm² vs 9.9 (6.2) cm², median (range) 7.1 (2.
4 to 22.9) cm² vs 8.4 (3.0 to 25.0) cm² vs 7.4 (3.0 to 24.3) cm²
Duration: mean (SD) 8.7 (5.3) months vs 12.3 (9.2) vs 11.8 (9.3) months, median
(range) 6.0 (3.0 to 36.0) months vs 9.0 (3.0 to 36.0) months vs 7.0 (3.0 to 35.0) months
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Robson 2004 (Continued)
Interventions Intervention 1 class: human growth hormone
Intervention 1 details (name and details of application): growth factor-repifermin (KGF-
2) higher dose (120 µg/cm²) + petrolatum gauze; Gauze dressing = ADAPTIC (Johnson
& Johnson); 2 x per week spray application of drug, then covered with dressing
Intervention 2 class: human growth hormone
Intervention 2 details (name and details of application): growth factor-repifermin (KGF-
2) lower dose (60 µg/cm²) + petrolatum gauze; Gauze dressing = ADAPTIC (Johnson
& Johnson); 2 x per week spray application of drug, then covered with dressing
Intervention 3 class: nonadherent (placebo spray) placebo + petrolatum gauze: gauze
dressing= ADAPTIC (Johnson & Johnson)
Intervention 3 details (name and details of application): not reported
Compression: multi-layer sustained graduated compression bandage system (DY-
NAFLEX, Johnson & Johnson)
Other co-interventions: pre-study screening period involved debridement and biopsy to
check infection
Outcomes Intervention 1: 58/112
Intervention 2: 72/123
Intervention 3: 72/117
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized, double-blinded”
Comment: described as randomised but no
details of methods for sequence generation
Allocation concealment (selection bias) Unclear risk Quote: “randomized, double-blinded”
Comment: described as randomised but no
details of methods for allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “randomized, double-blinded”
Comment: no information on who was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “randomized, double-blinded”
Comment: no information on who was
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 18% vs 15% vs 13% dropout,
reasons given, ITT analysis
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Unclear risk No evidence of other sources of bias
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All domain risk of bias Low risk Low/unclear
Romanelli 2015a
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: venous leg ulcer, venous insufﬁciency established by colour Doppler
test, no measurable improvement over 6 weeks standard treatment
Exclusion criteria: diabetes, autoimmune disease, peripheral arterial disease ABPI < 0.8,
smokers, ulcer with signs of infection
Participant characteristics
Number participants: 40
Age: 68 (5) vs 65 (2) years
% male: 7(35) vs 5(25)
Ulcer details
Size: mean (SD) 26 (4) vs 24 (5) cm²
Duration: mean (SD) 24 (6) vs 20 (4) weeks
Interventions Intervention 1 class: PMM
Intervention 1 details (name and details of application): collagen membrane + non
adherent + alginate; ProHeal (MedSkin Solutions) + Adaptic (Systa Genix) + Curasorb
(Kendal); dressing changed twice a week
Intervention 2 class: alginate
Intervention 2 details (name and details of application): Curasorb (Kendal); dressing
changed twice a week
Compression: short stretch bandaging (Rosidal K, Lohmann and Rauscher)
Other co-interventions: saline used to cleanse wounds
Outcomes Intervention 1: 6/20
Intervention 2: 5/20
Notes Funding type: industry
Funding details: MedSkin Solutions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomisation was established by
a random permuted block of ﬁve patients,
prepared in advance”
Comment: not speciﬁed how the sequence
was generated
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Romanelli 2015a (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “randomisation was established by
a random permuted block of ﬁve patients,
prepared in advance”
Comment: allocation concealmentmethod
was not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in the anal-
ysis
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No evidence of additional sources of bias
All domain risk of bias Low risk Low/unclear
Romero-Cerecero 2012
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 10 months
Participants Inclusion criteria: people aged 18 to 70 with clinical diagnosis of chronic venous leg
ulcer 2 cm to 15 cm in diameter, < 10 years duration, no infection or severe oedema, no
previous topical treatment in previous month
Exclusion criteria: pregnancy or breastfeeding, sensitivity to topical treatments, oedema
in legs, diabetes
Participant characteristics
Number participants: 34
Age: 60.5 (17) vs 61.5 (20) years
% male: 7/17 (41) vs 3/17 (18)
Ulcer details
Size: mean (SD) 1894.8 (51.3) vs 2068.6 (52.9) (unit of size unclear)
Duration: < 1 year 32.2% vs 47.0%, 1 to 5 years 41.4% vs 32.2%, 6 to 10 years 23.4%
vs 17.6%
Interventions Intervention 1 class: A.pichinchensis extract
Intervention 1 details (name and details of application): administered weekly
Intervention 2 class: alginate
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Romero-Cerecero 2012 (Continued)
Intervention 2 details (name and details of application): 7% propylene glycol alginate
(control) administered weekly
Compression: not reported
Other co-interventions: “strict wound hygiene, plus debridement and the placement of
dressings”
Outcomes Intervention 1: 15/17
Intervention 2: 9/17
Notes Funding type and details: mixed
Funding details: CONACYT and Mexican Institute of Social Security
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “two treatment groups were ran-
domly organized” “treatments were ran-
domly assigned”
Comment: no information on how the ran-
domisation sequence was generated
Allocation concealment (selection bias) Unclear risk Quotes: “two treatment groups were ran-
domly organized” “treatments were ran-
domly assigned”
Comment: no information on how alloca-
tion was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quotes: “in order to blind the experimen-
tal procedure, both treatments were for-
mulated and packed in identical collapsible
tubes” “neither the patient nor the physi-
cian knew the identity of the treatments”
Comment: both participants and person-
nel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotes: “in order to blind the experimen-
tal procedure, both treatments were for-
mulated and packed in identical collapsible
tubes” “neither the patient nor the physi-
cian knew the identity of the treatments”
Comment: it appears that outcome assess-
ment was performed by personnel who
were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 6/17 vs 2/17 withdrawals; however there
was an ITTanalysis, the impact of thewith-
drawals is unclear but unbalanced
151Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Romero-Cerecero 2012 (Continued)
Selective reporting (reporting bias) Low risk There was no evidence of selective outcome
reporting
Other bias Low risk There was no evidence of any other source
of bias
All domain risk of bias High risk
Rubin 1990
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 months
Participants Inclusion criteria: ambulatory with lower-extremity chronic venous stasis ulceration
Exclusion criteria: history of non-compliance, signiﬁcant arterial insufﬁciency (Doppler
ankle brachial pressure index < 0.8), history of signiﬁcant associatedmedical risk factors e.
g. collagen vascular disease, uncontrolled diabetes, ongoing dermatologic disease, chronic
corticosteroid therapy
Participant characteristics
Number participants: 36
Age: not reported
% male: not reported
Ulcer details
Size: mean (range) 32.2 cm² (6.0 to 270) vs 76.0 cm² (0.02 to 600)
Duration: not reported
Interventions Intervention 1 class: foam
Intervention 1 details (name and details of application): PFD (Synthaderm Armour
Pharmaceutical); dressing changed on weekly and/or biweekly schedule
Intervention 2 class: paste bandage
Intervention 2 details (name and details of application): gauze bandage impregnated with
glycerin, zinc oxide and calamine lotion; dressing changed on weekly and/or biweekly
schedule
Compression: all participants had elastic bandages applied from toes to knees
Other co-interventions: wounds were cleansed routinely with 20% Poloxamer cleansing
solution Shur-Cleans (Merck & Co)
Outcomes Intervention 1: 7/17
Intervention 2: 18/19
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Rubin 1990 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “each patient was randomized by
the study co-ordinator”
Comment: unclear how randomisation se-
quence was generated
Allocation concealment (selection bias) Unclear risk Quote: “the study co-ordinator did not see
the randomization card and was therefore
blinded as to the treatment cohort”
Comment: blinding but unclear allocation
concealment.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “the study co-ordinator did not see
the randomization card and was therefore
blinded as to the treatment cohort”
Comment: not clear whether other person-
nel and participants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “the study co-ordinator did not see
the randomization card and was therefore
blinded as to the treatment cohort”
Comment: not clear whether outcome as-
sessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 9 (52.9%) of Group 1 withdrew due to
wound odour whereas 100% of group 2
completed the study
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing
Other bias Unclear risk No evidence of other sources of bias but
insufﬁcient evidence to be certain
All domain risk of bias High risk
Salim 1992
Methods RCT
Arms: 3
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: venous ulceration (diagnosed from history, examination and Doppler
assessment of arterial pressure at ankles) of one leg, on medial side, < 10 cm², occurring
for the ﬁrst time, not yet treated in any way, not infected or associated with gross leg
oedema
Exclusion criteria: surgery or injection sclerotherapy for varicose veins, alcoholism, preg-
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nancy, diabetes, hypertension, steroid or NSAIDSs in previous year, on regular medica-
tion, hepatic or renal disorder, serious underlying disease, rheumatoid arthritis, collagen
disease
Participant characteristics
Number participants: 168 randomised; 137 analysed
Age: mean (range) 56 (31 to 68) vs 57 (29 to 71) vs 58 (28 to 71) years
% male: 23 (50) vs 21 (47) vs 21 (46)
Ulcer details
Size: mean (SD) 5.3 (0.3) cm² vs 5.5 (0.1) vs 4.6 (0.2) cm²
Duration: mean 20 months vs 24 vs 22 months
Interventions Intervention 1 class: sulphadryl
Intervention 1 details (name and details of application): DL-cysteine powder + Terylene
and cotton gauze; powder manufactured by Sigma, Terylene dressing NADD (Johnson
& Johnson); powder liberally sprayed on ulcer, covered with dressings. Repeated every
day for 7 days, then weekly
Intervention 2 class: sulphadryl
Intervention 2 details (name and details of application): DL-methionine-methyl sulpho-
nium chloride powder + Terylene and cotton gauze; powder manufactured by Sigma,
Terylene dressing NADD (Johnson & Johnson); powder liberally sprayed on ulcer, cov-
ered with dressings. Repeated every day for 7 days, then weekly
Intervention 3 class: inactive powder (placebo)
Intervention 3 details (name and details of application): placebo powder + Terylene and
cotton gauze; powder manufactured by Sigma, Terylene dressing NADD (Johnson &
Johnson); powder liberally sprayed on ulcer, covered with dressings. Repeated every day
for 7 days, then weekly
Compression: below knee graduated compression bandage (layer of crepe bandage, layer
of Elset (Seton Ltd) and layer of Coban cohesive bandage (3M Health Care Ltd))
Other co-interventions: ulcer cleaned with olive oil and washed with saline. Skin sur-
rounding ulcer and of leg oiled with propylene glycol monostearate (BP)
Outcomes Intervention 1: 43/46
Intervention 2: 42/45
Intervention 3: 32/46
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomization was carried out by
drawing sealed envelopes”
Comment: unclear how the sequence was
generated
Allocation concealment (selection bias) Unclear risk Quote: “randomization was carried out by
drawing sealed envelopes”
Comment: unclear howallocationwas con-
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cealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the treatment code was only bro-
ken 3 months after treatment had started
(end point of the study)”
Comment: described as double-blind and
uses placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the treatment code was only bro-
ken 3 months after treatment had started
(end point of the study)”
Comment: described as double-blind; ap-
pears that blinded outcome assessment was
used
Incomplete outcome data (attrition bias)
All outcomes
High risk 9/55 vs 11/57 vs 11/56 excluded from anal-
ysis- reasons given
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No evidence of other sources of bias
All domain risk of bias High risk
Schulze 2001
Methods RCT
Arms: 3
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 4 weeks
Participants Inclusion criteria: moderate to heavily exuding leg ulcers of venous origin (ABPI > or
= 0.8 measured by Doppler ultrasound or colour Duplex sonography), < 1 cm deep, <
11cm wide
Exclusion criteria: wounds with hard black necrotic tissue, wounds with clinical signs
of infection, known hypersensitivity to study dressings, treatment in another research
study within previous 30 days
Participant characteristics
Number participants: 113
Age: 73.6 (13.9) vs 72.4 (13.5) vs 72.7 (14.5) years
% male: 16 (30) vs 10 (45) vs 12 (32)
Ulcer details
Size: mean (SD) 13.7 (12.2) cm² vs 18.5 (18.5) cm² vs 11.2 (13.2) cm², median (range)
8.8 (0.7 to 48.8) cm² vs 12.9 (0.3 to 75.2) cm² vs 7.5 (0.6 to 68.3) cm²
Duration:mean (SD) 49.5 (131.5)months vs 45.6 (97.2)months vs 35.0 (74.1)months,
range 0.5 to 744 vs 0.5 to 396 vs 0.2 to 360 months
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Schulze 2001 (Continued)
Interventions Intervention 1 class: foam
Intervention 1 details (name and details of application): Tielle plus hydropolymer ad-
hesive dressing (Johnson & Johnson Medical); changed when clinically required, maxi-
mum 7 days; secondary dressing of ﬁlm (Opsite ﬂexigrid, Smith & Nephew). Changed
when clinically required, maximum 7 days
Intervention 2 class: alginate
Intervention 2 details (name and details of application): Kaltostat wound dressing (Con-
vaTec)
Intervention 3 class: alginate
Intervention 3 details (name and details of application): Kaltostat wound dressing (Con-
vaTec); secondary dressing switched later in the study to sterile swabs (Topper-8, Johnson
& Johnson) due to side effects. Changed when clinically required, maximum 7 days
Compression: all participants had short-stretch compression bandaging
Other co-interventions: not reported
Outcomes Intervention 1: 2/54
Intervention 2: 3/22
Intervention 3: 1/37
Notes Funding type and details: industry
Funding details: Johnson & Johnson Medical
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “assignment to treatment groupwas
by random allocation according to a prede-
termined, computer-generated, randomi-
sation schedule”
Comment: appropriate sequence genera-
tion
Allocation concealment (selection bias) Unclear risk Quote: “the dressing details for each pa-
tient number were provided inside individ-
ually sealed envelopes, which the investiga-
tors opened on each new patient’s recruit-
ment”
Comment: unclear if envelopes were
opaque and sequentially numbered
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: trial described as “open”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: trial described as “open”
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Schulze 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk All participants accounted for, but high
number of withdrawals for adverse events
especially in alginate + ﬁlm group 10/22
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No evidence of other sources of bias
All domain risk of bias High risk
All domain risk of bias 2 High risk
Scurr 1994
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 6 weeks
Participants Inclusion criteria: venous ulcer (assessed with photoplethysmography, Doppler, ankle-
brachial pressure indices and duplex imaging)
Exclusion criteria: undergone chemotherapy or radiation treatment, on or recently re-
ceived steroid medication, diabetes, peripheral arterial disease
Participant characteristics
Number participants: 40
Age: 62 mean (years)
% male: 22 (55)
Ulcer details
Size: mean (SD) 2.28 (1.49) cm² vs 5.31 (5.46) cm²
Duration: not reported
Interventions Intervention 1 class: alginate
Intervention 1 details (name and details of application): Sorbsan (Steriseal); dressing
applied and covered with 2 layers of gauze and 1 layer surgical pad dressing. held in place
with tape. Dressing change frequency determined by wound discharge (range daily to
weekly)
Intervention 2 class: hydrocolloid
Intervention 2 details (name and details of application): DuoDerm (Convatec, US) also
known as Granuﬂex (UK); dressing applied and secured with tape. Changed every 2-7
days
Compression: class III graduated elastic compression stocking
Other co-interventions: before applying dressings, wounds were adequately debrided
and slough removed. Saline irrigation used to clean wounds at dressing changes
Outcomes Intervention 1: 6/20
Intervention 2: 2/20
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Notes Funding type and details: industry
Funding details: Grants from Steriseal Ltd and Dow B Hickam
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients ... were randomly allo-
cated either to the calcium alginate or the
hydrocolloid group”
Comment: method of sequence generation
unclear
Allocation concealment (selection bias) Unclear risk Quote: “patients ... were randomly allo-
cated either to the calcium alginate or the
hydrocolloid group”
Comment: method of allocation conceal-
ment unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk Authors noted difference in size between
groups due to one participant and per-
formed analyses both with and without
them
All domain risk of bias Low risk Low/unclear
Senet 2003
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
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Participants Inclusion criteria: at least one venous ulcer, duration at least 2 months, 3 cm² to 50 cm²,
no tendency for healing in past 2 months, venous disease conﬁrmed by venous duplex
ultrasound scan and clinical symptoms, absence of arterial insufﬁciency ABI > 0.8
Exlcusion criteria: pregnancy, allergy to hydrocolloid dressings, uncontrolled or evolving
systemic disease, serum creatinine > 180 umol/L, systemic corticosteroids or cytotoxic
drugs, limited physical capacity or immobility, ulcer with exposed tendon/bone, infected
ulcer requiring systemic antibiotics, uncontrolled diabetes, various serological ﬁndings
(details in paper)
Participant characteristics
Number participants: 15 randomised (data analysed for 13)
Age:mean (range) 72.3 (45 to 88) vs 72.3 (50 to 83) years
% male: 4 (57) vs 3 (50)
Ulcer details
Size: mean (range) 13.7 (4.8 to 27.25) cm² vs 10.85 (3.7 to 26.5) cm²
Duration: mean (range) 50.6 (4 to 240) vs 70 (24 to 120) months
Interventions Intervention 1 class: blood product
Intervention 1 details (name and details of application): frozen autologous platelets (FAP)
(suspension in saline) + hydrocolloid; Comfeel PlusOpaque (Coloplast); FAP suspension
applied to wound surface with syringe. Dressings changed 3 x per week
Intervention 2 class: saline/hydrocolloid (placebo)
Intervention 2 details (name and details of application): placebo (saline) + hydrocolloid;
placebo applied to wound surface with syringe. Dressings changed 3 x per week
Compression: standard graded compression with cotton bandages (Nylex, Laboratoires
URGO) and elastic bandages (Biﬂex Plus Forte, Laboratoires Thuasne)
Other co-interventions: not reported
Outcomes Intervention 1: 1/7
Intervention 2: 1/6
Notes Funding type and details: mixed
Funding details: grants from Institut national de la santé et de la recherchemédicale and
Coloplast
Note: participants randomised immediately after collection of platelets
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients who complied with entry
and exclusion criteria were randomised to
one of two treatment groups”
Comment: method of sequence generation
unclear
Allocation concealment (selection bias) Unclear risk Quote: “patients who complied with entry
and exclusion criteria were randomised to
one of two treatment groups”
Comment: method of allocation conceal-
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Senet 2003 (Continued)
ment unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: described as double-blind but
no details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: described as double-blind but
no details
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1/8 vs 1/7withdrawals, included in analysis
as failure to heal
Selective reporting (reporting bias) Unclear risk No evidence of selective reporting but re-
porting insufﬁcient
Other bias Unclear risk No evidence of other sources of bias but
reporting insufﬁcient
All domain risk of bias Low risk Low/unclear
Senet 2011
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: people with one or more hypertensive leg ulcers (deﬁned by clinical
criteria) 1 cm² to 30 cm², with hypertension and/or diabetes without clinical signs
of severe CVI and without signiﬁcant peripheral arterial occlusive disease (presence of
peripheral pulses or ABI > 0.8); if several ulcers, most recent chosen
Exclusion criteria: cutaneous vasculitis, systemic disease associated with pyoderma gan-
grenosum or necrotising vasculitis (e.g. rheumatoid arthritis), autoimmune disease, cry-
obulinemia, allergy to study materials, cancer, evolving systemic disease, creatinemia,
uncontrolled diabetes, exposed bone or joint, corticosteroids, immunosuppressive or cy-
totoxic drugs, iloprost in prior 3 months
Participant characteristics
Number participants: 64 randomised, data from 59
Age: 73.7 (8.3) vs 75.3 (9.7) years
% male: 12 (43) vs 11 (35)
Ulcer details
Size: mean (SD) 19.6 (20.1) cm² vs 24.4 (24.6) cm²
Duration: mean (SD) 11.8 (8.6) vs 10.5 (9.7)
Interventions Intervention 1 class: blood product
Intervention 1 details (name and details of application): Becaplermin (human platelet
derived growth factor) 0.1% in hydrogel + gauze; Regranex gel (Ethicon division of
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Johnson& JohnsonWoundManagement); continuous thin layer of gel applied, covered
with moist saline gauze and bandage. Treatment for 8 weeks
Intervention 2 class: hydrogel (placebo gel)
Intervention 2 details (name and details of application): DuoDerm Hydrogel (Conva-
Tec) + gauze; continuous thin layer of gel applied, covered with moist saline gauze and
bandage. Treatment for 8 weeks
Compression: not reported; unclear if bandage applied compression
Other co-interventions: wound irrigation with saline. Moist saline gauze and bandage
Outcomes Intervention 1: 10/28
Intervention 2: 8/31
Notes Funding type and details: mixed
Funding details: study supported by AP-HP (Assistance publique - Hôpitaux de Paris)
, the French Society of Dermatology, and the AFSSAPS (Agence nationale de sécurité
du médicament et des produits de santé); Johnson & Johnson provided study materials
(Regranex)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “eligible participants were ran-
domly assigned by facsimile through a cen-
tral automated system designed by the
Clinical Research Regional Department
(AP-HP)” “a computer engineer not re-
sponsible for data acquisition prepared the
assignments”
Comment: appropriate sequence genera-
tion method appears to have been used
Allocation concealment (selection bias) Low risk Quote: “a central automated system ... a
computer engineer not responsible for data
acquisition prepared the assignments”
Comment: appears to be appropriate allo-
cation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “all participants and investiga-
tors were blinded to assigned treatment”
“masked 15g tubes ... identical in color,
shape and size, were provided in blister
packs by the AP-HP central pharmacy”
Comment: blinding of both groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “all participants and investiga-
tors were blinded to assigned treatment”
“masked 15g tubes ... identical in color,
shape and size, were provided in blister
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packs by the AP-HP central pharmacy”
Comment: appears that assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 7/28 vs 13/31 did not receive treatment
or complete follow-up - ITTanalysis per-
formed but this is a very high rate of loss
with disparity between arms
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Unclear risk No evidence of other source of bias
All domain risk of bias High risk
Senet 2014
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 6 weeks
Participants Inclusion criteria: venous or predominantly venous leg ulcer (ABI > 0.8) between 2cm
and 13 cm in all directions, moderately or severely exudating in the phase of debridement
or formation of granulation tissue, size reduction < 20% in 4-week pre-study treatment
phase
Exclusion criteria: clinically infected ulcer requiring systemic antibiotics, surgery on
saphenous trunk within 2 months prior, systemic antibiotics 2 weeks prior, systemic
corticoids or cytostatics within 3 months prior, unbalanced diabetes, known allergy to
study dressings, pregnant or breastfeeding, taking part in another study
Participant characteristics
Number participants: 182 (1 erroneously enrolled and subsequently excluded)
Age: 72.1 (12.4) vs 75.1 (11.8) years
% male: 50 (53) vs 34 (39)
Ulcer details
Size: mean (SD) 15.4 (14.1) cm² vs 14.5 (13.4) cm²
Duration: mean (SD) 2.8 (4.2) years vs 2.9 (5.1) years
Interventions Intervention 1 class: foam
Intervention 1 details (name and details of application): Biatain (Coloplast A/S)
Intervention 2 class: silver (foam)
Intervention 2 details (name and details of application): Biatain-Ag (Coloplast A/S)
Compression: compression therapy was mandatory for all according to clinical practice
of the centre
Other co-interventions: not reported
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Outcomes Intervention 1: 3/94
Intervention 2: 7/87
Notes Funding type: industry
Funding details: Coloplast
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “centrally randomised (by com-
puter system)”
Comment: appropriate method of se-
quence generation
Allocation concealment (selection bias) Low risk Quote: “allocated ... using InteractiveVoice
Response Service (IVRS)”
Comment: appropriate allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the study was designed as dou-
ble-blinded. All products were ... packed in
identical packing and blinded by an exter-
nal company ... No dressings could be com-
pared by the subject or investigator in the
knowledge that they were different prod-
ucts”
Comment: effective blinding described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the planimetry records were read
blind by a person who was not aware of the
nature of the treatment”
Comment: blinded outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk 11 vs 18 withdrawals - reasons given and
ITT analysis performed but still a high level
of withdrawal and an imbalance between
the groups
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No evidence of other sources of bias
All domain risk of bias High risk
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Smith 1992
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 4 months
Participants Inclusion criteria: venous leg ulceration assessed by continuous wave ultrasound and
photoplethysmography
Exclusion criteria: brachial ankle systolic pressure < 0.75, diabetes, rheumatoid arthritis,
infected ulcers requiring treatment , known intolerance to iodine, neurological disease
causing trophic impairment
Participant characteristics
Number participants: 200
Age: 74 (12) vs 72 (13) vs 76 (8) vs 73 (11) years
% male: not reported
Ulcer details
Size: median (IQR) 3.1 (2 to 5) cm² vs 2.6 (2 to 4) cm² vs 13.3 (9 to 27) cm² vs 17.6
(9 to 38) cm²
Duration: median (IQR) 5 (3 to 9) vs 3 (2 to 10) vs 14 (2 to 45) vs 17 (6 to 58) months
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): Bioﬁlm (Clinimed); ulcer ﬁlled
with bioﬁlm powder until level with margins, then bioﬁlm dressing applied with 2cm
overlap
Intervention 2 class: povidone iodine
Intervention 2 details (name and details of application): standard Jelonet/Betadine dress-
ing; Betadine + Jelonet (Smith & Nephew); Dressing cut to exactly ﬁt ulcer and ab-
sorbant pad placed over
Compression: 2 layers of shaped Tubigrip or a Venosan 2002 stocking for all participants
Other co-interventions: ulcers cleansed with sterile isotonic saline
Outcomes Intervention 1: 38 + 12/64 + 35
Intervention 2: 43 + 4/62 + 39
Notes Funding type: industry
Fundingdetails: ClinimedLtdprovidedﬁnancial support to one study nurse co-ordinator
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “patients ... were randomly allo-
cated to each treatment group”
Comment: stratiﬁcation and block size
mentioned but not method of sequence
generation; ’Clerical errors’ with treatment
allocation - randomisation compromised
164Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Smith 1992 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: no information on how alloca-
tion was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Described as “not a blind study”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Described as “not a blind study”
Incomplete outcome data (attrition bias)
All outcomes
High risk 60 (30%) dropped out, reasons given. 5
received incorrect treatment due to ’clerical
error’, included as PP
Selective reporting (reporting bias) Low risk No evidence of this
Other bias Low risk No additional risks - see random sequence
generation
All domain risk of bias High risk
All domain risk of bias 2 High risk
Smith 1994
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 6 weeks
Participants Inclusion criteria: venous leg ulcer > 2.5 cm diameter
Exclusion criteria: condition which might affect wound healing (infection, immune
deﬁciency, steroid treatment, malignant disease), if ulcer not clearly venous, ﬁbrinolytic
or anticoagulant therapy
Participant characteristics
Number participants: 40
Age: not reported
% male: not reported
Ulcer details
Size: mean 12.74 cm² vs 22.17 cm²
Duration: not reported
Interventions Intervention 1 class: alginate
Intervention 1 details (name and details of application): gauze used as secondary dressing
Intervention 2 class: hydrocolloid
Intervention 2 details (name and details of application): improved formulationGranuﬂex
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Compression: compression bandaging used for all participants
Other co-interventions: wounds cleaned with saline
Outcomes Intervention 1: 2/18
Intervention 2: 4/22
Notes Funding type: industry
Funding details: Convatec
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “eligible patients were allocated
randomly”
Comment: no information on how ran-
domisation sequence generated
Allocation concealment (selection bias) Unclear risk Quote: “eligible patients were allocated
randomly”
Comment: no information on how alloca-
tion was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Trial described as open
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Trial described as open
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 6/18 vs 6/22 withdrawals, reasons given
Selective reporting (reporting bias) Low risk No evidence of this
Other bias Low risk No evidence of this
All domain risk of bias High risk
All domain risk of bias 2 High risk
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Solovastru 2015
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 30 days
Participants Inclusion criteria: chronic VLUs < 2 years duration
Exclusion criteria: conﬁned to bed 24 hours, ulcers covered by necrosis or ﬁbrin, infected
ulcers, multiresistant germs in wound, poorly controlled diabetes, those on dialysis,
advanced peripheral arterial occlusive disease (ABPI < 0.80 and presence of distal pulse)
, immunodeﬁciency, lymphopenia, hepatic insufﬁciency, renal insufﬁciency, anaemia,
autoimmune disease, BMI > 30, hypersensitivity to study materials, low white blood
cells or thrombocytes
Participant characteristics
Number participants: 29
Age: 58.0 vs 59.0 years
% male: 9 (60) vs 10 (71)
Ulcer details
Size: mean (SD) 4.36 (5.61) cm² vs 4.59 (3.46) cm²
Duration: mean 13 months vs 16 months
Interventions Intervention 1 class: ozonated oil
Intervention 1 details (name and details of application): ozonated oil and alpha-bisabolol
spray + gauze; sunﬂower oil with O³ (Neozone, Neovalis) and Azexin (AlfaWassermann)
; administered daily for 30 days
Intervention 2 class: emollient cream
Intervention 2 details (name and details of application): epithelialization cream (vitamins
A & E, talc, zinc oxide, Vaseline) + gauze; administered daily for 30 days
Compression: none
Other co-interventions: mechanical debridement at days 0, 7, 14
Outcomes Intervention 1: 5/15
Intervention 2: 0/14
Notes Funding type and details: not reported but authors employed by pharmaceutical com-
pany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly divided
into 2 groups”
Comment: no information on how se-
quence was generated
Allocation concealment (selection bias) Unclear risk Quote: “patients were randomly divided
into 2 groups”
Comment: no information on how alloca-
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tion was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis
Selective reporting (reporting bias) Low risk No evidence of this
Other bias Low risk No evidence of this
All domain risk of bias Low risk Low/unclear
Sopata 2016
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: until participants healed (maximum 40 weeks) or died
Participants Inclusion criteria: people with VLU conﬁrmed by ultrasound Doppler and ABPI, no
clinical signs of infection, no intolerance or allergy to octenidine dihydrochloride
Exclusion criteria: not reported
Participant characteristics
Number participants: 50
Age (years): female 39 to 91, 68.9 ± 12.2, mean = 70.5; male 24 to 93,65.7 ± 20.2, mean
= 70
% male: 15 (30)
Ulcer details
Size: female: 3.0 to 156.5 cm², 28.8 ± 28.5, mean = 24.2; male 2.8-75.2 cm², 20.4 ±
27.1, mean = 12.2
Duration: not reported
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): Granuﬂex (ConvaTec); dressing
changed every 2-4 days
Intervention 2 class: foam
Intervention 2 details (name and details of application): Biatain (Coloplast); dressing
changed every 2-4 days
Compression: short stretch bandages used for all participants, with a spiral two layer
bandaging technique
Other co-interventions: for 4 weeks prior to randomisation all participants were treated
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Sopata 2016 (Continued)
with nonadherent silicone N-A dressing (Systagenix) and Sterilux EX (Hartmann) gauze
bandages soaked in octenidine dihydrochloride antiseptic (Octenisept) and covered with
absorbent Zetuvit (Hartmann) dressing
Outcomes Intervention 1: 17/25
Intervention 2: 21/25
Notes Funding type: non-industry
Funding details: Grant from University of Medical Science, Poznan
Notes: Demographic data not presented by treatment group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “in the second period the patients
were randomly allocated to two groups”
Comment: no information on how the ran-
domisation sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “in the second period the patients
were randomly allocated to two groups”
Comment: no information on how the al-
location was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis (those
that did not have ﬁnal assessment explained
in text)
Selective reporting (reporting bias) High risk Study design does not have deﬁned time
end point
Other bias High risk No baseline information for study groups,
just split male vs female
All domain risk of bias High risk
All domain risk of bias 2 High risk
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Stacey 1997
Methods RCT
Arms: 3
Unit of randomisation: leg
Unit of analysis: leg
Follow-up: 9 months
Participants Inclusion criteria: proven venous ulcers 0.5 cm to 10 cm diameter
Exclusion criteria: diabetes, rheumatoid arthritis, arterial diease, cellulitis
Participant characteristics
Number participants: 133 legs (113 participants)
Age: median (range) 73 (33 to 89) vs 76 (31 to 89) vs 70.5 (36 to 92) years
% male: 17 (41) vs 16 (39) vs 22 (48)
Ulcer details
Size: mean 10.11 cm² vs 9.14 vs 11.02 cm², median (range) 3.60 (0.15 to 57.46) cm²
vs 2.94 cm² (0.24 to 75.37) cm² vs 4.57 cm² (0.36 to 61.32) cm²
Duration: median (range) 6.00 (0.25 to 192) vs 6.00 (0.25 to 5.04) vs 4.00 (0.25 to 2.
64) months
Interventions Intervention 1 class: paste bandage
Intervention 1 details (name and details of application): zinc oxide paste bandage; Vis-
copaste (Smith & Nephew); applied in spiral fashion from base of toes to just below the
knee. Changed weekly or sooner if excessive exudate
Intervention 2 class: paste bandage
Intervention 2 details (name and details of application): zinc oxide stockingette; Acoband
(Auspharm); applied from base of toes to just below knee. Changed weekly or sooner if
excessive exudate
Intervention 3 class: alginate
Intervention 3 details (name and details of application): Kaltostat (Faulding Pharma-
ceuticals); moistened with saline and applied over ulcer. Changed weekly or sooner if
excessive exudate
Compression: over dressings 2 elastocrepe bandages (Smith & Nephew) applied from
toe to knee and Tubigrip stockingette (Seton) over them
Other co-interventions: leg and foot washed in soap-water bath and ulcer debrided
Outcomes Intervention 1: 34/43
Intervention 2: 26/44
Intervention 3: 26/46
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no methods
given
Allocation concealment (selection bias) Unclear risk No information provided
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Stacey 1997 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 5/43 vs 6/44 vs 10/46 withdrawals, reasons
given. Imbalance between groups
Selective reporting (reporting bias) Low risk No evidence of this
Other bias Unclear risk Unclear if the analysis adjusted for some
clustering of data
All domain risk of bias High risk
Stacey 2000
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 9 months
Participants Inclusion criteria: venous ulcer (established with photoplethysmography - venous reﬁll-
ing time < 25s)
Exclusion criteria: arterial disease (ABPI < 0.9)
Participant characteristics
Number participants: 66
Age: Median (range) 72 (35 to 90) vs 70 (26 to 92) years
% male: 15 (36) vs 21 (48)
Ulcer details
Size: mean (SD) 5.06 (8.70) cm² vs 4.79 (8.24) cm², median (range) 1.79 (0.23 to 50.
76) cm² vs 2.09 (0.15 to 47.8) cm²
Duration: median (range) 3.0 (1 to 244) months vs 3.0 (0.75 to 360) months
Interventions Intervention 1 class: blood product
Intervention 1 details (name and details of application): platelet lysate-soaked gauze;
dressing changed twice weekly
Intervention 2 class: saline gauze (placebo/vehicle liquid)
Intervention 2 details (name and details of application): placebo (buffer solution) soaked
gauze; dressing changed twice weekly
Compression: dressings covered with Viscopaste bandage (Smith & Nephew) followed
by 2 Comprilan bandages (Beiersdorf ) and Tubigrip stockingette (Seton)
Other co-interventions: see above
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Outcomes Intervention 1: 34/42
Intervention 2: 33/44
Notes Funding type: mixed
Funding details: Medical Research Fund of Western Australia and Beiersdorf AG
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomisation was by a sealed en-
velope system”
Comment: no information on sequence
generation
Allocation concealment (selection bias) Unclear risk Quote: “randomisation was by a sealed en-
velope system”
Comment: no information on allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: described as “double blind” but
no further details given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: described as “double blind” but
no further details given
Incomplete outcome data (attrition bias)
All outcomes
High risk 5/42 vs 6/44 withdrawals, reasons given,
over 10% lost
Selective reporting (reporting bias) Low risk No evidence of this
Other bias Low risk No evidence of this
All domain risk of bias High risk
Steele 1986
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 6 weeks
Participants Inclusion criteria: venous leg ulcers present for 3 months and > 2 cm²
Exclusion criteria: arterial disease (palpable dorsalis pedis and posterior tibial pulses and
absence of ischaemic skin signs), diabetes, rheumatoid arthritis, neurological disease,
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connective tissue disease
Participant characteristics
Number participants: 60
Age: mean (SE) 69.5 (2.4) vs 73.4 (1.6) years
% male: 8 (29) vs 8 (28)
Ulcer details
Size: mean (SE) 1264 (291) mm² vs 1759 (397) mm²
Duration: mean (SE) 16.6 (2.7) months vs 16.3 (2.5) months
Interventions Intervention 1 class: cadexomer iodine
Intervention 1 details (name and details of application) powder sprinkled onto ulcer and
covered with gauze. Changed 3 times per week
Intervention 2 class: standard treatment
Intervention 2 details (name and details of application): various including topical an-
tibiotics, antiseptics, hydrophilic agents, bland agents, steroids, dry dressings; dressing
applied and covered with gauze. Changed 3 times per week
Compression: all participants wore crepe compression bandages
Other co-interventions: ulcers cleansed with saline
Outcomes Intervention 1: 3/28
Intervention 2: 1/29
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote “the patients were divided into two
groups using random numbers”
Comment: unclear how the random num-
ber sequence was obtained
Allocation concealment (selection bias) Unclear risk Quote “the patients were divided into two
groups using random numbers”
Comment: unclear howallocationwas con-
cealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 57/60 completed and reasons for with-
drawal given
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Selective reporting (reporting bias) Unclear risk No evidence of this
Other bias Unclear risk No evidence of this
All domain risk of bias Low risk Low/unclear
Taddeucci 2004
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis:ulcer
Follow-up: 8 weeks
Participants Inclusion criteria: venous ulceration present for > 3 months
Exclusion criteria: arterial, metabolic or traumatic ulcers, infected ulcers with cellulitis,
immunosuppressive, corticosteroid or cytostatic therapy in previous 4 weeks, insulin-
dependent diabetes, concomitant diseases, pregnancy
Participant characteristics
Number participants: 17 participants (24 ulcers)
Age: not reported
% male: not reported
Ulcer details
Size: not reported
Duration: not reported
Interventions Intervention 1 class: hydrogel
Intervention 1 details (name and details of application): Hyaloﬁll-F (Fidia Advanced
Biopolymers); dressing applied and covered with sterile gauze. Changed every 2-3 days
initially then less frequently depending on wound condition
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): parafﬁn gauze; dressing applied
and covered with sterile gauze. Changed every 2-3 days initially then less frequently
depending on wound condition
Compression: compression bandage Pehacrepp E (Paul Hartmann)
Other co-interventions: initial debridement if necessary, then cleansing with saline at
every dressing change
Outcomes Intervention 1: 2/12
Intervention 2: 1/12
Notes Funding type and details: funding not reported but some authors work for Fidia Ad-
vanced Biopolymers
Risk of bias
Bias Authors’ judgement Support for judgement
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Taddeucci 2004 (Continued)
Random sequence generation (selection
bias)
Unclear risk Described as randomised study “subjects ...
were ... assigned sequentially to one of two
treatments”
Comment: unclear how randomisation se-
quence was generated
Allocation concealment (selection bias) Unclear risk Described as randomised study “subjects ...
were ... assigned sequentially to one of two
treatments”
Comment: unclear howallocationwas con-
cealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Trial described as “open”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Trial described as “open”
Incomplete outcome data (attrition bias)
All outcomes
High risk 1/12 vs 5/12 ulcers withdrawn, reasons
given; imbalance and larger numbers than
those healed
Selective reporting (reporting bias) Low risk No evidence of this
Other bias High risk Unit of analysis issue. Unclear if clustering
of some data adjusted for
All domain risk of bias High risk
All domain risk of bias 2 High risk
Tarvainen 1988
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 8 weeks
Participants Inclusion criteria: chronic exuding leg ulcer
Exclusion criteria: insulin-dependent diabetes, rheumatoid arthritis, connective tissue
disease, goitre, known allergy to iodine
Participant characteristics
Number participants: 27 randomised; 21 analysed
Age: 67.7 (13.3) vs 68.8 (14.6), range 39 to 86 vs 38 to 87 years
% male: 4 (29) vs 3 (23)
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Ulcer details
Non VLU: “[ulcers] were clinically judged to be mainly of venous origin”
Size: not reported
Duration: mean (SD) 54.8 (108.7) months vs 12.2 (23.0) months, range 1 to 360
months vs 1 to 72 months
Interventions Intervention 1 class: cadexomer iodine
Intervention 1 details (name and details of application): cadexomer iodine powder;
applied in 3mm layer, then “covered with protective clean compress”. Changed daily
Intervention 2 class: dextranomer
Intervention 2 details (name and details of application): dextranomer powder; applied
in 3mm layer, then “covered with protective clean compress”. Changed daily
Compression: “a normal compression bandage was applied”
Other co-interventions: ulcers washed with water or saline solution
Outcomes Intervention 1: 7/11
Intervention 2: 5/10
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “random allocation to treatment”
Comment: no details of sequence genera-
tion
Allocation concealment (selection bias) Unclear risk Quote: “each patient was allocated to the
treatment by using a sealed enclosure enve-
lope containing the treatment code of the
individual patient”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Described as “open”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Described as “open”
Incomplete outcome data (attrition bias)
All outcomes
High risk 3/14 vs 5/13 appear to have dropped out for
reasons other than healing - reasons given
but numbers do not tally with text
Selective reporting (reporting bias) Unclear risk Results section confusing - data don’t
match
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Other bias Unclear risk Reporting somewhat unclear; risks of bias
uncertain
All domain risk of bias High risk
All domain risk of bias 2 High risk
Thomas 1997
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 13 weeks
Participants Inclusion criteria: over 16 years. Venous leg ulcer maximum dimension 8 cm conﬁrmed
by medical history, clinical examination and ABPI > 0.8
Exclusion criteria: history of poor compliance, insulin-dependent diabetes, unlikely to
survive study period, previous adverse reaction to study materials, clinically infected
wounds
Participant characteristics
Number participants: 100
Age: 75.3 (14.4) vs 73.4 (13.2) years
% male: 16 (32) vs 13 (26)
Ulcer details
Non VLU: (pressure ulcers included in separate stratiﬁed analysis)
Size: mean (range) 335 (10 to 2758) mm² vs 431 (16 to 1876) mm²
Duration: no summary statistic, grouped data < 1 month (3 vs 2) 1 to 3 months (13 vs
9) > 3 months (34 vs 39)
Interventions Intervention 1 class: hydrocolloid
Intervention 1 details (name and details of application): Granuﬂex
Intervention 2 class: foam
Intervention 2 details (name and details of application): Tielle
Compression: type 3c compression bandage (Tensopress) applied over layer of or-
thopaedic wadding (Velband)
Other co-interventions: Wounds cleansed with 0.9% NaCl (saline) solution as necessary
Outcomes Intervention 1: 19/50
Intervention 2: 17/50
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “patients ... were allocated to the
two treatment groups on a randomised ba-
sis, using a system of sealed envelopes”
Comment: unclear how the randomisation
sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “patients ... were allocated to the
two treatment groups on a randomised ba-
sis, using a system of sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Described as “open”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Described as “open”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk No evidence of this
Other bias Unclear risk No evidence of this but reporting insufﬁ-
cient
All domain risk of bias High risk
All domain risk of bias 2 High risk
Tumino 2008
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 90 days
Participants Inclusion criteria: non-infected venous stasis or post-phlebitis ulcers
Exclusion criteria: hypersensitivity to study drug, pregnancy, neoplastic or other con-
comitant disease, previous use of local treatment for ulcer
Participant characteristics
Number participants: 100
Age: 64.9 (12.1) vs 67.7 (6.5) years
% male: 23 (46) vs 26 (52)
Ulcer details
Size: 6.6 (8.9) vs 4.7 (9.1) (unit of size unclear)
Duration: not reported
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Interventions Intervention 1 class: sucralfate
Intervention 1 details (name and details of application): SUC-LIS 95 (Lisapharma);
sucralfate hydrophilic gel; applied once daily for 30 to 90 days, covered with dry gauze
Intervention 2 class: hydrogel (placebo gel)
Intervention 2 details (name and details of application): manufactured by Lisapharma;
applied once daily for 30 to 90 days, covered with dry gauze
Compression: a few cases were covered with elastic bandage (no further details)
Other co-interventions: cleaning with saline and iodine solution following surgical re-
moval of debris
Outcomes Intervention 1: 43/50
Intervention 2: 5/50
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no informa-
tion on how sequence was generated
Allocation concealment (selection bias) Unclear risk No informationonhowallocationwas con-
cealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind anduses placebo
manufactured externally
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind anduses placebo
manufactured externally
Incomplete outcome data (attrition bias)
All outcomes
High risk 5/50 vs 4/50 dropouts or deviations from
protocol; not a high rate but close to the
event rate in the placebo arm
Selective reporting (reporting bias) Low risk No evidence of this
Other bias Low risk No evidence of this
All domain risk of bias High risk
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Vanscheidt 2012
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: locally infected chronic venous leg ulcer below knee joint (CVI grade
C6 according to CEAP classiﬁcation), conﬁrmed diagnosis of CVI, ulcer duration 4
weeks to 2 years, 2 cm² to 20 cm², presence of at least 2/9 infection criteria
Exclusion criteria: contraindication with local wound therapy and compression therapy
with bandages, hypersensitivity to study materials, previous or concomitant therapy with
non permitted local or systemic drug therapy
Participant characteristics
Number participants: 126 (demographics for 124)
Age: 66.9 (10.6) vs 68.7 (13.0) years
% male: 30 (51) vs 23 (35)
Ulcer details
Size: mean (SD) 6.68 (4.76) cm² vs 6.98 (5.51) cm²
Duration: not reported
Interventions Intervention 1 class: octenidine
Intervention 1 details (name and details of application): octenidine solution spray (+
non adhesive foam dressing); Ulcer completely moistened with spray at each dressing
change (at least once a week, maximum 3 x per week)
Intervention 2 class: foam (placebo (Ringer solution) spray)
Intervention 2 details (name and details of application): Ringer solution spray (+ non
adhesive foam dressing); ulcer completely moistened with spray at each dressing change
(at least once a week, maximum 3 x per week)
Compression: elastic bandages
Other co-interventions: non-adhesive foam dressing used for all
Outcomes Intervention 1: 15/60
Intervention 2: 16/66
Notes Funding type and details: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no methods
given
Allocation concealment (selection bias) Unclear risk Described as randomised but no methods
given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind. Methods not
clear about who was blinded
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as double-blind. Methods not
clear about who was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for dropouts explained - somewere
lost from analysis due to wound healing
which is our outcome of interest
Selective reporting (reporting bias) Low risk No evidence of this
Other bias Low risk No evidence of this
All domain risk of bias High risk
Vin 2002
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: venous leg ulcer > 30 days duration, not infected, venous aetiology
conﬁrmed by Doppler ultrasound and ABPI > or =0.8, between 2 cm and 10 cm in any
dimension. If multiple ulcers, largest selected (had to be 3 cm away from other ulcers)
Exclusion criteria: unwilling to wear compression bandages, immobile, concomitant
wound healing condition e.g. carcinoma, vasculitis, connective tissue disease, immune
system disorder, used corticosteroids, immunosuppressive agents, radiation therapy or
chemotherapy within 30 days prior
Participant characteristics
Number participants: 73
Age: 74.1 (12.1) vs 71.7 (11.4), range 33 to 87 vs 37 to 88 years
% male: 15 (40.5) vs 11 (30.6)
Ulcer details
Size: mean (SD) 7.0 (6.8) cm² vs 9.5 (9.5) cm², range 1.6 to 35.5 vs 1.2 to 34.5 cm²
Duration: mean (SD) 8.5 (11) vs 9.9 (20.2) months
Interventions Intervention 1 class: PMM
Intervention1details (name anddetails of application): Promogran (Johnson&Johnson)
(+ Adaptic); Promogran cut to ﬁt ulcer, Adaptic placed over the top. Dressing changed
at least twice weekly
Intervention 2 class: nonadherent
Intervention 2 details (name and details of application): Adaptic (Johnson and Johnson
Medical)
Compression: compression bandages Biﬂex 16+ graduated version with tension indicator
(Thuasne) worn continuously by all between dressing changes
Other co-interventions: wound cleaned with warm sterile saline before dressing. Gauze
pad (Topper, Johnson & Johnson) applied as secondary dressing to all
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Outcomes Intervention 1: 18/37
Intervention 2: 12/63
Notes Funding type and details: industry
Funding details: Johnson & Johnson Wound Management, France
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised study. No details
reported
Allocation concealment (selection bias) Unclear risk Described as randomised study. No details
reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “all measures were performed by
an investigator blinded to treatment allo-
cation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data reported for all participants, ITT and
PP analyses
Selective reporting (reporting bias) Low risk No evidence
Other bias Low risk No evidence
All domain risk of bias Low risk low/unclear
Zuccarelli 1992
Methods RCT
Arms: 2
Unit of randomisation: participant
Unit of analysis: participant
Follow-up: 12 weeks
Participants Inclusion criteria: leg ulcer clinic outpatients
Exclusion criteria: not reported
Participant characteristics
Number participants: 38
Age: not reported
% male: not reported
Ulcer details
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Non VLU: not reported
Size: not reported
Duration: not reported
Interventions Intervention 1 class: foam
Intervention 1 details (name and details of application): Allevyn
Intervention 2 class: hydrocolloid
Intervention 2 details (name and details of application): not reported
Compression: “elastic compression bandaging was standardised”
Other co-interventions: not reported
Outcomes Intervention 1: 9/19
Intervention 2: 9/19
Notes Funding type: industry (unclear)
Funding details: Smith and Nephew (unclear)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were recruited and ran-
domised..”
Comment: no information on sequence
generation
Allocation concealment (selection bias) Unclear risk Quote: “patients were recruited and ran-
domised..”
Comment: No information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included
Selective reporting (reporting bias) Unclear risk Limited information reported
Other bias Unclear risk Too little information to be conﬁdent
All domain risk of bias Low risk Low/unclear
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Abbreviations::ABI: ankle brachial index; ABPI: ankle brachial pressure index; BMI: body mass index; CEAP: Comprehensive Classi-
ﬁcation System for Chronic Venous Disorders; CVI : chronic venous insufﬁciency; DVT: deep vein thrombosis; HbA1c: glycated;
haemoglobin (average plasma glucose concentration (blood sugar levels)); HTA: health technology assessment; IQR: interquartile
range; ITT: intention-to-treat (an ITT analysis is a comparison of the treatment groups that includes all patients as originally
allocated after randomisation); IV: intravascular; LOCF: LAST IBSERVATION CARRIED FORWARD; NaCL: sodium chloride;
NIHR:National Institute for Health Research; PMM: protease-modulating-matrix; PP: per-protocol (a PP analysis is a comparison
of treatment groups that includes only those patients who completed treatment); RCT: randomised controlled trial; SD: standard
deviation; SE: standard error; SEM: standard error of the mean; SSD: silver sulfadiazine; VLU: venous leg ulcer; vs versus
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Acosta 1992 Did not report wound healing
Alvarez 2004 Did not report analysable healing data
Andersen 2002 Compares dressings of the same type
Andreev 2010 Did not report analysable healing data
Andriessen 2009 Did not report wound healing
Asselman 1995 Did not report analysable healing data
Bale 2004 Did not report wound healing
Bartoletti 1997 Dressing is not the only difference between groups
Bartoszewicz 2013 Did not report wound healing
Bastami 2012 Did not report wound healing
Beitner 1985 Did not report analysable healing data
Belcaro 2007 Did not report analysable healing data
Bianchi 2018 Only one eligible intervention, does not link network
Binic 2010 Did not report analysable healing data
Bruckner 2009 Did not report analysable healing data
Bull 1995a Compares dressings of the same type
Burgess 1993 Compares dressings of the same type
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Burgos 1989 Did not report wound healing
Cabete 2004 Did not report wound healing
Caetano 2009 Only one eligible intervention, does not link network
Callam 1987a Only one eligible intervention, does not link network
Cardinal 2009a Did not report analysable healing data
Cardinal 2009b Did not report analysable healing data
Carville 2008 Did not report wound healing
Casoni 2006 Only one eligible intervention, does not link network
Cervadoro 2003 Dressing is not the only difference between groups
Chaloner 1992 Did not report analysable healing data
Chaloner 2004a Compares dressings of the same type
Charles 2002a Did not report wound healing
Cherry 1992 Did not report wound healing
Cherry 1998 Did not report analysable healing data
Chiummariello 2009 Did not report analysable healing data
Choucair 1998 Dressing is not the only difference between groups
Collier 1992 Did not report analysable healing data
Cordts 1992 Dressing is not the only difference between groups
Cullen 2012 Did not report analysable healing data
D’Alicandro 2003 Did not report wound healing
Daltrey 1981 Did not report wound healing
Davis 1992 Did not report analysable healing data
De Caridi 2016 Did not report analysable healing data
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De la Brassinne 2006 Compares dressings of the same type
Dereure 2012b More than 25% non-venous ulcers
Dini 2010 Did not report wound healing
Dini 2013 Did not report analysable healing data
Dmochowska 1999 Did not report analysable healing data
Duhra 1992 Only one eligible intervention, does not link network
Egan 1983 Did not report wound healing
El Heneidy 2016 Only one eligible intervention, does not link network
Eriksson 1984a Dressing is not the only difference between groups
Eriksson 1984b Did not report analysable healing data
Eriksson 1984c Did not report analysable healing data
Eriksson 1991 Only one eligible intervention, does not link network
Falabella 1998 Did not report analysable healing data
Falanga 1996 Did not report wound healing
Falanga 1998 Only one eligible intervention, does not link network
Falanga 1999 Only one eligible intervention, does not link network
Falanga 2000 Only one eligible intervention, does not link network
Falanga 2001 Only one eligible intervention, does not link network
Farina 1997 Did not report analysable healing data
Fernández-Gines 2017 Ineligible population (includes participants with pressure ulcers)
Fischer 1984 Did not report wound healing
Floden 1978 Did not report analysable healing data
Frade 2012 Did not report analysable healing data
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Franek 2002 Did not report analysable healing data
Franks 2007 Compares dressings of the same type
Freak 1992a Did not report analysable healing data
Freak 1994 Did not report analysable healing data
Fumal 2002 Did not report analysable healing data
Galiano 2017 Only one eligible intervention, does not link network
Garcia 1984 Did not report analysable healing data
Garkaz 2014 Did not report analysable healing data
Gatti 2011 Did not report wound healing
Gethin 2008 Retracted study
Ghatnekar 2015 Compares dressings of the same type
Gibbons 2015 Only one eligible intervention, does not link network
Gibson 1995 Compares dressings of the same type
Gilligan 2014 More than 25% non-venous ulcers
Gravante 2013 Did not report analysable healing data
Groenewald 1980 Did not report analysable healing data
Groenewald 1981 Did not report analysable healing data
Gronberg 2014 Ineligible interventions
Grotewohl 1994 Did not report analysable healing data
Guarnera 2010 Only one eligible intervention, does not link network
Handﬁeld-Jones 1988 Did not report analysable healing data
Harding 2005 Only one eligible intervention, does not link network
Harding 2012 Compares dressings of the same type
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(Continued)
Harding 2013 Did not report wound healing
Harvey 1985 Did not report analysable healing data
He 2008 Did not report analysable healing data
Hellgren 1983 Did not report analysable healing data
Hill 2004 Did not report analysable healing data
Hillstrom 1988 Did not report analysable healing data
Holloway 1989 Did not report analysable healing data
Hornemann 1987 Did not report analysable healing data
Humbert 2014 Did not report analysable healing data
Hutchinson 1994 Did not report wound healing
Jasiel 1997a Did not report wound healing
Jasiel 1997b Did not report wound healing
Jones 2003 Compares dressings of the same type
Judy 2010 Did not report analysable healing data
Jørgensen 2006 Not an RCT
Jørgensen 2008 Did not report wound healing
Jørgensen 2009 Did not report analysable healing data
Kerihuel 2010 Did not report analysable healing data
Kikta 1988 Dressing is not the only difference between groups
Kirsner 2012 Only one eligible intervention, does not link network
Kirsner 2016a Only one eligible intervention, does not link network
Kirsner 2016b Only one eligible intervention, does not link network
Klemp 1986 Did not report wound healing
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(Continued)
Klostermann 1974 Did not report analysable healing data
Koksal 2003 Dressing is not the only difference between groups
Kopera 2005 Did not report analysable healing data
Krasowski 2015 Did not report analysable healing data
Kucharzewski 2012 Did not report wound healing
König 2005 Did not report analysable healing data
La Marca 1999 Compares dressings of the same type
Lammoglia-Ordiales 2012 Compares dressings of the same type
Larsen 1995 Did not report analysable healing data
Larsen 1997 Did not report analysable healing data
Larsen 2005 Compares dressings of the same type
Laudanska 1988 Did not report analysable healing data
Lazareth 2008 Did not report analysable healing data
Limová 1996 Compares dressings of the same type
Limová 2002 Compares dressings of the same type
Limová 2003 Compares dressings of the same type
Lindgren 1998 Only one eligible intervention, does not link network
Lindholm 1995 Did not report wound healing
Ljungberg 1998 Compares dressings of the same type
Lofferer 1982 Did not report analysable healing data
Lopez 1998 Did not report analysable healing data
Lundeberg 1990 Only one eligible intervention, does not link network
Lundeberg 1991 Only one eligible intervention, does not link network
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(Continued)
Maggio 2007 Did not report wound healing
Maggio 2012 Only one eligible intervention, does not link network
Mansson 1997 Did not report analysable healing data
Meaume 2005a Did not report analysable healing data
Meaume 2005c Did not report analysable healing data
Meaume 2008 Did not report analysable healing data
Meaume 2014 Did not report analysable healing data
Mehtar 1988 Did not report analysable healing data
Miller 2010 More than 25% non-venous ulcers
Milward 1991 Did not report analysable healing data
Moffatt 2014 More than 25% non-venous ulcers
Morimoto 2015 Not an RCT
Mosti 2010 Did not report analysable healing data
Mosti 2015 Did not report wound healing
Mostow 2005 Only one eligible intervention, does not link network
Mudge 2014 Did not report wound healing
Mulder 1995 Did not report analysable healing data
Mulligan 1988 Did not report analysable healing data
Nagl 2003 Did not report wound healing
Navratilova 2004 Only one eligible intervention, does not link network
Neander 2003 Did not report wound healing
Nelson 2011 Only one eligible intervention, does not link network
Nieves 2015 Only one eligible intervention, does not link network
Nowak 1996 Did not report analysable healing data
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(Continued)
Nyfors 1982 Did not report analysable healing data
Olyaie 2013 Only one eligible intervention, does not link network
Omar 2004 Only one eligible intervention, does not link network
Ortonne 1996 Did not report analysable healing data
Osman 2014 Only one eligible intervention, does not link network
Pardes 1993 Did not report wound healing
Passarini 1982 Did not report analysable healing data
Peschen 1997 Only one eligible intervention, does not link network
Pessenhofer 1989 Did not report analysable healing data
Pessenhofer 1992 Did not report analysable healing data
Petres 1994 Did not report analysable healing data
Planinsek 2007a Did not report analysable healing data
Planinsek 2007b Did not report analysable healing data
Polignano 2001 Did not report wound healing
Poskitt 1987 Only one eligible intervention, does not link network
Price 2004 Did not report wound healing
Prins 2000 Did not report analysable healing data
Purcell 2017 Ineligible population < 75% with venous aetiology
Rainey 1993 Did not report wound healing
Rainey 1996 Compares dressings of the same type
Raposio 2018 Quasi-RCT
Rivera-Arce 2007 Did not report analysable healing data
Robinson 1993 Compares dressings of the same type
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(Continued)
Robinson 1998 Did not report analysable healing data
Roldan 2009 Did not report analysable healing data
Romanelli 2006 Did not report analysable healing data
Romanelli 2008 Did not report analysable healing data
Romanelli 2009 Did not report wound healing
Romanelli 2011 Did not report analysable healing data
Romanelli 2015 Compares dressings of the same type
Rucigaj 2007 Did not report analysable healing data
Rundle 1981 Only one eligible intervention, does not link network
Sabolinski 1996 Dressing is not the only difference between groups
Santamato 2012 Did not report analysable healing data
Scalise 2017 Did not report wound healing
Schmutz 1997 Did not report wound healing
Schmutz 2008 Did not report analysable healing data
Serena 2011 Only one eligible intervention, does not link network
Serena 2014 Only one eligible intervention, does not link network
Serra 2010 Did not report analysable healing data
Sibbald 2005 Did not report analysable healing data
Sibbald 2007 Did not report analysable healing data
Sibbald 2011 Did not report analysable healing data
Siqueira 2014 Only one eligible intervention, does not link network
Skog 1983 Did not report analysable healing data
Smeets 2008 Did not report analysable healing data
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(Continued)
Smith-Strom 2006 Did not report analysable healing data
Soares 2009 Only one eligible intervention, does not link network
Sparholt 2002 Compares dressings of the same type
Sridhar 2017 Ineligible population
Sriram 2014 Ineligible population
Sriram 2015 Did not report analysable healing data
Stiller 1992 Only one eligible intervention, does not link network
Stone 2016a Did not report wound healing
Stone 2016b Only one eligible intervention, does not link network
Sánchez-Vázquez 2008 Did not report analysable healing data
Taradaj 2008 Only one eligible intervention, does not link network
Teepe 1993 Only one eligible intervention, does not link network
Texier 1980 Did not report analysable healing data
Thomas 1997a Compares dressings of the same type
Vanscheidt 2004 Compares dressings of the same type
Vanscheidt 2007 Only one eligible intervention, does not link network
Vas 2008 Only one eligible intervention, does not link network
Veraart 1994a Did not report wound healing
Vitse 2017 Only one eligible intervention, does not link network
Vowden 2007 Only one eligible intervention, does not link network
Vuerstaek 2006 Compares dressings of the same type
Wayman 2000 Only one eligible intervention, does not link network
Weiss 1996 Compares dressings of the same type
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(Continued)
Werner-Schlenzka 1994 Compares dressings of the same type
Westh 1998 Did not report wound healing
Wieman 2003 Compares dressings of the same type
Wild 2010 Did not report analysable healing data
Wong 2006 Did not assess eligible interventions
Woo 2009 Compares dressings of the same type
Woo 2010 Did not report analysable healing data
Wunderlich 1991 Did not report analysable healing data
Abbreviations:RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Alvarez 2017
Methods RCT; 2 arms
Participants 16 participants with venous leg ulcers with at least 6 months duration
Interventions Hyaluronic extracellular matrix
Nonadherent silicone foam dressing
Outcomes Complete wound healing at 16 weeks
Notes Identiﬁed in updated search March 2018
Interim analysis
Belcaro 2011
Methods RCT; 2 arms
Participants People with “difﬁcult” venous leg ulceration
Interventions Four weeks treatment with silver oxide ointment or “best management”
Outcomes Healing rate
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Belcaro 2011 (Continued)
Notes Abstracts only, unable to obtain full paper despite ILL
Cavalcanti 2017
Methods RCT; 2 arms
Participants 25 participants with chronic venous leg ulcers
Interventions Bacterial cellulose membrane
Triglyceride oil
Outcomes Complete wound healing at 120 days
Notes Identiﬁed in updated search March 2018
Colenci 2016
Methods RCT; 2 arms
Participants 29 participants with venous ulcers
Interventions Hemicellulose biomembrane
Collagenase
Outcomes Complete wound healing at 90 days
Notes Identiﬁed in updated search March 2018
Conference abstract only
Cullen 2017
Methods RCT; 2 arms
Participants 49 participants with venous leg ulcers
Interventions Collagen, oxidised regenerated cellulose and silver dressing
Nonadherent dressing
Outcomes Wound healing at 12 weeks
Notes Identiﬁed in updated search March 2018
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Glukhov 2017
Methods RCT; 4 arms
Participants 85 participants with venous leg ulcers (stage II)
Interventions Collagen and platelet-rich plasma
Foam, hydrogel, alginate or hydrocolloid dressings
Collagen only
Platelet rich plasma only
Outcomes Complete wound healing
Notes Identiﬁed in update search March 2018
Moreno-Eutimio 2017
Methods RCT; 2 arms
Participants 40 participants with venous leg ulcers
Interventions Polysacharide with zinc oxide
“Simple dressings”
Outcomes Complete wound healing may be reported
Notes Identiﬁed in update search March 2018
Spanish language - will require translation to conﬁrm eligibility
Oliveira 2017
Methods RCT; 2 arms
Participants 16 participants with 21 venous leg ulcers
Interventions Hydrocolloid dressing
Homologous platelet gel
Outcomes Complete wound healing
Notes Identiﬁed in updated search March 2018
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Polignano 2010
Methods RCT; 2 arms
Participants 29 participants with venous leg ulcers present for at least 6 months
Interventions Puriﬁed omental lipids (POL) cream
zinc oxide
Three months treatment/follow-up
Unclear if there is an additional difference between arms and ulcer aetiologies also unclear from Italian text
Outcomes Healing
Notes Paper in Italian, eligibility unclear without author contact and further translator assistance if eligible
Robinson 1988
Methods Unclear, potential RCT
Participants Potentially people with venous leg ulcers
Interventions Duoderm
Viscopaste PB7 bandage
Outcomes Not known
Notes Identiﬁed in updated search March 2018
Title record only
Somani 2017
Methods RCT; 2 arms
Participants 15 participants with venous leg ulcers of at least 6 months duration
Interventions Saline dressing
Blood-based topical treatment
Outcomes Complete closure reported for 5 participants in blood group versus 0 in saline group
Notes Identiﬁed in updated search March 2018
Would potentially contribute to extended base-case network
Abbreviations: ILL: inter-library loan; RCT: randomised controlled trial
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Characteristics of ongoing studies [ordered by study ID]
Jull 2018
Trial name or title Keratin4VLU
Methods 2-arm RCT
Participants People with a venous leg ulcer present for more than 26 weeks or an ulcer > 5 cm²
Interventions Keramatrix - keratin-based dressing
Usual care non-medicated dressing selected from the formulary of dressings available at each study centre.
These dressings will include hydrogel, alginate, hydroﬁbre, polyurethane foam and silicon-impregnated dress-
ings
Compression therapy in both arms; secondary dressings as appropriate
Outcomes Primary outcome - complete healing at 24 weeks
Starting date Recruitment began March 2017
Contact information a.jull@auckland.ac.nz
Notes NCT02896725
Abbreviation: RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Direct evidence - included in base-case network
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Alginate vs nonadherent 1 60 Risk Ratio (IV, Random, 95% CI) 1.08 [0.86, 1.36]
2 Cadexomer iodine vs
nonadherent
1 105 Risk Ratio (IV, Random, 95% CI) 1.0 [0.39, 2.56]
3 Film vs nonadherent 1 71 Risk Ratio (IV, Random, 95% CI) 1.34 [0.61, 2.92]
4 Foam vs nonadherent 1 132 Risk Ratio (IV, Random, 95% CI) 1.35 [0.89, 2.05]
5 Hyaluronic plus povidone vs
nonadherent
1 65 Risk Ratio (IV, Random, 95% CI) 1.93 [0.95, 3.92]
6 Hydrocolloid vs non-adherent 7 662 Risk Ratio (IV, Random, 95% CI) 1.26 [0.92, 1.72]
7 Hydroﬁbre vs nonadherent 1 82 Risk Ratio (M-H, Random, 95% CI) 1.47 [0.88, 2.46]
8 Hydrogel vs nonadherent 1 24 Risk Ratio (IV, Random, 95% CI) 2.0 [0.21, 19.23]
9 PMM vs nonadherent 1 74 Risk Ratio (IV, Random, 95% CI) 1.42 [0.80, 2.51]
10 SSD vs nonadherent 1 60 Risk Ratio (IV, Random, 95% CI) 0.79 [0.57, 1.10]
11 Foam vs alginate 1 113 Risk Ratio (IV, Random, 95% CI) 0.55 [0.10, 2.86]
12 Hydrocolloid vs alginate 2 80 Risk Ratio (IV, Random, 95% CI) 0.72 [0.15, 3.42]
13 Hydroﬁbre vs alginate 2 175 Risk Ratio (IV, Random, 95% CI) 1.47 [0.48, 4.47]
14 Paste bandage vs alginate 1 133 Risk Ratio (IV, Fixed, 95% CI) 1.22 [0.91, 1.63]
15 PMM vs alginate 2 140 Risk Ratio (IV, Random, 95% CI) 1.10 [0.84, 1.46]
16 Gentian violet vs cadexomer
iodine
1 60 Risk Ratio (IV, Random, 95% CI) 0.58 [0.27, 1.28]
17 Hydrocolloid vs cadexomer
iodine
1 104 Risk Ratio (IV, Random, 95% CI) 0.73 [0.26, 2.08]
18 Hydrocolloid vs foam 6 458 Risk Ratio (IV, Random, 95% CI) 0.92 [0.77, 1.08]
19 Ibuprofen foam vs foam 2 242 Risk Ratio (IV, Random, 95% CI) 0.88 [0.48, 1.61]
20 Octenidine vs foam 1 126 Risk Ratio (IV, Random, 95% CI) 1.03 [0.56, 1.90]
21 Paste bandage vs foam 1 36 Risk Ratio (IV, Random, 95% CI) 2.30 [1.29, 4.10]
22 PMM vs foam 1 187 Risk Ratio (IV, Random, 95% CI) 0.87 [0.30, 2.48]
23 PMM silver vs foam 1 30 Risk Ratio (IV, Random, 95% CI) 1.57 [0.84, 2.92]
24 Silver vs foam 4 397 Risk Ratio (M-H, Random, 95% CI) 1.65 [1.08, 2.52]
25 Saline gauze vs hyaluronic acid 1 88 Risk Ratio (IV, Random, 95% CI) 0.52 [0.23, 1.17]
26 PMM silver vs hydrocolloid 1 49 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.69, 1.67]
27 Povidone iodine vs hydrocolloid 1 200 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.69, 1.23]
28 Saline gauze vs hydrocolloid 1 28 Risk Ratio (IV, Fixed, 95% CI) 0.29 [0.07, 1.14]
29 Silver vs hydrocolloid 1 58 Risk Ratio (M-H, Random, 95% CI) 4.39 [2.23, 8.65]
30 Zinc oxide vs hydrocolloid 1 43 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.27, 3.33]
31 Sucralfate vs hydrogel 1 100 Risk Ratio (IV, Random, 95% CI) 8.60 [3.72, 19.90]
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Comparison 2. Direct evidence - not in base case network, in expanded base case
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood product vs emollient 1 197 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.94, 1.82]
2 Blood product vs hydrocolloid 1 13 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.07, 10.96]
3 Blood product vs hydrogel 1 44 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.14, 1.58]
4 Blood product vs saline gauze 1 86 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.86, 1.35]
5 Hyaluronic vs emollient cream 1 101 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.18, 3.25]
6 Growth factor vs hydrocolloid 1 29 Risk Ratio (M-H, Random, 95% CI) 1.83 [0.22, 15.51]
7 Growth factor vs hydrogel 1 59 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.64, 3.01]
8 Growth factor vs nonadherent 3 460 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.81, 1.14]
9 SSD vs emollient 1 57 Risk Ratio (M-H, Random, 95% CI) 6.21 [0.80, 48.38]
Comparison 3. Direct evidence - not in network
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 A. Pichinchensis vs alginate 1 34 Risk Ratio (M-H, Random, 95% CI) 1.67 [1.03, 2.70]
2 Non-adherent vs cellulose 1 48 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.38, 2.22]
3 Phenytoin vs no treatment 1 104 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.90, 1.74]
4 Cadexomer iodine vs standard
treatment
3 157 Risk Ratio (M-H, Random, 95% CI) 5.16 [1.56, 17.10]
5 Honey vs standard treatment 1 368 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.92, 1.36]
6 Papain vs hydrogel 2 70 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.25, 3.49]
7 Shale oil vs hydrogel 1 119 Risk Ratio (M-H, Random, 95% CI) 1.49 [0.82, 2.68]
8 Tripeptide copper vs hydrogel 1 57 Risk Ratio (M-H, Random, 95% CI) 0.07 [0.00, 1.26]
9 Hydrocolloid vs collagen 1 96 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.50, 1.18]
10 Hydrocolloid vs dextranomer 1 108 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.37, 1.60]
11 Hydrocolloid vs magnesium
sulphate
1 110 Risk Ratio (M-H, Random, 95% CI) 7.0 [0.37, 132.40]
12 Hydrocolloid vs nonadherent
or iodine
1 70 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.42, 1.48]
13 Ozonated oil vs zinc oxide 1 29 Risk Ratio (M-H, Random, 95% CI) 10.31 [0.62, 170.96]
14 Cadexomer iodine vs
dextranomer
2 63 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.64, 2.75]
15 Silica gel ﬁbre vs standard care 1 120 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.31, 1.26]
16 Silver vs non-silver 1 213 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.94, 1.16]
17 Sulphadryl vs inactive powder 1 168 Risk Ratio (M-H, Random, 95% CI) 1.31 [1.10, 1.56]
18 Tripeptide copper vs emollient
cream
1 58 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 7.86]
19 Tripeptide copper vs SSD 1 57 Risk Ratio (M-H, Random, 95% CI) 0.07 [0.00, 1.26]
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Analysis 1.1. Comparison 1 Direct evidence - included in base-case network, Outcome 1 Alginate vs
nonadherent.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 1 Alginate vs nonadherent
Study or subgroup alginate nonadherent Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Moffatt 1992b 26/30 24/30 100.0 % 1.08 [ 0.86, 1.36 ]
Total (95% CI) 30 30 100.0 % 1.08 [ 0.86, 1.36 ]
Total events: 26 (alginate), 24 (nonadherent)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nonadherent Favours alginate
Analysis 1.2. Comparison 1 Direct evidence - included in base-case network, Outcome 2 Cadexomer iodine
vs nonadherent.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 2 Cadexomer iodine vs nonadherent
Study or subgroup cadexomer iodine nonadherent Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Hansson 1998 8/56 7/49 100.0 % 1.00 [ 0.39, 2.56 ]
Total (95% CI) 56 49 100.0 % 1.00 [ 0.39, 2.56 ]
Total events: 8 (cadexomer iodine), 7 (nonadherent)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nonadherent Favours iodine
201Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Direct evidence - included in base-case network, Outcome 3 Film vs
nonadherent.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 3 Film vs nonadherent
Study or subgroup ﬁlm nonadherent Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Banerjee 1997 11/36 8/35 100.0 % 1.34 [ 0.61, 2.92 ]
Total (95% CI) 36 35 100.0 % 1.34 [ 0.61, 2.92 ]
Total events: 11 (ﬁlm), 8 (nonadherent)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nonadherent Favours ﬁlm
Analysis 1.4. Comparison 1 Direct evidence - included in base-case network, Outcome 4 Foam vs
nonadherent.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 4 Foam vs nonadherent
Study or subgroup foam nonadherent Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Callam 1992 31/66 23/66 100.0 % 1.35 [ 0.89, 2.05 ]
Total (95% CI) 66 66 100.0 % 1.35 [ 0.89, 2.05 ]
Total events: 31 (foam), 23 (nonadherent)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours foam Favours nonadherent
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Analysis 1.5. Comparison 1 Direct evidence - included in base-case network, Outcome 5 Hyaluronic plus
povidone vs nonadherent.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 5 Hyaluronic plus povidone vs nonadherent
Study or subgroup
hyaluronic
plus
povidone nonadherent Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Casoni 2002 15/32 8/33 100.0 % 1.93 [ 0.95, 3.92 ]
Total (95% CI) 32 33 100.0 % 1.93 [ 0.95, 3.92 ]
Total events: 15 (hyaluronic plus povidone), 8 (nonadherent)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nonadherent Favours hyaluronic povido
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Analysis 1.6. Comparison 1 Direct evidence - included in base-case network, Outcome 6 Hydrocolloid vs
non-adherent.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 6 Hydrocolloid vs non-adherent
Study or subgroup hydrocolloid nonadherent Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Backhouse 1987 21/28 22/28 21.7 % 0.95 [ 0.72, 1.27 ]
Blair 1988a 22/30 23/30 21.6 % 0.96 [ 0.71, 1.28 ]
Hansson 1998 5/48 7/49 6.4 % 0.73 [ 0.25, 2.14 ]
Leaper 1991 14/46 3/48 5.6 % 4.87 [ 1.50, 15.84 ]
Meredith 1988 19/25 6/25 10.9 % 3.17 [ 1.52, 6.58 ]
Moffatt 1992a 13/30 7/30 10.3 % 1.86 [ 0.86, 4.00 ]
Nelson 2007 72/127 69/118 23.6 % 0.97 [ 0.78, 1.20 ]
Total (95% CI) 334 328 100.0 % 1.26 [ 0.92, 1.72 ]
Total events: 166 (hydrocolloid), 137 (nonadherent)
Heterogeneity: Tau2 = 0.10; Chi2 = 19.15, df = 6 (P = 0.004); I2 =69%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours nonadherent Favours hydrocolloid
204Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 Direct evidence - included in base-case network, Outcome 7 Hydrofibre vs
nonadherent.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 7 Hydroﬁbre vs nonadherent
Study or subgroup hydroﬁbre nonadherent Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kelechi 2012 41/62 9/20 100.0 % 1.47 [ 0.88, 2.46 ]
Total (95% CI) 62 20 100.0 % 1.47 [ 0.88, 2.46 ]
Total events: 41 (hydroﬁbre), 9 (nonadherent)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nonadherent Favours hydroﬁbre
Analysis 1.8. Comparison 1 Direct evidence - included in base-case network, Outcome 8 Hydrogel vs
nonadherent.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 8 Hydrogel vs nonadherent
Study or subgroup Hydrogel Nonadherent Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Taddeucci 2004 2/12 1/12 100.0 % 2.00 [ 0.21, 19.23 ]
Total (95% CI) 12 12 100.0 % 2.00 [ 0.21, 19.23 ]
Total events: 2 (Hydrogel), 1 (Nonadherent)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nonadherent Favours hydrogel
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Analysis 1.9. Comparison 1 Direct evidence - included in base-case network, Outcome 9 PMM vs
nonadherent.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 9 PMM vs nonadherent
Study or subgroup PMM nonadherent Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Vin 2002 18/38 12/36 100.0 % 1.42 [ 0.80, 2.51 ]
Total (95% CI) 38 36 100.0 % 1.42 [ 0.80, 2.51 ]
Total events: 18 (PMM), 12 (nonadherent)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Direct evidence - included in base-case network, Outcome 10 SSD vs
nonadherent.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 10 SSD vs nonadherent
Study or subgroup SSD Nonadherent Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Blair 1988b 19/30 24/30 100.0 % 0.79 [ 0.57, 1.10 ]
Total (95% CI) 30 30 100.0 % 0.79 [ 0.57, 1.10 ]
Total events: 19 (SSD), 24 (Nonadherent)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Direct evidence - included in base-case network, Outcome 11 Foam vs alginate.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 11 Foam vs alginate
Study or subgroup Foam Alginate Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Schulze 2001 2/54 4/59 100.0 % 0.55 [ 0.10, 2.86 ]
Total (95% CI) 54 59 100.0 % 0.55 [ 0.10, 2.86 ]
Total events: 2 (Foam), 4 (Alginate)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Direct evidence - included in base-case network, Outcome 12 Hydrocolloid vs
alginate.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 12 Hydrocolloid vs alginate
Study or subgroup hydrocolloid alginate Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Scurr 1994 2/20 6/20 51.6 % 0.33 [ 0.08, 1.46 ]
Smith 1994 4/22 2/18 48.4 % 1.64 [ 0.34, 7.94 ]
Total (95% CI) 42 38 100.0 % 0.72 [ 0.15, 3.42 ]
Total events: 6 (hydrocolloid), 8 (alginate)
Heterogeneity: Tau2 = 0.66; Chi2 = 2.08, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Direct evidence - included in base-case network, Outcome 13 Hydrofibre vs
alginate.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 13 Hydroﬁbre vs alginate
Study or subgroup Hydroﬁbre alginate Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Armstrong 1997 6/21 2/23 33.2 % 3.29 [ 0.74, 14.53 ]
Harding 2001 17/66 17/65 66.8 % 0.98 [ 0.55, 1.76 ]
Total (95% CI) 87 88 100.0 % 1.47 [ 0.48, 4.47 ]
Total events: 23 (Hydroﬁbre), 19 (alginate)
Heterogeneity: Tau2 = 0.39; Chi2 = 2.19, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours alginate Favours hydroﬁbre
Analysis 1.14. Comparison 1 Direct evidence - included in base-case network, Outcome 14 Paste bandage
vs alginate.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 14 Paste bandage vs alginate
Study or subgroup paste bandage alginate Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Stacey 1997 60/87 26/46 100.0 % 1.22 [ 0.91, 1.63 ]
Total (95% CI) 87 46 100.0 % 1.22 [ 0.91, 1.63 ]
Total events: 60 (paste bandage), 26 (alginate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours alginate Favours paste bandage
208Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.15. Comparison 1 Direct evidence - included in base-case network, Outcome 15 PMM vs alginate.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 15 PMM vs alginate
Study or subgroup PMM alginate Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Petkov 1997 34/50 31/50 92.5 % 1.10 [ 0.82, 1.46 ]
Romanelli 2015a 6/20 5/20 7.5 % 1.20 [ 0.44, 3.30 ]
Total (95% CI) 70 70 100.0 % 1.10 [ 0.84, 1.46 ]
Total events: 40 (PMM), 36 (alginate)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Direct evidence - included in base-case network, Outcome 16 Gentian violet vs
cadexomer iodine.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 16 Gentian violet vs cadexomer iodine
Study or subgroup gentian violet cadexomer iodine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Ormiston 1985 7/30 12/30 100.0 % 0.58 [ 0.27, 1.28 ]
Total (95% CI) 30 30 100.0 % 0.58 [ 0.27, 1.28 ]
Total events: 7 (gentian violet), 12 (cadexomer iodine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Direct evidence - included in base-case network, Outcome 17 Hydrocolloid vs
cadexomer iodine.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 17 Hydrocolloid vs cadexomer iodine
Study or subgroup hydrocolloid cadexomer iodine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Hansson 1998 5/48 8/56 100.0 % 0.73 [ 0.26, 2.08 ]
Total (95% CI) 48 56 100.0 % 0.73 [ 0.26, 2.08 ]
Total events: 5 (hydrocolloid), 8 (cadexomer iodine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Direct evidence - included in base-case network, Outcome 18 Hydrocolloid vs
foam.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 18 Hydrocolloid vs foam
Study or subgroup Hydrocolloid foam Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Bowszyc 1995 24/41 24/41 21.2 % 1.00 [ 0.69, 1.44 ]
Charles 2002 34/60 18/31 20.3 % 0.98 [ 0.67, 1.42 ]
Norkus 2005 19/48 25/49 14.3 % 0.78 [ 0.50, 1.21 ]
Sopata 2016 17/25 21/25 27.7 % 0.81 [ 0.59, 1.11 ]
Thomas 1997 19/50 17/50 10.3 % 1.12 [ 0.66, 1.89 ]
Zuccarelli 1992 9/19 9/19 6.3 % 1.00 [ 0.51, 1.95 ]
Total (95% CI) 243 215 100.0 % 0.92 [ 0.77, 1.08 ]
Total events: 122 (Hydrocolloid), 114 (foam)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.07, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Direct evidence - included in base-case network, Outcome 19 Ibuprofen foam
vs foam.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 19 Ibuprofen foam vs foam
Study or subgroup ibuprofen foam foam Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Fogh 2012 9/60 11/60 56.3 % 0.82 [ 0.37, 1.83 ]
Gottrup 2008 8/62 8/60 43.7 % 0.97 [ 0.39, 2.41 ]
Total (95% CI) 122 120 100.0 % 0.88 [ 0.48, 1.61 ]
Total events: 17 (ibuprofen foam), 19 (foam)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Direct evidence - included in base-case network, Outcome 20 Octenidine vs
foam.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 20 Octenidine vs foam
Study or subgroup octenidine foam Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Vanscheidt 2012 15/60 16/66 100.0 % 1.03 [ 0.56, 1.90 ]
Total (95% CI) 60 66 100.0 % 1.03 [ 0.56, 1.90 ]
Total events: 15 (octenidine), 16 (foam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Direct evidence - included in base-case network, Outcome 21 Paste bandage
vs foam.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 21 Paste bandage vs foam
Study or subgroup Paste bandage foam Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Rubin 1990 18/19 7/17 100.0 % 2.30 [ 1.29, 4.10 ]
Total (95% CI) 19 17 100.0 % 2.30 [ 1.29, 4.10 ]
Total events: 18 (Paste bandage), 7 (foam)
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0047)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Direct evidence - included in base-case network, Outcome 22 PMM vs foam.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 22 PMM vs foam
Study or subgroup PMM foam Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Meaume 2012 6/93 7/94 100.0 % 0.87 [ 0.30, 2.48 ]
Total (95% CI) 93 94 100.0 % 0.87 [ 0.30, 2.48 ]
Total events: 6 (PMM), 7 (foam)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 1.23. Comparison 1 Direct evidence - included in base-case network, Outcome 23 PMM silver vs
foam.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 23 PMM silver vs foam
Study or subgroup PMM silver foam Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lanzara 2008 11/15 7/15 100.0 % 1.57 [ 0.84, 2.92 ]
Total (95% CI) 15 15 100.0 % 1.57 [ 0.84, 2.92 ]
Total events: 11 (PMM silver), 7 (foam)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.24. Comparison 1 Direct evidence - included in base-case network, Outcome 24 Silver vs foam.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 24 Silver vs foam
Study or subgroup silver foam Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dimakakos 2009 17/21 10/21 73.7 % 1.70 [ 1.04, 2.79 ]
Ivins 2006 2/25 1/20 3.3 % 1.60 [ 0.16, 16.40 ]
J rgensen 2005 5/65 5/64 12.7 % 0.98 [ 0.30, 3.24 ]
Senet 2014 7/87 3/94 10.3 % 2.52 [ 0.67, 9.44 ]
Total (95% CI) 198 199 100.0 % 1.65 [ 1.08, 2.52 ]
Total events: 31 (silver), 19 (foam)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Direct evidence - included in base-case network, Outcome 25 Saline gauze vs
hyaluronic acid.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 25 Saline gauze vs hyaluronic acid
Study or subgroup saline gauze hyaluronic acid Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Humbert 2013 7/43 14/45 100.0 % 0.52 [ 0.23, 1.17 ]
Total (95% CI) 43 45 100.0 % 0.52 [ 0.23, 1.17 ]
Total events: 7 (saline gauze), 14 (hyaluronic acid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 1.26. Comparison 1 Direct evidence - included in base-case network, Outcome 26 PMM silver vs
hydrocolloid.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 26 PMM silver vs hydrocolloid
Study or subgroup PMM silver hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hanft 2006 14/22 16/27 100.0 % 1.07 [ 0.69, 1.67 ]
Total (95% CI) 22 27 100.0 % 1.07 [ 0.69, 1.67 ]
Total events: 14 (PMM silver), 16 (hydrocolloid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
Test for subgroup differences: Not applicable
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Analysis 1.27. Comparison 1 Direct evidence - included in base-case network, Outcome 27 Povidone iodine
vs hydrocolloid.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 27 Povidone iodine vs hydrocolloid
Study or subgroup povidone iodine hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Smith 1992 47/101 50/99 100.0 % 0.92 [ 0.69, 1.23 ]
Total (95% CI) 101 99 100.0 % 0.92 [ 0.69, 1.23 ]
Total events: 47 (povidone iodine), 50 (hydrocolloid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 1.28. Comparison 1 Direct evidence - included in base-case network, Outcome 28 Saline gauze vs
hydrocolloid.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 28 Saline gauze vs hydrocolloid
Study or subgroup saline gauze hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Ohlsson 1994 2/14 7/14 100.0 % 0.29 [ 0.07, 1.14 ]
Total (95% CI) 14 14 100.0 % 0.29 [ 0.07, 1.14 ]
Total events: 2 (saline gauze), 7 (hydrocolloid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.076)
Test for subgroup differences: Not applicable
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Analysis 1.29. Comparison 1 Direct evidence - included in base-case network, Outcome 29 Silver vs
hydrocolloid.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 29 Silver vs hydrocolloid
Study or subgroup silver hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kucharzewski 2013 30/30 6/28 100.0 % 4.39 [ 2.23, 8.65 ]
Total (95% CI) 30 28 100.0 % 4.39 [ 2.23, 8.65 ]
Total events: 30 (silver), 6 (hydrocolloid)
Heterogeneity: not applicable
Test for overall effect: Z = 4.27 (P = 0.000019)
Test for subgroup differences: Not applicable
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Analysis 1.30. Comparison 1 Direct evidence - included in base-case network, Outcome 30 Zinc oxide vs
hydrocolloid.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 30 Zinc oxide vs hydrocolloid
Study or subgroup Favours hydrocolloid hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brandrup 1990 4/22 4/21 100.0 % 0.95 [ 0.27, 3.33 ]
Total (95% CI) 22 21 100.0 % 0.95 [ 0.27, 3.33 ]
Total events: 4 (Favours hydrocolloid), 4 (hydrocolloid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 1.31. Comparison 1 Direct evidence - included in base-case network, Outcome 31 Sucralfate vs
hydrogel.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 1 Direct evidence - included in base-case network
Outcome: 31 Sucralfate vs hydrogel
Study or subgroup sucralfate hydrogel Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Tumino 2008 43/50 5/50 100.0 % 8.60 [ 3.72, 19.90 ]
Total (95% CI) 50 50 100.0 % 8.60 [ 3.72, 19.90 ]
Total events: 43 (sucralfate), 5 (hydrogel)
Heterogeneity: not applicable
Test for overall effect: Z = 5.03 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Direct evidence - not in base case network, in expanded base case, Outcome 1
Blood product vs emollient.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 2 Direct evidence - not in base case network, in expanded base case
Outcome: 1 Blood product vs emollient
Study or subgroup blood product no treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Biland 1985 46/96 37/101 100.0 % 1.31 [ 0.94, 1.82 ]
Total (95% CI) 96 101 100.0 % 1.31 [ 0.94, 1.82 ]
Total events: 46 (blood product), 37 (no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Direct evidence - not in base case network, in expanded base case, Outcome 2
Blood product vs hydrocolloid.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 2 Direct evidence - not in base case network, in expanded base case
Outcome: 2 Blood product vs hydrocolloid
Study or subgroup blood product hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Senet 2003 1/7 1/6 100.0 % 0.86 [ 0.07, 10.96 ]
Total (95% CI) 7 6 100.0 % 0.86 [ 0.07, 10.96 ]
Total events: 1 (blood product), 1 (hydrocolloid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Direct evidence - not in base case network, in expanded base case, Outcome 3
Blood product vs hydrogel.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 2 Direct evidence - not in base case network, in expanded base case
Outcome: 3 Blood product vs hydrogel
Study or subgroup ﬁbrin no treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
De Araujo 2016 3/21 7/23 100.0 % 0.47 [ 0.14, 1.58 ]
Total (95% CI) 21 23 100.0 % 0.47 [ 0.14, 1.58 ]
Total events: 3 (ﬁbrin), 7 (no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Direct evidence - not in base case network, in expanded base case, Outcome 4
Blood product vs saline gauze.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 2 Direct evidence - not in base case network, in expanded base case
Outcome: 4 Blood product vs saline gauze
Study or subgroup blood product saline gauze Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Stacey 2000 34/42 33/44 100.0 % 1.08 [ 0.86, 1.35 ]
Total (95% CI) 42 44 100.0 % 1.08 [ 0.86, 1.35 ]
Total events: 34 (blood product), 33 (saline gauze)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Direct evidence - not in base case network, in expanded base case, Outcome 5
Hyaluronic vs emollient cream.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 2 Direct evidence - not in base case network, in expanded base case
Outcome: 5 Hyaluronic vs emollient cream
Study or subgroup hyaluronic acid emollient cream Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dereure 2012a 3/50 4/51 100.0 % 0.77 [ 0.18, 3.25 ]
Total (95% CI) 50 51 100.0 % 0.77 [ 0.18, 3.25 ]
Total events: 3 (hyaluronic acid), 4 (emollient cream)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Direct evidence - not in base case network, in expanded base case, Outcome 6
Growth factor vs hydrocolloid.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 2 Direct evidence - not in base case network, in expanded base case
Outcome: 6 Growth factor vs hydrocolloid
Study or subgroup Growth factor Hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rasmussen 1991 3/18 1/11 100.0 % 1.83 [ 0.22, 15.51 ]
Total (95% CI) 18 11 100.0 % 1.83 [ 0.22, 15.51 ]
Total events: 3 (Growth factor), 1 (Hydrocolloid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Direct evidence - not in base case network, in expanded base case, Outcome 7
Growth factor vs hydrogel.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 2 Direct evidence - not in base case network, in expanded base case
Outcome: 7 Growth factor vs hydrogel
Study or subgroup Growth factor Hydrogel Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Senet 2011 10/28 8/31 100.0 % 1.38 [ 0.64, 3.01 ]
Total (95% CI) 28 31 100.0 % 1.38 [ 0.64, 3.01 ]
Total events: 10 (Growth factor), 8 (Hydrogel)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Direct evidence - not in base case network, in expanded base case, Outcome 8
Growth factor vs nonadherent.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 2 Direct evidence - not in base case network, in expanded base case
Outcome: 8 Growth factor vs nonadherent
Study or subgroup Growth factor Nonadherent Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Robson 1995 3/12 2/12 1.2 % 1.50 [ 0.30, 7.43 ]
Robson 2001 22/63 9/31 7.3 % 1.20 [ 0.63, 2.29 ]
Robson 2004 130/225 72/117 91.6 % 0.94 [ 0.78, 1.13 ]
Total (95% CI) 300 160 100.0 % 0.96 [ 0.81, 1.14 ]
Total events: 155 (Growth factor), 83 (Nonadherent)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Nonadherent Favours growth factor
Analysis 2.9. Comparison 2 Direct evidence - not in base case network, in expanded base case, Outcome 9
SSD vs emollient.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 2 Direct evidence - not in base case network, in expanded base case
Outcome: 9 SSD vs emollient
Study or subgroup blood product no treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bishop 1992 6/28 1/29 100.0 % 6.21 [ 0.80, 48.38 ]
Total (95% CI) 28 29 100.0 % 6.21 [ 0.80, 48.38 ]
Total events: 6 (blood product), 1 (no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.081)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours no treatment Favours blood product
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Analysis 3.1. Comparison 3 Direct evidence - not in network, Outcome 1 A. Pichinchensis vs alginate.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 1 A. Pichinchensis vs alginate
Study or subgroup A. pichinchensis alginate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Romero-Cerecero 2012 15/17 9/17 100.0 % 1.67 [ 1.03, 2.70 ]
Total (95% CI) 17 17 100.0 % 1.67 [ 1.03, 2.70 ]
Total events: 15 (A. pichinchensis), 9 (alginate)
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours alginate Favours A. pinchinensis
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Analysis 3.2. Comparison 3 Direct evidence - not in network, Outcome 2 Non-adherent vs cellulose.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 2 Non-adherent vs cellulose
Study or subgroup Biocellulose Non-adherent Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alvarez 2012 7/25 7/23 100.0 % 0.92 [ 0.38, 2.22 ]
Total (95% CI) 25 23 100.0 % 0.92 [ 0.38, 2.22 ]
Total events: 7 (Biocellulose), 7 (Non-adherent)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Nonadherent Favours biocellulose
Analysis 3.3. Comparison 3 Direct evidence - not in network, Outcome 3 Phenytoin vs no treatment.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 3 Phenytoin vs no treatment
Study or subgroup phenytoin saline gauze Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hokkam 2011 35/54 26/50 100.0 % 1.25 [ 0.90, 1.74 ]
Total (95% CI) 54 50 100.0 % 1.25 [ 0.90, 1.74 ]
Total events: 35 (phenytoin), 26 (saline gauze)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours saline gauze Favours phenytoin
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Analysis 3.4. Comparison 3 Direct evidence - not in network, Outcome 4 Cadexomer iodine vs standard
treatment.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 4 Cadexomer iodine vs standard treatment
Study or subgroup Iodine Standard treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Harcup 1986 13/41 1/31 36.6 % 9.83 [ 1.36, 71.17 ]
Lindsay 1986 4/14 1/14 33.8 % 4.00 [ 0.51, 31.46 ]
Steele 1986 3/28 1/29 29.6 % 3.11 [ 0.34, 28.12 ]
Total (95% CI) 83 74 100.0 % 5.16 [ 1.56, 17.10 ]
Total events: 20 (Iodine), 3 (Standard treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.68 (P = 0.0073)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours standard Favours iodine
Analysis 3.5. Comparison 3 Direct evidence - not in network, Outcome 5 Honey vs standard treatment.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 5 Honey vs standard treatment
Study or subgroup Honey Standard treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jull 2008 104/187 90/181 100.0 % 1.12 [ 0.92, 1.36 ]
Total (95% CI) 187 181 100.0 % 1.12 [ 0.92, 1.36 ]
Total events: 104 (Honey), 90 (Standard treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours standard care Favours honey
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Analysis 3.6. Comparison 3 Direct evidence - not in network, Outcome 6 Papain vs hydrogel.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 6 Papain vs hydrogel
Study or subgroup papain no treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
De Araujo 2016 4/19 7/23 82.2 % 0.69 [ 0.24, 2.01 ]
Luiza 2015 2/16 0/12 17.8 % 3.82 [ 0.20, 73.00 ]
Total (95% CI) 35 35 100.0 % 0.94 [ 0.25, 3.49 ]
Total events: 6 (papain), 7 (no treatment)
Heterogeneity: Tau2 = 0.25; Chi2 = 1.19, df = 1 (P = 0.27); I2 =16%
Test for overall effect: Z = 0.09 (P = 0.92)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours no treatment Favours papain
229Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.7. Comparison 3 Direct evidence - not in network, Outcome 7 Shale oil vs hydrogel.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 7 Shale oil vs hydrogel
Study or subgroup shale oil gel parafﬁn gauze Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Beckert 2006 21/62 13/57 100.0 % 1.49 [ 0.82, 2.68 ]
Total (95% CI) 62 57 100.0 % 1.49 [ 0.82, 2.68 ]
Total events: 21 (shale oil gel), 13 (parafﬁn gauze)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours parafﬁn gauze Favours shale oil gel
Analysis 3.8. Comparison 3 Direct evidence - not in network, Outcome 8 Tripeptide copper vs hydrogel.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 8 Tripeptide copper vs hydrogel
Study or subgroup tripeptide copper SSD Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bishop 1992 0/29 6/28 100.0 % 0.07 [ 0.00, 1.26 ]
Total (95% CI) 29 28 100.0 % 0.07 [ 0.00, 1.26 ]
Total events: 0 (tripeptide copper), 6 (SSD)
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SSD Favours tripeptide copper
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Analysis 3.9. Comparison 3 Direct evidence - not in network, Outcome 9 Hydrocolloid vs collagen.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 9 Hydrocolloid vs collagen
Study or subgroup collagen hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Caprio 1992 20/49 25/47 100.0 % 0.77 [ 0.50, 1.18 ]
Total (95% CI) 49 47 100.0 % 0.77 [ 0.50, 1.18 ]
Total events: 20 (collagen), 25 (hydrocolloid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours collagen Favours hydrocolloid
Analysis 3.10. Comparison 3 Direct evidence - not in network, Outcome 10 Hydrocolloid vs dextranomer.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 10 Hydrocolloid vs dextranomer
Study or subgroup dextranomer hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kalis 1993 10/54 13/54 100.0 % 0.77 [ 0.37, 1.60 ]
Total (95% CI) 54 54 100.0 % 0.77 [ 0.37, 1.60 ]
Total events: 10 (dextranomer), 13 (hydrocolloid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hydrocolloid Favours dextranomer
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Analysis 3.11. Comparison 3 Direct evidence - not in network, Outcome 11 Hydrocolloid vs magnesium
sulphate.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 11 Hydrocolloid vs magnesium sulphate
Study or subgroup hydrocolloid magnesium sulphate Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Greguric 1994 3/55 0/55 100.0 % 7.00 [ 0.37, 132.40 ]
Total (95% CI) 55 55 100.0 % 7.00 [ 0.37, 132.40 ]
Total events: 3 (hydrocolloid), 0 (magnesium sulphate)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours mg sulphate Favours hydrocolloid
Analysis 3.12. Comparison 3 Direct evidence - not in network, Outcome 12 Hydrocolloid vs nonadherent or
iodine.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 12 Hydrocolloid vs nonadherent or iodine
Study or subgroup Hydrocolloid
nonadherent
or iodine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Arnold 1994 11/35 14/35 100.0 % 0.79 [ 0.42, 1.48 ]
Total (95% CI) 35 35 100.0 % 0.79 [ 0.42, 1.48 ]
Total events: 11 (Hydrocolloid), 14 (nonadherent or iodine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours hydrocolloid
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Analysis 3.13. Comparison 3 Direct evidence - not in network, Outcome 13 Ozonated oil vs zinc oxide.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 13 Ozonated oil vs zinc oxide
Study or subgroup ozonated oil zinc oxide Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Solovastru 2015 5/15 0/14 100.0 % 10.31 [ 0.62, 170.96 ]
Total (95% CI) 15 14 100.0 % 10.31 [ 0.62, 170.96 ]
Total events: 5 (ozonated oil), 0 (zinc oxide)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours zinc oxide Favours ozonated oil
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Analysis 3.14. Comparison 3 Direct evidence - not in network, Outcome 14 Cadexomer iodine vs
dextranomer.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 14 Cadexomer iodine vs dextranomer
Study or subgroup iodine dextranomer Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Moss 1987 2/21 1/21 9.8 % 2.00 [ 0.20, 20.41 ]
Tarvainen 1988 7/11 5/10 90.2 % 1.27 [ 0.59, 2.73 ]
Total (95% CI) 32 31 100.0 % 1.33 [ 0.64, 2.75 ]
Total events: 9 (iodine), 6 (dextranomer)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dextranomer Favours iodine
Analysis 3.15. Comparison 3 Direct evidence - not in network, Outcome 15 Silica gel fibre vs standard care.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 15 Silica gel ﬁbre vs standard care
Study or subgroup Silica gel ﬁbre Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brown 2014 10/60 16/60 100.0 % 0.63 [ 0.31, 1.26 ]
Total (95% CI) 60 60 100.0 % 0.63 [ 0.31, 1.26 ]
Total events: 10 (Silica gel ﬁbre), 16 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours standard care Favours silica gel ﬁbre
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Analysis 3.16. Comparison 3 Direct evidence - not in network, Outcome 16 Silver vs non-silver.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 16 Silver vs non-silver
Study or subgroup silver nonadherent Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Michaels 2009 95/107 90/106 100.0 % 1.05 [ 0.94, 1.16 ]
Total (95% CI) 107 106 100.0 % 1.05 [ 0.94, 1.16 ]
Total events: 95 (silver), 90 (nonadherent)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours silver Favours nonadherent
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Analysis 3.17. Comparison 3 Direct evidence - not in network, Outcome 17 Sulphadryl vs inactive powder.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 17 Sulphadryl vs inactive powder
Study or subgroup sulphadryl nonadherent Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Salim 1992 105/113 39/55 100.0 % 1.31 [ 1.10, 1.56 ]
Total (95% CI) 113 55 100.0 % 1.31 [ 1.10, 1.56 ]
Total events: 105 (sulphadryl), 39 (nonadherent)
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nonadherent Favours sulphadryl
Analysis 3.18. Comparison 3 Direct evidence - not in network, Outcome 18 Tripeptide copper vs emollient
cream.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 18 Tripeptide copper vs emollient cream
Study or subgroup tripeptide copper nonadherent Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bishop 1992 0/29 1/29 100.0 % 0.33 [ 0.01, 7.86 ]
Total (95% CI) 29 29 100.0 % 0.33 [ 0.01, 7.86 ]
Total events: 0 (tripeptide copper), 1 (nonadherent)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours nonadherent Favours tripeptide copper
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Analysis 3.19. Comparison 3 Direct evidence - not in network, Outcome 19 Tripeptide copper vs SSD.
Review: Dressings and topical agents for treating venous leg ulcers
Comparison: 3 Direct evidence - not in network
Outcome: 19 Tripeptide copper vs SSD
Study or subgroup tripeptide copper SSD Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bishop 1992 0/29 6/28 100.0 % 0.07 [ 0.00, 1.26 ]
Total (95% CI) 29 28 100.0 % 0.07 [ 0.00, 1.26 ]
Total events: 0 (tripeptide copper), 6 (SSD)
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SSD Favours tripeptide copper
A D D I T I O N A L T A B L E S
Table 1. Summary characteristics of individual studies
Study characteristic Details of studies
Publication Abstract or poster only: Caprio 1992; Casoni 2002; Hanft 2006; Ivins 2006; Kalis 1993;
Lanzara 2008; Petkov 1997; Zuccarelli 1992.
All other studies had a full publication
Multiple interventions Three arms: Bishop 1992; De Araujo 2016; Hansson 1998; Robson 1995.
All other studies had two arms
Unit of randomisation Ulcer: Caprio 1992
Leg: Stacey 1997
Unclear: Hanft 2006; Kalis 1993; Leaper 1991
All other studies used participants as the unit of randomisation
Funding Industry: Armstrong 1997; Backhouse 1987; Beckert 2006; Bishop 1992; Bowszyc 1995;
Charles 2002; Dereure 2012a; Fogh 2012; Gottrup 2008; Hansson 1998;Humbert 2013;
Jørgensen 2005; Kelechi 2012; Lanzara 2008; Leaper 1991; Meaume 2012; Moffatt 1992a;
Moffatt 1992b; Moss 1987; Nelson 2007; Norkus 2005; Robson 1995; Scurr 1994; Senet
2003; Senet 2014; Smith 1992; Smith 1994; Stacey 2000; Vin 2002; Zuccarelli 1992.
Others did not report funding source or reported no funding or a non-industry source
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Table 1. Summary characteristics of individual studies (Continued)
Follow-up time 4 weeks: Bishop 1992; Ivins 2006; Jørgensen 2005; Schulze 2001; 30 days: Solovastru 2015;
6 weeks: Armstrong 1997; Biland 1985;Fogh 2012; Gottrup 2008; Leaper 1991; Meredith
1988; Ohlsson 1994; Robson 1995; Scurr 1994; Senet 2014; Smith 1994;Steele 1986; 8
weeks: Brandrup 1990; Caprio 1992; Meaume 2012; Taddeucci 2004; Tarvainen 1988; 60
days: De Araujo 2016; Dereure 2012a; Humbert 2013; 9 weeks: Dimakakos 2009; Kalis
1993
10 weeks: Arnold 1994;12 weeks: Backhouse 1987; Blair 1988a; Blair 1988b; Callam
1992; Charles 2002; Hanft 2006; Hansson 1998; Harding 2001;Lanzara 2008; Luiza 2015;
Moffatt 1992a;Moffatt 1992b; Ormiston 1985; Rasmussen 1991; Robson 2001; Romanelli
2015a; Salim 1992; Senet 2003; Senet 2011; Vanscheidt 2012; Vin 2002; Zuccarelli 1992;
3 months: Casoni 2002; 90 days: Tumino 2008; 13 weeks:Arenbergerova 2013; Thomas
1997; 4 months: Smith 1992; 20 weeks: Beckert 2006; Kelechi 2012; Robson 2004; 24
weeks: Nelson 2007;26 weeks: Moss 1987; Petkov 1997; 9 months: Stacey 1997; Stacey
2000; 10months: Romero-Cerecero 2012; 12months; Norkus 2005; Rubin 1990;Unclear/
till healing: Greguric 1994; Sopata 2016 (max 40weeks) Kucharzewski 2013 (max 16weeks)
Included < 25% non venous leg ulcers Included non-venous leg ulcers: Armstrong 1997; Biland 1985; Brandrup 1990; Norkus
2005; Ohlsson 1994; Rasmussen 1991
Unclear: Backhouse 1987; Humbert 2013; Ivins 2006; Jørgensen 2005; Leaper 1991; Luiza
2015; Romero-Cerecero 2012; Senet 2011; Tarvainen 1988; Zuccarelli 1992.
All others enrolled only participants with VLU
VLU: venous leg ulcers
Table 2. Studies: status in network/review
Study Interventions No eligible inter-
ventions
Expanded base-
case
Base-case Sensitivity analysis Risk of bias
Alvarez 2012c Cellulose
Nonadherent
2 X X X High
Arenbergerova
2013b
Hydroﬁbre
Blood product
1
√
X X Very high
Armstrong 1997
a
Alginate
Hydroﬁbre
2
√ √ √
High
Arnold 1994c Hydrocolloid
Iodine OR non-
adherent
2 X X X Very high
Backhouse 1987
a
Nonadherent
Hydrocolloid
2
√ √ √
Low/Unclear
Banerjee 1997a Nonadherent
Film
2
√ √ √
Very high
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Table 2. Studies: status in network/review (Continued)
Beckert 2006c Shale oil
Hydrogel
2 X X X Low/unclear
Biland 1985b Blood product
Emollient cream
1
√
X X High
Bishop 1992b Tripeptide cop-
per
Emollient cream
SSD
3
√
X X Low/unclear
Blair 1988aa Nonadherent
Hydrocolloid
2
√ √ √
High
Blair 1988ba Nonadherent
SSD
2
√ √ √
High
Bowszyc 1995a Foam
Hydrocolloid
2
√ √ √
High
Brandrup 1990a Hydrocolloid
Zinc oxide
2
√ √ √
High
Brown 2014c Silica gel
Alternative
traditional dress-
ings
2 X X X Very high
Callam 1992a Nonadherent
Foam
√ √ √
Very high
Caprio 1992c Hydrocolloid
Collagen
2 X X X Low/unclear
Casoni 2002a Nonadherent
Hyaluronic+Povidone
2
√ √
X Low/unclear
Charles 2002a Foam
Hydrocolloid
2
√ √ √
Low/unclear
De Araujo 2016
b
Blood product
Hydrogel
Papain
3 (2 in network)
√
X X Low/unclear
Dereure 2012ab Hyaluronic acid
Emollient cream
2
√
X X Low/unclear
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Table 2. Studies: status in network/review (Continued)
Dimakakos
2009a
Foam
Silver
2
√ √ √
Low/unclear
Fogh 2012a Foam
Silver
2
√ √ √
High
Gottrup 2008a Foam
Silver
2
√ √ √
High
Greguric 1994c Magnesium sul-
phate
Hydrocolloid
2 X X X High
Hanft 2006a PMM silver
Hydrocolloid
2
√ √ √
High
Hansson 1998a Nonadherent
Cadexomer
iodine
Hydrocolloid
3
√ √ √
High
Harcup 1986c Standard care
Cadexomer
iodine
2 X X X Low/unclear
Harding 2001a Alginate
Hydroﬁbre
2
√ √ √
Very high
Hokkam 2011c Phenytoin
No treatment
2 X X X Low/unclear
Humbert 2013a Hyaluronic acid
Saline gauze
2
√ √ √
High
Ivins 2006a Foam
Silver
2
√ √ √
Low/unclear
Jørgensen 2005a Foam
Silver
2
√ √ √
Low/unclear
Jull 2008c Honey
Standard care
2 X X X Very high
Kalis 1993c Hydrocolloid
Dextranomer
2 X X X Very high
Kelechi 2012a Nonadherent
Hydroﬁbre
2
√ √ √
High
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Table 2. Studies: status in network/review (Continued)
Kucharzewski
2013a
Hydrocolloid
Silver
2
√ √ √
High
Lanzara 2008a PMM silver
Foam
2
√ √ √
High
Leaper 1991a Nonadherent
Hydrocolloid
2
√ √ √
High
Lindsay 1986c Standard care
Cadexomer
iodine
2 X X X Low/unclear
Luiza 2015c Papain
Hydrogel
2 X X X High
Meaume 2012a PMM
Foam
2
√ √ √
High
Meredith 1988a Nonadherent
Hydrocolloid
2
√ √ √
Low/unclear
Michaels 2009c Silver
non-silver
2 X X X High
Moffatt 1992aa Nonadherent
Hydrocolloid
2
√ √ √
Low/unclear
Moffatt 1992ba Alginate
Nonadeherent
2
√ √ √
Low/unclear
Moss 1987c Cadexomer
iodine
Dextranomer
2 X X X Very high
Nelson 2007a Nonadherent
Hydrocolloid
2
√ √ √
Very high
Norkus 2005a Foam
Hydrocolloid
2
√ √ √
Very high
Ohlsson 1994a Hydrocolloid
Saline gauze
2
√ √ √
Low/unclear
Ormiston 1985b Cadexomer
iodine
gentian violet
2
√ √
X High
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Table 2. Studies: status in network/review (Continued)
Petkov 1997a PMM
Alginate
2
√ √ √
Low/unclear
Rasmussen 1991
b
Growth factor
Hydrocolloid
1 X X
√
High
Robson 1995b Growth factor
Nonadherent
1 X X
√
Low/unclear
Robson 2001b Growth factor
Nonadherent
1 X X
√
High
Robson 2004b Growth factor
Nonadherent
1 X X
√
Low/unclear
Romanelli
2015aa
PMM
Alginate
2
√ √ √
Low/unclear
Romero-
Cerecero 2012c
A. Pichinchensis
Alginate
2 X X X High
Rubin 1990a Foam
paste bandage
2
√ √ √
High
Salim 1992c Sulphadryl
Inactive powder
2 X X X High
Schulze 2001a Foam
alginate
2
√ √ √
Very high
Scurr 1994a Hydrocolloid
Alginate
2
√ √ √
Low/unclear
Senet 2003b Blood product
Hydrocolloid
1 X X
√
Low/unclear
Senet 2011b Growth factor
Hydrogel
1 X X
√
High
Senet 2014a silver
foam
2
√ √ √
High
Smith 1992a Hydrocolloid
Povidone iodine
2
√ √ √
Very high
Smith 1994a Hydrocolloid
alginate
2
√ √ √
Very high
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Table 2. Studies: status in network/review (Continued)
Solovastru 2015
c
Ozonated oil
Emollient cream
2 X X X Low/unclear
Sopata 2016a hydrocolloid
foam
2
√ √ √
Very high
Stacey 1997a Paste bandage
alginate
2
√ √ √
High
Stacey 2000b Blood product
Saline gauze
1 X X
√
High
Steele 1986c Standard care
Cadexomer
iodine
2 X X X Low/unclear
Taddeucci 2004
a
Nonadherent
Hydrogel
2
√ √ √
Very high
Tarvainen 1988c Cadexomer
iodine
Dextranomer
2 X X X Very high
Thomas 1997a Foam
Hydrocolloid
2
√ √ √
Very high
Tumino 2008a Sucralfate
Hydrogel
2
√ √ √
High
Vanscheidt 2012
a
Octenidine
Foam
2
√ √
X High
Vin 2002a PMM
nonadherent
2
√ √ √
Low/unclear
Zuccarelli 1992a Foam
Hydrocolloid
2
√ √ √
Low/unclear
Abbreviations: PMM: protease modulating matrix; SSD: silver sulphadiazine
aStudy in original base-case
bStudy only included in sensitivity analysis
cStudy included in review but not in network
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Table 3. Direct comparisons for individual interventions compared with NMA results
Contrast/comparison Number of studies (par-
ticipants)
Studies RR (95% CI) direct ev-
idence. Random effects
(inverse variance) Het-
erogeneity statistics
NMA results (extended
base-case; consistency as-
sumption): RR (95%
CI)
Comparisons with nonadherent: RR > 1 indicates greater proportion healing with specified alternative treatment
Alginate 1 (113) Moffatt 1992b 1.08 (0.86 to 1.36) 1.21 (0.92 to 1.60)
Cadexomer iodine 1 (105) Hansson 1998 1.00 (0.39 to 2.56) 1.16 (0.50 to 2.69)
Film 1 (71) Banerjee 1997 1.34 (0.61 to 2.92) 1.34 (0.61 to 2.95)
Foam 1 (124) Callam 1992 1.35 (0.89 to 2.05) 1.15 (0.91 to 1.44)
Hyaluronic acid plus
povidone iodine
1 (55) Casoni 2002 1.93 (0.95 to 3.92) 1.93 (0.94 to 3.96)
Hydrocolloid 7 (662) Backhouse 1987; Blair
1988a; Hansson 1998;
Leaper 1991; Meredith
1988; Moffatt 1992a;
Nelson 2007
1.26 (0.92 to 1.72)
I² = 69%; P = 0.004
1.04 (0.85 to 1.29)
Hydroﬁbre 1 (82) Kelechi 2012 1.47 (0.88 to 2.46) 1.39 (0.93 to 2.08)
Hydrogel 1 (24) Taddeucci 2004 2.00 (0.21 to 19.23) 0.79 (0.39 to 1.62)
PMM 1 (74) Vin 2002 1.42 (0.80 to 2.51) 1.31 (0.93 to 1.84)
SSD 1 (60) Blair 1988b 0.79 (0.57 to 1.10) 0.81 (0.57 to 1.15)
Growth factora 3 (460) Robson 1995; Robson
2001; Robson 2004
0.96 (0.81 to 1.14)
I² = 0%; P = 0.65
0.95 (0.72 to 1.25)
Comparisons with alginate: RR > 1 indicates greater proportion healing with specified alternative treatment
Foam 1 (113) Schulze 2001 0.55 (0.10 to 2.86) 0.94 (0.72 to 1.23)
Hydrocolloid 2 (80) Scurr 1994; Smith 1994 0.72 (0.15 to 3.42)
I² = 52%; P = 0.15
0.86 (0.68 to 1.11)
Hydroﬁbre 2 (175) Armstrong 1997;
Harding 2001
1.47 (0.48 to 4.47)
I² = 54%; P = 0.14
1.15 (0.77 to 1.72)
Paste bandage 1 (133) Stacey 1997 1.22 (0.91 to 1.63) 1.39 (1.01 to 1.90)
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Table 3. Direct comparisons for individual interventions compared with NMA results (Continued)
PMM 2 (140) Petkov 1997; Romanelli
2015a
1.10 (0.84 to 1.46)
I² = 0%; P = 0.87
1.08 (0.83 to 1.40)
Comparisons with cadexomer iodine: RR > 1 indicates greater proportion healing with specified alternative treatment
Hydrocolloid 1 (104) Hansson 19980 0.73 (0.26 to 2.08) 0.90 (0.39 to 2.10)
Gentian violet 1 (60) Ormiston 1985 0.58 (0.27 1.28) 0.58 (0.26 to 1.29)
Comparisons with foam: RR > 1 indicates greater proportion healing with specified alternative treatment
Hydrocolloid 6 (458) Bowszyc 1995; Charles
2002; Norkus 2005;
Sopata 2016; Thomas
1997; Zuccarelli 1992
0.92 (0.77 to 1.08)
I² = 0%; P = 0.84
0.91 (0.78 to 1.07)
Ibuprofen 2 (242) Fogh 2012; Gottrup
2008
0.88 (0.48 to 1.61)
I² = 0%; P = 0.79
0.88 (0.48 to 1.62)
Octenidine 1 (126) Vanscheidt 2012 1.03 (0.56 to 1.90) 1.03 (0.55 to 1.92)
Paste bandage 1 (36) Rubin 1990 2.30 (1.29 to 4.10) 1.47 (0.99 to 2.17)
PMM 1 (187) Meaume 2012 0.87 (0.30 to 2.48) 1.14 (0.82 to 1.60)
PMM silver 1 (30) Lanzara 2008 1.57 (0.84 to 2.92) 1.15 (0.78 to 1.71)
Silver 4 (397) Dimakakos 2009;Ivins
2006; Jørgensen 2005;
Senet 2014
1.65 (1.08 to 2.52)
I² = 0%; P = 0.77
2.12 (1.46 to 3.07)
Comparisons with hyaluronic acid: RR > 1 indicates greater proportion healing with specified alternative treatment
Saline gauze 1 (88) Humbert 2013 0.52 (0.23 to 1.17) 0.57 (95% CI 0.28 to 1.
14)
Emollient cream 1 (101) Dereure 2012a 1.31 (0.31 to 5.55) 1.75 (0.87 to 3.52)
Comparisons with hydrocolloid: RR > 1 indicates greater proportion healing with specified alternative treatment
PMM silver 1 (49) Hanft 2006 1.07 (0.69 to 1.67) 1.27 (0.87 to 1.85)
Povidone iodine 1 (200) Smith 1992 0.92 (0.69 to 1.23) 0.92 (0.68 to 1.26)
Saline gauze 1 (28) Ohlsson 1994 0.29 (0.07 to 1.14) 0.34 (95% CI 0.15 to 0.
8)
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Table 3. Direct comparisons for individual interventions compared with NMA results (Continued)
Silver 1 (58) Kucharzewski 2013 4.39 (2.23 to 8.65)
Note 100% events in sil-
ver arm
2.32 (1.58 to 3.41)
Zinc oxide 1 (43) Brandrup 1990 0.95 (0.27 to 3.33) 0.95 (0.27 to 3.35)
Blood producta 1 (13) Senet 2003 0.86 (0.07 to 10.96) 0.38 (95% CI 0.17 to 0.
88)
Growth factora 1 (29) Rasmussen 1991 1.83 (0.22 to 15.51) 0.91 (0.71 to 1.17)
Comparisons withhydrogel: RR > 1 indicates greater proportion healing with specified alternative treatment
Sucralfate 1 (100) Tumino 2008 8.60 (3.72 to 19.90) 8.60 (3.68 to 20.07)
Blood producta 1 (44) De Araujo 2016 0.47 (0.14 to 1.58) 0.51 (CI 0.21 to 1.23)
Growth factora 1 (59) Senet 2011 1.38 (0.64 to 3.01) 1.20 (0.61 to 2.35)
Comparisons with blood product: RR > 1 indicates greater proportion healing with specified alternative treatment
Saline gauze 1 (67) Stacey 2000 0.93 (0.74 to 1.16) 0.89 (0.68 to 1.17)
Emollient cream 1 (147) Biland 1985 0.76 [0.55, 1.06] 0.79 (0.56 to 1.11)
Comparisons with emollient cream: RR > 1 indicates greater proportion healing with specified alternative treatment
SSD 1 (57) Bishop 1992 6.21 (0.80 to 48.38) 2.56 (1.01 to 6.53)
Abbreviations: PMM: protease modulating matrix; RR: relative risk; SSD: silver sulphadiazine
aNon-eligible linking intervention
Table 4. Interventions in the included studies
Intervention Number of included studies Included studies Number of participants in in-
cluded studies
A. Pichinchensis 1 Romero-Cerecero 2012 34
Alginate 10 Armstrong 1997; Harding 2001;
Moffatt 1992b;
Petkov 1997; Romanelli 2015a;
Romero-Cerecero 2012; Schulze
2001; Scurr 1994; Smith 1994;
Stacey 1997
735
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Table 4. Interventions in the included studies (Continued)
Blood producta 5 Arenbergerova 2013; Biland
1985; De Araujo 2016; Senet
2003; Stacey 2000
431
Cadexomer iodine 7 Hansson 1998; Harcup 1986;
Lindsay 1986; Moss 1987;
Ormiston 1985; Steele 1986;
Tarvainen 1988
433
Cellulose 1 Alvarez 2012 48
Collagen 2 Caprio 1992; Robson 1995 132
Dextranomer 3 Kalis 1993; Moss 1987;
Tarvainen 1988
171
Emollient cream 3 Biland 1985; Bishop 1992;
Dereure 2012a
384
Film 1 Banerjee 1997 56
Foam 18 Bowszyc 1995; Callam 1992;
Charles 2002; Dimakakos 2009;
Fogh 2012; Gottrup 2008; Ivins
2006; Jørgensen 2005; Lanzara
2008; Meaume 2012; Norkus
2005; Rubin 1990; Schulze
2001; Senet 2014; Sopata 2016;
Thomas 1997; Vanscheidt 2012;
Zuccarelli 1992
1672
Gentian violet 1 Ormiston 1985 60
Growth factora 5 Rasmussen 1991; Robson 1995;
Robson 2001; Robson 2004;
Senet 2011
560
Honey 1 Jull 2008 368
Hyaluronic acid 2 Dereure 2012a; Humbert 2013 189
Hyaluronic acid + povidone io-
dine
1 Casoni 2002 65
Hydrocolloid 25 Backhouse 1987; Blair 1988a;
Bowszyc 1995;Brandrup 1990;
Caprio 1992; Charles 2002;
Greguric 1994; Hanft 2006;
Hansson 1998; Kalis 1993;
2044
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Table 4. Interventions in the included studies (Continued)
Kucharzewski 2013; Leaper
1991; Meredith 1988; Moffatt
1992a; Nelson 2007; Norkus
2005; Ohlsson 1994; Rasmussen
1991; Scurr 1994; Senet 2003;
Smith 1992; Smith 1994; Sopata
2016; Thomas 1997; Zuccarelli
1992
Hydroﬁbre 4 Arenbergerova 2013; Armstrong
1997; Harding 2001; Kelechi
2012
329
Hydrogel 6 Beckert 2006; De Araujo
2016; Luiza 2015; Senet 2011;
Taddeucci 2004; Tumino 2008
393
Ibuprofen 2 Fogh 2012; Gottrup 2008 222
Magnesium sulphate 1 Greguric 1994 110
Nonadherent 20 Alvarez 2012; Arnold 1994;
Backhouse 1987; Banerjee 1997;
Blair 1988a; Blair 1988b; Callam
1992; Casoni 2002; Hansson
1998; Kelechi 2012; Leaper
1991; Moffatt 1992a; Moffatt
1992b; Meredith 1988; Nelson
2007; Robson 1995; Robson
2001; Robson 2004; Taddeucci
2004; Vin 2002
1725
Non silver 1 Michaels 2009 208
No treatment 1 Hokkam 2011 104
Octenidine 1 Vanscheidt 2012 106
Ozonated oil 1 Solovastru 2015 29
Papain 2 De Araujo 2016; Luiza 2015 70
Paste bandage 2 Rubin 1990; Stacey 1997 149
Phenytoin 1 Hokkam 2011 104
Povidone iodine 1 Smith 1992; 200
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Table 4. Interventions in the included studies (Continued)
PMM 4 Meaume 2012; Petkov 1997;
Romanelli 2015a; Vin 2002
400
PMM-silver 2 Hanft 2006; Lanzara 2008; 79
Saline gauze 3 Humbert 2013; Ohlsson 1994;
Stacey 2000
202
Shale oil 1 Beckert 2006 119
Silica gel ﬁbre 1 Brown 2014 120
Silver 6 Dimakakos 2009; Ivins 2006;
Jørgensen 2005; Kucharzewski
2013; Michaels 2009; Senet
2014;
663
SSD 2 Bishop 1992; Blair 1988b 146
Standard care/mixed
treatments
6 Arnold 1994; Brown 2014;
Harcup 1986; Jull 2008; Lindsay
1986; Steele 1986
715
Sucralfate 1 Tumino 2008 100
Suphadryl 1 Salim 1992 137
Tripeptide copper 1 Bishop 1992 86
Zinc oxide 2 Brandrup 1990; Solovastru 2015 72
Abbreviations: PMM: protease modulating matrix; SSD: silver sulphadiazine
aIneligible intervention included in expanded base-case to improve network connectivity
Table 5. Comparison of NMA results for base-case and two sensitivity analyses
NMA contrast Base-case RR (95% CI) Narrow sensitivity analysis
RR (95% CI)
Extended sensitivity analysis
RR (95% CI)
Sucralfate versus hydrogel 8.60 (3.66 to 20.2) --- 8.60 (3.68 to 20.1)
Sucralfate versus silver 6.99 (0.60 to 82.0) --- 2.80 (0.88 to 8.97)
Sucralfate versus foam 14.83 (1.30 to 169) --- 5.94 (1.96 to 18.0)
Sucralfate versus hydrocolloid 16.24 (1.43 to 185) --- 6.51 (2.17 to 19.6)
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Table 5. Comparison of NMA results for base-case and two sensitivity analyses (Continued)
Sucralfate versus nonadherent 17.15 (1.52 to 193) --- 6.80 (2.24 to 20.7)
Hydrogel versus silver 0.81 (0.08 to 8.19) 0.81 (0.08 to 8.20) 0.33 (0.15 to 0.72)
Hydrogel versus foam 1.73 (0.18 to 16.9) 1.72 (0.18 to 16.9) 0.69 (0.34 to 1.41)
Hydrogel versus hydrocolloid 1.89 (0.19 to 18.4) 1.88 (0.19 to 18.4) 0.76 (0.38 to 1.53)
Hydrogel versus nonadherent 1.99 (0.21 to 19.3) 2.00 (0.21 to 19.4) 0.79 (0.39 to 1.62)
Silver versus foam 2.12 (1.46 to 3.09) 2.12 (1.45 to 3.10) 2.12 (1.46 to 3.07)
Silver versus hydrocolloid 2.32 (1.58 to 3.43) 2.32 (1.57 to 3.44) 2.32 (1.58 to 3.41)
Silver versus nonadherent 2.45 (1.58 to 3.82) 2.47 (1.58 to 3.86) 2.43 (1.58 to 3.74)
Foam versus hydrocolloid 1.10 (0.93 to 1.28) 1.09 (0.93 to 1.29) 1.10 (0.94 to 1.28)
Foam versus nonadherent 1.16 (0.91 to 1.47) 1.16 (0.91 to 1.49) 1.15 (0.91 to 1.44)
Hydrocolloid versus nonadher-
ent
1.06 (0.84 to 1.32) 1.06 (0.85 to 1.33) 1.04 (0.85 to 1.29)
Abbreviations: CI: conﬁdence interval; RR: relative risk
Table 6. Ranks of treatments - base-case and two sensitivity analyses (ordered by mean rank)
Treatment Base-case (rank of 22)
Mean rank (SUCRA) and
maximum probability and its
corresponding rank
Narrow sensitivity analysis
(rank of 17)
Mean rank (SUCRA) and
maximum probability and its
corresponding rank
Extended base-case (rank of
25)#
Mean rank (SUCRA) and
maximum probability and its
corresponding rank
Sucralfate 1.5 (1.0) 91% (rank 1) --- 1.1 (1.0) 93% (rank 1)
Silver 3.2 (0.9) 38% (rank 3) 1.9 (0.9) 40% (rank 2) 2.7 (0.9) 50% (rank 2)
Hyaluronic acid
+ povidone iodine
5.8 (0.8) 32% (rank 21) --- 5.3 (0.8) 21% (rank 3)
Paste bandage 5.8 (0.8) 19% (rank 5) 4.0 (0.8) 26% (rank 3) 5.4 (0.8) 22% (rank 4)
Hydroﬁbre 8.3 (0.7) 14% (rank 7) 5.9 (0.7) 17% (rank 5) 8.1 (0.7) 16% (rank 6)
Hydrogel 8.9 (0.6) 39% (rank 2) 6.4 (0.7) 39% (rank 1) 16.9 (0.3) 15% (rank 20)
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Table 6. Ranks of treatments - base-case and two sensitivity analyses (ordered by mean rank) (Continued)
PMM 9.4 (0.6) 15% (rank 9) 7.0 (0.6) 19% (rank 6) 9.0 (0.7) 16% (rank 8)
PMM silver 9.5 (0.6) 12% (rank 8) 6.8 (0.6) 15% (rank 5) 8.9 (0.7) 13% (rank 7)
Film 10.1 (0.6) 9% (rank 5) 7.5 (0.6) 10% (rank 3) 10.2 (0.6) 9% (rank 5)
Alginate 10.9 (0.5) 17% (rank 10) 8.1 (0.6) 20% (rank 7) 10.5 (0.6) 16% (rank 10)
Octenidine 11.4 (0.5) 7% (rank 7) --- 11.4 (0.6) 9% (rank 6)
Foam 12.0 (0.5) 18% (rank 11) 9.0 (0.5) 20% (rank 9) 11.5 (0.6) 17% (rank 11)
Cadexomer iodine 12.1 (0.5) 9% (rank 19) 9.0 (0.5) 9% (rank 4) 11.8 (0.5) 8% (rank 19)
Zinc oxide 13.3 (0.4) 13% (rank 20) 10.5 (0.4) 14% (rank 15) 14.4 (0.4) 8% (rank 25)
Ibuprofen-releasing foam 14.1 (0.4) 12% (rank 18) --- 14.3 (0.4) 9% (rank 18)
Hydrocolloid 14.3 (0.4) 21% (rank 15) 11.0 (0.4) 25% (rank 11) 14.0 (0.5) 18% (rank 14)
Nonadherent 15.2 (0.3) 18% (rank 15) 11.8 (0.3) 25% (rank 13) 15.3 (0.4) 15% (rank 15)
Povidone iodine 15.2 (0.3) 14% (rank 17) 11.8 (0.3) 17% (rank 13) 15.5 (0.4) 12% (rank 17)
Hyaluronic acid 15.7 (0.3) 18% (rank 4) 12 (0.3) 38% (rank 16) 17.0 (0.3) 19% (rank 22)
Gentian violet 17.4 (0.2) 19% (rank 21) --- 18.4 (0.3) 16% (rank 25)
SSD 18.1 (0.2) 23% (rank 19) 14 (0.2) 28% (rank 15) 18.8 (0.3) 16% (rank 19)
Saline gauze 21.0 (0) 69% (rank 22) 16.3 (0) 77% (rank 17) 23.0 (0.1) 33% (rank 24)
Abbreviations:PMM: protease modulating matrix; SSD: silver sulphadiazine; SUCRA surface under the cumulative ranking curve
# ranks for extra treatments not reported
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Table 7. Contributions matrix
Mixed
treat-
ment
com-
parisons
Di-
rect com-
parisons
(risk of
bias)
Silver vs
HC
HC vs
NA
Foam vs
NA
HC vs
Foam
Silver vs
foam
Sucral-
fate vs
HC
Silver vs
NA
Sucral-
fate vs
NA
Sucral-
fate vs
silver
Sucral-
fate vs
foam
Hyaluronic
+ povi-
done
iodine vs
nonad-
herent
(low)
Hydro-
colloid
vs nonad-
herent
(high)
3.0 80.6 32.7 6.2 1.2 17.9 28.9 2.7 11.1 10.9
Hyaluronic
acid vs
saline
gauze
(high)
Hydroﬁ-
bre
vs nonad-
herent
(high)
0.2 0.6 1.0 0.3 0.1 0.1 0.7 0.4 0.2 0.2
Hydrogel
vs nonad-
her-
ent (very
high)
3.4 5.2 2.6 3.4
PMM
vs nonad-
herent
0.3 0.8 2.1 0.6 0.1 0.3 1.3 0.1 0.5 0.8
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Table 7. Contributions matrix (Continued)
(low)
PMM sil-
ver vs hy-
drocol-
loid
(high)
1.0 0.1 1.2 2.2 0.4 0.1 0.4 0.3 0.6
Hydro-
colloid vs
povi-
done io-
dine (very
high)
Hydro-
colloid vs
saline
gauze
(low)
0.2 0.1 2.7 0.1 1.9 1.8 1.9
Silver
vs hydro-
colloid
(high)
32.5 0.1 0.9 2.2 12.9 0.1 15.9 7.2 0.5
Hydro-
colloid vs
zinc oxide
(high)
SSD
vs nonad-
herent
(high)
0.1 0.5 0.9 0.4 0.5
Cadex-
omer io-
dine
vs nonad-
herent
(high)
0.8 0.3 0.2 0.3 0.1 0.1
Sucralfate
vs hydro-
gel (high)
25.1 32.4 18.7 21.4
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Table 7. Contributions matrix (Continued)
Film
vs nonad-
her-
ent (very
high)
Foam
vs nonad-
her-
ent (very
high)
2.5 5.4 21.4 5.3 1.0 1.8 9.1 0.3 3.3 5.8
Growth
factor
vs nonad-
herent
(low)
0.5 0.2 16.2 0.2 22.7 12.2 13.8
Hydro-
colloid vs
alginate
(high)
0.3 0.5 0.5 0.1 0.3 0.1
Hydroﬁ-
bre vs al-
gi-
nate (very
high)
0.2 0.6 1.0 0.3 0.1 0.4 0.7 0.1 0.5 0.6
Paste
ban-
dage vs al-
ginate
(high)
0.4 0.4 1.3 0.7 0.2 0.2 0.8 0.5 0.6
PMM vs
alginate
(low)
0.1 0.4 0.7 0.1 0.1 0.5 0.1 0.2 0.2
Foam vs
algi-
nate (very
high)
0.1 0.1 0.4 0.3 0.1 0.1 0.2 0.1 0.2
Hydro-
colloid vs
blood
product
0.1 1.2 0.8 0.9 0.9
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Table 7. Contributions matrix (Continued)
(low)
Hydroﬁ-
bre
vs blood
prod-
uct (very
high)
0.4 0.5 0.3 0.4
Hydrogel
vs blood
product
(low)
0.2 0.1 4.8 0.1 4.2 3.4 3.7
Blood
product
vs saline
gauze
(high)
0.2 0.1 2.7 0.1 1.9 1.8 1.9
Blood
product
vs emol-
lient
cream
(high)
0.1 0.6 1.0 0.5 0.5
Hydro-
colloid vs
cadex-
omer io-
dine
(high)
0.8 0.3 0.2 0.3 0.1 0.1
Gen-
tian violet
vs cadex-
omer io-
dine
(high)
Hyaluronic
acid vs
emollient
cream
(low)
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Table 7. Contributions matrix (Continued)
SSD vs
emollient
cream
(low)
0.1 0.5 0.9 0.4 0.5
Hydro-
colloid vs
foam
(very
high)
26.6 6.0 31.2 75.5 11.1 2.1 13.3 0.3 7.0 13.1
Ibupro-
fen foam
vs foam
(high)
Octeni-
dine vs
foam
(high)
Paste
bandage
vs foam
(high)
0.4 0.4 1.3 0.7 0.2 0.2 0.8 0.5 0.6
PMM vs
foam
(high)
0.3 0.4 1.4 0.5 0.1 0.1 0.8 0.4 0.5
PMM sil-
ver vs
foam
(high)
1.0 0.1 1.2 2.2 0.4 0.1 0.4 0.3 0.6
Silver vs
foam
(low)
31.0 0.1 0.9 2.2 71.9 0.1 24.7 11.6 0.5
Hydro-
colloid
vs growth
factor
(high)
0.4 0.1 0.7 0.1 0.3 0.5 0.5
Hydrogel
vs hydro-
colloid
0.1 0.1 16.9 0.1 23.0 12.7 14.3
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Table 7. Contributions matrix (Continued)
(high)
RISKOF
BIAS
FOR
Mixed
Treat-
ment
Compar-
ison
High High High Very
high
Low High High High High High
Abbreviations:HC: hydrocolloid; NA: nonadherent; PMM: protease modulating matrix; SSD: silver sulphadiazine
Table 8. Inconsistency factors - base-case and extended base-case
Loop RoRR and 90%CI P value Loop heterogeneity
tau² (loop)
Foam-hydrocolloid-silver 2.44 (90%CI 1.23 to 4.84) 0.033 0
Nonadherent-alginate-foam 2.28 (90%CI 0.54 to 9.67) 0.349 0
Alginate-foam-PMM 2.26 (90%CI 0.43 to 11.94) 0.419 0
Nonadherent-cadexomer-
hydrocolloid
1.81 (90%CI 0.25 to 13.24) 0.625 0.104
Nonadherent-alginate-
hydrocolloid
1.66 (90%CI 0.35 to 7.74) 0.59 0.103
Foam-hydrocolloid-PMM sil-
ver
1.60 (90%CI 0.83 to 3.08) 0.24 0
Alginate-foam-hydrocolloid 1.40 (90%CI 0.26 to 7.39) 0.74 0
Nonadherent-alginate-PMM 1.26 (90%CI 0.72 to 2.21) 0.503 0
Nonadherent-foam-PMM 1.25 (90%CI 0.43 to 3.62) 0.73 0
Nonadherent-alginate-
hydroﬁbre
1.18 (90%CI 0.61 to 2.26) 0.684 0
Nonadherent-foam-
hydrocolloid
1.06 (90%CI 0.55 to 2.06) 0.878 0.042
Alginate-foam-paste bandage 1.03 (90%CI 0.23 to 4.58) 0.974 0
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Table 8. Inconsistency factors - base-case and extended base-case (Continued)
Extended base-case only
Nonadherent-growth factor-
hydrogel
3.00 (90%CI 0.40 to 22.43) 0.370 0
Blood product-hydrocolloid-
saline gauze
2.78 (90%CI 0.24 to 31.92) 0.491 0
Nonadherent-growth factor-
hydrocolloid
2.23 (90%CI 0.21 to 23.65) 0.577 0.078
Quadratic loops
Alginate-blood product-hydro-
colloid-hydroﬁbre
7.34 (90%CI 0.12 to 460.27) 0.428 0.487
Nonadherent-blood product-
hydroﬁbre-hydrogel
4.7 (90%CI 0.15 to 148.15) 0.461 0
Nonadherent-blood product-
hydrocolloid-hydroﬁbre
4.09 (90%CI 0.03 to 493.5) 0.629 0.096
Blood product-emol-
lient cream-hyaluronic acid-
saline gauze
3.68 (90%CI 0.89 to 15.16) 0.131 0
Blood product-growth factor-
hydrocolloid-hydrogel
1.38 (90%CI 0.07 to 28.86) 0.862 0
Nonadherent-blood product-
hydrocolloid-hydrogel
1.15 (90%CI 0.02 to 82.36) 0.957 0.096
Abbreviations:CI: conﬁdence interval; PMM: protease modulating matrix; RoRR: ratio of relative risks
Table 9. Node splitting
Comparison Direct RR (95% CI) Indirect RR (95% CI) RoRR (90% CI)
Alginate vs nonadherent 1.08 (95% CI 0.86 to 1.36) 1.52 (95% CI 1.07 to 2.15) 0.71 (90% CI 0.50 to 1.02)
Foam vs nonadherent 1.35 (95% CI 0.87 to 2.08) 1.10 (95% CI 0.83 to 1.47) 1.22 (90% CI 0.79 to 1.89)
Hydrocolloid vs nonadherent 0.94 (95% CI 0.72 to 1.23) 2.01 (95% CI 0.56 to 7.23) 0.47 (90% CI 0.16 to 1.39)
Hydroﬁbre vs nonadherent 1.47 (95% CI 0.84 to 2.56) 1.35 (95% CI 0.71 to 2.56) 1.09 (90% CI 0.53 to 2.23)
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Table 9. Node splitting (Continued)
Hydrogel vs nonadherent 2.00 (95% CI 0.21 to 19.1) 0.76 (95% CI 0.36 to 1.64) 2.62 (90% CI 0.35 to 19.5)
PMM vs nonadherent 1.46 (95% CI 0.80 to 2.67) 1.29 (95% CI 0.85 to 1.96) 1.13 (90% CI 0.61 to 2.11)
Foam vs alginate 0.55 (95% CI 0.10 to 2.87) 0.95 (95% CI 0.72 to 1.27) 0.57 (90% CI 0.14 to 2.36)
Hydrocolloid vs alginate 0.70 (95% CI 0.24 to 2.06) 0.87 (95% CI 0.67 to 1.14) 0.81 (90% CI 0.31 to 2.05)
Hydroﬁbre vs alginate 1.18 (95% CI 0.66 to 2.10) 1.09 (95% CI 0.57 to 2.10) 1.08 (90% CI 0.51 to 2.29)
Paste bandage vs alginate 1.22 (95% CI 0.91 to 1.63) 2.41 (95% CI 1.28 to 4.53) 0.51 (90% CI 0.28 to 0.91)
PMM vs alginate 1.08 (95% CI 0.76 to 1.53) 1.07 (95% CI 0.57 to 1.98) 1.01 (90% CI 0.55 to 1.85)
Hydrocolloid vs foam 0.92 (95% CI 0.76 to 1.12) 0.90 (95% CI 0.64 to 1.28) 1.02 (90% CI 0.73 to 1.42)
Paste bandage vs foam 2.30 (95% CI 1.29 to 4.09) 1.17 (95% CI 0.79 to 1.72) 1.97 (90% CI 1.10 to 3.55)
PMM vs foam 0.87 (95% CI 0.30 to 2.51) 1.19 (95% CI 0.81 to 1.74) 0.73 (90% CI 0.28 to 1.90)
PMM silver vs foam 1.57 (95% CI 0.83 to 2.96) 0.96 (95% CI 0.59 to 1.57) 1.64 (90% CI 0.83 to 3.21)
Silver vs foam 1.65 (95% CI 1.08 to 2.51) 4.12 (95% CI 2.06 to 8.22) 0.40 (90% CI 0.20 to 0.79)
PMM silver vs hydrocolloid 1.07 (95% CI 0.68 to 1.7) 1.75 (95% CI 0.91 to 3.37) 0.61 (90% CI 0.31 to 1.2)
Silver vs hydrocolloid 4.39 (95% CI 2.23 to 8.62) 1.76 (95% CI 1.12 to 2.75) 2.50 (90% CI 1.26 to 4.95)
Emollient cream vs blood prod-
uct
0.76 (95% CI 0.54 to 1.09) 2.78 (95% CI 0.53 to 14.62) 0.28 (90% CI 0.07 to 1.15)
Hydrocolloid vs blood product 1.17 (95% CI 0.09 to 14.81) 2.39 (95% CI 0.91 to 6.32) 0.49 (90% CI 0.05 to 4.84)
Hydroﬁbre vs blood product 0.33 (95% CI 0.01 to 7.82) 3.65 (95% CI 1.31 to 10.19) 0.09 (90% CI 0.01 to 1.5)
Hydrogel vs blood product 2.13 (95% CI 0.63 to 7.25) 1.33 (95% CI 0.33 to 5.42) 1.6 (90% CI 0.33 to 7.69)
Saline gauze vs blood product 0.93 (95% CI 0.71 to 1.21) 0.34 (95% CI 0.1 to 1.18) 2.71 (90% CI 0.93 to 7.85)
Hyaluronic acid vs emollient
cream
0.76 (95% CI 0.18 to 3.24) 2.78 (95% CI 1.13 to 6.8) 0.28 (90% CI 0.07 to 1.15)
Hydrocolloid vs growth factor 0.55 (95% CI 0.06 to 4.6) 1.11 (95% CI 0.84 to 1.46) 0.49 (90% CI 0.08 to 3.01)
Hydrogel vs growth factor 0.72 (95% CI 0.33 to 1.6) 1.55 (95% CI 0.39 to 6.11) 0.47 (90% CI 0.12 to 1.78)
Hyaluronic acid vs saline gauze 2.32 (95% CI 1.06 to 5.07) 0.64 (95% CI 0.14 to 2.89) 3.63 (90% CI 0.87 to 15.21)
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Table 9. Node splitting (Continued)
Hydrocolloid vs saline gauze 3.5 (95% CI 0.87 to 14.06) 1.91 (95% CI 0.57 to 6.39) 1.84 (90% CI 0.39 to 8.7)
Abbreviations:CI: conﬁdence interval; PMM: protease modulating matrix; RoRR: ratio of relative risks; RR: relative risk
A P P E N D I C E S
Appendix 1. Glossary of network meta-analysis (NMA) terms
Arm-specific outcomes/arm-level data: raw outcome data (e.g. mean (SD) or risk) for each arm of the trial (see also treatment
contrast).
Assumptions for NMA: in common with all meta-analysis, the true treatment effect across trials is assumed to be described by a fixed-
effect or random-effects model. Additionally, transitivity is assumed and, concurrently, exchangeability and consistency.
Baseline risk: the absolute risk of the outcome in the ’control’ group. This is affected by the presence of prognostic factors. Some
authors have used the baseline risk as a proxy effect modifier, but in general the effect estimate (RR/OR/HR) is independent of the
baseline risk; on the other hand, the absolute risk difference depends on baseline risk.
Bayesian approach: the explicit quantitative use of external evidence in the design, monitoring, analysis, interpretation of a health-
care evaluation. In the Bayesian paradigm, prior beliefs about parameters in the models are speciﬁed and factored into the estimation.
Posterior distributions of model parameters are then derived from the prior information and the observed data. In NMA, it is common
to use non-informative priors for effect estimates.
Coherence/consistency: the direct effect estimate (e.g. mean difference or log odds ratio) is the same as the sum of the indirect effect
estimates.
Connected network: a group of linked interventions, such that every trial in the network has at least one intervention in common
with at least one other trial. Sometimes individual comparisons are not connected to the rest of the network (disconnected network)
and can sometimes be joined in by extending the network to include supplementary interventions.
Contour-enhanced funnel plot: contour-enhanced funnel plots show areas of statistical signiﬁcance, and they can help in distinguishing
publication bias from other possible reasons for asymmetry. In a network of interventions, each study estimates the relative effect of
different interventions, so asymmetry in the funnel plot cannot be judged. To account for this, an adaptation of the funnel plot can be
used, in which the standard error is plotted against an adjusted effect size for each study: the adjusted effect size for a comparison is the
study-speciﬁc effect size minus the mean for the meta-analysis for that comparison.
Contrast/study-level data: outcome data for the comparison (e.g. mean difference, odds ratio).
Decision space/decision set: the interventions in the decision set are the focal treatments of interest to systematic review authors.
Deviance Information Criterion (DIC): the DIC is a measure of the balance between model ﬁt (the posterior mean deviance) and
model complexity (the leverage) and calculated as the sum of these two; the smaller the DIC, the better the model. DIC is often used to
compare models, for example, comparing ﬁxed-effect and random-effects models. If there is an important difference in DIC between
models, there is evidence of heterogeneity.
Direct evidence/direct comparison: head-to-head comparison of two treatments, for example, A versus B (see also indirect evidence).
Edge: line representing a direct comparison on a network diagram.
Effect modifier: effect modiﬁcation occurs when the effect of A versus B (as the RR/OR/HR for binary outcomes) is signiﬁcantly
different in two or more subgroups, and this leads to heterogeneity, either within trials or between trials, or both. Factors that give rise
to subgroup effects are called effect modiﬁers, and it is important to identify potential effect modiﬁers and allow for them in the analysis.
The identiﬁcation of signiﬁcant effect modiﬁers may lead to stratiﬁcation (separate analyses for each subgroup) or to a decision not to
combine data from different trials in a meta-analysis. In general, trials have different distributions of effect modiﬁers (e.g. proportion
of people with and without diabetes), leading to inconsistency between trials in the treatment effect. This is often magniﬁed when
there is a network of different comparisons.
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Exchangeability: it is assumed that treatments in a NMA are exchangeable, so, if treatment B had been given to patients in the indirect
A versus C trials and if A had been given in the B versus C indirect trials, then the true AB differences in these indirect studies would be
identical to the true AB difference in direct A versus B trials, or at least from the same common distribution. Furthermore, if patients
in other trials within the wider linked network (e.g. D versus E trials) were given A and B, the AB differences would also be the same
or from the same distribution. This assumption breaks down when there are effect modifiers.
Fixed-effect: the true treatment effect is assumed to be constant across trials (ﬁxed-effect) - see also random-effects and transitivity.
Global inconsistency: inconsistency across a network is described as global inconsistency. It can be evaluated statistically by ﬁtting
models that allow and do not allow for inconsistency. A ’leave-one comparison-out’ approach, often called ’node splitting,’ can also be
applied, with each direct comparison being excluded from the network and then estimating the difference between this direct evidence
and the indirect evidence from the network.
Heterogeneity in a NMA: patients are not randomised to different trials. Therefore, there may be systematic differences in study
characteristics or the distribution of patient characteristics across trials. If these characteristics inﬂuence the treatment effects (i.e. are
effect modifiers), then there are systematic differences in treatment effects across trials, which is called between-trial heterogeneity.
There may also be within-trial heterogeneity if there are subgroups of an effect modiﬁer for which results are reported separately.
In a NMA, the term, ’heterogeneity’ applies to variation in effect modiﬁers within a single comparison (e.g. A versus B); the term,
’inconsistency’ refers to the imbalance in effect modiﬁers between comparisons.
Heterogeneity variance parameter (τ²): in a random-effectsmodel we assume there is heterogeneity for each pairwise comparison (e.g.
A versus B) with variance (τ ²AB ), but in a NMA we often assume that there is a common heterogeneity amongst all the comparisons in
the network; this common heterogeneity has a variance (τ ²), which is called the ’heterogeneity variance parameter’. It can be compared
with empirical distributions of heterogeneity values typically found in meta-analyses (Salanti 2014; Turner 2012).
Inconsistency/incoherence: this occurs when the effect estimate derived from an indirect comparison is not the same as the effect
estimate derived from a direct comparison. For example, in a network of three interventions, there is inconsistency if dAB(direct)
dAB(indirect), where dAB(indirect) = dAC(direct) - dBC(direct); the effect estimates are given as mean differences or log (odds ratios/
risk ratios/hazard ratios). Note that in order to investigate inconsistency there must be both indirect and direct evidence (loops in the
network). See also global inconsistency.
Inconsistency factor: this is the absolute difference between the direct and indirect estimates on the log scale (or the logarithm of
the ratio of the two odds/hazard ratios) for one of the comparisons in a loop. A statistically low-powered z-test and a 95% CI of the
inconsistency is computed to determine whether this difference is signiﬁcant.
Indirect evidence/indirect comparison: comparison of two treatments, for example, A versus B, obtained from combinations of other
comparisons (e.g. trials comparing A versus C and trials comparing B with C) (see also direct evidence).
Indirect comparison meta-analysis: meta-analysis of a set of treatments that are linked via common comparator(s), but none are
compared directly; evidence is combined in a single internally consistent model.
Leverage: this is the effective number of parameters of the model, which is calculated differently for ﬁxed-effect and random-effects
models, with the latter having greater complexity.
Likelihood (function): the likelihood function is a tool for inferring the underlying distribution of the observed data. To do this, we
propose a model to represent the data - often a parametric distribution is assumed (e.g. binomial) - and unknown parameters of that
distribution are determined, given the data, by maximising the likelihood (the larger the likelihood, the closer the model ﬁt).
Loop (of evidence): combination of direct and indirect evidence, such that the interventions in the network diagram can be linked to
form a closed loop.
Meta-analysis: a statistical synthesis of the results from two or more separate studies. Methods involve calculating a weighted average
of effect estimates from the separate studies.
Mixed treatment comparison meta-analysis: another name for network meta-analysis.
Model: a statistical model is a (simpliﬁed) mathematical representation of the system we wish to learn about, and which generates
our observed data. The model will usually depend on some known factors, such as other variables measured alongside the data, and
some unknown parameters that we wish to determine. Then having determined the unknown parameters, the model should be able to
simulate data that are an approximation of the real data, allowing us to make inferences from the data.
Multi-arm trial: individual trial that compares more than two interventions. It is important to take into account correlations within
these trials in the analysis.
Network: trials must be linked in a network of interventions, such that every trial in the network has at least one intervention in
common with at least one other trial.
Network diagram: graphical representation of the interventions in the network. It consists of nodes representing the interventions
and edges representing the comparisons. The amount of available information can be presented by ’weighting’ the nodes and edges
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using different node sizes and line thicknesses according to the number of studies reporting that treatment or comparison respectively.
Other types of weighting are discussed in Chaimani 2013.
Network meta-analysis (NMA):NMA is the simultaneous combination of data from randomised comparisons of multiple competing
treatments (A versus B, A versus C, A versus D, B versus D, and so on), to deliver an internally consistent set of estimates while
respecting the randomisation in the evidence. The use of indirect estimates can provide information on comparisons for which no trials
exist. It can also improve the precision of the direct estimate by reducing the width of the CIs compared with the direct evidence alone.
Node: intervention represented on a network diagram, usually by a circle of weighted size.
Pairwise meta-analysis: meta-analysis of one or more trials of direct comparisons (e.g. A versus B) - see direct evidence.
Prognostic factors: population or study characteristics that affect the risk of the outcome. In a sufﬁciently large randomised trial that
is free from bias, prognostic factors are distributed evenly between intervention groups and do not affect the effect estimate (RR/OR/
HR for binary outcomes) unless they are effect modifiers, but they do affect the baseline risk and absolute risk difference.
Random-effects: trial-speciﬁc treatment differences are assumed to be from a common distribution - see also fixed-effect and transi-
tivity.
Ranking: ordering of treatments according to their relative effectiveness.
Sparse data: data with wide conﬁdence intervals because of few events as a consequence of small studies or short follow-up periods.
Study-level data: see contrast.
SUCRA: Surface Under the Cumulative RAnking. This is a measure of the probability that the given treatment is the best. Thus, a
SUCRA would be 1 (or 100%) when a treatment was certain to be the best and 0 (0%) when a treatment was certain to be the worst.
Supplementary set (of interventions): interventions added to the network to provide additional evidence on relative treatment effects
of the decision set. This may be to connect an otherwise unconnected network of treatments, to increase the precision of the treatment
effect estimates or to help address between-trial heterogeneity.
Transitivity: NMA requires a transitivity assumption, such that there is no imbalance in the distribution of effect modifiers across the
different types of treatment comparisons (see also exchangeability).
’Unadjusted’ meta-analysis: meta-analysis of all the treatment arms for a particular treatment (e.g. all A arms). This breaks the
randomisation and should not be done.
References include: Caldwell 2005; Caldwell 2014; Chaimani 2013; Cipriani 2013; Dias 2013; Dias 2014; Grant 2013; Jansen 2013;
Lu 2004; Salanti 2008; Salanti 2011; Salanti 2014; Soares 2014; Spiegelhalter 2003; Thorlund 2012; Tu 2012; WinBUGS 2016.
Appendix 2. Search strategies
Cochrane Specialised Wounds Register
1 MESH DESCRIPTOR Bandages EXPLODE ALL AND INREGISTER
2 MESH DESCRIPTOR Alginates EXPLODE ALL AND INREGISTER
3 MESH DESCRIPTOR Hydrogels EXPLODE ALL AND INREGISTER
4 MESH DESCRIPTOR Honey EXPLODE ALL AND INREGISTER
5 MESH DESCRIPTOR Silver EXPLODE ALL AND INREGISTER
6 MESH DESCRIPTOR Silver Sulfadiazine EXPLODE ALL AND INREGISTER
7 MESH DESCRIPTOR Charcoal EXPLODE ALL AND INREGISTER
8 MESH DESCRIPTOR Silicones EXPLODE ALL AND INREGISTER
9 MESH DESCRIPTOR Colloids EXPLODE ALL AND INREGISTER
10 MESH DESCRIPTOR Polyurethanes EXPLODE ALL AND INREGISTER
11 dressing* or pad or pads or gauze or tulle or ﬁlm or bead or foam* or non-adherent or “non adherent” or hydrocolloid* or “sodium
hyaluronate” or alginat* or hydrogel* or silver* or honey* or matrix or iodine* or “protease modulat*” or “capillary action” or charcoal
or silicon* or polymer* or polyurethane* or hydrocellular or hydropolymer* or carboxymethylcellulose or carboxymethyl-cellulose or
gelatin* or NaCMC or “gel forming” or gel-forming AND INREGISTER
12 ((odour or odor) near3 absorb*) AND INREGISTER
13 primapore or curasorb or seasorb or sorbsan or advadraw or vacutex or tegaderm or opsite or allevyn or biatain or medihoney or
activon tulle or granuﬂex or “nu derm” or aquacel or iodoﬂex or iodozyme or xeroform or carboﬂex or cutimed or sorbact or promogran
or acticoat or “urgosorb silver” or mepitel or urgotul or activheal or alione or askina or comfeel or duoderm or ﬂexigran or hydrocoll or
nu-derm or “ultec pro” or mepilex or versiva or urgoclean or cutinova or tegasorb or dermaﬁlm or replicare or signadress or algoplaque
or varihesive or advasorb or copa or lyofoam or permafoam or polymem or suprasorb or transorbent or trufoam or urgocell or kendall
or kerraboot or cavi-care AND INREGISTER
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14 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 AND INREGISTER
15 MESH DESCRIPTOR Metronidazole EXPLODE ALL AND INREGISTER
16 metronidazole AND INREGISTER
17 MESH DESCRIPTOR Administration, Topical EXPLODE ALL AND INREGISTER
18 MESH DESCRIPTOR Anti-Bacterial Agents EXPLODE ALL AND INREGISTER
19 #17 AND #18 AND INREGISTER
20 (topical near2 (antibiotic* or antimicrobial* or antibacterial*)) AND INREGISTER
21 MESH DESCRIPTOR Iodophors EXPLODE ALL AND INREGISTER
22 #17 AND 21 AND INREGISTER
23 ((topical near2 iodin*) or “cadexomer iodine”) AND INREGISTER
24 MESH DESCRIPTOR Collagenases EXPLODE ALL AND INREGISTER
25 #24 AND #17 AND INREGISTER
26 (topical near2 collagen*) AND INREGISTER
27 MESH DESCRIPTOR Phenytoin EXPLODE ALL AND INREGISTER
28 #27 AND #17 AND INREGISTER
29 (topical near2 phenytoin) AND INREGISTER
30 MESH DESCRIPTOR Zinc Oxide EXPLODE ALL AND INREGISTER
31 #30 AND #17 AND INREGISTER
32 (topical near2 zinc) AND INREGISTER
33 (iodosorb or actiformcool or aquaﬂo or ﬂamazine or silvadene) AND INREGISTER
34 MESH DESCRIPTOR Ointments EXPLODE ALL AND INREGISTER
35 (ointment* or lotion* or cream* or powder* or gel or gels) AND INREGISTER
36 (topical near (agent* or preparation* or therap* or treatment*)) AND INREGISTER
37 #15 or #16 or #19 or #20 or #22 or #23 or #25 or #26 or #28 or #29 or #31 or #32 or #33 or #34 or #35 or #36 AND INREGISTER
38 #14 or #37 AND INREGISTER
39 MESH DESCRIPTOR Leg ulcer EXPLODE ALL AND INREGISTER
40 ((varicose next ulcer*) or (venous next ulcer*) or (leg next ulcer*) or (stasis next ulcer*) or (crural next ulcer*) or (ulcus next cruris)
or (ulcer next cruris)) AND INREGISTER
41 #39 OR #40
42 #38 AND #41
The Cochrane Central Register of Controlled Clinical Trials (CENTRAL)
#1 MeSH descriptor: [Bandages] explode all trees
#2 MeSH descriptor: [Alginates] explode all trees
#3 MeSH descriptor: [Hydrogels] explode all trees
#4 MeSH descriptor: [Honey] explode all trees
#5 MeSH descriptor: [Silver] explode all trees
#6 MeSH descriptor: [Silver Sulfadiazine] explode all trees
#7 MeSH descriptor: [Charcoal] explode all trees
#8 MeSH descriptor: [Silicones] explode all trees
#9 MeSH descriptor: [Colloids] explode all trees
#10 MeSH descriptor: [Polyurethanes] explode all trees
#11 (dressing* or pad or pads or gauze or tulle or ﬁlm or bead or foam* or non-adherent or “non adherent” or hydrocolloid* or “sodium
hyaluronate” or alginat* or hydrogel* or silver* or honey* or matrix or iodine* or “protease modulat*” or “capillary action” or charcoal
or silicon* or polymer* or polyurethane* or hydrocellular or hydropolymer* or carboxymethylcellulose or carboxymethyl-cellulose or
gelatin* or NaCMC or “gel forming” or gel-forming):ti,ab,kw
#12 ((odour or odor) near/3 absorb*):ti,ab,kw
#13 (primapore or curasorb or seasorb or sorbsan or advadraw or vacutex or tegaderm or opsite or allevyn or biatain or medihoney or
activon tulle or granuﬂex or “nu derm” or aquacel or iodoﬂex or iodozyme or xeroform or carboﬂex or cutimed or sorbact or promogran
or acticoat or “urgosorb silver” or mepitel or urgotul or activheal or alione or askina or comfeel or duoderm or ﬂexigran or hydrocoll or
nu-derm or “ultec pro” or mepilex or versiva or urgoclean or cutinova or tegasorb or dermaﬁlm or replicare or signadress or algoplaque
or varihesive or advasorb or copa or lyofoam or permafoam or polymem or suprasorb or transorbent or trufoam or urgocell or kendall
or kerraboot or cavi-care):ti,ab,kw
#14 {or #1-#13}
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#15 MeSH descriptor: [Metronidazole] explode all trees
#16 metronidazole:ti,ab,kw
#17 MeSH descriptor: [Anti-Bacterial Agents] explode all trees
#18 MeSH descriptor: [Administration, Topical] explode all trees
#19 {and #17-#18}
#20 (topical near/2 (antibiotic* or antimicrobial* or antibacterial*)):ti,ab,kw
#21 MeSH descriptor: [Iodophors] explode all trees
#22 {and #18, #21}
#23 ((topical near/2 iodin*) or (“cadexomer iodine”)):ti,ab,kw
#24 MeSH descriptor: [Collagenases] explode all trees
#25 {and #18, #24}
#26 (topical near/2 collagen*):ti,ab,kw
#27 MeSH descriptor: [Phenytoin] explode all trees
#28 {and #18, #27}
#29 (topical near/2 phenytoin):ti,ab,kw
#30 MeSH descriptor: [Zinc Oxide] explode all trees
#31 {and #18, #30}
#32 (topical near/2 zinc):ti,ab,kw
#33 (iodosorb or actiformcool or aquaﬂo or ﬂamazine or silvadene):ti,ab,kw
#34 MeSH descriptor: [Ointments] explode all trees
#35 (ointment* or lotion* or cream* or powder* or gel or gels):ti,ab,kw
#36 (topical next (agent* or preparation* or therap* or treatment*)):ti,ab,kw
#37 {or #15-#16, #19-#20, #22-#23, #25-#26, #28-#29, #31-#36}
#38 {or #14, #37}
#39 MeSH descriptor: [Leg Ulcer] this term only
#40 MeSH descriptor: [Varicose Ulcer] explode all trees
#41 (varicose next ulcer* or venous next ulcer* or leg next ulcer* or stasis next ulcer* or crural next ulcer* or ulcus next cruris or ulcer
next cruris):ti,ab,kw
#42 {or #39-#41}
#43 {and #38, #42}
Ovid MEDLINE
1 exp Bandages/
2 exp Alginates/
3 exp Hydrogels/
4 exp Honey/
5 exp Silver/
6 exp Silver Sulfadiazine/
7 exp Charcoal/
8 exp Silicones/
9 exp Colloids/
10 Polyurethanes/
11 (dressing* or pad or pads or gauze or tulle or ﬁlm or bead or foam* or non-adherent or “non adherent” or hydrocolloid* or “sodium
hyaluronate” or alginat* or hydrogel* or silver* or honey* or matrix or iodine* or “protease modulat*” or “capillary action” or charcoal
or silicon* or polymer* or polyurethane* or hydrocellular or hydropolymer* or carboxymethylcellulose or carboxymethyl-cellulose or
gelatin* or NaCMC or “gel forming” or gel-forming).tw.
12 ((odour or odor) adj3 absorb*).tw.
13 (primapore or curasorb or seasorb or sorbsan or advadraw or vacutex or tegaderm or opsite or allevyn or biatain or medihoney or
activon tulle or granuﬂex or “nu derm” or aquacel or iodoﬂex or iodozyme or xeroform or carboﬂex or cutimed or sorbact or promogran
or acticoat or “urgosorb silver” or mepitel or urgotul or activheal or alione or askina or comfeel or duoderm or ﬂexigran or hydrocoll or
nu-derm or “ultec pro” or mepilex or versiva or urgoclean or cutinova or tegasorb or dermaﬁlm or replicare or signadress or algoplaque
or varihesive or advasorb or copa or lyofoam or permafoam or polymem or suprasorb or transorbent or trufoam or urgocell or kendall
or kerraboot or cavi-care).tw.
14 or/1-13
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15 exp Metronidazole/
16 metronidazole.tw.
17 exp Administration, Topical/
18 exp Anti-Bacterial Agents/
19 and/17-18
20 (topical adj2 (antibiotic* or antimicrobial* or antibacterial*)).tw.
21 exp Iodophors/
22 and/17,21
23 ((topical adj2 iodin*) or “cadexomer iodine”).tw.
24 exp Collagenases/
25 and/17,24
26 (topical adj2 collagen*).tw.
27 exp Phenytoin/
28 and/17,27
29 (topical adj2 phenytoin).tw.
30 exp Zinc Oxide/
31 and/17,30
32 (topical adj2 zinc).tw.
33 (iodosorb or actiformcool or aquaﬂo or ﬂamazine or silvadene).tw.
34 exp Ointments/
35 (ointment* or lotion* or cream* or powder* or gel or gels).tw.
36 (topical adj (agent* or preparation* or therap* or treatment*)).tw.
37 or/15-16,19-20,22-23,25-26,28-29,31-36
38 or/14,37
39 Leg Ulcer/
40 exp Varicose Ulcer/
41 (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris).tw.
42 or/39-41
43 and/38,42
44 randomized controlled trial.pt.
45 controlled clinical trial.pt.
46 randomi?ed.ab.
47 placebo.ab.
48 clinical trials as topic.sh.
49 randomly.ab.
50 trial.ti.
51 or/44-50
52 exp animals/ not humans.sh.
53 51 not 52
54 43 and 53
Ovid Embase
1 exp “bandages and dressings”/
2 exp honey/
3 exp hydrogel/
4 exp Calcium Alginate/
5 silver/
6 charcoal/
7 silicone derivative/
8 exp colloid/
9 polyurethan/
10 (dressing* or pad or pads or gauze or tulle or ﬁlm or bead or foam* or non-adherent or “non adherent” or hydrocolloid* or “sodium
hyaluronate” or alginat* or hydrogel* or silver* or honey* or matrix or iodine* or “protease modulat*” or “capillary action” or charcoal
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or silicon* or polymer* or polyurethane* or hydrocellular or hydropolymer* or carboxymethylcellulose or carboxymethyl-cellulose or
gelatin* or NaCMC or “gel forming” or gel-forming).ti,ab.
11 ((odour or odor) adj3 absorb*).ti,ab.
12 (primapore or curasorb or seasorb or sorbsan or advadraw or vacutex or tegaderm or opsite or allevyn or biatain or medihoney or
activon tulle or granuﬂex or “nu derm” or aquacel or iodoﬂex or iodozyme or xeroform or carboﬂex or cutimed or sorbact or promogran
or acticoat or “urgosorb silver” or mepitel or urgotul or activheal or alione or askina or comfeel or duoderm or ﬂexigran or hydrocoll or
nu-derm or “ultec pro” or mepilex or versiva or urgoclean or cutinova or tegasorb or dermaﬁlm or replicare or signadress or algoplaque
or varihesive or advasorb or copa or lyofoam or permafoam or polymem or suprasorb or transorbent or trufoam or urgocell or kendall
or kerraboot or cavi-care).ti,ab.
13 or/1-12
14 exp metronidazole/
15 metronidazole.ti,ab.
16 topical drug administration/
17 exp Antibiotic Agent/
18 and/16-17
19 (topical adj2 (antibiotic* or antimicrobial* or antibacterial*)).ti,ab.
20 exp cadexomer iodine/
21 and/16,20
22 “cadexomer iodine”.ti,ab.
23 exp silver/ or exp sulfadiazine silver/
24 and/16,23
25 exp collagenase/
26 and/16,25
27 (topical adj2 collagen*).ti,ab.
28 phenytoin/
29 and/16,28
30 (topical adj2 phenytoin).ti,ab.
31 exp zinc oxide/
32 and/16,31
33 (topical adj2 zinc).ti,ab.
34 (iodosorb or actiformcool or aquaﬂo or ﬂamazine or silvadene).ti,ab.
35 exp ointment/
36 (ointment* or lotion* or cream* or powder* or gel or gels).ti,ab.
37 (topical adj (agent* or preparation* or therap* or treatment*)).ti,ab.
38 or/14-15,18-19,21-22,24,26-27,29-30,32-37
39 or/13,38
40 exp leg ulcer/
41 (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris).ti,ab.
42 or/40-41
43 and/39,42
44 Randomized controlled trials/
45 Single-Blind Method/
46 Double-Blind Method/
47 Crossover Procedure/
48 (random* or factorial* or crossover* or cross over* or cross-over* or placebo* or assign* or allocat* or volunteer*).ti,ab.
49 (doubl* adj blind*).ti,ab.
50 (singl* adj blind*).ti,ab.
51 or/44-50
52 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
53 human/ or human cell/
54 and/52-53
55 52 not 54
56 51 not 55
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57 43 and 56
EBSCO CINAHL Plus
S55 S41 AND S54
S54 S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53
S53 TI allocat* random* or AB allocat* random*
S52 MH “Quantitative Studies”
S51 TI placebo* or AB placebo*
S50 MH “Placebos”
S49 TI random* allocat* or AB random* allocat*
S48 MH “Random Assignment”
S47 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S46 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S45 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S44 TI clinic* N1 trial* or AB clinic* N1 trial*
S43 PT Clinical trial
S42 MH “Clinical Trials+”
S41 S37 AND S40
S40 S38 OR S39
S39 TI (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris) OR AB (varicose
ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris)
S38 (MH “Leg Ulcer”) OR (MH “Venous Ulcer”)
S37 S13 OR S36
S36 S14 OR S15 OR S18 OR S19 OR S21 OR S22 OR S24 OR S25 OR S27 OR S28 OR S30 OR S31 OR S32 OR S33 OR S34
OR S35
S35 TI (topical N3 agent* or topical N3 preparation* or topical N3 therap* and topical N3 treatment*) OR AB (topical N3 agent* or
topical N3 preparation* or topical N3 therap* and topical N3 treatment*)
S34 TI (ointment* or lotion* or cream* or powder* or gel or gels) OR AB (ointment* or lotion* or cream* or powder* or gel or gels)
S33 (MH “Ointments”)
S32 TI (iodosorb or actiformcool or aquaﬂo or ﬂamazine or silvadene) OR AB (iodosorb or actiformcool or aquaﬂo or ﬂamazine or
silvadene)
S31 TI (topical N2 zinc) OR AB (topical N2 zinc)
S30 S16 AND S29
S29 (MH “Zinc Oxide”)
S28 TI (topical N2 phenytoin) OR AB (topical N2 phenytoin)
S27 S16 AND S26
S26 (MH “Phenytoin+”)
S25 TI (topical N2 collagen*) OR AB (topical N2 collagen*)
S24 S16 AND S23
S23 (MH “Collagen”)
S22 TI “cadexomer iodine” OR AB “cadexomer iodine”
S21 S16 AND S20
S20 (MH “Iodophors+”)
S19 TI (topical N2 (antibiotic* or antimicrobial* or antibacterial*)) ORAB (topical N2 (antibiotic* or antimicrobial* or antibacterial*))
S18 S16 AND S17
S17 (MH “Antiinfective Agents+”)
S16 (MH “Administration, Topical+”)
S15 TI metronidazole OR AB metronidazole
S14 (MH “Metronidazole”)
S13 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12
S12 AB (primapore or curasorb or seasorb or sorbsan or advadraw or vacutex or tegaderm or opsite or allevyn or biatain or medihoney
or activon tulle or granuﬂex or “nu derm” or aquacel or iodoﬂex or iodozyme or xeroform or carboﬂex or cutimed sorbact or promogran
or acticoat or “urgosorb silver” or mepitel or urgotul or activheal or alione or askina or comfeel or duoderm or ﬂexigran or hydrocoll
or nu-derm or “ultec pro” or mepilex or versiva or urgoclean or cutinova or tegasorb or dermaﬁlm or or replicare or signadress or
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algoplaque or varihesive or advasorb or copa or lyofoam or permafoam or polymem or suprasorb or transorbent or trufoam or urgocell
or kendall or kerraboot or cavi-care)
S11 TI (primapore or curasorb or seasorb or sorbsan or advadraw or vacutex or tegaderm or opsite or allevyn or biatain or medihoney or
activon tulle or granuﬂex or “nu derm” or aquacel or iodoﬂex or iodozyme or xeroform or carboﬂex or cutimed sorbact or promogran
or acticoat or “urgosorb silver” or mepitel or urgotul or activheal or alione or askina or comfeel or duoderm or ﬂexigran or hydrocoll or
nu-derm or “ultec pro” or mepilex or versiva or urgoclean or cutinova or tegasorb or dermaﬁlm or replicare or signadress or algoplaque
or varihesive or advasorb or copa or lyofoam or permafoam or polymem or suprasorb or transorbent or trufoam or urgocell or kendall
or kerraboot or cavi-care)
S10 TI odor N3 absorb* or AB odor N3 absorb*
S9 TI odour N3 absorb* or AB odour N3 absorb*
S8 AB (dressing* or pad or pads or gauze or tulle or ﬁlm or bead or foam* or non-adherent or “non adherent” or hydrocolloid* or
“sodium hyaluronate” or alginat* or hydrogel* or silver* or honey* or matrix or iodine* or “protease modulat*” or “capillary action”
or charcoal or silicon* or polymer* or polyurethane* or hydrocellular or hydropolymer* or carboxymethylcellulose or carboxymethyl-
cellulose or gelatin* or NaCMC or “gel forming” or gel-forming)
S7 TI (dressing* or pad or pads or gauze or tulle or ﬁlm or bead or foam* or non-adherent or “non adherent” or hydrocolloid* or
“sodium hyaluronate” or alginat* or hydrogel* or silver* or honey* or matrix or iodine* or “protease modulat*” or “capillary action”
or charcoal or silicon* or polymer* or polyurethane* or hydrocellular or hydropolymer* or carboxymethylcellulose or carboxymethyl-
cellulose or gelatin* or NaCMC or “gel forming” or gel-forming)
S6 (MH “Silver”) or (MH “Silver Sulfadiazine”) or (MH “Colloids+”) or (MH “Polyurethanes”)
S5 (MH “Honey”)
S4 (MH “Charcoal”)
S3 (MH “Silicones”)
S2 (MH “Alginates”)
S1 (MH “Bandages and Dressings+”)
Appendix 3. Assessing risk of bias
1. Was the allocation sequence randomly generated? (Part of ’Selection bias’)
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random number generator; coin tossing; shufﬂing cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufﬁcient information about the sequence generation process provided to permit a judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed? (Part of ’Selection bias’)
Low risk of bias
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Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially-numbered drug containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: use of an open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate
safeguards (e.g. envelopes were unsealed, non-opaque, or not sequentially numbered); alternation or rotation; date of birth; case record
number; any other explicitly unconcealed procedure.
Unclear
Insufﬁcient information provided to permit a judgement of low or high risk of bias. This is usually the case if themethod of concealment
is not described, or not described in sufﬁcient detail to allow a deﬁnite judgement, for example if the use of assignment envelopes is
described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
3. Blinding - was knowledge of the allocated interventions adequately prevented during the study? (Performance bias for
blinding of participants and caregivers; detection bias for outcome assessors)
Low risk of bias
Any one of the following.
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be inﬂuenced by
lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others unlikely to introduce bias.
High risk of bias
Any one of the following.
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be inﬂuenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Unclear
Either of the following.
• Insufﬁcient information to permit judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed? (Attrition bias)
Low risk of bias
Any one of the following.
• No missing outcome data.
• Reasons for missing outcome data are unlikely to be related to true outcome (for survival data, censoring unlikely to be
introducing bias).
• Missing outcome data are balanced in numbers across intervention groups, with similar reasons for missing data across groups.
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• For dichotomous outcome data, the proportion of missing outcomes compared with the observed event risk is not enough to
have a clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, a plausible effect size (difference in means or standardised difference in means) among missing
outcomes is not enough to have a clinically relevant impact on the observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Any one of the following.
• Reason for missing outcome data are likely to be related to the true outcome, with either an imbalance in numbers or reasons for
missing data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with the observed event risk is enough to induce
clinically relevant bias in the intervention effect estimate.
• For continuous outcome data, a plausible effect size (difference in means or standardised difference in means) among missing
outcomes is enough to induce a clinically relevant bias in the observed effect size.
• ’As-treated’ analysis done with a substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear
Either of the following.
• Insufﬁcient reporting of attrition/exclusions to permit a judgement of low or high risk of bias (e.g. number randomised not
stated, no reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Either of the following.
• The study protocol is available and all of the study’s prespeciﬁed (primary and secondary) outcomes that are of interest in the
review have been reported in the prespeciﬁed way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were prespeciﬁed (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following.
• Not all of the study’s prespeciﬁed primary outcomes have been reported.
• One or more primary outcomes is/are reported using measurements, analysis methods, or subsets of the data (e.g. subscales) that
were not prespeciﬁed.
• One or more reported primary outcomes was/were not prespeciﬁed (unless clear justiﬁcation for their reporting is provided, such
as an unexpected adverse effect).
• One or more outcomes of interest in the review is/are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufﬁcient information provided to permit a judgement of low or high risk of bias. It is likely that the majority of studies will fall into
this category.
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6. Other sources of potential bias (Outcome reporting bias)
Low risk of bias
The study appears to be free of other sources of bias.
High risk of bias
There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the speciﬁc study design used; or
• has been claimed to have been fraudulent; or
• had some other problem.
Unclear
There may be a risk of bias, but there is either:
• insufﬁcient information to assess whether an important risk of bias exists; or
• insufﬁcient rationale or evidence that an identiﬁed problem will introduce bias.
Appendix 4. Summary of comparisons not included in the network
Comparisons for which there is only direct evidence
Standard care versus honey
One trial compared honey with a range of other dressing types. Jull 2008 randomised 368 people to honey or standard care which
included a number of different options. The risk ratio (RR) for complete healing was 1.12 (95% conﬁdence interval (CI) 0.92 to 1.36).
This was very low-certainty evidence, downgraded twice for risk of bias and once for imprecision.
Standard care versus cadexomer iodine
Three trials compared cadexomer iodine with groups treated with a variety of other treatments. Harcup 1986; Lindsay 1986 and
Steele 1986 randomised a total of 157 people to either cadexomer iodine or a range of other treatments which could be classed as
standard treatment. The pooled random-effects RR for healing was 5.16 (95% CI 1.56, 17.10; I2 =0%). This is low-quality evidence,
downgraded twice for imprecision due to wide conﬁdence intervals and low numbers of participants.
Phenytoin versus no treatment
One study Hokkam 2011 randomised 104 participants to phenytoin or no treatment (in addition to compression). The RR for
complete healing was 1.25 (95% CI 0.90 to 1.74). There may be little or no difference between groups; this was low-certainty evidence,
downgraded twice for low numbers of participants and events and wide conﬁdence intervals which include the possibility of harm as
well as beneﬁt or no effect.
Hydrocolloid versus either nonadherent or iodine
One study randomised participants to either a hydrocolloid or a nonadherent or povidone iodine-based dressing. Arnold 1994 ran-
domised 70 people. The RR was 0.79 (95% CI 0.42 to 1.48). This was very low-certainty evidence, downgraded twice for risks of bias
and twice for imprecision.
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Sulphadryl versus inactive powder
One study randomised participants to one of two sulphadryl powders or to a third inactive powder group. Salim 1992 randomised 168
participants. The RR was 1.31 (95% CI 1.10 to 1.56). This was low-certainty evidence downgraded once for imprecision and once for
attrition bias.
Silica gel fibre versus either mepitel or mepilex
One trial randomised participants to either silica gel ﬁbre dressing or to treatment with either nonadherent or foam dressings. Brown
2014 randomised 121 people. The RR was 0.63 (95% CI 0.31 to 1.26). This is low- (or very low-) quality evidence, downgraded for
lack of blinding (detection bias and maybe also performance bias) and imprecision.
Comparisons which were considered to be partly relevant clinically and were not included in the network
Cellulose versus nonadherent
One trial randomised 48 participants to either a cellulose dressing or a nonadherent dressing (Alvarez 2012). The RR was 0.92 (95%
CI 0.38 to 2.22). This is very low-certainty evidence, downgraded once for risk of bias and twice for imprecision.
Shale oil versus hydrogel
One trial randomised 119 participants to either shale oil or a hydrogel without the shale oil (Beckert 2006) The RR was 1.49 (95% CI
0.82 to 2.68). This is low-certainty evidence, downgraded twice for imprecision.
Hydrocolloid versus collagen
One trial randomised 96 participants to either a hydrocolloid dressing or a lyophilised collagen dressing (Caprio 1992).The RR was
0.77 (95% CI 0.50 to 1.18). This is low-certainty evidence, downgraded twice for imprecision.
Papain versus hydrogel
Two trials randomised a total of 70 participants to either papain or hydrogel (De Araujo 2016; Luiza 2015). De Araujo was a three-arm
trial with a total of 63 participants which also randomised 21 participants to an ineligible intervention, a blood product; the comparison
between this and hydrogel was included in the expanded base-case sensitivity analysis. The RR for the comparison of papain with
hydrogel was 0.94 (95% CI 0.25, 3.49; I2 = 16%). This is very low-certainty evidence, downgraded once for inconsistency and twice
for imprecision.
Hydrocolloid versus magnesium sulphate
One trial randomised 110 participants to either hydrocolloid dressing or magnesium sulphate paste (Greguric 1994) The RR was 7.00
(95% CI 0.37 to 132.40). This is very low-certainty evidence, downgraded once for risk of bias and twice for imprecision.
Hydrocolloid versus dextranomer
One trial randomised 108 participants to either hydrocolloid dressing or dextranomer treatment (Kalis 1993). The RR was 0.77 (95%
CI 0.37 to 1.60). This was very low-certainty evidence, downgraded twice for risk of bias and twice for imprecision.
Silver versus non silver
One trial randomised 208 participants to either a silver-based or a non-silver-based dressing (Michaels 2009). The RR was 1.05 (0.94
to 1.16). This was low-certainty evidence, downgraded once for risk of bias and once for imprecision
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Cadexomer iodine versus dextranomer
Two trials randomised participants to either cadexomer iodine or dextranomer treatments (Moss 1987; Tarvainen 1988).The RR was
1.33 (95%CI 0.64 to 2.75; I2 = 0%). This was very low-certainty evidence, downgraded twice for risk of bias and twice for imprecision.
Ozonated oil versus emollient cream
One trial randomised 29 participants to either ozonated oil or an emollient cream without the ozonated oil (Solovastru 2015). The RR
was 10.31 (95% CI 0.62 to 170.96). This was low-certainty evidence, downgraded twice for imprecision.
A. Pichinchensis versus alginate
One trial randomised 34 participants to treatment with eitherA. Pichinchensis extract or an alginate topical treatment (Romero-Cerecero
2012). The RR was 1.67 (95% CI 1.03 to 2.70). This was low-certainty evidence, downgraded once for risk of bias and once for
imprecision.
Comparisons with tripeptide copper
One three-armed study randomised participants to tripeptide copper, silver sulfadiazine (SSD) or an emollient cream without either
active ingredient. The comparison between SSD and emollient cream is included in the expanded base-case network; the other two
comparisons are summarised here.
Tripeptide copper versus SSD
Bishop 1992 randomised a total of 86 participants, of whom 57 were relevant to this comparison. The RR was 0.07 (95% CI 0.00 to
1.26). This was low-certainty evidence, downgraded twice for imprecision.
Tripeptide copper versus emollient cream
Bishop 1992 randomised a total of 86 participants, of whom 58 were relevant to this comparison. The RR was 0.33 (0.01 to 7.86).
This was low-certainty evidence downgraded twice for imprecision.
Appendix 5. Base-case and sensitivity analyses
We conducted a network meta-analysis (NMA) for the base-case and then carried out sensitivity analyses; one examined risk of bias
and the others investigated a restricted network and an extended network. For each network, we examined the results in two ways:
as risk ratios (RR) with their 95% CIs for each intervention compared with every other intervention in the network (NMA effect
estimates); and for the network as a whole, giving the rank order for the interventions in the network and the probability that a particular
intervention is the best, second best, etc treatment.
5.1 Base-case network
The base-case NMA included 22 treatments (12 dressings: foam, hydrocolloid, hydroﬁbre, alginate, ibuprofen-releasing foam, non-ad-
herent, paste bandage, protease-modulating (PMM), PMM-silver, silver-containing, ﬁlm, saline gauze; and 10 topical agents: hydrogel,
cadexomer iodine, gentian violet, hyaluronic acid, hyaluronic-acid with povidone iodine, octenidine, povidone iodine, SSD, sucralfate
and zinc oxide) and generated results for 231 mixed treatment contrasts (i.e. all possible pairwise combinations of the interventions).
There were 31 direct contrasts of which 24 were informed by only one study and the average number of events per mixed treatment
contrast was around six (1479/231). Data were sparse and there was uncertainty around the estimates. The network diagram is shown
in Figure 7.
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Figure 7. Network diagram for the base-case, coded by risk of bias (3 categories)Key: green = low/unclear;
yellow = high; red = very high overall risk of bias for the contrast. The number of studies for each contrast is
given in
We summarised results for the base-case NMA as a whole using rankograms: data for each intervention are shown as the probability
that each intervention is the best, second best, third best treatment, etc. These probabilities are based on uncertainty, reﬂecting the
effectiveness from the network contrasts and the precision around the estimates. The closer the probability of a rank to 100% (or 0%)
and the narrower the distribution across different ranks, the greater the conﬁdence in the ranking (see Figure 8 and Table 6). There was
some overlap of the individual rankograms, illustrated in Figure 9, which shows both the confusion, together with some indication that
sucralfate, hydrogel and silver dressings may be the best treatments and that the worst treatments may be saline gauze and hyaluronic
acid. Across all treatments there was some uncertainty in the middle ranking of treatments, although the mean rank of one treatment
(sucralfate) was close to 1 and the worst treatment was 21 (out of 22). Surface under the cumulative ranking curve (SUCRA) values
were generally between 0.2 and 0.8, but two treatments had a SUCRA value of 1 or 0 (sucralfate - 1, and saline gauze - 0), with another
treatment having values of 0.9 or 0.1 (silver 0.9).
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Figure 8. Rankograms for the base-case network showing the probability that each intervention is the best,
second best, third best treatment, etc.
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Figure 9. Rankograms for all treatments in base-case network showing the probability that each
intervention is the best, second best, third best treatment, etc.
Numerically, sucralfate had by far the highest probability of being the best treatment (91%), and saline gauze was most likely to be the
worst treatment (69%). However, the sucralfate ranking is likely to be artiﬁcially high: sucralfate is connected to the core of the network
via hydrogel and the direct evidence for sucralfate versus hydrogel involves one study with 43 (of 50) healing events for sucralfate and
ﬁve healing events for hydrogel. The comparison linking sucralfate to the core of the network (hydrogel versus nonadherent) has two
and one events respectively in a very small study (24 participants). The NMA results for all comparisons with sucralfate have very wide
CIs and large point estimates. Consequently, sucralfate (versus other interventions) has a ﬁnite probability of having a very large effect
estimate (at the upper conﬁdence limit), in turn leading to an artiﬁcially high probability of being the best treatment.
Examination of the results for each of the individual contrasts in the base-case NMA revealed that the majority of CIs were wide or
very wide, often crossing at least one default minimally important difference (MID); i.e. the value of 0.75 or 1.25 was included in
the CI (see Sensitivity analysis, GRADE assessment). Results for a representative set of contrasts are given in Table 5, showing the
three mostly highly-ranked treatments in the base-case network (sucralfate, hydrogel and silver dressings) and three commonly used
treatments (foam, hydrocolloid and non-adherent dressings). Several of the contrasts with sucralfate and silver had the whole of the CI
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above the default MID (i.e the whole conﬁdence interval lay above 1.25). In the case of sucralfate, the relevant direct evidence also had
small numbers of events in at least one arm, and was based on data from one direct study (’fragility’).
We examined inconsistency in the base-case network as a whole, comparing consistency and inconsistency analyses. There was no
signiﬁcant inconsistency (P = 0.566) (Appendix 7). There may be inconsistency at a local level for one loop (foam-hydrocolloid-silver)
and for four contrasts: paste bandage versus alginate; paste bandage versus foam; silver versus hydrocolloid and silver versus foam
(Appendix 7).
5.2 Pre-specified sensitivity analyses
We conducted the planned sensitivity analysis according to risk of bias, restricting the network to those studies at low or unclear risk
of bias. Only 15 studies with eight interventions (nonadherent, alginate, foam, hyaluronic acid plus povidone iodine, hydrocolloid,
PMM, saline gauze and silver dressings) remained, but they were joined in a network.
For most contrasts, the point estimates showed a smaller effect and the CIs were wider (data not shown). The exceptions to this were
comparisons with nonadherent dressing, for which the point estimates were larger. Mean ranks were in the order (highest ﬁrst): silver
(mean rank 2.3), hyaluronic acid plus povidone iodine (2.7), PMM (4.0), hydrocolloid (4.2), foam (4.3), alginate (4.6), nonadherent
(6.4), saline gauze (7.5). Rankograms were broad with the exception of saline gauze. The sensitivity analysis reinforced the ﬁndings of
the base-case network, but with less precision, although effect estimates appeared smaller.
We did not conduct the second pre-speciﬁed sensitivity analysis (assuming an available case analysis rather than imputing no event for
missing values) because more than two thirds (32/47) of studies were not judged to be at high risk of attrition bias, and few of those
that were had differential missing data.
We then carried out two post-hoc sensitivity analyses, described below.
5.3. Sensitivity analysis: narrow dataset
The narrow dataset included 41 studies (of 47 in the base-case) in 3435 participants with 1331 events. This encompassed 17 different
interventions (11 dressings: foam, hydrocolloid, hydroﬁbre, alginate, non-adherent, paste bandage, protease-modulating (PMM),
PMM-silver, silver-containing, ﬁlm, saline gauze; and six topical agents: hydrogel, cadexomer iodine, hyaluronic acid, povidone iodine,
SSD, and zinc oxide) in 26 direct contrasts and these informed 136 mixed treatment contrasts; only six contrasts were informed by
more than one study. There were 12 triangular loops.
Rankograms for the narrow dataset sensitivity analysis are shown in Figure 10 and the mean rank and SUCRA value, probability at
the maximum and rank at the peak in Table 6. There was slightly more of a distinction between interventions, but still overlap of
rankograms and only saline gauze had a SUCRA value of 0 or 1. Even in the absence of sucralfate, the mean rank order was the same
as that for the base-case.
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Figure 10. Rankograms for the narrow sensitivity analysis showing the probability that each intervention is
the best, second best, third best treatment, etc.
The results for the same set of individual contrasts as the base-case are given in Table 5. These are very similar to those for the base-case.
In the narrow network as a whole, there was no signiﬁcant inconsistency (P-value 0.273, c.f. base-case 0.566). At the local level, the
same four contrasts suggested inconsistency as in the basecase, with identical RoRRs. Again the foam-hydrocolloid-silver loop had
inconsistency, with the same RoRR as the base-case (Appendix 7). There was little asymmetry in the funnel plot.
5.4 Sensitivity analysis - extended base-case
The extended base-case dataset included three additional treatments to give more links via ineligible and partly relevant interventions
(blood product, emollient cream and growth factor), in order to convert ‘hanging’ treatments to ‘core’ treatments (especially hydrogel
and saline gauze), thus reinforcing the network. The network diagram for the extended base-case, including ’Risk of bias’ judgements
is shown in Figure 3. There were 59 studies (c.f. 47 in the base-case) in 5156 participants with 1925 events. This encompassed 25
different interventions in 40 direct contrasts and these informed 300 mixed treatment contrasts; only eight contrasts were informed by
more than one study. There were 15 triangular loops and six quadratic loops.
Results for individual mixed treatment contrasts in the extended base-case are shown in Figure 11; Figure 12; Figure 13; Figure 14;
Figure 15; Figure 16; Figure 17; Figure 18; Figure 19; Figure 20; Figure 21. The results for the same set of contrasts as the base-case
are given in Table 5 and some differences were found. In particular, all contrasts with sucralfate (except sucralfate versus hydrogel,
which was unchanged) showed considerably smaller point estimates in the extended base-case and much narrower conﬁdence intervals.
Secondly, contrasts with hydrogel had point estimates favouring the comparator, rather than hydrogel as found for the base-case; the
exception to this was the contrast hydrogel versus silver, which had a point estimate more in favour of silver in the extended base-case.
CIs for contrasts with hydrogel were much smaller for the extended base-case. The other contrasts in Table 5 had very similar results
for the extended base-case as the base-case.
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Figure 11. Comparisons of alginate with other treatments in the extended base-case network with risk of
bias
Figure 12. Comparisons of cadexomer iodine with other treatments in the extended base-case network
with risk of bias
279Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 13. Comparisons of foam with other treatments in the extended base-case network with risk of bias
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Figure 14. Comparisons of hydrocolloid with other treatments in the extended base-case network with risk
of bias
Figure 15. Comparisons of hydrofibre with other treatments in the extended base-case network with risk of
bias
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Figure 16. Comparisons of hydrogel with other treatments in the extended base-case network with risk of
bias
Figure 17. Comparisons of paste bandage with other treatments in the extended base-case network with
risk of bias
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Figure 18. Comparisons of PMM and PMM silver with other treatments in the extended base-case network
with risk of bias
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Figure 19. Comparisons of saline gauze with other treatments in the extended base-case network with risk
of bias
284Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 20. Comparisons of silver and SSD with other treatments in the extended base-case network with
risk of bias
Figure 21. Comparisons of nonadherent with other treatments in the extended base-case network with risk
of bias
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Rankograms for the extended base-case sensitivity analysis are shown in Figure 4 and the mean rank, SUCRA value and peak probability
and its rank in Table 6. The combined rankograms chart is shown in Figure 5: the distinction between interventions was similar to that
of the base-case, but the silver treatment had a higher probability at the maximum (50% versus 38%) and saline gauze and hydrogel had
approximately half the peak probabilities of the base-case (33% and 20% respectively). Sucralfate had a SUCRA value of 1, but no other
treatment had a value of 1 or 0. Importantly, the extended base-case showed that the mean rank for hydrogel was considerably larger
than for the base-case (16.9 compared with 8.9) and hydrogel no longer had a peak probability of being the second best treatment,
instead it was most likely to be ranked 20th best. Otherwise the mean rank order was the same as that for the base-case. This instability
for some treatments is likely to occur because in the base-case the direct evidence (from small studies) had an important contribution.
In the extended base-case network as a whole, there was no signiﬁcant inconsistency (P value 0.326, c.f. base-case 0.566). For node-
splitting, the same four contrasts suggested inconsistency as for the basecase, with very similar RoRRs. Again the foam-hydrocolloid-
silver loop had inconsistency, with the same RoRR as the base-case (Appendix 7). There was little asymmetry in the funnel plot (Figure
6).
In view of the instability in the base-case network and its dependence on small studies in critical positions, we decided to report the
results of the extended base-case sensitivity analysis in the main text and the ’Summary of ﬁndings’ table.
Appendix 6. Risk of bias in the network
The percentage contributions to the mixed treatment contrasts from each direct contrast are shown in Table 7 for the extended base-
case network contrasts comparing all combinations of silver, sucralfate, non-adherent, foam and hydrocolloid, these were obtained by
applying the CINeMA web tool (CINeMA 2017).
We calculated the risk of bias for each contrast in the NMA (based on the direct evidence); risk of bias for each mixed treatment contrast
is shown in the last row of Table 7 (see Assessment of risk of bias in included studies).
The contributions to the whole network from each direct contrast were not available from the web tool, but we estimated the risk of
bias for the whole network to be high, based on a chart showing contributions to all the mixed treatment contrasts (Figure 22).
Figure 22. Risk of bias contributions to each NMA comparison in the extended base-case network (vertical
scale 0% to 100%)red = very high risk of bias, yellow = high risk of bias, green = low risk of bias
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Appendix 7. Inconsistency in the base-case network and sensitivity analyses
7.1 Inconsistency in the network as a whole
We conducted both consistency and inconsistency analyses. The latter gave the following results for the base-case network and the two
sensitivity analyses.
Base-case network: the P value for the 10 inconsistency parameters all being zero was 0.566 and Chi2 (10) was 8.64 (i.e. no signiﬁcant
inconsistency).
Restricted base-case network: the P value for the 10 inconsistency parameters all being zero was 0.273 and Chi2 (10) was 12.19 (i.e.
no signiﬁcant inconsistency).
Extended base-case network sensitivity analysis: P value for 17 inconsistency parameters all being zero was 0.3259 and Chi2 (17) was
19.05 (i.e. no signiﬁcant inconsistency).
7.2 Inconsistency for each contrast in the extended base-case (local inconsistency)
We report local inconsistency for the extended base-case only. Firstly, we examined inconsistency factors, comparing results from the
direct evidence with those from the indirect evidence for each contrast informed by a loop. We report results as the ratio of risk ratios
(RoRR), with its 90% conﬁdence interval (CI) for the 15 triangular loops and six quadratic loops (Table 8), assuming a common
heterogeneity estimate within each loop (the ﬁrst set of results in Table 8 have the same values as the base-case). At the 90% signiﬁcance
level, there appeared to be inconsistency in the foam-hydrocolloid-silver loop (RoRR 2.44, 90%CI 1.23 to 4.84). The results also
suggested some non-signiﬁcant potential inconsistency in all other loops (because the 90% CI crosses 2 or 0.5 or both).
Secondly, a node-splitting approach was taken. The results following node-splitting for indirect and direct NMA estimates for the
extended network are shown in Table 9, together with the ratio of risk ratios (RoRR) (indirect/direct) with its 90% CI (the 90%
signiﬁcance level was chosen for this test because of its lack of power). The ’indirect’ estimate is the result when the NMA is run in the
absence of the direct evidence for that contrast. This is only meaningful if the two interventions in the contrast are joined indirectly
through the rest of the network; therefore, we report node splitting results for only 28 (of 40) direct contrasts. We made the following
observations:
• Results for four contrasts suggested inconsistency at the 90% conﬁdence level: paste bandage versus alginate (RoRR 0.51, 90%
CI 0.28 to 0.91); paste bandage versus foam (RoRR 1.97, 90% CI 1.10 to 3.55); silver versus hydrocolloid (RoRR 2.50, 90% CI
1.26 to 4.95) and silver versus foam (RoRR 0.40, 90% CI 0.20 to 0.79).
• There was potential for inconsistency for eight other contrasts (with the CI including either 0.5 or 2, or both): hydroﬁbre versus
nonadherent (RoRR 1.09, 90% CI 0.53 to 2.23); protease-modulating dressing versus nonadherent (RoRR 1.13, 90% CI 0.61 to
2.11); foam versus alginate (RoRR 0.57, 90% CI 0.14 to 2.36); hydrogel versus nonadherent (RoRR 2.62, 90% CI 0.35 to 19.5);
hydrocolloid versus alginate (RoR 0.81, 90% CI 0.31 to 2.05); hydroﬁbre versus alginate (RoRR 1.08, 90% CI 0.51 to 2.29); PMM
versus foam (RoRR 0.73, 90% CI 0.28 to 1.90); PMM silver versus hydrocolloid (RoRR 0.61, 90% CI 0.31 to 1.19); PMM silver
versus foam (RoRR 1.64, 90% CI 0.83 to 3.21); hyaluronic acid versus saline gauze.(RoRR 3.63, 90% CI 0.87 to 15.21) and
hydrocolloid versus saline gauze (RoRR 1.84. 90% CI 0.39 to 8.7). The contrasts linked to ineligible interventions also showed
potential for inconsistency (see Table 9).
However, all the CIs were wide and there was uncertainty around whether there was inconsistency or not.
287Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
Gill Norman: co-ordinated the review; extracted data; checked the quality of data extraction; analysed or interpreted data; performed
statistical analysis; checked the quality of the statistical analysis; produced the ﬁrst draft of the review; contributed to writing and editing
the review; approved the ﬁnal review prior to submission; and is a guarantor of the review.
Maggie Westby: designed the review; analysed or interpreted data; performed statistical analysis; checked the quality of the statistical
analysis; produced the ﬁrst draft of the review; contributed to writing or editing the review; approved the ﬁnal review prior to submission;
and is a guarantor of the review.
Amber Rithalia: extracted data; checked the quality of data extraction; checked the quality of the statistical analysis; and approved the
ﬁnal review prior to submission.
Nikki Stubbs: analysed or interpreted data; advised on the review; and approved the ﬁnal review prior to submission.
Marta Soares: designed the review; analysed or interpreted data; advised on the review; performed previouswork that was the foundation
of the current review; and approved the ﬁnal review prior to submission.
Jo Dumville: conceived and designed the review; analysed or interpreted data; contributed to writing or editing the review; secured
funding; and approved the ﬁnal review prior to submission.
Contributions of editorial base
Nicky Cullum (Co-ordinating Editor): edited the protocol and the review; advised on methodology, interpretation and content;
approved the ﬁnal review prior to submission.
Gill Rizzello (Managing Editor): co-ordinated the editorial process, advised on content; edited the protocol and the review.
Reetu Child and Naomi Shaw: (Information Specialists) designed the search strategy, ran the searches and edited the search methods
section.
Ursula Gonthier (Editorial Assistant): edited the Plain Language Summary, tables and reference sections.
D E C L A R A T I O N S O F I N T E R E S T
Gill Norman: my employment at the University of Manchester while completing this work was funded by the NIHR and focused on
high-priority Cochrane reviews in the prevention and treatment of wounds.
Maggie Westby: my employment at the University of Manchester while completing this work was funded by the NIHR and focused
on high-priority Cochrane reviews in the prevention and treatment of wounds.
Amber Rithalia: none known.
Nikki Stubbs: I have received consultancy payments fromCogora, a healthcaremarketing agency, and expenses for conference attendance.
Funding from pharmaceutical companies supports training and education events in the service and I have received payments for non
product-related educational sessions. These have been unrelated to the subject matter of the systematic review and have never been in
support or in pursuit of the promotion of products.
Marta Soares: none known.
Jo Dumville: I received research funding from the NIHR for the production of systematic reviews focusing on high-priority Cochrane
reviews in the prevention and treatment of wounds.
Andrew Jull (peer reviewer): I was lead author of an excluded study. No other conﬂicts to declare.
Clifford Richardson (peer reviewer): I work at the University of Manchester and know some of the members of the author team, but
do not work with them in any capacity.
288Dressings and topical agents for treating venous leg ulcers (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S O U R C E S O F S U P P O R T
Internal sources
• Division of Nursing, Midwifery and Social Work, School of Health Sciences, Faculty of Biology, Medicine and Health,
University of Manchester, UK.
External sources
• National Institute for Health Research, UK.
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure and Cochrane Programme
Grant funding (NIHR Cochrane Programme Grant 13/89/08 - High Priority Cochrane Reviews in Wound Prevention and
Treatment) to Cochrane Wounds. The views and opinions expressed herein are those of the authors and do not necessarily reﬂect
those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
• National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC)
Greater Manchester Centre, UK.
Jo Dumville was partly funded by the National Institute for Health Research Collaboration for Leadership in Applied Health
Research and Care (NIHR CLAHRC) Greater Manchester. The funder had no role in the design of the studies, data collection and
analysis, decision to publish, or preparation of the manuscript. However, the review may be considered to be afﬁliated to the work of
the NIHR CLAHRC Greater Manchester. The views expressed herein are those of the authors and not necessarily those of the NHS,
NIHR or the Department of Health.
• NIHR Biomedical Research Centre, UK.
This review was co-funded by the NIHR Manchester Biomedical Research Centre. The views expressed in this publication are those
of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The following decisions were made which represent differences between the review and the published protocol (Norman 2017).
Establishment of a narrower base-case of interventions for the main network: after mapping the network of eligible interventions
we made the decision to restrict the network to interventions in use in clinical practice rather than primarily research contexts. This
both increased the clinical relevance of the results of the analysis and rendered it more amenable to analysis. The number of included
interventions remained high, and was further increased by a sensitivity analysis using an expanded data set to examine the stability
of the network. Studies which were not included in the network remained in the review and are summarised by direct evidence. We
additionally conducted a sensitivity analysis using a narrower set of interventions which were more widely used.
We also made the decision to treat as excluded studies those trials which included only one relevant intervention and which did not
perform a linking function in the network; we had planned to list these as included studies with limited data extraction. This was a
pragmatic decision made because of the large number of these studies; they are instead clearly identiﬁable in the list of excluded studies.
We had considered performing a grouped analysis which would have looked at wider groupings of dressing types. Experience (Westby
2017) suggested that this was unlikely to provide useful additional information so we did not conduct this.
We had planned for the potential to conduct various sensitivity analyses which were not in practice appropriate, full details of these are
nevertheless provided in the methods.
We had planned to search trials registers and to contact review groups working on ongoing relevant reviews. Time constraints due to
the very large number of identiﬁed studies meant that this was not undertaken; however a full update search was conducted and all
other reference cross-checking was undertaken.
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